Title of Invention

A CYCLIC UREA DERIVATIVES AND A COMPOSITION COMPRISING THE SAME

Abstract

The invention relates to novel products having formula (I), wherein: p denotes 0 to 2; R and R1 denote O or NH; R2 and R3 denote hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl and heteroaryl, or R2 and R3, together with the carbon atom to which they are bound, form a carbocyclic or heterocyclic radical, all of said radicals being optionally substituted; A1 denotes a single bond, alkyl, allyl and propynyl; Y and Y1 denote H, OCF<sub>3</sub>, S(O)nCF<sub>3</sub>, S(O)nAlk, SO<sub>2</sub>CHF<sub>2</sub>, SO<sub>2</sub>CF2CF<sub>3</sub>, -O-CF<sub>2</sub>-CHF<sub>2</sub>, -O-CHF<sub>2</sub>, -O-CH2-CF<sub>3</sub>, SF<sub>5</sub> and SO2NR5R<sub>6</sub>, whereby R5 and R6 are selected from among hydrogen, alkyl, alkenyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl and heteroaryl, which are optionally substituted, or R5 and R6, together with N to which they are bound, form a heterocyclic radical; A2 denotes Al, CO and SO2; B2 denotes a heterocyclic radical which is optionally substituted with one or more substituents which are selected from the values of Y2; Y2 denotes hydrogen, halogen, hydroxyl, cyano, alkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -O-alkenyl, -O-alkynyl, O-cycloalkyl, S(O)n-alkyl, -S(O)n-alkenyl, -S(O)n-alkynyl, S(O)n-cycloalkyl, -COOR<sub>13</sub>3,-OCOR<sub>3</sub>, NR5R<sub>6</sub>, CONR5R<sub>6</sub>, S(O)n-NR5R<sub>6</sub>,-NR<sub>10</sub>-CO-R<sub>13</sub>, -NR<sub>10</sub>-SO<sub>2</sub>-R<sub>13</sub>, -NH-SO<sub>2</sub>-NR5R<sub>6</sub>, -NR<sub>10</sub>-CO-NR5R<sub>6</sub>, -NR10-CS-NR5R<sub>6</sub>, -NR10-COOR<sub>13</sub>, all of said radicals being optionally substituted; and n denotes an integer of between 0 and 2. The aforementioned products are in all the isomeric forms and the salts thereof for use as medicaments

Full Text

being chosen from the values defined in claim 1 and it being understood that when p represents the integer 0, R and Rl represent oxygen, Al represents a single bond or alkyl, Y and Yl, which may be identical or different, are such that one represents hydrogen and the other represents S02NH2, A2 represents CH2 and B2 represents an optionally substituted heterocyclic radical, then R2 and R3 do not represent one hydrogen and the other an alkyl chain optionally interrupted with 0, S or Nalk, always substituted with a hydroxamate -CO-NHOH said product of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said product of formula (I). 8) The product of formula (I) as defined in any one of the claims, in which one from among Y and Yl represents a hydrogen atom and the other is chosen from S(0)nCF3, S02CHF2 and S02CF2CF3, the other substituents of said product of formula (I) being chosen from the values defined in claim 1, said product of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said product of formula (I). 9) The product of formula (I) as defined in any one of the claims, such that all the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl radicals defined in claim 1 are optionally substituted with one or more radicals, which may be identical or different, chosen from halogen, cyano, hydroxyl, alkoxy, CF3, nitro, phenyl, carboxyl which is free, salified, esterified with an alkyl radical or amidated with a radical NRllaR12a, -C(=0)-R9a, -NRllaR12a, -C(=0)-NRllaR12a, -N(R10a)-C(=0)- R9a, -N(R10a)-C(=0)-OR8a, N(R10a)-C(=0)-NRllaR12a, N(R10a)-S(0)n-R9a, -S(0)n-R9a, -N(RlOa)-S(O)n-NRllaR12a or -(0)n-NRllaR12a/ all the aryl and heteroaryl radicals above furthermore being optionally substituted with an ethylenedioxy radical, R8a represents hydrogen, alkyl, alkenyl, phenyl, phenylalkyl, heteroaryl or heteroarylalkyl, R9a represents alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, phenyl, phenylalkyl, heteroaryl or heteroarylalkyl, RlOa represents hydrogen or alkyl, Rlla and R12a, which may be identical or different represent hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, phenyl, phenylalkyl, optionally substituted with one or more substituents, which may be identical or different, chosen from halogen, hydroxyl, C1-C4 alkyl or C1-C4 alkoxy, or alternatively Rlla and R12a form, with the nitrogen atom to which they are attached, a cyclic radical chosen from pyrrolidyl, piperidyl, piperazinyl, morpholinyl, indolinyl, pyrindolinyl, tetrahydroquinolyl, thiazolidinyl and naphthyridyl, said product of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said product of formula (I). 10) The product of formula (I) as defined in any one of the claims, such that p represents the integer 0, the other substituents of said product of formula (I) having the values defined in any one of the claims. 11) The product of formula (I) as defined in any one of the claims, such that p represents the integer 1, the other substituents of said product of formula (I) having the values defined in any one of the claims. 12) The product of formula (I) as defined in any one of the claims, such that p represents the integer 2, the other substituents of said product of formula (I) having the values defined in any one of the preceding claims. 13) The product of formula (I) as defined in any one of the claims, such that Rl represents 0, the other substituents of said product of formula (I) having the values defined in any one of the claims. 14) The product of formula (I) as defined in any one of the claims, such that R represents 0, the other substituents of said product of formula (I) having the values defined in any one of the claims. 15) The product of formula (I) as defined in any one of the claims, such that R2 and R3, which may be identical or different, represent hydrogen, alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, phenyl, phenylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl and heteroarylalkyl, which are optionally substituted, or alternatively R2 and R3 form, together with the carbon atom to which they are attached, a carbocyclic or heterocyclic radical, these radicals being 3 - to 10-membered and the heterocyclic radical containing one or more hetero atoms chosen from 0, S, N and NR7b, all these radicals being optionally substituted, all the above radicals being optionally substituted with one or more radicals chosen from halogen, cyano, hydroxyl, alkyl and alkoxy containing 1 to 4 carbon atoms, CF3, nitro, phenyl, carboxyl which is free, salified, esterified with an alkyl radical or amidated with a radical NRllbR12b, -C(=0)-R9b, -NRllbR12b and -C(=0)-NRllbR12b, R7b represents a hydrogen atom, an alkyl radical or a phenyl radical, R9 represents hydrogen, alkyl, cycloalkyl, cycloalkylalkyl or phenyl, Rllb and R12b, which may be identical or different, represent hydrogen, alkyl, cycloalkyl or phenyl, or alternatively Rllb and R12b form, with the nitrogen atom to which they are attached, an optionally substituted piperazinyl radical, the other substituents of said product of formula (I) having the values defined in any one of the claims. 16) The product of formula (I) as defined in any one of the claims, such that R2 and R3, which may be identical or different, are chosen from hydrogen, alkyl, phenylalkyl, pyridylalkyl, benzothienylalkyl and thienylbenzothienylalkyl, which are optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, alkyl and alkoxy radicals containing from one to 4 carbon atoms, or alternatively R2 and R3 form, together with the carbon atom to which they are attached, a 3 - to 6-membered cycloalkyl or heterocycloalkyl radical containing a nitrogen atom, the other substituents of said products of formula (I) having the values defined in any one of the claims. 17) The product of formula (I) as defined in any one of the claims, such that R2 and R3, which may be identical or different, are chosen from hydrogen, alkyl, hydroxyalkyl, phenylalkyl, hydroxyphenylalkyl, pyridylalkyl, benzothienylalkyl or thienylbenzothienylalkyl, or alternatively R2 and R3 form, together with the carbon atom to which they are attached, a cycloalkyl radical containing from 3 to 6 carbon atoms or an azetidinyl, pyrrolidyl or piperidyl radical, the other substituents of said products of formula (I) having the values defined in any one of the claims. 18) The product of formula (I) as defined in any one of the claims, such that R2 and R3, which may be identical or different, are chosen from hydrogen, alkyl, hydroxyalkyl, phenylalkyl and hydroxyphenylalkyl, or alternatively R2 and R3 form, together with the carbon atom to which they are attached, a cycloalkyl radical containing from 3 to 6 carbon atoms. 19) The product of formula (I) as defined in any one of the claims, such that one from among R2 and R3 is chosen from hydrogen and alkyl, and the other from among R2 and R3 is chosen from all the values of R2 and R3, or alternatively R2 and R3 form, together with the carbon atom to which they are attached, a cycloalkyl radical containing from 3 to 6 carbon atoms, the other substituents of said product of formula (I) having the values defined in any one of the claims. 20) The product of formula (I) as defined in any one of the claims, such that R2 and R3, which may be identical or different, represent hydrogen and alkyl, or alternatively R2 and R3 form, together with the carbon atom to which they are attached, a cycloalkyl radical containing from 3 to 6 carbon atoms, the other substituents of said product of formula (I) having the values defined in any one of the claims. 21) The product of formula (I) as defined in any one of the claims, such that R2 and R3, which may be identical or different, represent hydrogen and CH3, or alternatively R2 and R3 form, together with the carbon atom to which they are attached, a cyclopropyl radical, the other substituents of said product of formula (I) having the values defined in any one of the claims. 22) The product of formula (I) as defined in any one of the claims, such that Al represents a single bond and A2 is chosen from a single bond, a linear or branched alkyl radical containing not more than 6 carbon atoms and allyl, propynyl, C=0 and S02 radicals, the other substituents of said product of formula (I) having the values defined in any one of the claims. 23) The product of formula (I) as defined in any one of the preceding claims, such that Al represents a single bond and A2 is chosen from a single bond, alkyl, allyl, propynyl, C=0 and S02 radicals, the other substituents of said product of formula (I) having the values defined in any one of the claims. 24) The product of formula (I) as defined in any one of the claims, such that Al represents a single bond and A2 represents un alkyl or C=0 radical, the other substituents of said product of formula (I) having the values defined in any one of the claims. 25) The product of formula (I) as defined in any one of the claims, such that Al represents a single bond and A2 represents C=0, -CH2-CH2- or -CH2, the other substituents of said product of formula (I) having the values defined in any one of the claims. 26) The product of formula (I) as defined in any one of the claims, such that Al represents a single bond and A2 represents -CH2, the other substituents of said product of formula (I) having the values defined in any one of the claims. 27) The product of formula (I) as defined in any one of the claims, in which Y and Yl are such that one represents a hydrogen atom, a halogen atom or an amino radical and the other is chosen from 0CF3, -0-CF2-CHF2, -0-CHF2, -0-CH2-CF3, -SF5, -S(0)n-CF3, -S(0)n-Alk, -S02CHF2, S02CF2CF3, -S02NH2, -S-CF2-CF2-CF3, -S-Alk-O-Alk, -S-Alk-OH, -S-Alk-CN, -S-Alk-morpholino, -S-Alk-pyrrolidinyl and -S-Alk-piperazinyl, the morpholino, pyrrolidinyl and piperazinyl radicals being optionally substituted with Alk, in which Alk represents an alkyl radical containing from 1 to 4 carbon atoms, the other substituents of said product of formula (I) having the values defined in any one of the claims. 28) The product of formula (I) as defined in any one of the claims, such that Y represents a hydrogen atom and Yl is chosen from -0CF3, S(0)n-CF3, S(0)n-CH3, S02CHF2 and S02-N(alk)2, the other substituents of said product of formula (I) having the values defined in any one of the claims. 29) The product of formula (I) as defined in any one of the claims, such that Y represents a hydrogen atom and Yl is chosen from -0CF3, S(0)n-CF3 and S02CHF2, the other substituents of said product of formula (I) having the values defined in any one of the claims. 30) The product of formula (I) as defined in any one of the claims, such that Y represents a hydrogen atom and Yl is chosen from -OCF3 and S(0)n-CF3, the other substituents of said product of formula (I) having the values defined in any one of the claims. 31) The product of formula (I) as defined in any one of the claims, such that Y represents a hydrogen atom and Yl is chosen from -OCF3, S-CF3 and S(0)2-CF3, the other substituents of said product of formula (I) having the values defined in any one of the claims. 32) The product of formula (I) as defined in any one of the claims, such that B2 represents a monocyclic or bicyclic heteroaryl radical chosen from pyridyl, pyrimidinyl, quinolyl, azaindolyl, 1H-pyrrolo [2,3-b]pyridinyl, quinazolyl, thiazolyl, imidazolyl, pyrazolyl, furazanyl, isoxazolyl, morpholinyl, pyrrolidinyl, furyl, piperidyl, thienyl, chromenyl, oxochromenyl, indolyl, pyrrolyl, purinyl, benzoxazinyl, benzimidazolyl and benzofuranyl radicals, these radicals being optionally substituted with one or more radicals chosen from the values of Y2, the other substituents of said product of formula (I) having the values defined in any one of the claims. 33) The product of formula (I) as defined in any one of the claims, such that B2 represents a heteroaryl radical chosen from 3 - or 4 -pyridyl, pyrimidinyl, 3 - or 4-quinolyl, azaindolyl, quinazolyl, thiazolyl, imidazolyl, pyrazolyl, furazanyl and isoxazolyl radicals, these radicals being optionally substituted with one or more radicals chosen from the values of Y2, the other substituents of said product of formula (I) having the values defined in any one of the claims. 34) The product of formula (I) as defined in any one of the claims, such that B2 represents a heteroaryl radical chosen from 3- or 4-pyridyl, pyrimidinyl, 3- or 4-quinolyl, azaindolyl and quinazolyl radicals, these radicals being optionally substituted with one or more radicals chosen from the values of Y2, the other substituents of said product of formula (I) having the values defined in any one of the claims. 35) The product of formula (I) as defined in any one of the claims, such that B2 represents 4-pyridyl and 4-quinolyl and lH-pyrrolo[2,3-b]pyrid-3-yl radicals optionally substituted with one or more radicals chosen from the values of Y2 defined in any one of the claims, the other substituents of said product of formula (I) having the values defined in any one of the claims. 36) The product of formula (I) as defined in any one of the claims, such that Y2 represents hydrogen, halogen, hydroxy1, cyano, alkyl, alkoxy, phenyl, COOH, COOAlk, CONR5R6, NR5R6, -NR10-COOR6, -NR10-C0-R6, -NR10-CS-NR5R6, -NR10-CO-NR5R6 or -NR10-SO2-R6, all these radicals being optionally substituted, R5 and R6, which may be identical or different, are chosen from hydrogen, alkyl, cycloalkyl, phenyl and 5- or 6-membered heteroaryl radicals containing 1 to 3 hetero atoms chosen from 0, N and S, all these radicals being optionally substituted, or alternatively R5 and R6 form, with the nitrogen atom to which they are attached, an optionally substituted pyrrolidinyl, piperidyl, piperazinyl, morpholinyl or quinazolinyl radical, RIO represents hydrogen or alkyl, all the alkyl, alkoxy, cycloalkyl and phenyl radicals above, and also the ring formed by R5 and R6 with the atom to which they are attached, being optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and the following radicals: cyano; hydroxyl; alkyl; alkoxy; 0CF3; CF3; S(0)n-CF3; nitro; oxo; thioxo; OCOAlk; phenyl, itself optionally substituted with one or more radicals chosen from halogen atoms and alkyl and alkoxy radicals; -OCOAlk; NH2, NHAlk, N(Alk)2, N(alk)(phenylalkyl), N(Alk)(aminoalkyl), N(Alk)(alkylaminoalkyl) N(Alk)(dialkylaminoalkyl); carboxyl in free form or esterified with an alkyl radical, all the phenyl radicals above also being optionally substituted with an alkylenedioxy radical, all the alkyl radicals above also being optionally substituted with one or more saturated or partially unsaturated 4- to 7-membered heterocyclic radicals containing at least one nitrogen atom N and also 0 to 2 other hetero atoms chosen from 0, N and S, all the pyrrolidinyl and quinazolinyl radicals above also being optionally substituted with oxo or thioxo, all the alkyl and alkoxy radicals above being linear or branched and containing not more than 6 carbon atoms, all the cycloalkyl radicals above containing not more than 7 carbon atoms, the other substituents of said product of formula (I) having the values defined in any one of the claims. 37) The product of formula (I) as defined in any one of the claims, such that Y2 represents hydrogen, halogen, hydroxyl, cyano, alkyl, alkoxy, phenyl, CONR5R6, NR5R6, -NR10-COOH, -NRlO-COOAlk, -NR10-CO-R6, -NR10-CS-NR5R6, -NR10-CO-NR5R6 or -NR10-SO2-R6, R5 and R6, which may be identical or different, are chosen from hydrogen; alkyl; cycloalkyl; phenyl; pyrimidinyl; thienyl; pyridyl; quinolyl; thiazolyl optionally substituted with one or two halogen atoms; pyran optionally substituted with one or more OCOAlk; phenyl substituted with one or more radicals chosen from halogen atoms and alkyl, alkoxy, amino, alkylamino, dialkylamino radicals and carboxyl in free form or esterified with an alkyl radical; alkyl substituted with phenyl, which is itself optionally substituted with one or more radicals chosen from halogen atoms, alkyl, alkoxy, amino, alkylamino, dialkylamino, carboxyl in free form or esterif ied with an alkyl radical; alkyl substituted with piperazinyl, which is itself optionally substituted with one or more radicals chosen from Alk, Alk-OH and pyridyl; alkyl substituted with imidazolyl; alkyl substituted with one or more radicals chosen from NH2, NHAlk, N(Alk)2, N(alk) (phenylalkyl) , N(Alk)(aminoalkyl), N(Alk)(alkylaminoalkyl) and N(Alk)(dialkylaminoalkyl); alkyl substituted with morpholinyl optionally substituted with one or two Alk; alkyl substituted with pyrrolidinyl; alkyl substituted with piperidyl, which is itself optionally substituted with one or two Alk; alkyl substituted with thiomorpholinyl; alkyl substituted with azetidinyl; alkyl substituted with azepanyl, which is optionally substituted with oxo, or alternatively R5 and R6 form, with the nitrogen atom to which they are attached, a pyrrolidinyl; piperidyl; piperazinyl; morpholinyl; or quinazolinyl radical, all these radicals being optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and alkyl, hydroxyl and alkoxy radicals, and phenyl radicals the latter of which is itself optionally substituted with one or more radicals chosen from halogen atoms and alkyl and alkoxy radicals, the pyrrolidinyl and quinazolinyl radicals also being optionally substituted with oxo or thioxo, the piperazinyl radical itself being optionally substituted with one or more radicals chosen from Alk, Alk-OH and pyridyl, RIO represents hydrogen or alkyl, all the alkyl or Alk and alkoxy radicals above being linear or branched and containing not more than 6 carbon atoms, all the cycloalkyl radicals above containing not more than 7 carbon atoms, all the phenyl radicals also being optionally substituted with a radical chosen from CF3, -0CF3, nitro and alkylenedioxy, the other substituents of said product of formula (I) having the values defined in any one of the claims. 38) The product of formula (I) as defined in any one of the claims, such that Y2 represents VI, halogen, hydroxyl, -C(=NH)NH2, 0V1, 0-C0-V1, C00V1, C0V1, C0-NV1V2, -NV1V2, -NH-C0-V1, -NH-C00-V1, -NH-NH-C0-V1, -NV1-C0-HV1V2, -NV1-C0-NHV1, -NH-C0-NHV1, -NH-S02-NHV1 and -NH-S02-V1, in which VI and V2, which may be identical or different, represent a hydrogen atom, an alkyl, cycloalkyl or phenyl radical or a heterocyclic radical such as pyridinyl, pyrazolyl, imidazolyl, dihydroimidazolyl, tetrazolyl, morpholinyl, piperazinyl, piperazinylalkyl, alkylpiperazinyl, phenylpiperazinyl, thienyle, furanyl, piperidyl, methylpiperidyl, pyridyl, pyrrolidyl and pyrrolidylalkyl, all the alkyl, phenyl and heterocyclic radicals being optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, alkyl, alkoxy, CF3, NH2, NHalk, N(alk)2 radicals and a phenyl radical, itself optionally substituted with one or more substituents chosen from halogen atoms and hydroxyl or alkoxy radicals, all the phenyl and heterocyclic radicals above furthermore being optionally substituted with one or more alkyl radicals, the phenyl radicals furthermore being optionally substituted with NR5R6 in which R5 and R6 are as defined in claim 1, the other substituents of said product of formula (I) having the values defined in any one of the claims. 39) The product of formula (I) as defined in any one of the claims, such that Y2 represents hydrogen, halogen, alkyl, cycloalkyl, hydroxyl, alkoxy, carboxyl which is free or esterified with an alkyl or phenyl radical, NH2, NHalk, N(alk)2 and phenyl, all the alkyl, alkoxy and phenyl radicals being optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, C1-C4 alkyl, C1-C4 alkoxy, CF3, NH2, NHalk and N(alk)2 radicals and a phenyl radical, which is itself optionally substituted with one or more substituents chosen from halogen atoms and hydroxyl or alkoxy radicals, all the phenyl radicals furthermore being optionally substituted with one or more C1-C4 alkyl radicals and optionally substituted with NR5R6 in which R5 and R6 are as defined above, the other substituents of said product of formula (I) having the values defined in any one of the claims. 40) The product of formula (I) as defined in any one of the claims, such that Y2 represents hydrogen, F, CI, CH3, CH2CH3, OH, OCH3, NH2, NHAlk and phenyl optionally substituted with NR5R6 in which R5 and R6 are as defined in claim 1, the other substituents of said product of formula (I) having the values defined in any one of the claims. 41) The product of formula (I) as defined in any one of the claims, such that B2 represents 4 -pyridyl and 4 - quinolyl radicals substituted with one or more radicals chosen from F, CI, OH and OCH3, the other substituents of said product of formula (I) having the values defined in any one of the claims. 42) The product of formula (I) as defined in any one of the claims, corresponding to formula (IC): in which YC and Y1C are such that one represents a hydrogen atom, a halogen atom or an amino radical and the other is chosen from -0CF3, -0-CF2-CHF2, -0-CHF2, -0-CH2-CF3 , -SF5, -S(0)n-CF3, -S(0)n-Alk, -S02CHF2, S02CF2CF3, -S02NH2, -S-CF2-CF2-CF3, -S-Alk-0-Alk, -S-Alk-OH, -S-Alk-CN, -S-Alk-morpholino, -S-Alk-pyrrolidyl and -S-Alk-piperazinyl, the morpholino, pyrrolidyl and piperazinyl radicals being optionally substituted with Alk, with Alk representing an alkyl radical containing from 1 to 4 carbon atoms, or alternatively the phenyl radical forms with its substituents YC and Y1C one of the two following radicals: with Alk representing an alkyl radical containing from 1 to 4 carbon atoms, R2C and R3C, which may be identical or different, represent hydrogen or optionally substituted alkyl, or alternatively R2C and R3C, which may be identical or different, represent hydrogen or optionally substituted alkyl or alternatively R2C and R3C form, together with the carbon atom to which they are attached, a C3-C10 cycloalkyl or heterocycloalkyl radical, A2C represents a single bond or CH2, B2C represents pyridyl, pyrimidyl, quinolyl, azaindolyl, quinazolyl, thiazolyl, imidazolyl, pyrazolyl, furazanyl, isoxazolyl, morpholinyl, pyrrolidyl, furyl, piperidyl, chromenyl, oxochromenyl, quinazolyl, thienyl, indolyl, pyrrolyl, purinyl, benzoxazinyl, benzimidazolyl or benzofuryl radicals, optionally substituted with one or more radicals chosen from the values of Y2A, Y2CA represents hydrogen, halogen, hydroxyl, cyano, alkyl, alkoxy, phenyl, COOH, COOAlk, CONR5R6, NR5R6, -NR10-COOH, -NR10-COOAlk, -NR10-CO-R6, -NR10-CS-NR5R6, -NR10-CO-NR5R6 or -NR10-SO2-R6, all these radicals being optionally substituted, R5 and R6, which may be identical or different, are chosen from hydrogen, alkyl, cycloalkyl, phenyl, pyrimidyl, thienyl, pyridyl, quinolyl, thiazolyl and pyran, all these radicals being optionally substituted, or alternatively R5 and R6 form, with the nitrogen atom to which they are attached, an optionally substituted pyrrolidyl, piperidyl, piperazinyl, morpholinyl or quinazolinyl radical, RIO represents hydrogen or alkyl, all the alkyl, alkoxy, cycloalkyl and phenyl radicals above, and also the ring formed by R5 and R6 with the atom to which they are attached, being optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and the following radicals: cyano; hydroxyl; alkyl; alkoxy; 0CF3; CF3; S(0)n-CF3; nitro; oxo; thioxo; OCOAlk; phenyl, itself optionally substituted with one or more radicals chosen from halogen atoms and alkyl and alkoxy radicals; -OCOAlk; NH2, NHAlk, N(Alk)2, N(alk)(phenylalkyl), N(Alk)(aminoalkyl) N(Alk)(alkylaminoalkyl) N(Alk) (dialkylaminoalkyl) ; carboxyl in free form or esterified with an alkyl radical, all the phenyl radicals above also being optionally substituted with an alkylenedioxy radical, all the alkyl radicals above also being optionally substituted with one or more radicals chosen from the following radicals: piperazinyl, itself optionally substituted with Alk, Alk-OH and pyridyl; imidazolyl; morpholinyl; pyrrolidyl; piperidyl, itself optionally substituted with one or two alk; azepanyl optionally substituted with oxo, all the pyrrolidyl and quinazolinyl radicals above also being optionally substituted with oxo or thioxo, all the alkyl and alkoxy radicals above being linear or branched and containing not more than 6 carbon atoms, all the cycloalkyl radicals above containing not more than 7 carbon atoms, n represents an integer from 0 to 2, said products of formula (IC) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (IC) . 43) The product of formula (I) as defined in any one of the claims, corresponding to formula (IA): in which: Y1A represents -0CF3, S(0)n-CF3 and S02CHF2, B2a represents 4-quinolyl and 4-pyridyl radicals optionally substituted with one or more radicals chosen from the values of Y2A, Y2A has the meaning given in any one of the claims for Y2, R2A and R3A, which may be identical or different, represent hydrogen or optionally substituted alkyl, or alternatively R2A and R3A form, together with the carbon atom to which they are attached, a C3-C10 cycloalkyl or heterocycloalkyl radical, all the alkyl and phenyl radicals being optionally substituted with one or more radicals chosen from halogen, OH, alk, Oalk, 0CF3, S(0)n-CF3, CF3, NH2, NHAlk and N(alk)2, n represents an integer fom 0 to 2, said product of formula (IA) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said product of formula (IA). 44) The product of formula (IA) as defined in the preceding claim, in which Y1A, B2a, R2A and R3A have the meanings given above and Y2A represents halogen, -OH, -alk, Oalk, -Oacyl, -NR5AR6A, -C02H, -C02alk, -C0- NR5AR6A, -S(0)n-CF3, -NH-S(0)n-CF3 or phenyl radicals, alk representing a linear or branched alkyl radical containing not more than 6 carbon atoms, all the alkyl, alkoxy and phenyl radicals being optionally substituted, R5A and R6A, which may be identical or different, represent hydrogen, alkyl, cycloalkyl or phenyl, the alkyl and phenyl radicals being optionally substituted, or alternatively R5A and R6A form, with the nitrogen atom to which they are attached, a cyclic radical chosen from pyrrolidyl, piperidyl, piperazinyl, morpholinyl, piperazinyl, indolinyl, pyrindolinyl, tetrahydroquinolyl and azetidinyl radicals, all the alkyl, alkoxy and phenyl radicals being optionally substituted with one or more radicals chosen from halogen, OH, alk, Oalk, 0CF3, S(0)n-CF3, CF3, NH2, NHAlk and N(alk) 2, n represents an integer from 0 to 2, said product of formula (IA) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said product of formula (IA). 45) The product of formula (I) as defined in any one of the claims, corresponding to formula (IA) in which: Y1A represents -0CF3, SCF3 or S(0)2-CF3, B2a represents a 4-quinolyl or 4-pyridyl radical optionally substituted with one or two radicals chosen from halogen, -OH, alk, -Oalk, -C02H, -C02alk, -NR5AR6A, -CF3, -0CF3 and optionally substituted phenyl, R5A and R6A, which may be identical or different, represent hydrogen, alkyl, cycloalkyl or phenyl, the alkyl and phenyl radicals being optionally substituted, or alternatively R5A and R6A form, with the nitrogen atom to which they are attached, a cyclic radical chosen from pyrrolidyl, piperidyl, piperazinyl, morpholinyl, piperazinyl and azetidinyl radicals, R2A and R3A, which may be identical or different, represent hydrogen or optionally substituted alkyl, or alternatively R2A and R3A form, together with the carbon atom to which they are attached, a C3-C6 cycloalkyl or heterocycloalkyl radical, all the alkyl and phenyl radicals being optionally substituted with one or more radicals chosen from halogen, OH, alk, Oalk, 0CF3, S(0)n-CF3, CF3, NH2, NHalk and N(alk)2, said product of formula (IA) being in any possible, racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said product of formula (IA) . 46) The product of formula (I) as defined in any one of the claims, corresponding to formula (IA) in which: Y1A represents -0CF3, SCF3 or S(0)2-CF3, B2a represents a 4-quinolyl or 4-pyridyl radical optionally substituted with one or two radicals chosen from halogen, -OH, alk and -Oalk, R2A and R3A, which may be identical or different, represent hydrogen and linear or branched alkyl containing not more than 4 carbon atoms optionally substituted with a hydroxyl radical, or alternatively R2A and R3A form, together with the carbon atom to which they are attached, a C3-C6 cycloalkyl radical, said product of formula (IA) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said product of formula (IA). 47) The product of formula (I) as defined in any one of the claims, corresponding to formula (IA) in which Yla represents 0CF3, SCF3 or S (0)2CF3 and R2A and R3A, which may be identical or different, represent hydrogen and CH3, or alternatively R2A and R3A form, together with the carbon atom to which they are attached, a cyclopropyl radical, the other substituents having the values given in any one of the claims, said product of formula (IA) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said product of formula (IA). 48) The product of formula (I) as defined in any one of the claims, corresponding to formula (IB): in which R2, R3, Al, Y, Yl, A2, B2 and Y2 have the meanings given in any one of the claims, said product of formula (IB) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said product of formula (IB). 49) The product of formula (IB) as defined in the preceding claim, in which Yl represents 0CF3, SCF3 or S(0)2CF3 and R2 and R3, which may be identical or different, represent hydrogen and CH3 or, alternatively R2 and R3 form, together with the carbon atom to which they are attached, a cyclopropyl radical, the other substituents having values given in any one of the claims, said product of formula (IB) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said product of formula (IB). 50) The product of formula (I) as defined in any one of the claims, the names of which are below: (S)-5-methyl-l-quinol-4-ylmethyl-3-(4-trifluoromethane- sulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate (S)-5-methyl-l-pyrid-4-ylmethyl-3-(4-trifluoromethane- sulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate (S)-5-methyl-l-quinol-4-ylmethyl-3-(4-trifluoromethyl- sulfanylphenyl)imidazolidine-2,4-dione trifluoroacetate - 5,5-dimethyl-l-quinol-4-ylmethyl-3-(4-trifluoromethane- sulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate (R)-5-methyl-l-quinol-4-ylmethyl-3-(4-trifluoromethane-sulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate - (R)-5-methyl-l-quinol-4-ylmethyl-3-(4-trifluoromethyl-sulfanylphenyl)imidazolidine-2,4-dione trifluoroacetate - (R)-5-methyl-l-pyrid-4-ylmethyl-3-(4-trifluoromethane-sulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate - (R)-5-methyl-l-(3-methylpyrid-4-ylmethyl)-3-(4-tri-fluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate - (R)-4-methyl-3-quinol-4-ylmethyl-5-thioxo-l-(4-tri-fluoromethylsulfanylphenyl)imidazolidin-2-one trifluoroacetate - (R)-5-isopropyl-l-quinol-4-ylmethyl-3-(4-trifluoro- methylsulfanylphenyl)imidazolidine-2,4-dione trifluoroacetate - (R)-5-isopropyl-l-quinol-4-ylmethyl-3-(4-trifluoro- methanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate - (R)-5-(4-hydroxy-benzyl)-l-quinol-4-ylmethyl-3-(4-tri-fluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate - (R)-5-(4-hydroxy-benzyl)-l-pyrid-4-ylmethyl-3-(4-tri-fluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate - (R)-5-(1-hydroxy-ethyl)-l-quinol-4-ylmethyl-3- (4-tri-fluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate - 4-quinol-4-ylmethyl-6-(4-trifluoromethylsulfanylphenyl) -4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate - 4-quinol-4-ylmethyl-6-(4-trifluoromethanesulfonyl- phenyl)-4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate - 4-pyrid-4-ylmethyl-6-(4-trifluoromethylsulfanylphenyl)- 4,6-diazaspiro [2.4]heptane-5,7-dione trifluoroacetate - 4-pyrid-4-ylmethyl-6-(4-trifluoromethanesulfonyl- phenyl)-4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate - (R)-1-(3-hydroxypyrid-4-ylmethyl)-5-methyl-3-(4-tri fluoromethylsulf anylphenyl) imidazolidine-2,4-dione trifluoroacetate - 5,5-dimethyl-l-quinol-4-ylmethyl-3-(4-trifluoromethoxy- phenyl)imidazolidine-2,4-dione trifluoroacetate 5,5-dimethyl-l-quinol-4-ylmethyl-3-(4-trifluoromethylsulf anylphenyl) imidazolidine-2,4-dione trifluoroacetate - 5,5-dimethyl-1-(3-methylpyrid-4-ylmethyl)-3-(4-tri- fluoromethoxyphenyl)imidazolidine-2,4-dione trifluoroacetate - 5,5-dimethyl-1-(3-methylpyrid-4-ylmethyl)-3-(4-trifluoromethylsulf anylphenyl) imidazolidine-2,4-dione trifluoroacetate - 5,5-dimethyl-1-(3-methylpyrid-4-ylmethyl)-3-(4-tri-fluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate 1-(3-hydroxypyrid-4-ylmethyl)-5,5-dimethyl-3- (4-tri-fluoromethoxyphenyl)imidazolidine-2,4-dione trifluoroacetate 1-(3-hydroxypyrid-4-ylmethyl)-5,5-dimethyl-3-(4-trifluoromethylsulf anylphenyl) imidazolidine-2,4-dione trifluoroacetate 1-(3-hydroxypyrid-4-ylmethyl)-5,5-dimethyl-3-(4-tri-fluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate 4-quinol-4-ylmethyl-6-(4-trifluoromethoxyphenyl)-4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate 4-(3-methylpyrid-4-ylmethyl)-6-(4-trifluoromethylsulf-anylphenyl)-4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate 4-(3-hydroxypyrid-4-ylmethyl)-6-(4-urifluoromethoxy-phenyl)-4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate, - 4-(3-hydroxypyrid-4-ylmethyl)-6-(4-trifluoromethylsulf-anylphenyl)-4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate 4-(3-hydroxypyrid-4-ylmethyl) -6-(4-trifluoromethane-sulfonylphenyl)-4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate, said product of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said product of formula (I). 51) The product of formula (I) as defined in any one of the claims, the names of which are given below: {4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethyl]pyrid-2-yl}cyclo-propanecarboxamide trifluoroacetate; - 5,5-dimethyl-1- [2-(pyrid-2-ylamino)pyrid-4-ylmeth-yl]-3 -(4-trifluoromethylsulfanylphenyl)imidazolidine-2,4-dione; compound with trifluoroacetic acid; - N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethyl]pyrid-2-yl}isobutyramide; compound with trifluoroacetic acid; - N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethyl]pyrid-2-yljpropionamide; compound with trifluoroacetic acid; - 1-(2-aminopyrid-4-ylmethyl)-5,5-dimethyl-3-(4-tri-fluoromethylsulfanylphenyl)imidazolidine-2,4-dione hydrochloride; loromethyl-yl}pyrid- - N- ^4- lb , i-aimeunyi-z , I-UIUAU-J - v±-UJ-J.J_j-uoromethyl-sulf anylphenyl) imidazolidin-1-ylmethyl]pyrid-2-yl}-3-piperid-1-ylpropionamide trifluoroacetate; - N-{4- [5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethyl]pyrid-2-yl}-3- [4-(2-hydroxyethyl)piperazin-1-yl]propionamide trifluoroacetate; - N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethyl]pyrid-2-yl}-3-morpholin-4-ylpropionamide trifluoroacetate; - N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethyl] pyrid-2-yl}-3-pyrrolidin-1-ylpropionamide trifluoroacetate; - N-{4- [5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethyl]pyrid-2-yl}-3-(4-methylpiperazin-1-yl)propionamide trifluoroacetate; - 1-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethyl]pyrid-2-yl}-3-phenylurea; 1- [2- (6-ethylpyrid-2-ylamino)pyrid-4-ylmethyl]-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)imidazol-idine-2,4-dione; 5,5-dimethyl-l-[2-(4-methylpyrid-2-ylamino)pyrid-4-ylmethyl]-3-(4-trifluoromethylsulfanylphenyl)imidazol idine-2 ,4-dione; 5,5-dimethyl-l-[2-(6-methylpyrid-2-ylamino)pyrid-4-ylmethyl]-3-(4-trifluoromethylsulfanylphenyl)imi-dazolidine-2,4-dione; 1- [2- (4,6-dimethylpyrid-2-ylamino)pyrid-4-ylmeth-yl] -5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione; 1- [2-(3,5-dichloropyrid-2-ylamino)pyrid-4-ylmeth-yl]-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione; - 5,5-dimethyl-l-[2-(pyrid-4-ylamino)pyrid-4-ylmeth-yl] -3-(4-trifluoromethylsulfanylphenyl)imidazolidine-2,4-dione; - 5, 5-dimethyl-l- [2- (pyrid-3-ylamino) pyrid-4-ylmeth-yl]-3-(4-trifluoromethylsulfanylphenyl)imidazolidine-2,4-dione; - N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethyl]pyrid-2-yl}-3-(2-oxoazepan-1-yl)propionamide; 3-(benzylmethylamino)-N-{4-[5,5-dimethyl-2,4-di-oxo-3-(4-trifluoromethylsulfanylphenyl)imidazolidin-1-ylmethyl]pyrid-2-yl}propionamide; - 4,5-diacetoxy-6-acetoxymethyl-2-(3-{4-[5,5-dimeth- yl-2, 4-dioxo-3-(4-trifluoromethylsulfanylphenyl)- imidazolidin-1-ylmethyl]pyrid-2-yl}thioureidoacetic acid; 5,5-dimethyl-l-[2-(5-methylpyrid-2-ylamino)pyri-din-4-ylmethyl]-3-(4-trifluoromethylsulfanylphenyl)imidazolidine-2 ,4-dione; - N-{4- [5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethyl sulf anylphenyl) imidazolidin-1-ylmethyl]pyrid-2-yl}-3,5- dimethoxybenzamide trifluoroacetate; 5,5-dimethyl-l-[2-(pyrazin-2-ylamino)pyrid-4-yl-methyl]-3-(4-trifluoromethylsulfanylphenyl)imidazolidine-2,4-dione trifluoroacetate; - N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethyl]pyrid-2-yl}-3-(3-methylpiperid-1-yl)propionamide trifluoroacetate; - N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethyl]pyrid-2-yl}-3- (3,5-dimethylpiperid-1-yl)propionamide trifluoroacetate; - N-{4- [5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethyl sulf anylphenyl) imidazolidin-1-ylmethyl]pyrid-2-yl}-3- methoxybenzamide trifluoroacetate; {4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl) imidazolidin-1-ylmethyl]pyrid-2-yl}pyr-azine-2-carboxamide trifluoroacetate; {4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl) imidazolidin-1-ylmethyl]pyrid-2-yl}thio-phene-2-carboxamide trifluoroacetate; - N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethyl sulf anylphenyl) imidazolidin-1-ylmethyl] pyrid-2-yl}-4- methylbenzamide; compound with trifluoroacetic acid; l-isoquinolin-5-yl-5,5-dimethyl-3-(4-trifluoromethylsulf anylphenyl) imidazolidine-2,4-dione; - 3-(4-acetylpiperazin-l-yl)-N-{4-[5,5-dimethyl-2,4- dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazolidin-1- ylmethyl]pyrid-2-yl}propionamide; 3-[4-(2-diethylaminoethyl)piperazin-l-yl]-N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl) imidazolidin-1-ylmethyl]pyrid-2-yl}propionamide; - N-{4- [5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethyl sulf anylphenyl) imidazolidin-1-ylmethyl]pyrid-2-yl}-3- (2,6-dimethylmorpholin-4-yl)propionamide; - N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethyl]pyrid-2-yl}-3- (4-pyrrolidin-l-ylpiperid-l-yl)propionamide; - N- {4- [5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethyl]pyrid-2-yl}-2-(4-pyrrolidin-1-ylpiperid-l-yl)acetamide; 5,5-dimethyl-l-[2-(4-methylpyrid-3-ylamino)pyrid-4-ylmethyl]-3-(4-trifluoromethylsulfanylphenyl)imidazolidine-2 ,4-dione; 5,5-dimethyl-l-[2-(6-morpholin-4-ylpyrid-3-yl-amino)pyrid-4-ylmethyl]-3-(4-trifluoromethylsulfanylphenyl) imidazolidine-2,4-dione; 1- [2-(2,6-dimethylpyrid-3-ylamino)pyrid-4-ylmeth-yl] -5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)imidazolidine-2 ,4-dione; methyl 5-{4- [5,5-dimethyl-2,4-dioxo-3-(4-tri-fluoromethylsulfanylphenyl)imidazolidin-1-ylmethyl]pyrid-2-ylamino}pyridine-2-carboxylate; - 1-[2-(2,6-dimethoxypyrid-3-ylamino)pyrid-4-ylmeth-yl] -5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)imid-azolidine-2,4-dione; 1-[2-(6-fluoropyrid-3-ylamino)pyrid-4-ylmethyl]-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)imidazol-idine-2,4-dione; 1-[2-(6-methoxypyrid-3-ylamino)pyrid-4-ylmethyl]-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)imidazol-idine-2,4-dione, said products of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said product of formula (I). 52) As a medicinal product, the product of formula (I) as defined in claims 1 to 51, and also the prodrugs thereof, the said product of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with pharmaceutically acceptable mineral and organic acids or with pharmaceutically acceptable mineral and organic bases of said product of formula (I). 53) As a medicinal product, the product of formula (IC) as defined in the preceding claims, and also the prodrugs thereof, said product of formula (IC) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with pharmaceutically acceptable mineral and organic acids or with pharmaceutically acceptable mineral and organic bases of said product of formula (IC). 54) As a medicinal product, the product of formula (IA) as defined in the preceding claims, and also the prodrugs thereof, the said product of formula (IA) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with pharmaceutically acceptable mineral and organic acids or with pharmaceutically acceptable mineral and organic bases of said product of formula (IA). 55) As a medicinal product, the product as defined in claim 50 or 51, and the prodrugs thereof, and the addition salts with pharmaceutically acceptable mineral and organic acids or with pharmaceutically acceptable mineral and organic bases of these products. 56) A pharmaceutical composition containing, as active principle, at least one of the medicinal products as defined in claims 52 to 55. 57) A pharmaceutical composition containing, as active principle, at least one of the medicinal products as defined in claim 44. 58) The pharmaceutical composition as defined in the claims, also containing active principles of other chemotherapy medicinal products for combating cancer. 59) The pharmaceutical composition as claimed in any one of the claims, characterized in that it is used as a medicinal product, in particular for cancer chemotherapy. 60) The use of the product of formula (I) as defined in any one of the claims or of pharmaceutically acceptable salts of said product of formula (I) for the preparation of medicinal products for inhibiting the activity of protein kinases and especially of a protein kinase. 61) The use of a product of formula (I) as defined in the preceding claim or of pharmaceutically acceptable salts of said product of formula (I) in which the protein kinase is a protein tyrosine kinase. 62) The use of a product of formula (I) as defined in any one of the claims or of pharmaceutically acceptable salts of said product of formula (I) , in which the protein kinase is chosen from the following group: EGFR, Fak, FLK-1, FGFR1, FGFR2, FGFR3, FGFR4, FGFR5, fit-1, IGF-1R, KDR, PLK, PDGFR, tie2, VEGFR, AKT, Raf. 63) The use of a product of formula (I) as defined in any one of the claims or of pharmaceutically acceptable salts of the said product of formula (I) in which the protein kinase is IGF1R. 64) The use of a product of formula (I) as defined in any one of the claims or of a pharmaceutically acceptable salt of said product of formula (I) in which the protein kinase is FAK. 65) The use of a product of formula (I) as defined in any one of the claims or of a pharmaceutically acceptable salt of said product of formula (I) in which the protein kinase is AKT. 66) The use of a product of formula (I) as defined in any one of the claims or of a pharmaceutically acceptable salt of said product of formula (I) in which the protein kinase is in a cell culture. 67) The use of a product of formula (I) as defined in any one of the claims or of a pharmaceutically acceptable salt of said product of formula (I) in which the protein kinase is in a mammal. 68) The use of a product of formula (I) as defined in any one of the claims or of pharmaceutically acceptable salts of said product of formula (I), for the preparation of a medicinal product for preventing or treating a disease characterized by the deregulation of the activity of a protein kinase. 69) The use of a product of formula (I) as claimed in the preceding claim, in which the disease to be prevented or treated is in a mammal. 70) The use of a product of formula (I) as defined in any one of the claims or of pharmaceutically acceptable salts of said product of formula (I), for the preparation of a medicinal product for preventing or treating a disease belonging to the following group: disorders of blood vessel proliferation, fibrotic disorders, disorders of mesangial cell proliferation, metabolic disorders, allergies, asthma, thrombosis, diseases of the nervous system, retinopathy, psoriasis, rheumatoid arthritis, diabetes, muscle degeneration, oncology diseases and cancers. 71) The use of a product of formula (I) as defined in any one of the claims or of a pharmaceutically acceptable salt of said product of formula (I) , for the preparation of a medicinal product for treating oncology diseases. 72) The use of a product of formula (I) as defined in any one of the claims or of pharmaceutically acceptable salts of said product of formula (I) for the preparation of a medicinal product for treating cancers. 73) The use of a product of formula (I) as claimed in the preceding claim, in which the disease to be treated is a cancer of solid tumors. 74) The use of a product of formula (I) as claimed in the preceding claim, in which the disease to be treated is a cancer that is resistant to cytotoxic agents. 75) The use of a product of formula (I) as defined in any one of the claims or of a pharmaceutically acceptable salt of said product of formula (I) for the preparation of a medicinal product for treating cancers including breast cancer, stomach cancer, cancer of the colon, lung cancer, cancer of the ovaries, cancer of the uterus, brain cancer, cancer of the kidney, cancer of the larynx, cancer of the lymphatic system, cancer of the thyroid, cancer of the urogenital tract, cancer of the tract including the seminal vesicle and prostate, bone cancer, cancer of the pancreas and melanomas. 76) The use of a product of formula (I) as claimed in the preceding claim, in which the disease to be treated is a breast cancer, cancer of the colon or lung cancer. 77) The use of a product of formula (I) as defined in any one of the claims, or of a pharmaceutically acceptable salt of said product of formula (I) , for the preparation of a medicinal .. product for cancer chemotherapy. 78) The use of a product of formula (I) as defined in any one of the claims or of a pharmaceutically acceptable salt of said product of formula (I), for the preparation of a medicinal product for cancer chemotherapy, used alone or in combination. 79) The use of a product of formula (I) as defined in any one of the claims or of a pharmaceutically acceptable salt of said product of formula (I) for the preparation of a medicinal product to be used alone or in combination with a chemotherapy or radiotherapy, or alternatively in combination with other therapeutic agents. 80) The use of a product of formula (I) as claimed in the preceding claim, in which the therapeutic agents may be commonly used antitumor agents. 81) The product of formula (I) as defined in any one of the claims, as protein kinase inhibitor, said product of formula * (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with pharmaceutically acceptable mineral and organic acids or with pharmaceutically acceptable mineral and organic bases of said product of formula (I) , and also prodrugs thereof. 82) The product of formula (I) as defined in any one of the claims, as an IGF1R inhibitor. 83) The product of formula (IA) as defined in the claims, as an IGF1R inhibitor. ABSTRACT The invention relates to novel products having formula (I), wherein: p denotes 0 to 2; R and Rl denote O or NH; R2 and R3 denote hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl and heteroaryl, or R2 and R3, together with the carbon atom to which they are bound, form a carbocyclic or heterocyclic radical, all of said radicals being optionally substituted; Al denotes a single bond, alkyl, allyl and propynyl; Y and Yl denote H, OCF3, S(0)nCF3, S(0)nAlk, S02CHF2, S02CF2CF3, -0-CF2-CHF2, -0-CHF2, -0-CH2-CF3, SF5 and S02NR5R6, whereby R5 and R6 are selected from among hydrogen, alkyl, alkenyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl and heteroaryl, which are optionally substituted, or R5 and R6, together with N to which they are bound, form a heterocyclic radical; A2 denotes Al, CO and S02; B2 denotes a heterocyclic radical which is optionally substituted with one or more substituents which are selected from the values of Y2; Y2 denotes hydrogen, halogen, hydroxyl, cyano, alkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -O-alkenyl, -O-alkynyl, O-cycloalkyl, S(0)n-alkyl, -S(0)n-alkenyl, -S(0)n-alkynyl, S(0)n-cycloalkyl, -COOR13,-OCOR13, NR5R6, CONR5R6, S(O)n-NR5R6,-NR10-CO-R13, -NR10-SO2-R13, -NH-S02-NR5R6, -NR10-CO-NR5R6, -NR10-CS-NR5R6, -NR10-COOR13, all of said radicals being optionally substituted; and n denotes an integer of between 0 and 2. The aforementioned products are in all the isomeric forms and the salts thereof for use as medicaments. NOVEL CYCLIC UREA DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE OF THE SAME AS KINASE INHIBITORS The present invention relates to nbvel cyclic urea derivatives, to a process for preparing them, to their use as medicinal products, to pharmaceutical compositions containing them and to the pharmaceutical use of such derivatives for preventing and treating, complaints that may be modulated by inhibiting the activity of protein kinases. The present invention relates to novel cyclic urea derivatives that have inhibitory effects on protein kinases. The products of the present invention may thus be used especially for preventing or treating complaints capable of being modulated by inhibiting the activity of protein kinases. The inhibition and regulation of protein kinases especially constitute a powerful new mechanism of action for treating a large number of solid tumors. Such complaints that the products of the present patent application can treat are thus most particularly solid tumors. Such protein kinases belong especially to the following group: EGFR, Fak, FLK-1, FGFR1, FGFR2, FGFR3, FGFR4, FGFR5, flt-1, IGF-IR, KDR, PLK,PDGFR, tie2, VEGFR, AKT, Raf. The protein kinase IGF1-R (Insulin Growth Factor-1 Receptor) is particularly indicated. The protein kinase FAK is also indicated. The protein kinase AKT is also indicated. The present invention thus relates particularly to novel inhibitors of the IGF-IR receptor that may be used for oncology treatments. The present invention also relates to novel FAK receptor inhibitors that may be used for oncology treatments. The present invention also relates to novel AKT receptor inhibitors that may be used for oncology treatments. Cancer remains a disease for which the existing treatments are clearly insufficient. Certain protein kinases, especially including IGF-1R (Insulin Growth Factor 1 Receptor) , play an important role in many cancers. The inhibition of such protein kinases is potentially important in the chemotherapy of cancers, especially for suppressing the growth or survival of tumors. The present invention thus relates to the identification of novel products that inhibit such protein kinases. Protein kinases participate in signaling events that control the activation, growth and differentiation of cells in response either to extracellular mediators or to changes in the environment. In general, these kinases belong to two groups: those that preferentially phosphorylate serine and/or threonine residues and those that preferentially phosphorylate tyrosine residues [S.K. Hanks and T. Hunter, FASEB. J., 1995, 9, pages 576-596] . The serine/threonine kinases are, for example, the isoforms of the protein kinases C [A.C. Newton, J. Biol. Chem., 1995, 270, pages 28495-28498] and a group of cycline-dependent kinases, for instance cdc2 [J. Pines, Trends in Biochemical Sciences, 1995, 18, pages 195-197]. Tyrosine kinases comprise growth factor receptors, for instance the epidermal growth factor (EGF) receptor [S. Iwashita and M. Kobayashi, Cellular Signalling, 1992, 4, pages 12 3-132], and cytosol kinases, for instance p56tck, p59fYn and ZAP-70 and the kinases csk [C. Chan et. al., Ann. Rev. Immunol., 1994, 12, pages 555-592]. Abnormally high levels of kinase protein activity have been implicated in many diseases, resulting from abnormal cellular functions. This may arise either directly or indirectly from a dysfunction in the mechanisms for controlling the kinase activity, linked, for example, to a mutation, an overexpression or an inappropriate activation of the enzyme, or an over- or underproduction of cytokines or of growth factors, also involved in the transduction of the signals upstream or downstream of the kinases. In all these cases, a selective inhibition of the action of the kinases offers hope of a beneficial effect. The type 1 receptor for in the insulin-like growth factor (IGF-I-R) is a transmembrane receptor with tyrosine kinase activity which binds firstly to IGFI, but also to IGFI I and to insulin with lower affinity. The binding of IGFI to its receptor results in oligomerization of the receptor, the activation of tyrosine kinase, intermolecular autophosphorylation and the phosphorylation of cell substrates (main substrates: IRS1 and She) . The receptor activated by its ligand induces mitogenic activity in normal cells. However, IGF-I-R plays an important role in "abnormal" growth. Several clinical reports underline the important role of the IGF-1 route in the development of human cancers: IGF-I-R is often found overexpressed in many types of tumor (breast, colon, lung, sarcoma, etc.) and its presence is often associated with a more aggressive phenotype. High concentrations of circulating IGFI are strongly correlated with a risk of prostate cancer, lung cancer and breast cancer. Furthermore, it has been widely documented that IGF-I-R is necessary for establishing and maintaining the transformed phenotype in vitro as in vivo [Baserga R, Exp. Cell. Res., 1999, 253, pages 1-6]. The kinase activity of IGF-I-R is essential for the transformation activity of several oncogenes: EGFR, PDGFR, the large T antigen of the SV40 virus, activated Ras, Raf, and v-Src. The expression of IGF-I-R in normal fibroblasts induces a neoplastic phenotype, which may then result in the formation of a tumor in vivo. The expression of IGF-I-R plays an important role in substrate-independent growth. IGF-I-R has also been shown to be a protector in chemotherapy-induced and radiation-induced apoptosis, and cytokine-induced apoptosis. Furthermore, the inhibition of endogenous IGF-I-R with a negative dominant, the formation of a triple helix or the expression of an antisense sequence brings about suppression of the transforming activity in vitro and reduction of tumor growth in animal models. Among the kinases for which a modulation of the activity is desired, FAK (Focal Adhesion Kinase) is also a preferred kinase. FAK is a cytoplasmic tyrosine kinase that plays an important role in tranducing the signal transmitted by the integrins, a family of heterodimeric receptors of cellular adhesion. FAK and the integrins are colocalized in perimembrane structures known as adhesion plaques. It has been shown in many cell types that the activation of FAK and its phosphorylation on tyrosine residues and in particular its autophosphorylation on tyrosine 397 were lependent on the binding of the integrins to their extracellular ligands and thus induced during cellular idhesion [Kornberg L, and al. J. Biol. Chem. 267(33) : 13439-442 (1992)]. The autophosphorylation on tyrosine -97 of FAK represents a binding site for another tyrosine :inase, Src, via its SH2 domain [Schaller et al. Mol. 'ell. Biol. 14 : 1680-1688 1994 ; Xing et al. Mol. Cell. iol. 5 : 413-421 1994] . Src can then phosphorylate FAK n tyrosine 925, thus recruiting the adapter protein Grb2 and inducing in certain cells activation of the ras and MAP kinase pathway involved in controlling cellular proliferation [Schlaepfer et al. Nature ; 372 : 786-791 1994; Schlaepfer et al. Prog. Biophy. Mol. Biol. 71: 435-478 1999 ; Schlaepfer and Hunter, J. Biol. Chem. 272: 13189-13195 1997]. The activation of FAK can thus induce the jun Nonterminal kinase (JNK) signaling pathway and result in the progression of the cells to the Gl phase of the cellular cycle [Oktay et al., J. Cell. Biol.145: 1461-1469 1999]. Phosphatidylinositol-3-OH kinase (PI3-kinase) also binds to FAK on tyros ine 3 97 and thi s interact ion might be necessary for the activation of PI3-kinase [Chen and Guan, Proc. Nat. Acad. Sci. USA. 91: 10148-10152 1994/ Ling et al. J. Cell. Biochem. 73: 533-544 1999]. The FAK/Src complex phosphorylates various substrates, for instance paxillin and pl3 0CAS in fibroblasts [Vuori et al. Mol. Cell. Biol. 16: 2606-2613 1996]. The results of numerous studies support the hypothesis that FAK inhibitors might be useful in treating cancer. Studies have suggested that FAK might play an important role in in vitro cell proliferation and/or survival. For example, in CHO cells, certain authors have demonstrated that the overexpression of pi 2 5 FAK induces an acceleration of the Gl to S transition, suggesting that pl25FAK promotes cellular proliferation [Zhao J.-H et al. J. Cell Biol. 143: 1997-2008 1998]. Other authors have shown that tumor cells treated with FAK antisense oligonucleotides lose their adhesion and go into apoptosis (Xu et al, Cell Growth Differ. 4: 413-418 1996) . It has also been demonstrated that FAK promotes the migration of cells in vitro. Thus, fibroblasts that are deficient for the expression of FAK ("knockout" mice for FAK) show a rounded morphology and deficiencies in cell migration in response to chimiotactic signals, and these defects are suppressed by reexpression of FAK [DJ. Sieg et al. , J. Cell Science. 112: 2677-91 1999] . The overexpression of the C-terminal domain of FAK (FRNK) blocks the stretching of adherent cells and reduces cellular migration in vitro [Richardson A. and Parsons J.T. Nature. 380: 538-540 1996], The overexpression of FAK in CHO or COS cells or in human astrocytoma cells promotes migration of the cells. The involvement of FAK in promoting the proliferation and migration of cells in numerous cell types in vitro suggests the potential role of FAK in neoplastic processes. A recent study has effectively demonstrated the increase in the proliferation of tumor cells in vivo after induction of the expression of FAK in human astrocytoma cells [Cary L.A. et al. J. Cell Sci. 109: 1787-94 1996; Wang D et al. J. Cell Sci. 113: 4221-4230 2000] . Furthermore, immunohistochemical studies on human biopsies have demonstrated that FAK is overexpressed in prostate cancer, breast cancer, thyroid cancer, cancer of the colon, melanoma, brain cancer and lung cancer, the level of expression of FAK being directly correlated to the tumors having the most aggressive phenotype [Weiner TM, et al. Lancet. 342 (8878): 1024-1025 1993; Owens et al. Cancer Research. 55: 2752-2755 1995; Maung K. et al. Oncogene 18: 6824-6828 1999; Wang D et al. J. Cell Sci. 113: 4221-4230 2000]. Protein kinase AKT (also known as PKB) and phosphoinositide 3-kinase (PI3K) are involved in a cell signaling pathway that transmits signals from growth factors activating membrane receptors. This transduction pathway is involved in numerous cellular functions: regulation of apoptosis, control of transcription and translation, glucose metabolism, angiogenesis and mitochondrial integrity. First identified as an important component of insulin-dependent signaling pathways regulating metabolic responses, serine/threonine kinase AKT was then identified as a mediator playing a key role in survival induced with growth factors. It has been shown that AKT can inhibit death by apoptosis induced by various stimuli, in a certain number of cell types and tumor cells. In accordance with these findings, it has been shown that AKT can, by phosphorylation of given serine residues, inactivate BAD, GSK3(3, caspase-9, and Forkhead transcription factor, and can activate IKKalpha and e-NOS. It is interesting to note that the protein BAD is found hyper-phosphorylated in 11 human tumor cell lines out of 41 studied. Furthermore, it has been shown that hypoxia modulates the induction of VEGF in cells transformed with Ha-ras by activating the PI3K/AKT pathway and by involving the binding sequence of the HIF-1 (hypoxia inducible factor-1) transcription factor known as HRE for nhypoxy-responsive element". AKT plays a very important role in cancer pathologies. The amplification and/or overexpression of AKT has been reported in many human tumors, for instance gastric carcinoma (amplification of AKT1), ovary carcinoma, breast carcinoma or pancreatic carcinoma (amplification and overexpression of AKT2) and breast carcinomas deficient in estrogen receptors, and also androgen-independent prostate carcinomas (overexpression of AKT3). Furthermore, AKT is constitutively activated in all the PTEN (-/-) tumors, the PTEN phosphatase being deleted or inactivated by mutations in many types of tumors, for instance carcinomas of the ovary, of the prostate, of the endometrium, glioblastomas and melanomas. AKT is also involved in the oncogenic activation of bcr-abl (references: Khawaja A. , Nature 1999, 401, 33-34; Cardone et al. Nature 1998, 282, 1318-1321; Kitada S. et al., Am J Pathol 1998 Jan; 152(1): 51-61; Mazure NM et al. Blood 1997, 90, 3322-3331; Zhong H. et al. Cancer Res. 2000, 60, 1541-1545). One subject of the present invention is thus the products of general formula (I) : in which p represents an integer from 0 to 2, R and Rl, which may be identical or different, represent 0 or NH, R2 and R3, which may be identical or different, represent hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl and heteroaryl which are optionally substituted, or alternatively R2 and R3 form, together with the carbon atom to which they are attached, a carbocyclic or heterocyclic radical, these radicals being 3 - to 10 - membered and the heterocyclic radical containing one or more hetero atoms chosen from 0, S, N and NR7, all these radicals optionally being substituted, Al represents a single bond, an alkyl radical or an allyl or propynyl radical, Y and Yl, which may be identical or different, are such that one from among Y and Yl is chosen from 0CF3, -0-CF2-CHF2, -0-CHF2, -0-CH2-CF3, S02NR5R6, SF5 and -S(0)n-alkyl and the other from among Y and Yl is chosen from these same values and in addition from the following values: hydrogen, halogen, hydroxyl, alkoxy, nitro, CN, NR5R6, optionally substituted alkyl, optionally substituted aryl and heteroaryl, CF3, O-alkenyl, O-alkynyl, O-cycloalkyl, S(O)n-alkenyl, S(0)n-alkynyl, S(0)n-cycloalkyl, free, salified or esterified carboxyl and CONR5R6, or alternatively the phenyl radical forms with its substituents Y and Yl the following radicals: with p representing the integer 2, 3 or 4, the radical thus formed being optionally substituted with one or more alkyl radicals that are themselves optionally substituted, R5 and R6, which may be identical or different, are chosen from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl and heteroaryl, which are optionally substituted, or alternatively R5 and R6 form, with the nitrogen atom to which they are attached, a 3- to 10-membered heterocyclic radical containing one or more hetero atoms chosen from 0, S, N and NR7, which is optionally substituted, A2, which may be identical to or different from Al, represents the values of Al and CO and S02, B2 represents a saturated or unsaturated monocyclic or bicyclic heterocyclic radical containing 1 or more identical or different hetero atoms chosen from 0, S, N and NR7, optionally substituted with one or more identical or different substitutents chosen from the values of Y2, R7 represents a hydrogen atom or an alkyl, cycloalkyl, phenyl, acyl, S(0)2Alk, S(0)2Aryl, S(0)2heteroaryl or S(0)2NR5R6 radical, Y2 represents hydrogen, halogen, hydroxyl, cyano, alkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aryl, heteroaryl, -0-alkenyl, -0-alkynyl, -O-cycloalkyl, -S(O)n-alkyl, -S(0)n-alkenyl, -S(0)n-alkynyl, S(0)n-cycloalkyl, C00R13, -0C0R13, NR5R6, CONR5R6, S(0)n-NR5R6, -NR10-CO-R13, -NR10-SO2-R13, NH-S02-NR5R6, -NR10-CO-NR5R6, -NR10-CS-NR5R6, -NR10-C00R13, all these radicals optionally being substituted, all the alkyl, alkenyl, alkynyl and alkoxy radicals above being linear or branched and containing not more than 6 carbon atoms, all the cycloalkyl and heterocycloalkyl radicals above containing not more than 7 carbon atoms, all the aryl and heteroaryl radicals above containing not more than 10 carbon atoms, all the carbocyclic and heterocyclic alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl and heteroaryl radicals above, and also the ring formed by R5 and R6 with the atom to which they are attached, optionally being substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and cyano, hydroxyl, alkoxy, CF3, nitro, aryl, heteroaryl, -C(=0)-0R9, -C(=0)-R8, -NR11R12, -C(=0)- NR11R12, -N(R10)-C(=0)-R8, -N(R10)-C(=0)-0R9, N(R10)-C(=0)-NR11R12, -N(R10)-S(0)n- R8, -S(0)n-R8, -N(R10) -S (0) n-NRHR12 or -S (0) n-NRHR12 radicals, all the aryl and heteroaryl radicals above furthermore being optionally substituted with one or more radicals chosen from alkyl, alkoxy and alkylenedioxy radicals, all the cyclic radicals above, and also the ring formed by R5 and R6 with the atom to which they are attached, being moreover optionally substituted with one or more radicals chosen from oxo and thioxo, n represents an integer from 0 to 2, R8 represents alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl, R9 represents the values of R8 and hydrogen, RIO represents hydrogen or alkyl, Rll and R12, which may be identical or different, represent hydrogen, C3-C6 cycloalkyl, C1-C4 alkyl and phenyl, optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and cyano, hydroxyl, alkoxy, CF3, nitro, phenyl and free, salified, esterified or amidated carboxyl radicals, or alternatively Rll and R12 form, with the nitrogen atom to which they are attached, a 5- to 7-membered cyclic radical containing one or more hetero atoms chosen from 0, S, N and NR7 and preferably a cyclic amine, R13, which may be identical to or different than R5 or R6, being chosen from the values of R5 or R6, it being understood that the products of formula (I) are as defined below from a) to d): a) when p represents the integer 0, R represents oxygen, Rl represents oxygen, Al represents a single bond or alkyl, Y and Yl, which may be identical or different, are such that at least one represents 0CF3 or Salk, A2 represents a single bond or alkyl and B2 represents an optionally substituted heterocyclic radical, then R2 and R3 do not represent one hydrogen and the other imidazolylalkyl, b) when p represents the integer 0, R and Rl represent oxygen, Al represents a single bond or alkyl, Y and Yl, which may be identical or different, are such that at least one represents 0CF3, SOAlk, S (0)2alk or S02NH2, A2 represents CH2 and B2 represents an optionally substituted heterocyclic radical, then R2 and R3 do not represent one hydrogen and the other an alkyl chain optionally interrupted with 0, S or Nalk always substituted with a hydroxamate -CO-NHOH c) when p represents the integer 0, R and Rl represent oxygen, Al represents a single bond or alkyl, Y and Yl, which may be identical or different, are such that at least one represents S (0)nAlk, A2 represents a single bond and B2 represents an optionally substituted 5- or 6-membered aromatic heterocyclic radical, then R2 and R3 are not chosen from hydrogen, alkyl, arylalkyl, aryl and heteroaryl, d) when p represents an integer from 0 to 2, R and Rl represent oxygen, Al represents a single bond, Y and Yl, which may be identical or different, are such that one represents S02Alk or S02NH2 and the other represents NR5R6, A2 represents a single bond or alkylene and B2 represents an optionally substituted 5- to 10-membered heterocyclic radical, then R2 and R3 do not both represent hydrogen, said products of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (I) . A subject of the present invention is thus the products of general formula (I) as defined above in which p represents an integer from 0 to 2, R and Rl, which may be identical or different, represent 0 or NH, R2 and R3, which may be identical or different, represent hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl and heteroaryl which are optionally substituted, or alternatively R2 and R3 form, together with the carbon atom to which they are attached, a carbocyclic or heterocyclic radical, these radicals being 3- to 10- membered and the heterocyclic radical containing one or more hetero atoms chosen from 0, S, N and NR7, all these radicals optionally being substituted, Al represents a single bond, an alkyl radical or an allyl or propynyl radical, Y and Yl, which may be identical or different, are such that one from among Y and Yl is chosen from 0CF3, S (0)nCF3, S(0)nAlk, S02CHF2, S02CF2CF3 and S02NR5R6 and the other from among Y and Yl is chosen from these same values and in addition from the following values: hydrogen, halogen, hydroxyl, alkoxy, NR5R6, optionally substituted alkyl, optionally substituted aryl and heteroaryl, CF3 , 0-allyl, O-propynyl, O-cycloalkyl, S(0)n-allyl, S(0)n-propynyl, S(0)n-cycloalkyl, free, salified or esterified carboxyl and CONR5R6 in which R5 and R6, which may be identical or different, are chosen from hydrogen, alkyl, alkenyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl and heteroaryl, which are optionally substituted, or alternatively R5 and R6 form, with the nitrogen atom to which they are attached, a 3- to 10-membered heterocyclic radical containing one or more hetero atoms chosen from 0, S, N and NR7, which is optionally substituted, A2, which may be identical to or different from Al, represents the values of Al and CO and S02, B2 represents a saturated or unsaturated heterocyclic radical containing 1 or more identical or different hetero atoms chosen from 0, S, N and NR7, optionally substituted with one or more identical or different substitutents chosen from the values of Y2, R7 represents a hydrogen atom or an alkyl, cycloalkyl, phenyl, aryl, S(0)2alk, S(0)2aryl, S(0)2heteroaryl or S(0)2NRSR6 radical, Y2 represents hydrogen, halogen, hydroxyl, alkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, 0-allyl, O-propynyl, O-cycloalkyl, S(O)n-alkyl, S(O)n-allyl, S(O)n-propynyl, S (0)n-cycloalkyl, C00R9, 0C0R8, NR5R6, CONR5R6, S(0)n-R5R6, NHC0R8, NH-S(0)nR8 or NH-S(0)nCF3 or NH-S02-NR5R6, all these radicals being optionally substituted, all the alkyl, alkenyl, alkynyl and alkoxy radicals above being linear or branched and containing not more than 6 carbon atoms, all the cycloalkyl and heterocycloalkyl radicals above containing not more than 7 carbon atoms, all the aryl and heteroaryl radicals above containing not more than 10 carbon atoms, all the carbocyclic and heterocyclic alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl and heteroaryl radicals above optionally being substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and cyano, hydroxyl, alkoxy, CF3, nitro, aryl, heteroaryl, -C(=0)-0R9, -C(=0)-R8, -NR11R12, -C(=0)-NR11R12, -N(R10)-C(=0)-R8, -N(R10)-C(=0)-OR9, N(R10)-C(=0)-NR11R12, -N(R10)-S(0)n- R8, -S(0)n-R8, -N(R10) -S (0) n-NRHR12 or -S (0) n-NRHR12 radicals, all the aryl and heteroaryl radicals above furthermore being optionally substituted with one or more radicals chosen from alkyl and alkylenedioxy radicals, n represents an integer from 0 to 2, R8 represents alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl, R9 represents the values of R8 and hydrogen, RIO represents hydrogen or alkyl, Rll and R12, which may be identical or different, represent hydrogen, C3-C6 cycloalkyl, C1-C4 alkyl and phenyl, optionally substituted with one or. more radicals, which may be identical or different, chosen from halogen atoms and cyano, hydroxyl, alkoxy, CF3, nitro, phenyl and free, salified, esterified or amidated carboxyl radicals, or alternatively Rll and R12 form, with the nitrogen atom to which they are attached, a 5- to 7-membered cyclic radical containing one or more hetero atoms chosen from 0, S, N and NR7 and preferably a cyclic amine, it being understood that the products of formula (I) are as defined below from a) to d): a) when p represents the integer 0, R represents oxygen, Rl represents oxygen, Al represents a single bond or alkyl, Y and Yl, which may be identical or different, are such that at least one represents 0CF3 or Salk, A2 represents a single bond or alkyl and B2 represents an optionally substituted heterocyclic radical, then R2 and R3 do not represent one hydrogen and the other imidazolylalkyl, b) when p represents the integer 0, R and Rl represent oxygen, Al represents a single . bond or alkyl, Y and Yl, which may be identical or different, are such that at least one represents 0CF3, SOAlk, S (0)2alk or S02NH2, A2 represents CH2 and B2 represents an optionally substituted heterocyclic radical, then R2 and R3 do not represent one hydrogen and the other an alkyl chain optionally interrupted with 0, S or Nalk always substituted with a hydroxamate -CO-NHOH c) when p represents the integer 0, R and Rl represent oxygen, Al represents a single bond or alkyl, Y and Yl, which may be identical or different, are such that at least one represents S(0)nAlk, A2 represents a single bond and B2 represents an optionally substituted 5- or 6-membered aromatic heterocyclic radical, then R2 and R3 are not chosen from hydrogen, alkyl, arylalkyl, aryl and heteroaryl, d) when p represents an integer from 0 to 2, R and Rl represent oxygen, Al represents a single bond, Y and Yl, which may be identical or different, are such that one represents S02Alk or S02NH2 and the other represents NR5R6, A2 represents a single bond or alkylene and B2 represents an optionally substituted 5- to 10-membered heterocyclic radical, then R2 and R3 do not both represent hydrogen, said products of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (I) . One subject of the present invention is thus the products of general formula (I) as defined above in which p represents an integer from 0 to 2, R and Rl, which may be identical or different, represent 0 or NH, R2 and R3, which may be identical or different, represent hydrogen, alkyl, alkenyl, cycloalkyl, phenyl and heteroaryl, which are optionally substituted, or alternatively R2 and R3 form, together with the carbon atom to which they are attached, a carbocyclic or heterocyclic radical, these radicals being from 3- to 10-membered and the heterocyclic radical containing one or more hetero atoms chosen from 0, S, N and NR7, all these radicals being optionally substituted, Al represents a single bond, an alkyl radical or an allyl or propynyl radical, Y and Yl, which may be identical or different, are such that one from among Y and Yl is chosen from 0CF3, S(0)nCF3, S(0)nAlk, S02CHF2, S02CF2CF3 and S02NR5R6 and the other from among Y and Yl is chosen from these same values and in addition from the following values: hydrogen, halogen, hydroxyl, alkoxy, NR5R6, optionally substituted alkyl and phenyl, and optionally substituted pyrazolyl and pyridyl, with R5 and R6, which may be identical or different, chosen from hydrogen, alkyl, alkenyl, cycloalkyl, heterocycloalkyl, phenyl and heteroaryl, which are optionally substituted, or alternatively R5 and R6 form, with the nitrogen atom to which they are attached, a 3- to 10-membered heterocyclic radical containing one or more hetero atoms chosen from 0, S, N and NR7, which are optionally substituted, A2, which may be identical to or different than Al, represents the values of Al and CO and S02, B2 represents a saturated or unsaturated heterocyclic radical containing one or more identical or different hetero atoms chosen from 0, S, N and NR7, optionally substituted with one or more identical or different substituents chosen from the values of Y2, R7 represents a hydrogen atom or an alkyl, cycloalkyl or phenyl radical, Y2 represents hydrogen, halogen, hydroxyl, alkyl, alkoxy, cycloalkyl, heterocycloalkyl, phenyl, heteroaryl, O-cycloalkyl, S(0)n-alk, S (0)n-cycloalkyl, C00R9, 0C0R8, NR5R6, CONR5R6, S(0)n-R5R6, NHC0R8 and NH-S(0)nR8, all these radicals being optionally substituted, all the above alkyl, alkenyl, alkynyl and alkoxy radicals being linear or branched and containing up to 6 carbon atoms, all the above cycloalkyl and heterocycloalkyl radicals containing up to 7 carbon atoms, all the above aryl and heteroaryl radicals containing up to 10 carbon atoms, all the above alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, carbocyclic and heterocyclic radicals being optionally substituted with one or more identical or different radicals chosen from halogen atoms and cyano, hydroxyl, alkoxy, CF3, nitro, phenyl, heteroaryl, -C(=0)-0R9, -C(=0)-R8, -NR11R12, -C(=0)-NR11R12, -N(R10)-C(=0)-R8, -N(R10)-C(=0)-0R9, N(R10)-C(=0)-NR11R12, -N(R10)- S(0)n-R8, -S(0)n-R8, -N(R10) -S (O) n-NRHR12 and -S(0)n- NR11R12, all the aryl and heteroaryl radicals above moreover being optionally substituted with one or more radicals chosen from alkyl and alkylenedioxy radicals, n represents an integer from 0 to 2, R8 represents alkyl, cycloalkyl, cycioalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, phenyl and phenylalkyl, R9 represents the values of R8 and hydrogen, RIO represents hydrogen or alkyl, Rll and R12, which may be identical or different, represent hydrogen, C1-C4 alkyl and phenyl, optionally substituted with one or more identical or different radicals chosen from halogen atoms and hydroxyl, alkoxy, CF3, nitro, phenyl and free, salified, esterified or amidated carboxyl radicals, or alternatively Rll and R12 form, with the nitrogen atom to which they are attached, a 5- to 7-membered cyclic radical containing one or more hetero atoms chosen from 0, S, N and NR7 and preferably a cyclic amine, it being understood that the products of formula (I) are as defined below from a) to d): a) when p represents the integer 0, R represents Oxygen, Rl represents Oxygen, Al represents a single bond or alkyl, Y and Yl, which may be identical or different, are such that at least one represents 0CF3 or Salk, A2 represents a single bond or alkyl and B2 represents an optionally substituted heterocyclic radical, then R2 and R3 do not represent a hydrogen for one and imidazolylalkyl for the other, b) when p represents the integer 0, R and Rl represent Oxygen, Al represents a single bond or alkyl, Y and Yl, which may be identical or different, are such that at least one represents OCF3, SOAlk, S(O)2alk or S02NH2, A2 represents CH2 and B2 represents an optionally substituted heterocyclic radical, then R2 and R3 do not represent a hydrogen atom for one and, for the other, an alkyl chain optionally interrupted with 0, S, Nalk always substituted with a hydroxamate -CO-NHOH, c) when p represents the integer 0, R and Rl represent Oxygen, Al represents a single bond or alkyl, Y and Yl, which may be identical or different, are such that at least one represents S(0)nAlk, A2 represents a single bond and B2 represents an optionally substituted 5- or 6-membered aromatic heterocyclic radical, then R2 and R3 are not chosen from hydrogen, alkyl, arylalkyl, aryl and heteroaryl, d) when p represents an integer from 0 to 2, R and Rl represent oxygen, Al represents a single bond, Y and Yl, which may be identical or different, are such that one represents S02Alk or S02NH2 and the other represents NR5R6, A2 represents a single bond or alkylene and B2 represents an optionally substituted 5- to 10-membered heterocyclic radical, then R2 and R3 do not both represent hydrogen, said products of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (I) . One subject of the present invention is thus the products of formula (I) as defined above in which Y and Yl, which may be identical or different, are such that one from among Y and Yl is chosen from 0CF3, -0-CF2-CHF2, -0-CHF2, -0-CH2-CF3, S(0)nCF3, -S-CF2-CF2-CF3, -S(0)n-Alk, -S-Alk-0-Alk, -S-Alk-OH, -S-Alk-CN, -S-Alk-heterocycloalkyl, -S02CHF2, -S02CF2CF3, -S02NR5R6 and -SF5, with Alk representing an alkyl radical containing from 1 to 4 carbon atoms, and the other from among Y and Yl is chosen from the following values: hydrogen, halogen, nitro, NR5R6, free or esterified carboxyl and CONR5R6, or alternatively the phenyl radical forms with its substituents Y and Yl one of the following radicals: the radical thus formed being optionally substituted with one or more alkyl radicals that are themselves optionally substituted, the other substituents on said products of formula (I) being chosen from the values defined in claim 1 and it being understood that: a) when p represents the integer 0, R represents oxygen, Rl represents Oxygen, Al represents a single bond or alkyl, Y and Yl, which may be identical or different, are such that one represents hydrogen and the other represents OCF3 or Salk, A2 represents a single bond or alkyl and B2 represents an optionally substituted heterocyclic radical, then R2 and R3 do not represent hydrogen for one and imidazolylalkyl for the other, b) when p represents the integer 0, R and Rl represent Oxygen, Al represents a single bond or alkyl, Y and Yl, which may be identical or different, are such that one represents hydrogen and the other represents 0CF3, SOAlk, S(0)2alk or S02NH2, A2 represents CH2 and B2 represents an optionally substituted heterocyclic radical, then R2 and R3 do not represent hydrogen for one and, for the other, an alkyl chain optionally interrupted with O, S, Nalk always substituted with a hydroxamate-CO-NHOH, c) when p represents the integer 0, R and Rl represent Oxygen, Al represents a single bond or alkyl, Y and Yl, which may be identical or different, are such that one represents hydrogen and the other represents S(0)nAlk, A2 represents a single bond and B2 represents an optionally substituted 5- or 6-membered aromatic heterocyclic radical, then R2 and R3 are not chosen from hydrogen, alkyl, arylalkyl, aryl and heteroaryl, said products of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (I) . A subject of the present invention is thus the products of general formula (I) as defined above in which one from among Y and Yl represents a hydrogen atom and the other is chosen from 0CF3, S(0)nCF3, S(0)nAlk, S02CHF2, S02CF2CF3 and S02NR5R6, the other substituents of said products of formula (I) being chosen from the values defined above, it being understood that: a) when p represents the integer 0, R represents oxygen, Rl represents oxygen, Al represents a single bond or alkyl, Y and Yl, which may be identical or different, are such that one represents hydrogen and the other represents 0CF3 or Salk, A2 represents a single bond or alkyl and B2 represents an optionally substituted heterocyclic radical, then R2 and R3 do not represent one hydrogen and the other imidazolylalkyl, b) when p represents the integer 0, R and Rl represent oxygen, Al represents a single bond or alkyl, Y and Yl, which may be identical or different, are such that one represents hydrogen and the other represents 0CF3, SOAlk, S(0)2alk or S02NH2, A2 represents CH2 and B2 represents an optionally substituted heterocyclic radical, then R2 and R3 do not represent one hydrogen and the other an alkyl chain optionally interrupted with 0, S or Nalk always substituted with a hydroxamate -CO-NHOH c) when p represents the integer 0, R and Rl represent oxygen, Al represents a single bond or alkyl, Y and Yl, which may be identical or different, are such that one represents hydrogen and the other represents S(0)nAlk, A2 represents a single bond and B2 represents an optionally substituted 5- or 6-membered aromatic heterocyclic radical, then R2 and R3 are not chosen from hydrogen, alkyl, arylalkyl, aryl and heteroaryl, said products of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (I) . A subject of the present invention is thus the products of general formula (I) as defined above in which one from among Y and Yl represents a hydrogen atom and the other is chosen from S(0)nCF3, SOAlk, S(0)2Alk, S02CHF2, S02CF2CF3 and S02NR5R6, the other substituents of said products of formula (I) being chosen from the values defined above and it being understood that the products of formula (I) are as defined below in a) and b): a) when p represents the integer 0, R and Rl represent. oxygen, Al represents a single bond or alkyl, Y and Yl, which may be identical or different, are such that one represents hydrogen and the other represents SOAlk, S(0)2alk or S02NH2, A2 represents CH2 and B2 represents an optionally substituted heterocyclic radical, then R2 and R3 do not represent one hydrogen and the other an alkyl chain optionally interrupted with O, S or Nalk always substituted with a hydroxamate -CO-NHOH b) when p represents the integer 0, R and Rl represent oxygen, Al represents a single bond or alkyl, Y and Yl, which may be identical or different, are such that one represents hydrogen and the other represents SOAlk or S(0)2Alk, A2 represents a single bond and B2 represents an optionally substituted 5- or 6-membered aromatic heterocyclic radical, then R2 and R3 are not chosen from hydrogen, alkyl, arylalkyl, aryl and heteroaryl, said products of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (I) . A subject of the present invention is thus the products of general formula (I) as defined above in which one from among Y and Yl represents a hydrogen atom and the other is chosen from S(0)nCF3, S02CHF2, S02CF2CF3 and S02NR5R6, the other substituents of said products of formula (I) being chosen from the values defined above and it being understood that when p represents the integer 0, R and Rl represent oxygen, Al represents a single bond or alkyl, Y and Yl, which may be identical or different, are such that one represents hydrogen and the other represents S02NH2, A2 represents CH2 and B2 represents an optionally substituted heterocyclic radical, then R2 and R3 do not represent one hydrogen and the other an alkyl chain optionally interrupted by 0, S or Nalk, always substituted with a hydroxamate -CO-NHOH said products of formula (I) being in any possible racemic, enantiomeric and diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (I) . In the products of formula (I) and subsequently, the terms indicated have the following meanings: the term "Hal", "Halo" or halogen denotes fluorine, chlorine, bromine or iodine atoms, - the term "alkyl", "alk", "Alk" or "ALK" denotes a linear or branched radical containing not more than 12 carbon atoms, chosen from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, sec-pentyl, tert-pentyl, neopentyl, hexyl, isohexyl, sec-hexyl, tert-hexyl, heptyl, octyl, nonyl, decyl, undecyl and dodecyl radicals, and also the linear or branched positional isomers thereof. Mention is made more particularly of alkyl radicals containing not more than 6 carbon atoms, and especially methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, linear or branched pentyl and linear or branched hexyl radicals. - the term "alkenyl radical" denotes a linear or branched radical containing not more than 12 carbon atoms and preferably 4 carbon atoms, chosen, for example, from the following values: ethenyl or vinyl, propenyl or allyl, 1-propenyl, n-butenyl, i-butenyl, 3-methyl-2- butenyl, n-pentenyl, hexenyl, heptenyl, octenyl, cyclohexylbutenyl and decenyl, and also the linear or branched positional isomerers thereof. Among the alkenyl values that may be mentioned particularly are the values allyl or butenyl. - the term "alkynyl radical" denotes a linear or branched radical containing not more than 12 carbon atoms and preferably 4 carbon atoms, chosen, for example, from the following values: ethynyl, propynyl or propargyl, butynyl, n-butynyl, i-butynyl, 3-methyl-2-butynyl, pentynyl or hexynyl, and also the linear or branched positional isomers thereof. Among the alkynyl values that are mentioned more particularly is the propargyl value. the term "alkoxy radical" denotes a linear or branched radical containing not more than 12 carbon atoms and preferably 6 carbon atoms chosen, for example, from methoxy, ethoxy, propoxy, isopropoxy, linear, secondary or tertiary butoxy, pentoxy, hexoxy and heptoxy radicals, and also the linear or branched positional isomers thereof, - the term "alkoxycarbonyl radical" or alkyl-O-CO-denotes a linear or branched radical containing not more than 12 carbon atoms, in which the alkyl radical has the meaning given above: examples that may be mentioned include methoxycarbonyl and ethoxycarbonyl radicals, - the term "alkylenedioxy radical" or -O-alkylene-0-denotes a linear or branched radical containing not more than 12 carbon atoms, in which the alkylene radical has the meaning given above: examples that may be mentioned include methylenedioxy and ethylenedioxy radicals, - the term "alkylsulfinyl" or alkyl-SO- denotes a linear or branched radical containing not more than 12 carbon atoms, in which the alkyl radical has the meaning given above and preferably contains 4 carbon atoms, - the term "alkylsulfonyl" or alkyl-S02- denotes a linear or branched radical containing not more than 12 carbon atoms, in which the alkyl radical has the meaning given above and preferably contains 4 carbon atoms, - the term "alkylsulfonylcarbamoyl" or alkyl-S02-NH-C(=0)- denotes a linear or branched radical containing not more than 12 carbon atoms, in which the alkyl radical has the meaning given above and preferably contains 4 carbon atoms, - the term "alkylthio" or alkyl-S- denotes a linear or branched radical containing not more than 12 carbon atoms and especially represents methylthio, ethylthio, isopropylthio and heptylthio radicals, - the term "cycloalkyl radical" denotes a 3- to 10-membered monocyclic or bicyclic carbocyclic radical and especially denotes cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl radicals, - the term "-0-cycloalkyl radical" denotes a radical in which the cycloalkyl radical has the meaning given above, - the term "cycloalkenyl radical" denotes a 3- to 10-membered monocyclic or bicyclic nonaromatic carbocyclic radical containing at least one double bond, and especially denotes cyclobutenyl, cyclopentenyl and cyclohexenyl radicals, the term "cycloalkylalkyl radical" denotes a radical in which cycloalkyl and alkyl are chosen from the values indicated above: this radical thus denotes, for example, cyclopropylmethyl, cyclopentylmethyl, cyclo-hexylmethyl and cycloheptylmethyl radicals, - the term "acyl radical" or r-CO- denotes a linear or branched radical containing not more than 12 carbon atoms, in which the radical r represents a hydrogen atom or an alkyl, cycloalkyl, cycloalkenyl, cycloalkyl, heterocycloalkyl or aryl radical, these radicals having the values indicated above and being optionally substituted as indicated: examples that are mentioned include the formyl, acetyl, propionyl, butyryl or benzoyl radical, or alternatively valeryl, hexanoyl, acryloyl, crotonoyl or carbamoyl, - the term "acyloxy radical" means acyl-O- radicals in which acyl has the meaning given above: examples that are mentioned include acetoxy or propionyloxy radicals, the term "acylamino radical" means acyl-NH-radicals in which acyl has the meaning given above, the term "aryl radical" denotes unsaturated monocyclic radicals or unsaturated radicals consisting of fused carbocyclic rings. Examples of such aryl radicals that may be mentioned include phenyl or naphthyl radicals. Mention is made more particularly of the phenyl radical. - the term "arylalkyl" means radicals resulting from the combination of the optionally substituted alkyl radicals mentioned above and the optionally substituted aryl radicals also mentioned above: examples that are mentioned include benzyl, phenylethyl, 2-phenethyl, triphenylmethyl or naphthalenemethyl radicals, the term "heterocyclic radical" denotes a saturated carbocyclic radical (heterocycloalkyl) or unsaturated carbocyclic radical (heteroaryl) which is at least 6-membered, interrupted with one or more hetero atoms, which may be identical or different, chosen from oxygen, nitrogen and sulfur atoms. Heterocycloalkyl radicals that may especially be ment ioned include dioxolane, dioxane, dithiolane, thiooxolane, thiooxane, oxiranyl, oxolanyl, dioxolanyl, piperazinyl, piperidyl, pyrrolidyl, imidazolidinyl, pyrazolidinyl, morpholinyl, or tetrahydrofuryl, tetrahydrothienyl, chromanyl, dihydrobenzofuranyl, indolinyl, piperidyl, perhydropyranyl, pyrindolinyl, tetrahydroquinolyl, tetrahydroisoquinolyl and thioazolidinyl radicals, all these radicals being optionally substituted. Among the heterocycloalkyl radicals that may especially be mentioned are optionally substituted piperazinyl, optionally substituted piperidyl, optionally substituted pyrrolidinyl, imidazolidinyl, pyrazolidinyl, morpholinyl and thioazolidinyl radicals and thioazolidinyl radicals: mention may be made even more particularly of optionally substituted morpholinyl, pyrrolidinyl and piperazinyl radicals; the term "heterocycloalkylalkyl radical" means radicals in which the heterocycloalkyl and alkyl residues have the above meanings; - among the 5-membered heteroaryl radicals that may be mentioned are furyl radicals such as 2-furyl, thienyl radicals such as 2-thienyl and 3-thienyl, and pyrrolyl, diazolyl, thiazolyl, thiadiazolyl, thiatriazolyl, isothiazolyl, oxazolyl, oxadiazolyl, 3 - or 4-isoxazolyl, imidazolyl, pyrazolyl and isoxazolyl radicals. Among the 6-membered heteroaryl radicals that may especially be mentioned are pyridyl radicals such as 2-pyridyl, 3-pyridyl and 4-pyridyl, and pyrimidyl, pyrimidinyl, pyridazinyl, pyrazinyl and tetrazolyl radicals; - as fused heteroaryl radicals containing at least one hetero atom chosen from sulfur, nitrogen and oxygen, examples that may be mentioned include benzothienyl such as 3-benzothienyl, benzofuryl, benzofuranyl, benzopyrrolyl, benzimidazolyl, benzoxazolyl, thionaphthyl, indolyl, purinyl, quinolyl, isoquinolyl and naphthyridinyl. Among the fused heteroaryl radicals that may be mentioned more particularly are benzothienyl, benzofuranyl, indolyl, quinolyl, benzimidazolyl, benzothiazolyl, furyl, imidazolyl, indolizinyl, isoxazolyl, isoquinolyl, isothiazolyl, oxadiazolyl, pyrazinyl, pyridazinyl, pyrazolyl, pyridyl, pyrimidinyl, pyrrolyl, quinazolinyl, 1,3,4-thiadiazolyl, thiazolyl and thienyl radicals and triazolyl groups, these radicals optionally being substituted as indicated for the heteroaryl radicals/ - the term "cyclic amine" denotes a 3- to 8-membered cycloalkyl radical in which one carbon atom is replaced i with a nitrogen atom, the cycloalkyl radical having the meaning given above and also possibly containing one or more other hetero atoms chosen from 0, S, S02, N and NR7 with R7 as defined above; examples of such cyclic amines that may be mentioned include pyrrolidyl, piperidyl, morpholinyl, piperazinyl, indolinyl, pyrindolinyl and tetrahydroquinolyl radicals. The term "patient" denotes human beings, but also other mammals. The term "prodrug" denotes a product that may be converted in vivo via metabolic mechanisms (such as hydrolysis) into a product of formula (I) . For example, an ester of a product of formula (I) containing a hydroxyl group may be converted by hydrolysis in vivo into its parent molecule. Alternatively, an ester of a product of formula (I) containing a carboxyl group may be converted by in vivo hydrolysis into its parent molecule. Examples of esters of the products of formula (I) containing a hydroxyl group that may be mentioned include the acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylenebis-P-hydroxynaphthoates, gentisates, isethionates, di-p-tolyltartrates, methanesulfonates, ethanesulfonates, benzenesulfonates, p-toluenesulfonates, cyclohexylsulfamates and quinates. Esters of products of formula (I) that are particularly useful, containing a hydroxyl group, may be prepared from acid residues such as those described by Bundgaard et. al. , J. Med. Chem. , 1989, 32, page 2503-2507: these esters especially include substituted (aminomethyl)benzoates, dialkylaminomethylbenzoates in which the two alkyl groups may be linked together or may be interrupted with an oxygen atom or with an optionally substituted nitrogen atom, ie. an alkylated nitrogen atom, or alternatively (morpholinomethyl)benzoates, eg. 3- or 4-(morpholinomethyl)benzoates, and (4-alkyl-piperazin-l-yl)benzoates, eg. 3- or 4-(4-alkylpiperazin-1-yl)benzoates. The carboxyl radical(s) of the products of formula (I) may be salified or esterified with various groups known to those skilled in the art, among which nonlimiting examples that may be mentioned include the following compounds: - among the salification compounds, mineral bases such as, for example, one equivalent of sodium, potassium, lithium, calcium, magnesium or ammonium, or organic bases such as, for example, methylamine, propylamine, trimethylamine, diethylamine, triethylamine, N,N-dimethylethanolamine, tris(hydroxymethyl)amino-methane, ethanolamine, pyridine, picoline, dicyclohexylamine, morpholine, benzylamine, procaine, lysine, arginine, histidine or N-methylglucamine, - among the esterification compounds, alkyl radicals to form alkoxycarbonyl groups such as, for example, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl or benzyloxycarbonyl, these alkyl radicals possibly being substituted with radicals chosen, for example, from halogen atoms and hydroxyl, alkoxy, acyl, acyloxy, alkylthio, amino or aryl radicals, such as, for example, in chloromethyl, hydroxypropyl, methoxymethyl, propionyloxymethyl, methylthiomethyl, dimethylaminoethyl, benzyl or phenethyl groups. The term "esterified carboxyl" means, for example, radicals such as alkyloxycarbonyl radicals, for example methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butyl or tert-butyloxycarbonyl, cyclobutyloxycarbonyl, cyclopentyloxycarbonyl or cyclohexyloxycarbonyl. Mention may also be made of radicals formed with readily cleavable ester residues, such as methoxymethyl or ethoxymethyl radicals; acyloxyalkyl radicals such as pivaloyloxymethyl, pivaloyloxyethyl, acetoxymethyl or acetoxyethyl/ alkyloxycarbonyloxyalkyl radicals such as methoxycarbonyloxy methyl or ethyl radicals, and isopropyloxycarbonyloxy methyl or ethyl radicals. A list of such ester radicals may be found, for example, in European patent EP 0 034 536. The term "amidated carboxyl" means radicals of the type -CONR5R6 as defined above: also intended are the radicals NCOR6R7 in which the radicals R6 and R7, which may be identical or different, represent a hydrogen atom or an alkyl radical containing from 1 to 4 carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl radicals and especially amino, alkylamino and dialkylamino radicals. The term "alkylamino radical" means linear or branched methylamino, ethylamino, propylamino or butylamino radicals. Alkyl radicals containing not more than 4 carbon atoms are preferred, the alkyl radicals possibly being chosen from the alkyl radicals mentioned above. The term Mialkylamino radical" means, for example, dimethylamino, diethylamino and methylthylamino radicals. As previously, alkyl radicals containing not more than 4 carbon atoms, chosen from the list indicated above, are preferred. The radicals NR5R6 or NR6R7 may also represent a heterocycle which may or may not comprise an additional hetero atom. Mention may be made of pyrrolyl, imidazolyl, indolyl, piperidyl, morpholinyl and piperazinyl radicals. The piperidyl, morpholinyl and piperazinyl radicals are preferred. The term "salified carboxyl" means the salts formed, for example, with one equivalent of sodium, potassium, lithium, calcium, magnesium or ammonium. Mention may also be made of the salts formed with organic bases such as methylamine, propylamine, trimethylamine, diethylamine and triethylamine. The sodium salt is preferred. When the products of formula (I) comprise an amino radical that may be salified with an acid, it is clearly understood that these acid salts also form part of the invention. Mention may be made of the salts obtained, for example, with hydrochloric acid or methanesulfonic acid. The addition salts with mineral or organic acids of the products of formula (I) may be, for example, the salts formed with hydrochloric acid, hydrobromic acid, hydriodic acid, nitric acid, sulfuric acid, phosphoric acid, propionic acid, acetic acid, trifluoroacetic acid, formic acid, benzoic acid, maleic acid, fumaric acid, succinic acid, tartaric acid, citric acid, oxalic acid, glyoxylic acid, aspartic acid, ascorbic acid, alkylmonosulfonic acids such as, for example, methanesulfonic acid, ethanesulfonic acid or propanesulfonic acid, alkyldisulfonic acids such as, for example, methanedisulfonic acid or a,p-ethanedisulfonic acid, arylmonosulfonic acids such as benzenesulfonic acid, and aryldisulfonic acids. It may be recalled that stereoisomerism may be defined in its broad sense as the isomerism of compounds having the same structural formulae but whose various groups are arranged differently in space, especially such as in monosubstituted cyclohexanes whose substituent may be in an axial or equatorial position, and the various possible rotational conformations of ethane derivatives. However, there is another type of stereoisomerism, due to the different spatial arrangements of fixed substituents, either on double bonds or on rings, which is often referred to as geometrical isomerism or cis-trans isomerism. The term "stereoisomer" is used in the present patent application in its broadest sense and thus relates to all the compounds indicated above. A subject of the invention is especially the products of formula (I) as defined above in which one from among Y and Yl represents a hydrogen atom and the other is chosen from S(0)nCF3, S02CHF2 and S02CF2CF3, the other substituents of said products of formula (I) being chosen from the values defined above, said products of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (I). A subject of the invention is especially the products of formula (I) as defined above such that all the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclo-alkyl, aryl or heteroaryl radicals defined above are optionally substituted with one or more radicals, which may be identical or different, chosen from halogen, cyano, hydroxyl, alkoxy, CF3, nitro, phenyl, carboxyl which is free, salified, esterified with an alkyl radical or amidated with a radical NRllaR12a, -C(=0)-R9a, -NRllaR12a, -C(=0)-NRllaR12a, -N(R10a)-C(=0)-R9a, -N(R10a)-C(=0)-OR8a, N(R10a)-C(=0)-NRllaR12a, -N(R10a)- S(0)n-R9a, -S(0)n-R9a, -N(R10a)-S(0)n-NRllaR12a or -S(0)n-NRllaR12a, all the aryl and heteroaryl radicals above furthermore being optionally substituted with an ethylenedioxy radical, R8a represents hydrogen, alkyl, alkenyl, phenyl, phenylalkyl, heteroaryl or heteroarylalkyl, R9a represents alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, phenyl, phenylalkyl, heteroaryl or heteroarylalkyl, RlOa represents hydrogen or alkyl, Rlla and R12a, which may be identical or different represent hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, phenyl, phenylalkyl, optionally substituted with one or more substituents, which may be identical or different, chosen from halogen, hydroxyl, C1-C4 alkyl or C1-C4 alkoxy, or alternatively Rlla and R12a form, with the nitrogen atom to which they are attached, a cyclic radical chosen from pyrrolidyl, piperidyl, piperazinyl, morpholinyl, indolinyl, pyrindolinyl, tetrahydroquinolyl, thiazolidinyl and naphthyridyl, said products of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (I). A subject of the invention is especially the products of formula (I) as defined above in such that p represents the integer 0, the other substituents of said products of formula (I) each having any one of the values defined above. A subject of the invention is especially the products of formula (I) as defined above such that p l represents the integer 1, the other substituents of said products of formula (I) having any one of the values defined above. A subject of the invention is especially the products of formula (I) as defined above such that p represents the integer 2, the other substituents of said products of formula (I) having the values defined in the present invention. A subject of the invention is especially the products of formula (I) as defined above such that Rl represents 0, the other substituents of said products of formula (I) having any one of the values defined above. A subject of the invention is especially the products of formula (I) as defined above such that R represents 0, the other substituents of said products of formula (I) having any one of the values defined above. A subject of the invention is especially the products of formula (I) as defined above such that R2 and R3, which may be identical or different, represent hydrogen, alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, phenyl, phenylalkyl, heterocycloalkyl, heterocyclo-alkylalkyl, heteroaryl and heteroarylalkyl, which are optionally substituted, or alternatively R2 and R3 form, together with the carbon atom to which they are attached, a carbocyclic or heterocyclic radical, these radicals being 3- to 10-membered and the heterocyclic radical containing one or more hetero atoms chosen from 0, S, N and NR7b, all these radicals being optionally substituted, all the above radicals being optionally substituted with one or more radicals chosen from halogen, cyano, hydroxyl, alkyl and alkoxy containing 1 to 4 carbon atoms, CF3, nitro, phenyl, carboxy which is free, salified, esterified with an alkyl radical or amidated with a radical NRllbR12b, -C(=0)-R9b, -NRllbR12b and -C(=0)-NRllbR12b, R7b represents a hydrogen atom, an alkyl radical or a phenyl radical, R9 represents hydrogen, alkyl, cycloalkyl, cycloalkyl- alkyl or phenyl, Rllb and R12b, which may be identical or different, represent hydrogen, alkyl, cycloalkyl or phenyl, or alternatively Rllb and R12b form, with the nitrogen atom to which they are attached, an optionally substituted piperazinyl radical, the other substituents of said products of formula (I) having any one of the values defined above. A subject of the invention is especially the products of formula (I) as defined above such that R2 and R3, which may be identical or different, are chosen from hydrogen, alkyl, phenylalkyl, pyridylalkyl and benzo-thienylalkyl, which are optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, alkyl and alkoxy radicals containing from one to 4 carbon atoms, or alternatively R2 and R3 form, together with the carbon atom to which they are attached, a 3- to 6-membered cycloalkyl or heterocycloalkyl radical containing a nitrogen atom, the other substituents of said products of formula (I) having any one of the values defined above. A subject of the invention is especially the products of formula (I) as defined above such that R2 and R3, which may be identical or different, are chosen from hydrogen, alkyl, hydroxyalkyl, phenylalkyl, hydroxy-phenylalkyl, pyridylalkyl, benzothienylalkyl or thienylbenzothienylalkyl, or alternatively R2 and R3 form, together with the carbon atom to which they are attached, a cycloalkyl radical containing from 3 to 6 carbon atoms or an azetidinyl, pyrrolidyl or piperidyl radical, the other substituents of said products of formula (I) having any one of the values defined above. A subject of the invention is especially the products of formula (I) as defined above such that R2 and R3, which may be identical or different, are chosen from hydrogen, alkyl, hydroxyalkyl, phenylalkyl and hydroxy-phenylalkyl, or alternatively R2 and R3 form, together with the carbon atom to which they are attached, a cycloalkyl radical containing from 3 to 6 carbon atoms. A subject of the invention is especially the products of formula (I) as defined above such that one from among R2 and R3 is chosen from hydrogen and a 1 ky 1, and the other from among R2 and R3 is chosen from all the values of R2 and R3, or alternatively R2 and R3 form, together with the carbon atom to which they are attached, a cycloalkyl radical containing from 3 to 6 carbon atoms, the other substituents of said products of formula (I) having any one of the values defined above. A subject of the invention is especially the products of formula (I) as defined above such that R2 and R3, which may be identical or different, represent hydrogen and alkyl, or alternatively R2 and R3 form, together with the carbon atom to which they are attached, a cycloalkyl radical containing from 3 to 6 carbon atoms, the other substituents of said products of formula (I) having any one of the values defined above. A subject of the invention is especially the products of formula (I) as defined above such that R2 and R3, which may be identical or different, represent hydrogen and CH3, or alternatively R2 and R3 form, together with the carbon atom to which they are attached, a cyclopropyl radical, the other substituents of said products of formula (I) having any one of the values defined above. A subject of the invention is especially the products of formula (I) as defined above such that Al represents a single bond and A2 is chosen from a single bond, a linear or branched alkyl radical containing not more than 6 carbon atoms and allyl, propynyl, C-0 and S02 radicals, the other substituents of said products of formula (I) having any one of the values defined above. A subject of the invention is especially the products of formula (I) as defined in the present invention such that Al represents a single bond and A2 is chosen from a single bond or alkyl, allyl, propynyl, C=0 and S02 radicals, the other substituents of said products of formula (I) having the values defined above. One subject of the invention is especially the products of formula (I) as defined above such that Al represents a single bond and A2 is chosen from alkyl, allyl, propynyl, C=0 and S02 radicals, the other substituents of said products of formula (I) having any one of the values defined above. A subject of the invention is especially the products of formula (I) as defined above such that Al represents a single bond and A2 represents un alkyl or C=0 radical, the other substituents of said products of formula (I) having any one of the values defined above. A subject of the invention is especially the products of formula (I) as defined above such that Al represents a single bond and A2 represents C=0, -CH2-CH2-or -CH2, the other substituents of said products of formula (I) having any one of the values defined above. A subject of the invention is especially the products of formula (I) as defined above such that Al represents a single bond and A2 represents -CH2, the other substituents of said products of formula (I) having any one of the values defined above. A subject of the invention is especially the products of formula (I) as defined above in which Y and Yl are such that one represents a hydrogen atom, a halogen atom or an amino radical and the other is chosen i from -0CF3, -0-CF2-CHF2, -0-CHF2, -0-CH2-CF3, -SF5, -S (0)n-CF3, -S (0)n-Alk, -S02CHF2 , S02CF2CF3, -S02NH2, -S-CF2-CF2-CF3, -S-Alk-0-Alk, -S-Alk-OH, -S-Alk-CN, -S-Alk-morpholino, -S-Alk-pyrrolidinyl and -S-Alk-piperazinyl, the morpholino, pyrrolidinyl and piperazinyl radicals being optionally substituted with Alk, with Alk representing an alkyl radical containing from 1 to 4 carbon atoms, the other substituents of said products of formula (I) being chosen from the values defined in the present invention. A subject of the invention is especially the products of formula (I) as defined above such that Y represents a hydrogen atom and Yl is chosen from -0CF3, S(0)n-CF3, S(0)n-CH3, S02CHF2 and S02NH2, the other substituents of said products of formula (I) having any one of the values defined above. A subject of the invention is especially the products of formula (I) as defined above such that Y represents a hydrogen atom and Yl is chosen from -0CF3, S(0)n-CF3 and S02CHF2, the other substituents of said products of formula (I) having any one of the values defined above. A subject of the invention is especially the products of formula (I) as defined above such that Y represents a hydrogen atom and Yl is chosen from -0CF3 and S(0)n-CF3, the other substituents of said products of formula (I) having any one of the values defined above. A subject of the invention is especially the products of formula (I) as defined above such that Y represents a hydrogen atom and Yl is chosen from -0CF3, S-CF3 and S (0)2-CF3, the other substituents of said products of formula (I) having any one of the values defined above. One subject of the invention is especially the products of formula (I) as defined above in which B2 represents a monocyclic or bicyclic heteroaryl radical chosen from pyridyl, pyrimidinyl, quinolyl, azaindolyl, lH-pyrrolo[2,3-b]pyridinyl, quinazolyl, thiazolyl, imidazolyl, pyrazolyl, furazanyl, isoxazolyl, morpholinyl, pyrrolidinyl, furyl, piperidyl, thienyl, chromenyl, oxochromenyl, indolyl, pyrrolyl, purinyl, benzoxazinyl, benzimidazolyl and benzofuranyl radicals, these radicals being optionally substituted with one or more radicals chosen from the values of Y2, the other substituents of said products of formula (I) having the values defined for the products of formula (I). A subject of the invention is especially the products of formula (I) as defined above such that B2 represents a heteroaryl radical chosen from 3- or 4-pyridyl, 3 - or 4-quinolyl, imidazolyl, thiazolyl, indolyl, pyrazolyl, pyrrolyl, pyrimidyl, purinyl, benzoxazinyl, benzimidazolyl and benzofuranyl radicals, these radicals being optionally substituted with one or more radicals chosen from the values of Y2, the other substituents of said products of formula (I) having any one of the values defined above. A subject of the invention is especially the products of formula (I) as defined above such that B2 represents a heteroaryl radical chosen from 4-pyridyl, 4-quinolyl, imidazolyl, thiazolyl, pyrazolyl, pyrrolyl, pyrimidyl and purinyl radicals, these radicals being optionally substituted with one or more radicals chosen from the values of Y2, the other substituents of said products of formula (I) having any one of the values defined above. In particular in the products of formula (I), B2 represents a heteroaryl radical chosen from 3- or 4-pyridyl, pyrimidinyl, 3 - or 4-quinolyl, azaindolyl, quinazolyl, thiazolyl, imidazolyl, pyrazolyl, furazanyl and isoxazolyl radicals, these radicals being optionally substituted with one or more radicals chosen from the values of Y2, the other substituents on said products of formula (I) having the values defined in the present invention. In particular in the products of formula (I) , B2 represents a heteroaryl radical chosen from 3- or 4-pyridyl, pyrimidinyl, 3- or 4-quinolyl, azaindolyl and quinazolyl radicals, these radicals being optionally substituted with one or more radicals chosen from the values of Y2, the other substituents on said products of formula (I) having the values defined in the present invention. A subject of the invention is the products of formula (I) as defined in the present invention such that B2 represents the 4-pyridyl and 4-quinolyl, 1H-pyrrolo[2,3-b]pyridine-4-yl radicals, optionally substituted with one or more radicals chosen from the values of Y2 defined in the present invention, the other substituents of said products of formula (I) having any one of the values defined in the present invention. In particular in the products of formula (I) of the present invention, Y2 may represent the 2-amino-4-pyridyl radical in which the amino radical is optionally substituted as indicated for the radical NR5R6 as defined above or below and in the experimental section, the other substituents on said products of formula (I) possibly taking the values as defined in the present invention for said substituents. In particular, the products of formula (I) of the present invention are such that Y2 represents hydrogen, halogen, hydroxyl, cyano, alkyl, alkoxy, phenyl, COOH, COOAlk, CONR5R6, NR5R6, -NR10-COOR6, -NR10-CO-R6, -NR10-CS-NR5R6, -NR10-CO-NR5R6 or -NR10-SO2-R6, all these radicals being optionally substituted, R5 and R6, which may be identical or different, are chosen from hydrogen, alkyl, cycloalkyl, phenyl and 5- or 6-membered heteroaryl radicals containing 1 to 3 hetero atoms chosen from 0, N and S, all these radicals being optionally substituted, or alternatively R5 and R6 form, with the nitrogen atom to which they are attached, an optionally substituted pyrrolidinyl, piperidyl, piperazinyl, morpholinyl or quinazolinyl radical, RIO represents hydrogen or alkyl, all the above alkyl, alkoxy, cycloalkyl and phenyl radicals, and also the ring formed by R5 and R6 with the atom to which they are attached, being optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and the following radicals: cyano; hydroxyl; alkyl; alkoxy; 0CF3; CF3; S(0)n-CF3; nitro; oxo; thioxo; OCOAlk; phenyl, itself optionally substituted with one or more radicals chosen from halogen atoms and alkyl and alkoxy radicals; -OCOAlk; NH2, NHAlk, N(Alk)2, N(alk)(phenylalkyl), N(Alk)(aminoalkyl), N(Alk)(alkylaminoalkyl), N(Alk)(dialkylaminoalkyl); carboxyl, free or esterified with an alkyl radical, all the above phenyl radicals moreover being optionally substituted with an alkylenedioxy radical, all the above alkyl radicals moreover being optionally substituted with one or more saturated or partially unsaturated, 4- to 7-membered heterocyclic radicals containing at least one nitrogen atom N and also 0 to 2 other hetero atoms chosen from 0, N and S, all the pyrrolidinyl and quinazolinyl radicals above moreover being optionally substituted with oxo or thioxo, all the above alkyl and alkoxy radicals being linear or branched and containing up to 6 carbon atoms, all the above cycloalkyl radicals containing up to 7 carbon atoms, the other substituents on said products of formula (I) having the values defined above. In particular, R5 and R6 may represent the following heteroaryl radicals: pyridyl, pyrazinyl, pyrimidinyl, thienyl, thiazolyl and oxazolyl, all these radicals being optionally substituted. In particular in the products of formula (I) of the present invention, the alkyl radicals may be substituted with heterocyclic radicals chosen from the following radicals: thiomorpholin-4-yl, thiazolidin-3-yl, azetidin-1-yl, piperazinyl, imidazolyl, morpholinyl, pyrrolidinyl, piperidyl and azepanyl radicals, all these radicals being optionally substituted as indicated above and especially with one or more radicals chosen from alkyl, hydroxyalkyl, oxo, pyridyl and phenyl optionally substituted with one or more radicals chosen from halogen atoms and alkyl, hydroxyl, alkoxy, CN, carboxyl or amino radicals, which are themselves optionally substituted. Mention may be made, for example, of piperazinyl radicals optionally substituted with Alk, Alk-OH, pyridyl or phenyl, itself optionally substituted with one or more radicals chosen from halogen atoms and alkyl, hydroxyl, alkoxy, CN, carboxyl and amino radicals, which are themselves optionally substituted; piperidyl optionally substituted with one or two Alk; azepanyl optionally substituted with oxo. One subject of the present invention is the products of formula (I) as defined above such that Y2 represents hydrogen, halogen, hydroxyl, cyano, alkyl, alkoxy, phenyl, CONR5R6, NR5R6, -NR10-COOH, -NRlO-COOAlk, -NR10-CO-R6, -NR10-CS-NR5R6, -NR10-CO-NR5R6 or -NR10-S02-R6, R5 and R6, which may be identical or different, are chosen from hydrogen; alkyl; cycloalkyl/ phenyl; pyrimidinyl; thienyl; pyridyl; quinolyl; thiazolyl optionally substituted with one or two halogen atoms; pyran optionally substituted with one or more OCOAlk; phenyl substituted with one or more radicals chosen from halogen atoms and alkyl, alkoxy, amino, alkylamino, dialkylamino and carboxyl which is free or esterified with an alkyl radical; alkyl substituted with phenyl, which is itself optionally substituted with one or more radicals chosen from halogen atoms, alkyl, alkoxy, amino, alkylamino, dialkylamino and carboxyl, which is free or esterified with an alkyl radical; alkyl substituted with piperazinyl, which is itself optionally substituted with one or more radicals chosen from Alk, Alk-OH and pyridyl; alkyl substituted with imidazolyl; alkyl substituted with one or more radicals chosen from NH2, NHAlk, N(Alk)2, N(alk)(phenylalkyl), N(Alk)(aminoalkyl), N(Alk)(alkyl-aminoalkyl) and N(Alk)(dialkylaminoalkyl); alkyl substituted with morpholinyl, which is optionally substituted with one or two Alk; alkyl substituted with pyrrolidinyl; alkyl substituted with piperidyl, which is itself optionally substituted with one or two Alk; alkyl substituted with thiomorpholinyl; alkyl substituted with azetidinyl; alkyl substituted with azepanyl, which is itself optionally substituted with oxo, or alternatively R5 and R6 form, with the nitrogen atom to which they are attached, a pyrrolidinyl; piperidyl; piperazinyl; morpholinyl; or quinazolinyl radical, all these radicals being optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and alkyl, hydroxy1 and alkoxy radicals and phenyl, which is itself optionally substituted with one or more radicals chosen from halogen atoms and alkyl and alkoxy radicals, the pyrrolidinyl and quinazolinyl radicals moreover being optionally substituted with oxo or thioxo, the piperazinyl radical itself being optionally substituted with one or more radicals chosen from Alk, Alk-OH and pyridyl, RIO represents hydrogen or alkyl, all the above alkyl or Alk and alkoxy radicals being linear or branched and containing up to 6 carbon atoms, all the above cycloalkyl radicals containing up to 7 carbon atoms, all the phenyl radicals moreover being optionally substituted with a radical chosen from CF3, -0CF3, nitro and alkylenedioxy, the other substituents on said products of formula (I) having any of the values defined above. Among the preferred structures of the present invention, mention may be made of the products of formula (1) whose three structures are given below, in which the values of NR14R15 are chosen from the values of NR5R6 and the values of the Alkyl, Aryl and Heteroaryl radicals are chosen from the values of the alkyl, aryl and heteroaryl radicals as defined above and optionally substituted as defined in the present invention. A subject of the invention is especially the products of formula (I) as defined above such that B2 represents 4-pyridyl and 4-quinolyl radicals, optionally substituted with one or more radicals chosen from the values of Y2, the other substituents on said products of formula (I) having any of the values defined above. A subject of the invention is especially the products of formula (I) as defined above such that Y2 represents VI, halogen, hydroxyl, -C(=NH)NH2, 0V1, 0-C0-V1, C00V1, C0V1, C0-NV1V2, -NV1V2, -NH-C0-V1, -NH-C00-V1, -NH-NH-C0-V1, -NV1-C0-NV1V2, -NV1-C0-NHV1, -NH-C0-NHV1, -NH-S02-NHV1 and -NH-S02-V1, in which VI and V2, which may be identical or different, represent a hydrogen atom, an alkyl, cycloalkyl or phenyl radical or a heterocyclic radical such as pyridyl, pyrazolyl, imidazolyl, dihydroimidazolyl, tetrazolyl, norpholinyl, piperazinyl, piperazinylalkyl, alkylpiperazinyl, phenylpiperazinyl, thienyle, furanyl, piperidyl, methylpiperidyl, pyridyl, pyrrolidyl and pyrrolidylalkyl, all the alkyl, phenyl and heterocyclic radicals being optionally substituted with one or more radicals chosen :rom halogen atoms and hydroxyl, alkyl, alkoxy, CF3, NH2, JHalk, N(alk)2 radicals and a phenyl radical, itself optionally substituted with one or more substituents rhosen from halogen atoms and hydroxyl or alkoxy radicals, all the phenyl and heterocyclic radicals above furthermore being optionally substituted with one or more alkyl radicals, the phenyl radicals furthermore being optionally substituted with NR5R6 in which R5 and R6 are as defined above, the other substituents of said products of formula (I) having any one of the values defined above. A subject of the invention is especially the products of formula (I) as defined above such that Y2 represents hydrogen, halogen, alkyl, cycloalkyl, hydroxyl, alkoxy, carboxyl which is free or esterified with an alkyl or phenyl radical, NH2, NHalk, N(alk)2 and phenyl, all the alkyl, alkoxy and phenyl radicals being optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, C1-C4 alkyl, C1-C4 alkoxy, CF3, NH2, NHalk and N(alk)2 radicals and a phenyl radical, which is itself optionally substituted with one or more substituents chosen from halogen atoms and hydroxyl or alkoxy radicals, all the phenyl radicals furthermore being optionally substituted with one or more C1-C4 alkyl radicals and optionally substituted with NR5R6 in which R5 and R6 are as defined above, the other substituents of said products of formula (I) having any one of the values defined above. A subject of the invention is especially the products of formula (I) as defined above such that Y2 represents hydrogen, F, CI, CH3, CH2CH3, OH, 0CH3, NH2, NHAlk and phenyl optionally substituted with NR5R6 in which R5 and R6 are as defined above, the other substituents of said products of formula (I) having any one of the values defined above. A subject of the invention is especially the products of formula (I) as defined above such that B2 represents 4-pyridyl and 4-quinolyl radicals substituted with one or two radicals chosen from F, CI, OH and 0CH3, the other substituents of said products of formula (I) having any one of the values defined above. In certain products of formula (I) of the present invention, the following group: In the products of formula (I) of the present invention, R2 and R3 may especially form together a cycloalkyl or heterocycloalkyl radical, or alternatively, identical or different, may especially represent hydrogen and methyl radicals. Products of formula (I) as defined above corresponding to formula (CI): in which YC and Y1C are such that one represents a hydrogen atom, a halogen atom or an amino radical and the other is chosen from -0CF3, -0-CF2-CHF2, -0-CHF2, -0-CH2-CF3 , -SF5, -S (0)n-CF3 , -S(0)n-Alk, -S02CHF2, S02CF2CF3, -S02NH2, -S-CF2-CF2-CF3, -S-Alk-0-Alk, -S-Alk-OH, -S-Alk-CN, -S-Alk-morpholino, -S-Alk-pyrrolidinyl and -S-Alk-piperazinyl, the morpholino, pyrrolidinyl and piperazinyl radicals being optionally substituted with Alk, with Alk representing an alkyl radical containing from 1 to 4 carbon atoms, or the phenyl radical forms with its substituents YC and Y1C one of the following two radicals: R2C and R3C, which may be identical or different, represent hydrogen or optionally substituted alkyl, or alternatively R2C and R3C form, together with the carbon atom to which they are attached, a C3-C10 eyeloalkyl or heterocycloalkyl radical, A2C represents a single bond or CH2, B2C represents pyridyl, pyrimidinyl, quinolyl, azaindolyl, quinazolyl, thiazolyl, imidazolyl, pyrazolyl, furazanyl, isoxazolyl, morpholinyl, pyrrolidinyl, furyl, piperidyl, chromenyl, oxochromenyl, quinazolyl, thienyl, indolyl, pyrrolyl, purinyl, benzoxazinyl, benzimidazolyl and benzofuranyl radicals, optionally substituted with one or more radicals chosen from the values of Y2A, Y2CA represents hydrogen, halogen, hydroxyl, cyano, alkyl, alkoxy, phenyl, COOH, COOAlk, CONR5R6, NR5R6, -NR10-COOH, -NR10-COOAlk, -NR10-CO-R6, -NR10-CS-NR5R6, -NR10-CO-NR5R6 or -NR10-SO2-R6, all these radicals being optionally substituted, R5 and R6, which may be identical or different, are chosen from hydrogen, alkyl, cycloalkyl, phenyl, pyrimidinyl, thienyl, pyridyl, quinolyl, thiazolyl and pyran, all these radicals being optionally substituted, or alternatively R5 and R6 form, with the nitrogen atom to which they are attached, an optionally substituted pyrrolidinyl, piperidyl, piperazinyl, morpholinyl or quinazolinyl radical, RIO represents hydrogen or alkyl, all the above alkyl, Alk or ALK, alkoxy, cycloalkyl and phenyl radicals, and also the ring formed by R5 and R6 with the atom to which they are attached, being optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and cyano; hydroxyl; alkyl; alkoxy; 0CF3; CF3; S(0)n-CF3; nitro; oxo; thioxo; OCOAlk; phenyl, itself optionally substituted with one or more radicals chosen from halogen atoms and alkyl and alkoxy radicals; -OCOAlk; NH2, NHAlk, N(Alk)2, N(alk) (phenylalkyl) , N(Alk) (aminoalkyl) , N(Alk) (alkylaminoalkyl) , N(Alk) (dialkylaminoalkyl); carboxyl, which is free or ester if ied with an alkyl radical, all the above phenyl radicals moreover being optionally substituted with an alkylenedioxy radical, all the above alkyl radicals moreover being optionally substituted with one or more radicals chosen from the following radicals: piperazinyl, which is itself optionally substituted with Alk, Alk-OH and pyridyl; imidazolyl; morpholinyl; pyrrolidinyl; piperidyl, which is itself optionally substituted with one or two alk; azepanyl, optionally substituted with oxo, all the pyrrolidinyl and quinazolinyl radicals above moreover being optionally substituted with oxo or thioxo, all the above alkyl and alkoxy radicals being linear or branched and containing up to 6 carbon atoms, all the above cycloalkyl radicals containing up to 7 carbon atoms, n represents an integer from 0 to 2, said products of formula (CI) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (CI) . In particular in the products of formula (I), the radical below that may be formed by phenyl with its substituents Y and Yl: A subject of the present invention is especially the products of formula (I) as defined above and corresponding to formula (IA) : in which: Y1A represents -0CF3, S(0)n-CF3 and S02CHF2, B2a represents 4-quinolyl and 4-pyridyl radicals optionally substituted with one or more radicals chosen from the values of Y2A, Y2A has the meaning given above for Y2, R2A and R3A, which may be identical or different, represent hydrogen or optionally substituted alkyl, or alternatively R2A and R3A form, together with the carbon atom to which they are attached, a C3-C10 cycloalkyl or heterocycloalkyl radical, all the alkyl and phenyl radicals being optionally substituted with one or more radicals chosen from halogen, OH, alk, Oalk, 0CF3, S(0)n-CF3, CF3, NH2, NHAlk and N(alk)2, n represents an integer fom 0 to 2, said products of formula (IA) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (IA) . A subject of the present invention is especially the products of formula (IA) as defined above in which Y1A, B2a, R2A and R3A have the meanings given above and Y2A represents halogen, -OH, -alk, Oalk, -Oacyl, -NR5AR6A, -C02H, -C02alk, -CO-NR5AR6A, -S(0)n-CF3, -NH-S(0)n-CF3 or phenyl radicals, alk representing a linear or branched alkyl radical containing not more than 6 carbon atoms, all the alkyl, alkoxy and phenyl radicals being optionally substituted, R5A and R6A, which may be identical or different, represent hydrogen, alkyl, cycloalkyl or phenyl, the alkyl and phenyl radicals being optionally substituted, or alternatively R5A and R6A form, with the nitrogen atom to which they are attached, a cyclic radical chosen from pyrrolidyl, piperidyl, piperazinyl, morpholinyl, indolinyl, pyrindolinyl, tetrahydroquinolyl and azetidinyl radicals, all the alkyl, alkoxy and phenyl radicals being optionally substituted with one or more radicals chosen from halogen, OH, alk, Oalk, 0CF3, S(0)n-CF3, CF3, NH2, NHAlk and N(alk)2, n represents an integer from 0 to 2, said products of formula (IA) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (IA) . A subject of the present invention is especially the products of formula (IA) as defined above in which: Y1A represents -0CF3, SCF3 or S(0)2-CF3, B2a represents a 4-quinolyl or 4-pyridyl radical optionally substituted with one or two radicals chosen from halogen, -OH, alk, -Oalk, -C02H, -C02alk, -NR5AR6A, -CF3, -0CF3 and optionally substituted phenyl, R5A and R6A, which may be identical or different, represent hydrogen, alkyl, cycloalkyl or phenyl, the alkyl and phenyl radicals being optionally substituted, or alternatively R5A and R6A form, with the nitrogen atom to which they are attached, a cyclic radical chosen from pyrrolidyl, piperidyl, piperazinyl, morpholinyl, piperazinyl and azetidinyl radicals, R2A and R3A, which may be identical or different, represent hydrogen or optionally substituted alkyl, or alternatively R2A and R3A form, together with the carbon atom to which they are attached, a C3-C6 cycloalkyl or heterocycloalkyl radical, all the alkyl and phenyl radicals being optionally substituted with one or more radicals chosen from halogen, OH, alk, Oalk, 0CF3, S (0) n-CF3, CF3, NH2, NHalk and N(alk)2, said products of formula (IA) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (IA) . A subject of the present invention is especially the products of formula (IA) as defined above corresponding to formule (IA) in which: Y1A represents -0CF3, SCF3 or S(0)2-CF3, B2a represents a 4-quinolyl or 4-pyridyl radical optionally substituted with one or two radicals chosen from halogen, -OH, alk and -Oalk, R2A and R3A, which may be identical or different, represent hydrogen and linear or branched alkyl containing not more than 4 carbon atoms optionally substituted with a hydroxyl radical, or alternatively R2A and R3A form, together with the carbon atom to which they are attached, a C3-C6 cycloalkyl radical, said products of formula (IA) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (IA). A subject of the present invention is especially the products of formula (IA) as defined above corresponding to formula (IA) in which Yla represents 0CF3, SCF3 or S(0)2CF3 and R2A and R3A, which may be identical or different, represent hydrogen and CH3, or alternatively R2A and R3A form, together with the carbon atom to which they are attached, a cyclopropyl radical, the other substituents having any one of the values defined above, said products of formula (IA) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (IA) . A subject of the present invention is also the products of formula (I) as defined above corresponding to formula (IB): in which R2, R3, Al, Y, Yl, A2, B2 and Y2 have the meanings given above said products of formula (IB) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (IB) . A subject of the present invention is also the products of formula (IB) as defined above in which Yl represents 0CF3, SCF3 or S (0) 2CF3 and R2 and R3, which may be identical or different, represent hydrogen and CH3 or, alternatively R2 and R3 form, together with the carbon atom to which they are attached, a cyclopropyl radical, the other substituents having any of the values given above, said products of formula (IB) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (IB). Among the products of the invention that are preferred, mentioned may be made more specifically of the products of formula (I) as defined above, the names of which are below: (S)-5-methyl-l-quinol-4-ylmethyl-3-(4-trifluoromethane-sulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate (S)-5-methyl-l-pyrid-4-ylmethyl-3-(4-trifluoromethane-sulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate (S)-5-methyl-l-quinol-4-ylmethyl-3-(4-trifluoromethyl-sulfanylphenyl)imidazolidine-2,4-dione trifluoroacetate - 5,5-dimethyl-l-quinol-4-ylmethyl-3-(4-trifluoromethane-sulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate (R)-5-methyl-l-quinol-4-ylmethyl-3-(4-trifluoromethane-sulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate (R)-5-methyl-l-quinol-4-ylmethyl-3-(4-trifluoromethyl-sulfanylphenyl)imidazolidine-2,4-dione trifluoroacetate (R)-5-methyl-l-pyrid-4-ylmethyl-3-(4-trifluoromethane-sulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate (R)-5-methyl-l-(3-methylpyrid-4-ylmethyl)-3-(4-tri-fluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate (R)-4-methyl-3-quinol-4-ylmethyl-5-thioxo-l-(4-tri-fluoromethylsulfanylphenyl)imidazolidin-2-one trifluoroacetate (R)-5-isopropyl-l-quinol-4-ylmethyl-3-(4-trifluoro-methylsulfanylphenyl)imidazolidine-2,4-dione trifluoroacetate (R)-5-isopropyl-l-quinol-4-ylmethyl-3-(4-trifluoro-methanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate (R)-5-(4-hydroxy-benzyl)-l-quinol-4-ylmethyl-3- (4-tri-fluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate (R)-5-(4-hydroxy-benzyl)-l-pyrid-4-ylmethyl-3-(4-tri-fluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate (R)-5-(1-hydroxy-ethyl)-l-quinol-4-ylmethyl-3-(4-tri-fluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate 4-quinol-4-ylmethyl-6-(4-trifluoromethylsulfanylphenyl) -4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate 4-quinol-4-ylmethyl-6-(4-trifluoromethanesulfonylphenyl) -4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate - 4-pyrid-4-ylmethyl-6-(4-trifluoromethylsulfanylphenyl)- 4,6-diazaspiro [2.4]heptane-5,7-dione trifluoroacetate 4-pyrid-4-ylmethyl-6-(4-trifluoromethanesulfonylphenyl) -4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate (R)-1-(3-hydroxypyrid-4-ylmethyl)-5-methyl-3-(4-tri-fluoromethylsulfanylphenyl)imidazolidine-2,4-dione trifluoroacetate - 5,5-dimethyl-l-quinol-4-ylmethyl-3-(4-trifluoromethoxy- phenyl)imidazolidine-2,4-dione trifluoroacetate 5,5-dimethyl-l-quinol-4-ylmethyl-3-(4-trifluoromethylsulf anylphenyl) imidazolidine-2,4-dione trifluoroacetate 5,5-dimethyl-l-(3-methylpyrid-4-ylmethyl)-3- (4-tri-fluoromethoxyphenyl)imidazolidine-2,4-dione trifluoroacetate 5,5-dimethyl-1-(3-methylpyrid-4-ylmethyl)-3-(4-tri-fluoromethylsulfanylphenyl)imidazolidine-2,4-dione trifluoroacetate 5,5-dimethyl-1-(3-methylpyrid-4-ylmethyl)-3- (4-tri-fluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate 1-(3-hydroxypyrid-4-ylmethyl)-5,5-dimethyl-3-(4-tri-fluoromethoxyphenyl)imidazolidine-2,4-dione trifluoroacetate 1-(3-hydroxypyrid-4-ylmethyl)-5,5-dimethyl-3-(4-tri-fluoromethylsulfanylphenyl)imidazolidine-2,4-dione trifluoroacetate 1-(3-hydroxypyrid-4-ylmethyl)-5,5-dimethyl-3-(4-tri-fluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate 4-quinol-4-ylmethyl-6-(4-trifluoromethoxyphenyl)-4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate 4-(3-methylpyrid-4-ylmethyl)-6-(4-trifluoromethylsulf-anylphenyl)-4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate 4-(3-hydroxypyrid-4-ylmethyl)-6-(4-trifluoromethoxyphenyl) -4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate, - 4-(3-hydroxypyrid-4-ylmethyl)-6-(4-trifluoromethylsulf-anylphenyl)-4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate 4-(3-hydroxypyrid-4-ylmethyl)-6-(4-trifluoromethanesulf onylphenyl) -4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate, said products of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (I) . Among the preferred products of the invention, mention may be made most particularly of the products of formula (I) as defined above, the names of which are given below: cyclopropanecarboxylic acid {4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazolidin-1-ylmethyl]pyridin-2-yl}amide trifluoroacetate; 5,5-dimethyl-l- [2-(pyrid-2-ylamino)pyridin-4-ylmethyl]-3-(4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione; compound with trifluoroacetic acid; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}isobutyramide; compound with trifluoroacetic acid; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}propionamide; compound with trifluoroacetic acid; 1-(2-aminopyridin-4-ylmethyl)-5,5-dimethyl-3- (4-trifluoromethylsulfanylphenyl)imidazolidine-2,4-dione hydrochloride; pyridine-2-carboxylic acid {4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazolidin-1-ylmethyl] pyridin-2-yl}amide trifluoroacetate; N-{4- [5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}-3-piperidin-l-ylpropionamide trifluoroacetate; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}-3-[4-(2-hydroxyethyl)piperazin-l-yl]propionamide trifluoroacetate; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}-3-morpholin-4-ylpropionamide trifluoroacetate; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}-3-pyrrolidin-1-ylpropionamide trifluoroacetate; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}-3-(4-methylpiperazin-l-yl)propionamide trifluoroacetate; l-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}-3-phenylurea; 1- [2- (6-ethylpyridin-2-ylamino)pyridin-4-ylmethyl] -5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione; 5,5-dimethyl-l-[2-(4-methylpyridin-2-ylamino)-pyridin-4-ylmethyl]-3-(4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione; 5,5-dimethyl-l- [2-(6-methylpyridin-2-ylamino)-pyridin-4-ylmethyl]-3-(4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione; 1-[2-(4,6-dimethylpyridin-2-ylamino)pyridin-4-ylmethyl]-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl) imidazolidine-2,4-dione; 1-[2-(3,5-dichloropyridin-2-ylamino)pyridin-4-ylmethyl]-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl) imidazolidine-2,4-dione; 5,5-dimethyl-l-[2-(pyridin-4-ylamino)pyridin-4-ylmethyl]-3- (4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione; 5,5-dimethyl-l-[2-(pyridin-3-ylamino)pyridin-4-ylmethyl]-3-(4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}-3-(2-oxoazepan-1-yl)propionamide; 3-(benzylmethylamino)-N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazolidin-1-ylmethyl]pyridin-2-yl}propionamide; 4,5-diacetoxy-6-acetoxymethyl-2-(3-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)- imidazolidin-1-ylmethyl]pyridin-2-yl}thioureidoacetic acid; 5,5-dimethyl-1-[2-(5-methylpyridin-2-ylamino)-pyridin-4-ylmethyl]-3-(4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethyl-sulfanylphenyl)imidazolidin-1-ylmethyl]pyridin-2-yl}-3,5-dimethoxybenzamide trifluoroacetate; 5,5-dimethyl-1-[2-(pyrazin-2-ylamino)pyridin-4-ylmethyl]-3-(4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione trifluoroacetate; N-{4- [5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}-3-(3-methylpiperidin-l-yl)propionamide trifluoroacetate; N-{4- [5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}-3-(3,5-dimethylpiperidin-1-yl)propionamide trifluoroacetate; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}-3-methoxybenzamide trifluoroacetate; pyrazine-2-carboxylic acid {4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazolidin-1-ylmethyl]pyridin-2-yl}amide trifluoroacetate; thiophene-2-carboxylic acid {4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazolidin-1-ylmethyl]pyridin-2-yl}amide trifluoroacetate; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}-4-methylbenzamide; compound with trifluoroacetic acid; l-isoquinolin-5-yl-5,5-dimethyl-3-(4-trifluoromethylsulf anylphenyl) imidazolidine-2,4-dione; 3-(4-acetylpiperazin-l-yl)-N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazolidin-1-ylmethyl]pyridin-2-yl}propionamide; 3-[4-(2-diethylaminoethyl)piperazin-l-yl]-N-{4- [5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl) imidazolidin-l-ylmethyl]pyridin-2-yl}propionamide; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}-3-(2,6-dimethylmorpholin-4-yl)propionamide; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}-3-(4-pyrrolidin-l-ylpiperid-l-yl)propionamide; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}-2-(4-pyrrolidin-1-ylpiperidin-l-yl)acetamide; 5,5-dimethyl-1-[2-(4-methylpyridin-3-ylamino)-pyridin-4-ylmethyl] -3- (4-trif luoromethylsulf anylphenyl) -imidazolidine-2,4-dione; 5,5-dimethyl-l-[2-(6-morpholin-4-ylpyridin-3-ylamino)pyridin-4-ylmethyl]-3-(4-trifluoromethylsulf anylphenyl) imidazolidine-2,4-dione; 1-[2-(2,6-dimethylpyridin-3-ylamino)pyridin-4-ylmethyl]-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl) imidazolidine-2,4-dione; methyl 5-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethyl]pyridin-2-ylamino}pyridine-2-carboxylate; 1-[2-(2,6-dimethoxypyridin-3-ylamino)pyridin-4-ylmethyl]-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl) imidazolidine-2,4-dione; 1-[2-(6-fluoropyridin-3-ylamino)pyridin-4-ylmethyl]-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl) imidazolidine-2,4-dione; 1-[2-(6-methoxypyridin-3-ylamino)pyridin-4-ylmethyl]-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl) imidazolidine-2,4-dione, said products of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (I). A subject of the present invention is also a process for preparing the products of general formula (I) as defined above, characterized in that: either a product of formula (II) : in which Y' and Yl' have the meanings given above for Y and Yl, respectively, in which the optional reactive functions are optionally protected and R has the meaning given above, is reacted in the presence of a tertiary base with a product of formula (III) : in which X represents -A2'-B2'-Y2' or hydrogen, and A2' , B2' , Y2' , R2' and R3' have the meanings given above, respectively, for A2', B2', Y2', R2' and R3' in which the optional reactive functions are optionally protected above, to obtain a product of formula (IV) : in which Y' , Yl', X, R, R2' and R3' have the meanings given above, which products of formula (IV) are, if necessary or if desired, subjected to any one or more of the following reactions, in any order: a) reaction for removal of any protecting groups that may be borne by Y', Yl', R, R2' and R3' and X when X represents -A2'-B2'-Y2'; b) reaction for hydrolysis of the >C=NH group to a ketone function c) action on the products of formula (IV) in which X represents a hydrogen atom, and after optional hydrolysis of the >C=NH group to a ketone function of a reagent of formula Hal-A2 '-B2 '-Y2 ' in which A2 ' , B2 ' and Y2 ' have the meanings given above and Hal represents a halogen atom, to obtain products of formula (Ii): in which Y', Yl', R2' , R3' , A2' , B2' and Y2' have the meanings given above, followed, if desired, by the action on these products of an agent for removing any protecting groups that may be borne by Y', Yl', R2' , R3' , A2', B2' and Y2' or, where appropriatel the action of an esterification, amidification or salification agent, or the product of formula (II) defined above is reacted in the presence of a tertiary base with a product of formula (III') : in which R2' and R3' have the meanings given above and Q represents either an alkali metal atom, for example sodium, or an alkyl radical containing from 1 to 6 carbon atoms, to obtain a product of formula (IVa): in which Y' , Yl' , R, R2' , R3' and X have the meanings given above, which product, if desired, is subjected to any one or more of the following reactions, in any order: a) reaction for removal of the possible protecting groups that may be borne by X; b) action on the products of formula (IVa), in which X represents a hydrogen atom, of a reagent of formula Hal-A2'-B2'-Y2' in which A2' , B2' and Y2' have the meanings given above and Hal represents a halogen atom, to obtain products of formula (Iii): in which Y' , Yl' , R, Rl, R2', R3' and A2' , B2' and Y2' have the meanings given above, followed, if desired, by the action on these products of an agent for removing any protecting groups that may be borne by Y' , Yl', R2', R3' , A2', B2' and Y2' or, where appropriate, the action of an esterification, amidification or salification agent, or a reagent of formula Hal-A2'-B2'-Y2', in which A2' , B2' , Y2' and Hal have the meanings given above, is reacted with a product of formula (IV) : in which Y' , Yl' , R2' and R3' have the meanings given above, to obtain a product of formula (IV"): in which Y', Yl' , R2', R3 ' , A2' , B2' and Y2' have the meanings given above, which product of formula (IV") is, if necessary or if desired, subjected to a reaction for removal of any protecting groups that may be borne by -A2'-B2'-Y2', followed, where appropriate, by the action of an esterification, amidation or salification agent. It may be noted that, depending on the values Y' , Yl', R2', R3', A2', B2' and Y2', the products of formulae (IV), (Ii) , (IVa), (Iii) and (IV') may be products of formula (I) and that, to obtain products or other products of formula (I), these products may be subjected if desired, and necessary, to one or more of the following conversion reactions, in any order: a) a reaction for esterification of an acid function, b) a reaction for saponification of an ester function to an acid function, c) a reaction for oxidation of an alkylthio group to the corresponding sulfoxide or sulfone group, d) a reaction for conversion of a ketone function to an oxime function, e) a reaction for reducing a free or esterified carboxyl function to an alcohol function, f) a reaction for conversion of an alkoxy function to a hydroxyl function, or alternatively of a hydroxyl function to an alkoxy function, g) a reaction for oxidation of an alcohol function to an aldehyde, acid or ketone function, h) a reaction for conversion of a nitrile radical to a tetrazolyl, i) a reaction for reduction of nitro compounds to amino compounds, j) a reaction for removal of the protecting groups that may be borne by the protected reactive functions, k) a reaction for salification with a mineral or organic acid or with a base to obtain the corresponding salt, 1) a reaction for resolution of the racemic forms to resolved products, said products of formula (I) thus obtained being in any possible racemic, enantiomeric or diastereoisomeric isomer form. It may be noted that such reactions for converting substituents into other substituents may also be performed on the starting materials, and also on the intermediates as defined above before continuing the synthesis according to the reactions indicated in the process described above. The various reactive functions that may be borne by certain compounds of the reactions defined above may, if necessary, be protected: these are, for example, hydroxyl, acyl, free carboxyl or amino and monoalkylamino radicals, which may be protected with the appropriate protecting groups. The following nonexhaustive list of examples of protection of reaction functions may be mentioned: - the hydroxyl groups may be protected, for example, with alkyl radicals such as tert-butyl, trimethylsilyl, tert-butyldimethylsilyl, methoxymethyl, tetrahydropyranyl, benzyl or acetyl, - the amino groups may be protected, for example, with acetyl, trityl, benzyl, tert-butoxycarbonyl, benzyloxycarbonyl, phthalimido radicals or other radicals known in peptide chemistry, - the acyl groups such as the formyl group may be protected, for example, in the form of cyclic or noncyclic ketals or thioketals such as dimethyl or diethylketal or ethylene dioxyketal, or diethylthioketal or ethylenedithioketal, - the acid functions of the products described above may be, if desired, amidated with a primary or secondary amine, for example in methylene chloride in the presence, for example, of 1-ethyl-3-(dimethylaminopropyl)carbo-diimide hydrochloride at room temperature: - the acid functions may be protected, for example, in i the form of esters formed with readily cleavable esters such as benzyl esters or tert-butyl esters, or esters known in peptide chemistry. These reactions a) to k) indicated above may be performed, for example, as indicated below. a) The products described above may, if desired, undergo, on the possible carboxyl functions, esterification reactions that may be performed according to the usual methods known to those skilled in the art. b) The possible conversions of ester functions into an acid function of the products described above may be, if desired, performed under the usual conditions known to those skilled in the art, especially by acid or alkaline hydrolysis, for example with sodium hydroxide or potassium hydroxide in alcoholic medium such as, for example, in methanol, or alternatively with hydrochloric acid or sulfuric acid. c) the possible alkylthio groups in the products described above, in which the alkyl radical is optionally substituted with one or more halogen atoms, especially fluorine, may, if desired, be converted into the corresponding sulfoxide or sulfone functions under the usual conditions known to those skilled in the art such as, for example, with peracids such as, for example, peracetic acid or meta-chloroperbenzoic acid, or alternatively with ozone, oxone or sodium periodate in a solvent such as, for example, methylene chloride or dioxane at room temperature. The production of the sulfoxide function may be promoted with an equimolar mixture of the product containing an alkylthio group and the reagent such as, especially, a peracid. The production of the sulfone function may be promoted with a mixture of the product containing an alkylthio group with an excess of the reagent such as, especially, a peracid. d) The reaction for conversion of a ketone function into an oxime may be performed under the usual conditions known to those skilled in the art, such as, especially, a reaction in the presence of an optionally O-substituted hydroxylamine in an alcohol such as, for example, ethanol, at room temperature or with heating. e) The possible free or esterified carboxyl functions of the products described above may be, if desired, reduced to an alcohol function by the methods known to those skilled in the art: the possible esterified carboxyl functions may be, if desired, reduced to an alcohol function by the methods known to those skilled in the art and especially with lithium aluminum hydride in a solvent such as, for example, tetrahydrofuran or dioxane or ethyl ether. The possible free carboxyl functions of the products described above may be, if desired, reduced to an alcohol function especially with boron hydride. f) The possible alkoxy functions such as, especially, methoxy, in the products described above, may be, if desired, converted into a hydroxyl function under the usual conditions known to those skilled in the art, for example with boron tribromide in a solvent such as, for example, methylene chloride, with pyridine hydrobromide or hydrochloride or with hydrobromic acid or hydrochloric acid in water or trifluoroacetic acid at reflux. g) The possible alcohol functions of the products described above may be, if desired, converted into an aldehyde or acid function by oxidation under the usual conditions known to those skilled in the art, such as, for example, by the action of manganese oxide to obtain the aldehydes, or of Jones' reagent to access the acids. h) The possible nitrile functions of the products described above may be, if desired, converted into tetrazolyl under the usual conditions known to those skilled in the art, such as, for example, by cycloaddition of a metal azide such as, for example, sodium azide or a trialkyltin azide on the nitrile function, as indicated in the method described in the article referenced as follows: J. Organometallic Chemistry., 33, 337 (1971) KOZIMA S. et al. It may be noted that the reaction for conversion of a carbamate into urea and especially of a sulfonylcarbamate into sulfonylurea may be performed, for example, at the reflux point of a solvent such as, for example, toluene, in the presence of the appropriate amine. It is understood that the reactions described above may be performed as indicated or alternatively, where appropriate, according to other common methods known to those skilled in the art. i) The removal of protecting groups such as, for example, those indicated above may be performed under the usual conditions known to those skilled in the art, especially via an acid hydrolysis performed with an acid such as hydrochloric acid, benzenesulfonic acid or para-toluenesulfonic acid, formic acid or trifluoroacetic acid, or alternatively via a catalytic hydrogenation. The phthalimido group may be removed with hydrazine. A list of various protecting groups that may be used will be found, for example, in patent BF 2 499 995. j) The products described above may, if desired, be subjected to salification reactions, for example with a mineral or organic acid or with a mineral or organic base according to the usual methods known to those skilled in the art. k) The possible optically active forms of the products described above may be prepared by resolving the racemic mixtures according to the usual methods known to those skilled in the art. The reaction of the products of formula (II) with the products of formula (III) is preferably performed in an organic solvent such as tetrahydrofuran or dichloroethane, but ethyl ether or isopropyl ether may also be used. The process is optionally performed in the presence of a tertiary base such as triethylamine or alternatively pyridine or methylethylpyridine. The possible reactive functions that are optionally protected in the product of formula (III), (IVa) or (IV") are the hydroxyl or amino functions. Usual protecting groups are used to protect these functions. Examples that may be mentioned include the following protecting groups for the amino radical: tert-butyl, tert-amyl, trichloroacetyl, chloroacetyl, benzhydryl, trityl, formyl, benzyloxycarbonyl. Protecting groups for the hydroxyl radical that may be mentioned include radicals such as formyl, chloroacetyl, tetrahydropyranyl, trimethylsilyl and tert-butyldimethylsilyl. It is clearly understood that the above list is not limiting and that other protecting groups, which are known, for example, in peptide chemistry, may be used. A list of such protecting groups is found, for example, in French patent 2 499 995, the content of which is incorporated herein by reference. The possible reactions for removal of the protecting groups are performed as indicated in said patent 2 4 99 995. The preferred method of removal is acid hydrolysis with acids chosen from hydrochloric acid, benzenesulfonic acid or para-toluenesulfonic acid, formic acid or trifluoroacetic acid. Hydrochloric acid is preferred. The possible reaction for hydrolysis of the >C=NH group to a ketone group is also preferably performed using an acid such as aqueous hydrochloric acid, for example at reflux. The action on the products of formula (IV), (IVa) or (IV) of the reagent of formula Hal-A2'-B2'-Y2' is performed in the presence of a strong base such as sodium hydride or potassium hydride. The process may be performed by phase-transfer reaction in the presence of quaternary ammonium salts such as tert-butylammonium. An example of removal of the tert-butyldimethylsilyl group using hydrochloric acid is given below in the examples. - The possible esterification of a free OH radical is performed under standard conditions. An acid or a functional derivative, for example an anhydride such as acetic anhydride in the presence of a base such as pyridine may be used, for example. The possible esterification or salification of a COOH group is performed under the standard conditions known to those skilled in the art. - The possible amidation of a COOH radical is performed under standard conditions. A primary or secondary amine may be used on a functional derivative of the acid, for example a symmetrical or mixed anhydride. A subject of the present invention is also a process for preparing the products of formula (I"): in which Y' , Yl' , Al, R, Rl, R2' and R3' have the meanings given above, characterized in that a product of formula (V): in which Al, Yl' and Y2' have the above meanings and Hal represents a halogen atom, is reacted with a product of formula (VI): in which R, Rl, R2' , R3' and X have the above meanings, the reaction being performed in the presence of a catalyst and optionally a solvent. As regards the products of formula (V) , the term "Hal" preferably denotes a chlorine atom, but may also represent a bromine or iodine atom. A subject of the invention is, more specifically, a process as defined above in which the catalyst is a metal in native or oxidized form or a base. The catalyst used may be a metal in native form, in metal oxide form or alternatively in the form of metal salts. The catalyst may also be a base. When the catalyst used is a metal, this metal may be copper or nickel. The metal salts may be a chloride or an acetate. It may be noted that when Al represents a single bond, a catalyst may be used. When Al represents alkyl, it is then an alkylation, which may be performed especially in the presence of a reagent such as a base. When the catalyst is a base, this base may be, for example, sodium hydroxide or potassium hydroxide and, if desired, dimethyl sulfoxide may be added to the reaction medium. A subject of the invention is, more specifically, a process as defined above in which the catalyst is chosen from cuprous oxide, cupric oxide, copper in native form and a base such as sodium hydroxide or potassium hydroxide. The copper in native form used as catalyst is preferably in the form of powder. A subject of the invention is particularly a process as defined above in which the catalyst is cuprous oxide. The solvent used is preferably chosen from high-boiling ethers such as, for example, phenyl oxide, diglyme, triglyme and dimethyl sulfoxide, but may also be, for example, a high-boiling oil such as paraffin or liquid petroleum jelly. It may be noted that, especially when Al represents a single bond, in the reaction of a product of formula (V) with a product of formula (VI) as defined above, palladium or a salt thereof as described, for example, in the following articles, or a copper salt with a ligand, for instance a 1,2-diaminocyclohexane derivative, may also be used as catalyst: Buchwald S .L. , J. AM. CHEM. SOC, 2002, 6043 and Buchwald S.L., J. AM. CHEM. SOC, 2001, 7727. A subject of the invention is, more particularly, a process as defined above, characterized in that the process is performed in the presence of a solvent of ether type such as phenyl ether, diglyme, triglyme, dimethyl sulfoxide, toluene or dioxane. A subject of the invention is, most particularly, a process as defined above in which the solvent used is phenyl ether or triglyme. The process for preparing the desired product, defined above, may be performed under pressure or at atmospheric pressure, preferably at elevated temperature. A subject of the invention is thus a process as defined above, characterized in that the reaction is performed at a temperature above 100°C and preferably above 150°C. A subject of the invention is, more specifically, a process as defined above, characterized in that the reaction is performed for more than 2 hours. A subject of the invention is, very specifically, a process as defined above, characterized in that the reaction is performed in the presence of cuprous oxide, in triglyme, at a temperature of greater than or equal to 200°C and for more than 3 hours. The products that are the subject of the present invention have advantageous pharmacological properties: it has been found that they especially have inhibitory properties on protein kinases. Among these protein kinases, mention may be made especially of IGF1R. FAK may also be mentioned. AKT may also be mentioned. Tests given in the experimental section below illustrate the inhibitory activity of products of the present invention with respect to such protein kinases. These properties thus make the products of general formula (I) of the present invention usable as medicinal products for treating malignant tumors. The products of formula (I) may also be used in the veterinary field. A subject of the invention is thus, as medicinal products, pharmaceutically acceptable products of general formula (I). A subject of the invention is, particularly, the use as medicinal products of the products whose names are below: (S)-5-methyl-l-quinol-4-ylmethyl-3-(4-trifluoromethane-sulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate (S)-5-methyl-l-pyrid-4-ylmethyl-3-(4-trifluoromethane-sulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate (S)-5-methyl-l-quinol-4-ylmethyl-3-(4-trifluoromethyl-sulfanylphenyl)imidazolidine-2,4-dione trifluoroacetate - 5,5-dimethyl-l-quinol-4-ylmethyl-3-(4-trifluoromethane- sulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate (R)-5-methyl-l-quinol-4-ylmethyl-3-(4-trifluoromethane-sulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate - (R)-5-methyl-l-quinol-4-ylmethyl-3-(4-trifluoromethyl-sulfanylphenyl)imidazolidine-2,4-dione trifluoroacetate - (R)-5-methyl-l-pyrid-4-ylmethyl-3-(4-trifluoromethane-sulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate - (R)-5-methyl-l-(3-methylpyrid-4-ylmethyl)-3- (4-tri-fluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate - (R)-4-methyl-3-quinol-4-ylmethyl-5-thioxo-l- (4-tri-fluoromethylsulfanylphenyl)imidazolidin-2-one trifluoroacetate - (R)-5-isopropyl-l-quinol-4-ylmethyl-3-(4-trifluoro- methylsulfanylphenyl)imidazolidine-2,4-dione trifluoroacetate - (R)-5-isopropyl-l-quinol-4-ylmethyl-3-(4-trifluoro- methanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate - (R)-5-(4-hydroxy-benzyl)-l-quinol-4-ylmethyl-3-(4-tri- fluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate - (R) -5-(4-hydroxy-benzyl)-l-pyrid-4-ylmethyl-3- (4-tri-fluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate - (R)-5-(1-hydroxy-ethyl)-l-quinol-4-ylmethyl-3-(4-tri-fluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate - 4-quinol-4-ylmethyl-6-(4-trifluoromethylsulfanylphenyl) -4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate - 4-quinol-4-ylmethyl-6-(4-trifluoromethanesulfonyl phenyl) -4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate - 4-pyrid-4-ylmethyl-6-(4-trifluoromethylsulfanylphenyl)- 4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate - 4-pyrid-4-ylmethyl-6-(4-trifluoromethanesulfonyl- phenyl)-4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate - (R)-1-(3-hydroxypyrid-4-ylmethyl)-5-methyl-3-(4-tri fluoromethylsulf anylphenyl) imidazolidine-2,4-dione trifluoroacetate - 5,5-dimethyl-l-quinol-4-ylmethyl-3-(4-trifluoromethoxy- phenyl)imidazolidine-2,4-dione trifluoroacetate 5,5-dimethyl-l-quinol-4-ylmethyl-3-(4-trifluoromethylsulf anylphenyl) imidazolidine-2,4-dione trifluoroacetate - 5, 5-dimethyl-1-(3-methylpyrid-4-ylmethyl)-3- (4-tri- fluoromethoxyphenyl)imidazolidine-2,4-dione trifluoroacetate - 5,5-dimethyl-l-(3-methylpyrid-4-ylmethyl)-3-(4-trifluoromethylsulf anylphenyl) imidazolidine-2,4-dione trifluoroacetate - 5,5-dimethyl-l-(3-methylpyrid-4-ylmethyl) -3-(4-tri-fluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate - 1-(3-hydroxypyrid-4-ylmethyl)-5,5-dimethyl-3-(4-tri-fluoromethoxyphenyl)imidazolidine-2,4-dione trifluoroacetate - 1-(3-hydroxypyrid-4-ylmethyl)-5,5-dimethyl-3-(4-tri-fluoromethylsulfanylphenyl)imidazolidine-2,4-dione trifluoroacetate - 1-(3-hydroxypyrid~4-ylmethyl)-5,5-dimethyl-3-(4-tri-fluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate - 4-quinol-4-ylmethyl-6-(4-trifluoromethoxyphenyl)-4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate 4-(3-methylpyrid-4-ylmethyl)-6-(4-trifluoromethylsulf-anylphenyl)-4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate - 4-(3-hydroxypyrid-4-ylmethyl)-6-(4-trifluoromethoxy phenyl) -4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate, - 4-(3-hydroxypyrid-4-ylmethyl)-6-(4-trifluoromethylsulf- anylphenyl)-4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate - 4-(3-hydroxypyrid-4-ylmethyl)-6-(4-trifluoromethane sulfonylphenyl) -4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate, said products of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the pharmaceutically acceptable addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (I). One subject of the invention is particularly the application, as medicinal products, of the products whose names are given below: cyclopropanecarboxylic acid {4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazolidin-1-ylmethyl]pyridin-2-yl}amide trifluoroacetate; 5,5-dimethyl-l-[2-(pyrid-2-ylamino)pyridin-4-ylmethyl]-3-(4-trifluoromethylsulfanylphenyl)- imidazolidine-2,4-dione; compound with trifluoroacetic acid; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl) imidazolidin-l-ylmethyl]pyridin-2-yl}isobutyramide; compound with trifluoroacetic acid; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}propionamide; compound with trifluoroacetic acid; 1-(2-aminopyridin-4-ylmethyl)-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)imidazolidine-2,4-dione hydrochloride; pyridine-2-carboxylic acid {4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazolidin-1-ylmethyl]pyridin-2-yl}amide trifluoroacetate; N-{4- [5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}-3-piperidin-l-ylpropionamide trifluoroacetate; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}-3-[4-(2-hydroxyethyl)piperazin-l-yl]propionamide trifluoroacetate; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}-3-morpholin-4-ylpropionamide trifluoroacetate; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}-3-pyrrolidin-1-ylpropionamide trifluoroacetate; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}-3-(4-methylpiperazin-l-yl)propionamide trifluoroacetate; 1-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}-3-phenylurea; 1- [2- (6-ethylpyridin-2-ylamino)pyridin-4-ylmethyl] -5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione; 5,5-dimethyl-l-[2-(4-methylpyridin-2-ylamino)-pyridin-4-ylmethyl]-3-(4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione; 5,5-dimethyl-l-[2-(6-methylpyridin-2-ylamino)-pyridin-4-ylmethyl]-3-(4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione; 1-[2- (4,6-dimethylpyridin-2-ylamino)pyridin-4-ylmethyl]-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl) imidazolidine-2,4-dione; 1-[2-(3,5-dichloropyridin-2-ylamino)pyridin-4-ylmethyl]-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl) imidazolidine-2,4-dione; 5,5-dimethyl-l- [2-(pyridin-4-ylamino)pyridin-4-ylmethyl]-3-(4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione; 5,5-dimethyl-l-[2-(pyridin-3-ylamino)pyridin-4-ylmethyl]-3-(4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-l-ylmethyl]pyridin-2-yl}-3-(2-oxoazepan-l-yl)propionamide; 3-(benzylmethylamino)-N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazolidin-l-ylmethyl] pyridin-2-yl}propionamide; 4,5-diacetoxy-6-acetoxymethyl-2-(3-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)-imidazolidin-l-ylmethyl]pyridin-2-yl}thioureidoacetic acid; 5,5-dimethyl-l-[2-(5-methylpyridin-2-ylamino)-pyridin-4-ylmethyl] -3- (4-trifluoromethylsulfanylphenyl) -imidazolidine-2,4-dione; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-l-ylmethyl]pyridin-2-yl}-3,5-iimethoxybenzamide trifluoroacetate; 5,5-dimethyl-l-[2-(pyrazin-2-ylamino)pyridin-4-ylmethyl]-3-(4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione trifluoroacetate; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-l-ylmethyl]pyridin-2-yl}-3-(3-methylpiperidin-l-yl)propionamide trifluoroacetate; N-{4- [5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}-3-(3,5-dimethylpiperidin-l-yl)propionamide trifluoroacetate; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethyl] pyridin-2-yl}-3-methoxybenzamide trifluoroacetate; pyrazine-2-carboxylic acid {4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazolidin-1-ylmethyl]pyridin-2-yl}amide trifluoroacetate; thiophene-2-carboxylic acid {4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazolidin-1-ylmethyl]pyridin-2-yljamide trifluoroacetate; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}-4-methylbenzamide; compound with trifluoroacetic acid; l-isoquinolin-5-yl-5,5-dimethyl-3-(4-trifluoromethylsulf anylphenyl) imidazolidine-2,4-dione; 3-(4-acetylpiperazin-l-yl)-N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazolidin-1-ylmethyl]pyridin-2-yl}propionamide; 3-[4-(2-diethylaminoethyl)piperazin-l-yl]-N-{4- [5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl) imidazolidin-1-ylmethyl] pyridin-2-yl}propionamide; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}-3-(2, 6-dimethylmorpholin-4-yl)propionamide; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethylJpyridin-2-yl}-3-(4-pyrrolidin-l-ylpiperid-l-yl)propionamide; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethyl-sulfanylphenyl)imidazolidin-1-ylmethyl]pyridin-2-yl}-2-(4-pyrrolidin-1-ylpiperidin-l-yl)acetamide; 5,5-dimethyl-1-[2-(4-methylpyridin-3-ylamino)-pyridin-4-ylmethyl]-3-(4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione; 5,5-dimethyl-1-[2-(6-morpholin-4-ylpyridin-3-ylamino)pyridin-4-ylmethyl]-3-(4-trifluoromethylsulfanylphenyl) imidazolidine-2,4-dione; 1-[2-(2,6-dimethylpyridin-3-ylamino)pyridin-4-ylmethyl]-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl) imidazolidine-2,4-dione; methyl 5-{4- [5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl) imidazolidin-1-ylmethyl]pyridin-2-ylamino}pyridine-2-carboxylate; 1-[2 -(2,6-dimethoxypyridin-3-ylamino)pyridin-4-ylmethyl] -5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl) imidazolidine-2,4-dione; 1- [2- (6-fluoropyridin-3-ylamino)pyridin-4-ylmethyl]-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl) imidazolidine-2,4-dione; 1-[2-(6-methoxypyridin-3-ylamino)pyridin-4-ylmethyl] -5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl) imidazolidine-2,4-dione, said products of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with pharmaceutically acceptable mineral and organic bases of said products of formula (I). The products may be administered parenterally, orally, perlingually, rectally or topically. A subject of the invention is also pharmaceutical compositions, characterized in that they contain as active principle at least one of the medicinal products of general formula (I). These compositions may be in the form of injectable solutions or suspensions, tablets, coated tablets, capsules, syrups, suppositories, creams, ointments and lotions. These pharmaceutical forms are prepared according to the usual methods. The active principle may be incorporated into excipients usually used in these compositions, such as aqueous or nonaqueous vehicles, talc, gum arabic, lactose, starch, magnesium stearate, cocoa butter, fatty substances of animal or plant origin, paraffin derivatives, glycols, various wetting, dispersing or emulsifying agents, and preserving agents. The usual dose, which varies according to the individual treated and the complaint under consideration, may be, for example, from 10 mg to 5 00 mg per day orally in man. The present invention thus relates to the use of products of formula (I) as defined above or of pharmaceutically acceptable salts of said products of formula (I) for the preparation of medicinal products for inhibiting the activity of protein kinases and especially of a protein kinase. The present invention thus relates to the use of products of formula (I) as defined above or of pharmaceutically acceptable salts of said products of i formula (I) in which the protein kinase is a protein tyrosine kinase. The present invention thus relates to the use of products of formula (I) as defined above or of pharmaceutically acceptable salts of said products of formula (I) in which the protein kinase is chosen from the following group: EGFR, Fak, FLK-1, FGFR1, FGFR2, FGFR3, FGFR4, FGFR5, flt-1, IGF-1R, KDR, PDGFR, tie2, VEGFR, AKT, Raf. The present invention thus relates particularly to the use of products of formula (I) as defined above or of pharmaceutically acceptable salts of said products of formula (I) in which the protein kinase is IGF1R. The present invention also relates to the use of products of formula (I) as defined above or of pharmaceutically acceptable salts of said products of formula (I) in which the protein kinase is FAK. The present invention also relates to the use of products of formula (I) as defined above or of pharmaceutically acceptable salts of said products of formula (I) in which the protein kinase is AKT. The present invention also relates to the use of products of formula (I) as defined above or of pharmaceutically acceptable salts of said products of formula (I) in which the protein kinase is in a cell culture, and also to this use in a mammal. The present invention thus relates to the use of products of formula (I) as defined above or of pharmaceutically acceptable salts of said products of formula (I) for the preparation of a medicinal product for preventing or treating a disease characterized by deregulation of the activity of a protein kinase and especially such a disease in a mammal. The present invention relates to the use of products of formula (I) as defined above or of pharmaceutically acceptable salts of said products of formula (I) for the preparation of a medicinal product for preventing or treating a disease belonging to the following group: disorders of blood vessel proliferation, fibrotic disorders, disorders of mesangial cell proliferation, metabolic disorders, allergies, asthma, thrombosis, diseases of the nervous system, retinopathy, psoriasis, rheumatoic arthritis, diabetes, muscle degeneration, oncology diseases and cancer. The present invention thus relates to the use of products of formula (I) as defined above or of pharmaceutically acceptable salts of said products of formula (I) for the preparation of a medicinal product for treating oncology diseases. The present invention relates particularly to the use of products of formula (I) as defined above or of pharmaceutically acceptable salts of said products of formula (I) for the preparation of a medicinal product for treating cancers. Among these cancers, the present invention is most particularly of interest in the treatment of solid tumors and the treatment of cancers that are resistant to cytotoxic agents. Among these cancers, the present invention relates most particularly to the treatment of breast cancer, stomach cancer, cancer of the colon, lung cancer, cancer of the ovaries, cancer of the uterus, brain cancer, cancer of the kidney, cancer of the larynx, cancer of the lymphatic system, cancer of the thyroid, cancer of the urogenital tract, cancer of the tract including the seminal vesicle and prostate, bone cancer, cancer of the pancreas and melanomas. The present invention is even more particularly of interest in treating breast cancer, cancer of the colon and lung cancer. The present invention also relates to the use of products of formula (I) as defined above or of pharmaceutically acceptable salts of said products of formula (I) for the preparation of a medicinal product for cancer chemotherapy. As medicinal products according to the present invention for cancer chemotherapy, the products of formula (I) according to the present invention may be used alone or in combination with chemotherapy or radiotherapy or alternatively in combination with other therapeutic agents. The present invention thus relates especially to the pharmaceutical compositions as defined above, also containing active principles of other chemotherapy medicinal products for combating cancer. Such therapeutic agents may be antitumor agents commonly used. As examples of known inhibitors of protein kinases, mention may be made especially of butyrolactone, flavopiridol, 2- (2-hydroxyethylamino)-6-benzylamino-9-methylpurine, olomucine, Glivec and Iressa. The products of formula (I) according to the present invention may thus also be advantageously used in combination with antiproliferative agents: as examples of such antiproliferative agents, but without, however, being limited to this list, mention may be made of aromatase inhibitors, antiestrogens, the topoisomerase I inhibitors, the topoisomerase II inhibitors, microtubule-active agents, alkylating agents, histone deacetylase inhibitors, farnesyl transferase inhibitors, COX-2 inhibitors, MMP inhibitors, mTOR inhibitors, antineoplastic antimetabolites, platinum compounds, compounds that reduce the activity of protein kinases and also anti-angiogenic compounds, gonadorelin agonists, antiandrogens, bengamides, biphophonates and trastuzumab. Examples that may thus be mentioned include anti-microtubule agents, for instance taxoids, vinca alkaloids, alkylating agents such as cyclophosphamide, DNA-intercalating agents, for instance cis-platinum, agents that are interactive on topoisomerase, for instance camptothecin and derivatives, anthracyclines, for instance adriamycin, antimetabolites, for instance 5-fluorouracil and derivatives, and the like. The present invention thus relates to products of formula (I) as protein kinase inhibitors, said products of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with pharmaceutically acceptable mineral and organic acids or with pharmaceutically acceptable mineral and organic bases of said products of formula (I), and also the prodrugs thereof. The present invention relates particularly to products of formula (I) as defined above, as IGF1R inhibitors. The present invention also relates to products of formula (I) as defined above as FAK inhibitors. The present invention also relates to products of formula (I) as defined above as AKT inhibitors. The present invention relates more particularly to the products of formula (IA) as defined above as IGF1R inhibitors. The products of formula (I) according to the present invention may be prepared by application or adaptation of known methods and especially of the methods described in the literature such as, for example, those described by R.C. Larock in: Comprehensive Organic Transformations, VCH publishers, 198 9. In the reactions described below, it may be necessary to protect reactive functional groups such as, for example, hydroxyl, amino, imino, thio or carboxyl groups, when these groups are desired in the final product but when their participation is not desired in the reactions for synthesizing the products of formula (I) . Conventional protecting groups may be used in accordance with the usual standard practices, for instance those described, for example, by T.W. Greene and P.G.M. Wuts in "Protective Groups in Organic Chemistry" John Wiley and Sons, 1991. The products of formula (II) used at the start of the invention may be obtained by the action of phosgene when X represents an oxygen atom, or of thiophosgene when K represents a sulfur atom, on the corresponding amine of formula (A) , i.e. the aminophenyl derivative bearing the substituents Y and Yl' as defined above. A product of this type is also described in French patent 2 329 276. The products of formula (III) or (III') are known or may be prepared from the corresponding cyanohydrin according to the process described in the publication: J. Am. Chem. Soc. (1953), 75, 4841. The products of formula (III) may be obtained by the action of a product of formula Y2-B2-A2-Hal on 2-cyano-2-aminopropane under the conditions stated above for the action of Y2-B2-A2-Hal on the products of formula (IV) . An example of a preparation of this type is described in the reference: - Jilek et al. Collect. Czech. Chem. Comm. 54 (8) 2248 (1989). The products of formula (IV) are described in French patent 2 329 276. The starting materials of formulae (V) and (VI), on which a process that is the subject of the invention is performed, to obtain the products of formula (I) , are known and commercially available or may be prepared according to methods known to those skilled in the art. The preparation of products of formula (VI) is described especially in the following publications: - Zhur. Preklad. Khim. 28, 969-75 (1955) (CA 50, 4881a, 1956) - Tetrahedron 43, 1753 (1987) - J. Org. Chem. 52, 2407 (1987) - Zh. Org. Khim. 21, 2006 (1985) - J. Fluor. Chem. 17, 345 (1981) or in: - German patent DRP 637 318 (1935) - European patent EP 0 13 0 875 - Japanese patent JP 81 121 524. The products of formula (VI) that are hydantoin derivatives are widely used and cited in the literature, for instance in the following articles: - J. Pharm. Pharmacol., 67, Vol. 19(4), p. 209-16 (1967) - Khim. Farm. Zh., 67, Vol. 1 (5) p. 51-2 - German patent 2 217 914 - European patent 0 091 596 - J. Chem. Soc. Perkin. Trans. 1, p. 219-21 (1974). The products of formula (I) of the present patent application as defined above, for which p represents the integer 0 and which thus constitute hydantoin derivatives, may be synthesized according to the process indicated above and especially according to the general scheme below which describes this synthesis on a solid support. The protocol that follows this scheme gives the operating conditions for such a synthesis on solid support of the products of formula (I) of the present patent application. The experimental section below more particularly gives an illustration of such a synthesis on a solid support according to the above protocol with the preparation of Examples 1 to 56 of the present patent application. Such a synthesis may be performed according to the general protocol below. Rink resin, protected with an Fmoc group, is deprotected with a 20% solution of piperidine in DMF. The resulting amine resin is coupled with an amino acid protected with an Fmoc group, in the presence of iiisopropylaminecarbodiimide (DIC) and hydroxybenzo-:riazole (HOBt). The supported N-Fmoc amino acid is then ieprotected with a 20% solution of piperidine in DMF. The free amine is reacted with an aldehyde dissolved in a 50/5 0 mixture of THF and triethyl orthoformate (TEOF) to jive a Schiff's base, which is reduced with sodium :yanoborohydride. The resulting amine is coupled with an .socyanate or an isothiocyanate to give the corresponding irea or thiourea. When the isocyanate is not commercially ivailable, it may be prepared from the corresponding amine by reaction with 1/3 equivalent of triphosgene in the presence of 2 equivalents of pyridine. The product is then cleaved with a 95% trifluoroacetic acid/water mixture. The urea thus released cyclizes to give the expected hydantoinine. In certain cases, the cleavage solution must be heated to 80 °C to obtain complete cyclization. The products of formula (I) of the present patent application as defined above, for which p represents the integer 1 and which thus constitute dihydrouracil derivatives, may be synthesized according to the process indicated above and especially according to the general scheme below which describes this synthesis on a solid support. The protocol that follows this scheme gives the operating conditions for such a synthesis of the products of formula (I) of the present patent application on a solid support. The experimental section below more particularly gives an illustration of such a synthesis on a solid support according to the above protocol with the preparation of Example 5 of the present patent application. For the synthesis of the dihydrouracils on a solid support, the protocol that follows may be used. Wang polystyrene resin (1.7 mmol/g) is used, for example, which resin is treated with a mixture of p-amino acid, 2,6-dichlorobenzoyl chloride and pyridine in DMF. After washing the resin is treated with a 10% solution of piperidine in DMF. The resulting free amine is reacted with an aldehyde in a mixture of THF/trimethyl orthoformate (TMOF). The resulting Schiff's base is reduced with sodium cyanoborohydride in a mixture of methanol, THF and acetic acid. The secondary amine obtained is acylated with phosgene and the resulting carbomoyl chloride is treated with a primary amine to give the corresponding urea. Cyclization to the dihydrouracil and cleavage of the final product are performed by treating with a strong base such as diazabicycloundecene (DBU). The products of formula (I) of the present patent application may thus be synthesized on a solid support as described above or in liquid phase according to the process indicated below: the experimental section of the present patent application gives an illustration of such a liquid-phase synthesis with the preparation of Examples 57 to 62. For this liquid-phase synthetic process, two routes A and B may be performed, each involving two steps. Route A: step a: the alkylation of the amino ester may be performed by reductive amination with an aromatic or heterocyclic aldehyde according to the general process described in Advanced Organic Reaction, March, third edition, page 798-800. In particular, the formation of the Schiff's base (intermediate) may be performed using an amino ester optionally in salt form, an aldehyde and optionally a dehydrating agent (for example magnesium sulfate) in a solvent, for instance dichloromethane or dichloroethane, at a temperature of between 0°C and the reflux point of the solvent. The imine formed may be isolated. The imine formed is reduced with a metal hydride, for instance sodium borohydride, in a solvent, for instance an alcohol (for example ethanol or methanol), at a temperature of between 0°C and the reflux point of the solvent. step b: the amino ester obtained is coupled with an isocyanate in a solvent, for instance THF or dichloromethane, with or without the presence of a base (for example triethylamine) or an acid (for example trifluoroacetic acid), at a temperature of between 0°C and the reflux point of the solvent. When the isocyanates are not commercially available, they are prepared from the corresponding amines and triphosgene or diphosgene or phosgene in the presence of a base (for example pyridine or triethylamine) according to the general procedure described in Advanced Organic Reaction, March, third edition, page 370. Route B: step a: the formation of the isocyanate may be performed by coupling an aromatic or heterocyclic amine with diphosgene in the presence of activated plant charcoal, in a solvent, for instance toluene, at a temperature of between -40°C and the reflux point of the solvent. The isocyanate formed is not isolated, and may react with the amino ester or its salt in the same solvent in the presence of a base, for instance triethylamine, at a temperature of between 0°C and the reflux point of the solvent, to give the 3-arylimidazolidine-2,4-dione derivative. step b: the coupling of this derivative with an alkyl halide is performed in the presence of a base, for instance potassium tert-butoxide or sodium hydride, in a solvent, for instance THF or DMF, at a temperature of between 0°C and the reflux point of the solvent. The products of formula (I) of the present patent application that constitute examples 201 to 2 07 of the present patent application were prepared as indicated below in the experimental section and as indicated in the schemes that follow: in these schemes, example I represents example 201, example II represents example 202, example III represents example 203, example IV represents example 204, example V represents example 205, example VI represents example 206 and example VII represents example 207. The synthesis of the products of formula (I) of the present patent application that constitute the products of examples 208 to 243 was performed using route B. The alkyl halide may be prepared from the corresponding carboxylic acids. The ethyl carboxylates were prepared by esterification of the carboxylic acids in ethanol in the presence of sulfuric acid, repeating the conditions described in Synthesis 2000, 1138. The reduction of the ethyl carboxylates to alcohol was performed in ethanol in the presence of sodium borohydride, repeating the conditions described in Synthesis 2000, 1665. The conversion of the alcohols thus obtained into alkyl halides was performed using dibromotriphenylphosphorane as halogenating agent, repeating the conditions described in J. Heterocyclic Chem., 30, 631 (1993). The alkyl halides may also be prepared by f ree-radical bromination of the corresponding methylenes in the presence of N-bromosuccinimide and benzoyl peroxide in carbon tetrachloride, repeating the conditions described in J. Heterocyclic Chem., 30, 631 (1993). Thus, we functionalized the pyridine nucleus in position 2 with a bromine or fluorine atom or alternatively with a nitrile group. The latter compound will also allow us to prepare various carbonyl compounds. The acidic hydrolysis of the nitrile in the presence of sulfuric acid, repeating the conditions described in J. Med. Chem. 1991, 34, 281-290, led to the carboxamide in dimeric form. Hydrolysis of the nitrile under milder conditions allowed us to obtain the expected carboxamide. Acidic hydrolysis of the nitrile in the presence of 5N hydrochloric acid, repeating the conditions described in J. Heterocyclic Chem. , 30, 631 (1993) , led to the corresponding carboxylic acid. The amide may be prepared from the carboxylic acid using 1- (3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride as coupling agent in dichloromethane, repeating the conditions described in J. Am. Chem. Soc. , 95, 875, (1973) . Various amine analogs were obtained by nucleophilic substitution of the chlorointermediate with amines under irradiation in a microwave oven, based on the conditions described in Tetrahedron 2002, 58, 1125. The amino analog was obtained by deprotection of the p-methoxybenzylamine group in the presence of trifluoroacetic acid, based on the conditions described in J. Chem. Soc., Perkin Trans. 1, 2002, 428-433. This amino derivative allowed access to other chemical functions, for instance the amide function, the carbamate function or the sulfonamide function. The acetamido derivative was obtained by acylation of the amine derivative in the presence of acetic anhydride, based on the conditions described in Tetrahedron Lett. 2002, 43, 3121. We also prepared the methyl and tert-butyl carbamates on the basis of the conditions described in J. Heterocyclic Chem., 22, 313 (1985) and in J. Org. Chem. 2002, 67, 4965. The amine derivative was also sulfonylated with mesyl chloride, based on the conditions described in J. Med. Chem., 1985, 28, 824. The above conditions were also used for the synthesis of compounds containing a disubstituted phenyl group. The hydantoin containing a pyridine nucleus disubstituted in position -2,6 with a bromine atom was prepared using the above conditions, starting with 2,6-dibromo-4-(hydroxymethyl)pyridine described in Synthesis 2000, 1665. The products may be purified as follows: Purification by LC/MS The products may be purified by LC/MS using a Waters FractionLynx system composed of a Waters model 600 gradient pump, a Waters model 515 regeneration pump, a Waters Reagent Manager dilution pump, a Waters model 2700 autoinjector, two Rheodyne model LabPro valves, a Waters model 996 diode array detector, a Waters model ZMD mass spectrometer and a Gilson model 2 04 fraction collector. The system was controlled by the Waters FractionLynx software. The separation was performed alternatively on two Waters Symmetry columns (C1Q, 5 /xM, 19x50 mm, catalog reference 186000210), one column undergoing regeneration with a 95/5 (v/v) water/acetonitrile mixture containing 0.07% (v/v) of trifluoroacetic acid, while the other column was being used for separation. The elution of the columns was performed using a linear gradient of from 5% to 95% of acetonitrile containing 0.07% (v/v) of trif luoroacetic acid in water, at a flow rate of 10 mL/min. At the outlet of the separation column, a thousandth of the effluent is separated with an LC Packing Accurate, diluted with methyl alcohol at a flow rate of 0.5 mL/min and conveyed to the detectors, in a proportion of 75% to the diode array detector, and the remaining 25% to the mass spectrometer. The rest of the effluent (999/1000) is conveyed to the fraction collector, where the flow is discarded as long as the mass of the expected product is not detected by the FractionLynx software. The molecular formulae of the expected products are supplied to the FractionLynx software, which triggers the collection of the product when the detected mass signal corresponds to the ion [M+H]+ and/or to the [M+Na]+. In certain cases, depending on the analytical LC/MS results, when a strong ion corresponding to [M+2H]++ was detected, the value corresponding to half of the calculated molecular mass (MW/2) is also supplied to the FractionLynx software. Under these conditions, the collection is also triggered when the signal for the mass of the ion [M+2H]++ and/or [M+Na+H]++ is detected. The products were collected in tared glass tubes. After collection, the solvents were evaporated of f, in a Savant AES 2 00 0 or Genevac HT8 centrifugal evaporator and the product masses were determined by weighing the tubes after evaporation of the solvents. The LC/MS analyses were performed on a Micromass model LCT machine connected to an HP 1100 machine. The abundance of the products was measured using an HP G1315A diode array detector over a 200-600 nm wavelength range and a Sedex 65 light scattering detector. The mass spectra were acquired over a range from 180 to 800. The data were analyzed using the Micromass MassLynx software. The separation was performed on a Hypersil BDS CI8, 3 /zm column (50 x 4.6 mm) , eluting with a linear gradient of from 5% to 90% of acetonitrile containing 0.05% (v/v) of trifluoroacetic acid (TFA) in water containing 0.05% (v/v) of TFA, over 3.5 min at a flow rate of 1 mL/min. The total analysis time, including the column re-equilibration time, is 7 minutes. The products of Examples 244 to 255 of the present invention were prepared as indicated in the experimental section and according to the general synthetic route of the scheme below: The products of Examples 256 to 2 63 of the present invention were prepared according to reaction Schemes 1 and 2 indicated below in which the figures 1 to 8 correspond, respectively, to Examples 256 to 263: the products of Examples 256 to 261 (i.e. products 1 to 6) were prepared according to Scheme 1 and the two thiohydantoin compounds of Examples 262 and 263 (i.e. products 7 and 8) were prepared according to Scheme 2. The nit ro compound i s prepared by nit rat ion of methyl 2-trifluoromethoxybenzoate by nitration (fuming > nitric acid), while controlling the temperature, according to the conditions described in the PCT patent Int. Appl. (2000), 564: WO 0069810. The corresponding amine is prepared by reduction of i the nitro function in the presence of SnCl2 in ethanol according to the same patent. The isocyanate is prepared by reaction of diphosgene dissolved in toluene at -20°C under the known usual conditions. The isocyanate is reacted with the quinoline derivative prepared according to the known methods in order to prepare the desired hydantoin. The acid is obtained by saponification using 2N sodium hydroxide in THF at 60°C. The amide is prepared by coupling of the desired amine using EDCI as coupling agent (standard coupling conditions). The alcohol is obtained by reduction of the ester in THF in the presence of LiAlH4. The halo derivatives R = CI and R = Br are prepared from commercial anilines according to the same synthetic scheme. The examples whose preparation follows illustrate the present invention without, however, limiting it Example 1 : preparation of (S)-5-methyl-l-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazol-idine-2,4-dione trifluoroacetate 2 g (1.02 mmol) of Polystyrene AM RAM (Rink resin) (0.51 mmol/g) are suspended in 20 ml of DMF in a 50 ml syringe fitted with a sinter. After agitation for 10 minutes, the DMF is filtered and replaced with 10 ml of a 2 0% solution of piperidine in DMF. After agitation for one hour at room temperature, the solution is filtered and the resin washed successively with 3 x 10 ml of DMF, 2 x 10 ml of methanol and 3 x 10 ml of DMF. A solution of 0.94 g of Fmoc-Ala(OH) (3 mmol), 0.41 g of HOBt (3 mmol) and 0.48 ml of DIC (3 mmol) in 10 ml of DMF is added to the resin. The syringe is agitated overnight at room temperature and the resin is then washed successively with 5 x 10 ml of DMF, 3 x 10 ml of MeOH and 5 x 10 ml of DCM. Next, 10 ml of a 20% solution of piperidine in DMF are introduced into the syringe. After agitation for 1 hour, the solution is filtered and the resin washed with 5 x 10 ml of DMF, 2 x 10 ml of MeOH, 3 x 10 ml of DCM and 3 x 10 ml of THF. Next, a solution of 0.79 g of quinoline-4-carboxaldehyde (5.1 mmol) in 10 ml of a 50/50 THF/TEOF mixture is added to the resin. After agitation overnight at room temperature, the solution is filtered and the resin washed with 10 x 10 ml of THF. 0.63 g of sodium cyanoborohydride in a mixture of 1.5 ml of MeOH, 3.5 ml of dichloroethane and 0.1 ml of acetic acid is then added to the resin. The resin is agitated overnight and then, after filtration, washed with 10 x 10 ml of DCM, 3 x 10 ml of MeOH and 5 x 10 ml of DCM. In parallel, a solution of 0.563 g of 4-(trifluoro-methanesulfonyl)aniline (2.5 mmol) is treated with 0.25 g of triphosgene (0.83 mmol), followed by 0.23 ml of pyridine (2.5 mmol) at 0°C under nitrogen. After the temperature has warmed gradually to room temperature, the reaction is stirred for 2 hours and a further 0.23 ml of pyridine in 1 ml of DMF is added to the mixture. The solution obtained is transferred into the syringe, which is agitated for 2 hours. The solution is then filtered and the resin washed with 5 x 10 ml of DCM, 3 x 10 ml of MeOH and 5 x 10 ml of DCM. Finally, the resin is treated with 5 ml of a 95% solution of trif luoroacetic acid in water. The mixture is agitated for 2 hours and then filtered. The resin is washed with 2 ml of MeOH, followed by 2 ml of DCM. The combined filtrates are evaporated under vacuum. 2 80 mg of crude product are thus obtained. After purification by preparative LC-MS, 240 mg (overall yield = 41%) of expected product are isolated in the form of a white solid. EIMS ( [M+H]+ : 464 Retention time (RT) = 3.12 min (YMC basic S5 column; 2-85% ACN/H20 gradient over 7 min) 1H NMR (300 MHz) (CDC13): 1.59(d, 3H); 4.11(t, 1H); 5.01 and 5.55(AB, 2H); 7.70 (d, 1H); 7.89(m, 1H); 7.99(m, 3H); 8.15(m, 2H); 8.3 0(d, 1H), 8.50(d, 1H); 9.22(d, 1H). Example 2 s Preparation of (S)-4-methyl-3 -quinol-4-ylmethyl-5-thioxo-l-(4-trifluoromethanesulfonylphenyl)-imldazolidin-2-one trifluoroacetate Resin 3, 0.036 mmol, prepared according to Example 1, is used for the preparation of the compound. 33 mg of thiocarbonyldiimidazole (0.18 mmol) are added to a solution of 41 mg of 4- (trif luoromethane-sulfonyl)aniline (0.18 mmol) in 3 ml of DCM. The reaction mixture is stirred for 2 hours at room temperature and then added directly to the resin. After stirring for 2 hours, the solution is filtered and the resin is then washed with 5 x 2 ml of DCM, 3 x 5 ml of MeOH and 5x2 ml of DCM. Finally, 2 ml of a 95% solution of TFA in water are added to the resin. After stirring for 2 hours, the mixture is filtered and the resin washed with 1 ml of MeOH and 1 ml of DCM. The combined filtrates are heated at 60°C for 2 hours and then concentrated under vacuum. After purification by preparative LC-MS, 1.8 mg of expected product are isolated. EIMS [(M+H]+): 480 RT= 4.72 min (YMC basic S5 column; 2-85% ACN/H20 gradient over 7 min) Example 3 : Preparation of (S)-5-methyl-l-pyrid-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazol-idine-2,4-dione trifluoroacetate The compound is prepared from 0.025 mmol of resin, 0.075 mmol of N-Fmoc-L-Ala (OH) , 0 .125 mmol of 4-pyridinecarboxaldehyde and 0.0625 mmol of 4-(trifluoro-methanesulfonyl)aniline, in the same way as in Example 1. After purification by preparative LC-MS, 5.6 mg of expected product are obtained. EIMS ([M+H]+): 414 RT = 2.72 min Example 4 : Preparation of (S)-5-methyl-1-pyrid-4-ylmethyl-3-(4-trifluoromethylsulfanylphenyl)imidazol-idine-2,4-dione trifluoroacetate The compound is prepared from 0.025 mmol of resin, 0.075 mmol of N-Fmoc-L-Ala (OH) , 0.125 mmol of 4-pyridinecarboxaldehyde and 0.0625 mmol of 4-(trifluoro-methanethio) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 1.3 mg of expected product are obtained. EIMS ([M+H]+): 382 RT = 2.83 min Example 5 : Preparation of (S)-5-methyl-l-quinol-4-ylmethyl-3-(4-trifluoromethylsulfanylphenyl)imidazol-idine-2,4-dione trifluoroacetate The compound is prepared from 0.02 5 mmol of resin, 0,075 mmol of N-Fmoc-L-Ala (OH) , 0.125 mmol of 4-quinolinecarboxaldehyde and 0.0625 mmol of 4- (trif luoromethanethio) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 0.6 mg of expected product is obtained. EIMS ([M+H]+): 432 RT = 3.14 min Example 6 : Preparation of l-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate The compound is prepared from 4 mmol of resin, 12 mmol of N-Fmoc-Gly (OH) , 20 mmol of 4-quinoline-carboxaldehyde, and 10 mmol of 4-(trifluoromethane-sulfonyl) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 1 g of expected product is obtained. EIMS ([M+H]+): 450 RT = 3.20 min Example 7 : Preparation of 5,5-dimethyl-l-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2, 4-dione trifluoroacetate The compound is prepared from 0.25 mmol of resin, 0.75 mmol of Fmoc-AIB- (OH) , 1.25 mmol of 4-quinoline-carboxaldehyde and 0.625 mmol of 4-(trifluoromethane-sulfonyl) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 22 mg of expected product are obtained. EIMS ([M+H]+): 478 RT = 4.26 min Example 8 : Preparation of (R) -5-methyl-l-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2, 4-dione trifluoroacetate The compound is prepared from 0.04 mmol of resin, 0.12 mmol of N-Fmoc-D-Ala (OH) , 0.20 mmol of 4-quinoline-carboxaldehyde and 0.10 mmol of 4-(trifluoromethane- sulfonyl) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 10 mg of expected product are obtained. EIMS ([M+H]+ ) : 464 RT = 4.3 6 min Example 9 : Preparation of (R)-5-methyl-l-quinol-4-ylmethyl-3-(4-trifluoromethylsulfanylphenyl)imidazol-idine-2,4-dione trifluoroacetate The compound is prepared from 0.04 mmol of resin, 0.12 mmol of N-Fmoc-D-Ala (OH) , 0.20 mmol of 4-quinoline-carboxaldehyde and 0.10 mmol of 4-(trifluoromethanethio) -aniline, in the same way as in Example 1. After purification by preparative LC-MS, 11 mg of expected product are obtained. EIMS ( [M+H]+) : 432 RT = 4.50 min Example 10 : Preparation of (R)-5-methyl-l-pyrid-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazol-idine-2,4-dione trifluoroacetate The compound is prepared from 0.28 mmol of resin, 0.84 mmol of N-Fmoc-D-Ala (OH) , 1.4 mmol of 4-pyridine-carboxaldehyde and 0.70 mmol of 4-(trifluoromethane-sulfonyl) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 105 mg of expected product are obtained. EIMS ([M+H]+ ): 414 RT = 2.40 min Example 11 : Preparation of (R)-5-methyl-l-pyrid-4-ylmethyl-3-(4-trifluoromethylsulfanylphenyl)imidazol-idine-2,4-dione trifluoroacetate The compound is prepared from 0.28 mmol of resin, 0.84 mmol of N-Fmoc-D-Ala (OH) , 1.4 mmol of 4-pyridine-carboxaldehyde and 0.70 mmol of 4-(trifluoromethanethio) -aniline, in the same way as in Example 1. After purification by preparative LC-MS, 91 mg of expected product are obtained. EIMS ([M+H]+): 382 RT = 2.52 min Example 12 : Preparation of (S)-5-methyl-1-(3- methylpyrid-4-ylmethyl)-3-(4-trifluoromethylsulfanyl- phenyl)imidazolidine-2,4-dione trifluoroacetate The compound is prepared from 0.04 mmol of resin, 0.12 mmol of N-Fmoc-L-Ala (OH) , 0.20 mmol of 3-methyl-4-pyridinecarboxaldehyde and 0.10 mmol of 4-(trifluoro-methanethio) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 17 mg of expected product are obtained. EIMS ([M+H]+): 396 RT = 4.2 0 min Example 13 : Preparation of (S)-5-methyl-l-(3-methylpyrid-4-ylmethyl)-3-(4-trifluoromethanesulfonyl-phenyl)imidazolidine-2,4-dione trifluoroacetate The compound is prepared from 0.04 mmol of resin, 0.12 mmol of N-Fmoc-L-Ala (OH) , 0.20 mmol of 3-methyl-4-pyridinecarboxaldehyde, and 0.10 mmol of 4- (trifluoro-methanesulfonyl)aniline, in the same way as in Example 1. After purification by preparative LC-MS, 16 mg of expected product are obtained. EIMS ([M+H]+): 428 RT = 4.07 min Example 14 : Preparation of (S)-4-methyl-3-pyrid-4-ylmethyl-5-thioxo-l-(4-trifluoromethylsulfanylphenyl)-imidazolidin-2-one trifluoroacetate The compound is prepared from 0.04 mmol of resin, 0.12 mmol. of N-Fmoc-L-Ala (OH) , 0.20 mmol of 4-pyridine-carboxaldehyde and 0.10 mmol of 4-(trifluoromethanethio) -aniline, in the same way as in Example 2. After purification by preparative LC-MS, 1.7 mg of expected product are obtained. EIMS ([M+H]+ ): 398 RT = 4.51 min Example 15 : Preparation of (S)-4-methyl-3-pyrid-4-ylmethyl-5-thioxo-l-(4-trifluoromethanesulfonylphenyl)-imidazolidin-2-one trifluoroacetate The compound is prepared from 0.04 mmol of resin, 0.12 mmol of N-Fmoc-L-Ala (OH) , 0.20 mmol of 4-pyridinecarboxaldehyde and 0.10 mmol of 4- (trifluoromethane-sulfonyl) aniline, in the same way as in Example 2. After purification by preparative LC-MS, 2.2 mg of expected product are obtained. EIMS ([M+H]+): 430 RT = 4.34 min Example 16 : Preparation of (R)-4-methyl-3-(3 -methylpyrid-4-ylmethyl)-5-thioxo-l-(4-trifluoromethyl-sulfanylphenyl)imidazolidin-2-one trifluoroacetate The compound is prepared from 0.04 mmol of resin, 0.12 mmol of N-Fmoc-D-Ala (OH) , 0.20 mmol of 3-methyl-4-pyridinecarboxaldehyde and 0.10 mmol of 4-(trifluoro-methanethio) aniline, in the same way as in Example 2. After purification by preparative LC-MS, 1.9 mg of expected product are obtained. EIMS ([M+H]+): 412 RT = 4.60 min Example 17 : Preparation of (R)-4-methyl-3-(3-methylpyrid-4-ylmethyl)-5-thioxo-l-(4-trifluoromethyl-sulfonylphenyl)imidazolidin-2-one trifluoroacetate The compound is prepared from 0.04 mmol of resin, 0.12 mmol of N-Fmoc-D-Ala (OH) , 0.20 mmol of 3-methyl-4-pyridinecarboxaldehyde and 0.10 mmol of 4-(trifluoro-methanesulfonyl)aniline, in the same way as in Example 2. After purification by preparative LC-MS, 4.5 mg of expected product are obtained. EIMS ([M+H]+): 444 RT = 4.41 min Example 18 : Preparation of (R)-5-methyl-l-(3-methylpyrid-4-ylmethyl) -3- (4-trifluoromethylsulfanyl-phenyl)imidazolidine-2,4-dione trifluoroacetate The compound is prepared from 0.04 mmol of resin, 0.12 mmol of N-Fmoc-D-Ala (OH) , 0.20 mmol of 3-methyl-4-pyridinecarboxaldehyde and 0.10 mmol of 4-(trifluoro-methanethio) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 14 mg of expected product are obtained. EIMS ([M+H]+): 396 RT = 4.22 min Example 19 : Preparation of (R)-5-methyl-l-(3-methylpyrid-4-ylmethyl)-3-(4-trifluoromethanesulfonyl-phenyl)imidazolidine-2,4-dione trifluoroacetate The compound is prepared from 0.04 mmol of resin, 0.12 mmol of N-Fmoc-D-Ala (OH) , 0.20 mmol of 3-methyl-4-pyridinecarboxaldehyde and 0.10 mmol of 4-(trifluoro-methanesulfonyl)aniline, in the same way as in Example 1. After purification by preparative LC-MS, 6.3 mg of expected product are obtained. EIMS ([M+H]+): 428 RT = 4.10 min Example 20 : Preparation of (R)-4-methyl-3-quinol-4-ylmethyl-5-thioxo-l- (4-trifluoromethylsulfanyIphenyl) -imidazolidin-2-one trifluoroacetate The compound is prepared from 0.04 mmol of resin, 0.12 mmol of N-Fmoc-D-Ala (OH) , 0.20 mmol of 4-qinoline-carboxaldehyde and 0.10 mmol of 4-(trifluoromethanethio) -aniline, in the same way as in Example 2. After purification by preparative LC-MS, 0.4 mg of expected product is obtained. EIMS ([M+H]+): 448 RT = 4.89 min Example 21 : Preparation of (R)-5-isopropyl-l-quinol-4-ylmethyl-3-(4-trifluoromethylsulfanylphenyl)imidazolidine-2, 4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of N-Fmoc-D-Val (OH) , 0.25 mmol of 4-quinoline-carboxaldehyde and 0.12 5 mmol of 4-(trifluoromethane- thio) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 0.3 mg of expected product is obtained. RT = 4.01 min EIMS ([M+H]+ ): 460 Example 22 : Preparation of (R)-5-isopropyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazol-idine-2,4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of N-Fmoc-D-Val (OH) , 0.25 mmol of 4-quinoline-carboxaldehyde and 0.125 mmol of 4-(trifluoromethane-sulfonyl) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 1 mg of expected product is obtained. EIMS ( [M+H]+) : 492 RT = 3.91 min Example 23 : Preparation of (R)-5-Benzyl-l-quinol-4-ylmethyl-3-(4-trifluoromethylsulfanylphenyl)imidazol-idine-2,4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of N-Fmoc-D-Phe (OH) , 0.25 mmol of 4-quinoline-carboxaldehyde and 0.125 mmol of 4-(trifluoromethane-thio) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 8.9 mg of expected product are obtained. EIMS ([M+H]+): 508 RT = 4.11 min Example 24 : Preparation of (R)-5-Benzyl-l-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazol-idine-2,4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of N-Fmoc-D-Phe (OH) , 0.25 mmol of 4-quinoline-carboxaldehyde and 0.125 mmol of 4-(trifluoromethane-sulfonyl)aniline, in the same way as in Example 1. After purification by preparative LC-MS, 5.9 mg of expected product are obtained. EIMS ([M+H]+) : 540 RT = 4,01 min Example 25 : Preparation of (R)-5-Benzyl-l-pyrid-4- ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazol- idine-2,4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of N-Fmoc-D-Phe (OH) , 0.25 mmol of 4-pyridine-carboxaldehyde and 0.12 5 mmol of 4-(trifluoromethane-sulfonyl) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 11.1 mg of expected product are obtained. EIMS ([M+H]+): 490 RT = 3.76 min Example 26 : Preparation of (R)-5-isobutyl-l-quinol-4-ylmethyl-3- (4-trif luoromethanesulfonylphenyl) imidazol-idine-2,4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of N-Fmoc-D-Leu (OH) , 0.25 mmol of 4-quinoline-carboxaldehyde and 0.125 mmol of 4-(trifluoromethane-sulfonyl) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 5.9 mg of expected product are obtained. RT = 4,02 min EIMS ([M+H]+): 506 Example 27 : Preparation of (R)-5-(4-hydroxy-benzyl)-1-quinol-4-ylmethyl-3- (4-trifluoromethylsulfanylphenyl) -imidazolidine-2,4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of N-Fmoc-D-Tyr (OH) , 0.25 mmol of 4-quinoline-carboxaldehyde and 0.125 mmol of 4-(trifluoromethane-thio) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 5.1 mg of expected product are obtained. EIMS ([M+H]+ ): 524 RT = 3.75 min Example 28 : Preparation of (R)-5-(4-hydroxy-benzyl)-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)-imidazolidine-2,4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of N-Fmoc-D-Tyr (OH) , 0.25 mmol of 4-quinoline-carboxaldehyde and 0.125 mmol of 4-(trifluoromethane-sulfonyl) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 1.8 mg of expected product are obtained. EIMS ([M+H]+): 556 RT = 3.66 min Example 2 9 : Preparation of (R)-5-(4-hydroxy-benzyl)-1-pyrid-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)-imidazolidine-2,4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of N-Fmoc-D-Tyr (OH) , 0.25 mmol of 4-pyridine-carboxaldehyde and 0.125 mmol of 4-(trifluoromethane-sulfonyl) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 0.7 mg of expected product is obtained. EIMS ([M+H]+): 506 RT = 3.48 min Example 3 0 : Preparation of (R)-5-(1-hydroxy-ethyl)-1-quinol-4-ylmethyl-3-(4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of N-Fmoc-D-Thr (OH) , 0.25 mmol of 4-quinoline-carboxaldehyde and 0.125 mmol of 4-(trifluoromethane-thio) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 4.2 mg of expected product are obtained. EIMS ([M+H]+): 462 RT = 3.52 min Example 31 : Preparation of (R)-5-(1-hydroxy-ethyl)-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)-imldazolidlne-2,4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of N-Fmoc-D-Thr (OH) , 0.25 mmol of 4-quinoline-carboxaldehyde and 0.125 mmol of 4-(trifluoromethane-sulfonyl) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 3.4 mg of expected product are obtained. EIMS ([M+H]+): 494 RT = 3.43 min Example 32 : Preparation of 4-quinol-4-ylmethyl-6-(4-trifluoromethylsulfanylphenyl)-4,6-diazaspiro[2.4]hept-ane-5,7-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of Fmoc-ACPC-(OH) , 0.25 mmol of 4-quinoline-carboxaldehyde and 0.125mmol of 4-(trifluoromethane-thio) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 7.5 mg of expected product are obtained. EIMS ([M+H]+): 444 RT = 3.68 min Example 33 : Preparation of 4-quinol-4-ylmethyl-6-(4-trifluoromethanesulfonylphenyl)-4,6-diazaspiro [2.4]-heptane-5,7-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of Fmoc-ACPC- (OH) , 0.25 mmol of 4-quinoline-carboxaldehyde and 0.125 mmol of 4-(trifluoromethane-sulfonyl) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 3.8 mg of expected product are obtained. EIMS ( [M+H]+) : 476 RT = 3.60 min Example 34 : Preparation of 4-pyrid-4-ylmethyl-6-(4-trifluoromethylsulfanylphenyl)-4,6-diazaspiro[2.4]hept-ane-5,7-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of Fmoc-ACPC- (OH) , 0.25 mmol of 4-pyridine-carboxaldehyde and 0.125 mmol of 4-(trifluoromethane-thio) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 1.7 mg of expected product are obtained. EIMS ([M+H]+): 394 RT = 3.43 min Example 35 : Preparation of 4-pyrid-4-ylmethyl-6-(4-trifluoromethanesulfonylphenyl)-4,6-diazaspiro [2.4]hept-ane-5,7-dione trifluoroacetate, The compound is prepared from 0.05 mmol of resin, 0.15 mmol of Fmoc-ACPC- (OH) , 0.25 mmol of 4-pyridine-carboxaldehyde, and 0.125 mmol of 4-(trifluoromethane-sulfonyl) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 1.4 mg of expected product are obtained. EIMS ([M+H]+): 426 RT = 3.3 5 min Example 36 : Preparation of (R)-5-benzo[b]thiophen-3-ylmethyl-l-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl) imidazolidine-2,4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of N-Fmoc-D-benzothienylAla(OH), 0.25 mmol of 4-quinolinecarboxaldehyde and 0 .125 mmol of 4-(trifluoro-methanesulfonyl)aniline, in the same way as in Example 1. After purification by preparative LC-MS, 5 mg of expected product are obtained. EIMS ([M+H]+ ): 596 RT = 4.12 min Example 37 : Preparation of (R)-5-benzo[b]thiophen-3-ylmethyl-l-pyrid-4-ylmethyl-3-(4-trifluoromethyl-sulfanylphenyl)imidazolidine-2,4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of N-Fmoc-D-benzothienylAla (OH) , 0.25 mmol of 4-pyridinecarboxaldehyde and 0.125 mmol of 4-(trifluoro-methanethio) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 1.4 mg of expected product are obtained. EIMS ([M+H]+): 514 RT = 3.35 min Example 38 : Preparation of (R)-5-benzo[b]thiophen-3-ylmethyl-1-pyrid-4-ylmethyl-3 -(4-tri fluoromethanesulf-onylphenyl)imidazolidine-2,4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of N-Fmoc-D-benzothienylAla (OH) , 0.25 mmol of 4-pyridinecarboxaldehyde and 0.125 mmol of 4-(trifluoromethanesulf onyl)aniline, in the same way as in Example 1. After purification by preparative LC-MS, 8.5 mg of expected product are obtained. EIMS ([M+H]+): 546 RT = 3.90 min Example 39 : Preparation of (S)-5-pyrid-2-ylmethyl-1-quinol-4-ylmethyl-3- (4-trifluoromethylsulfanylphenyl) -imidazolidine-2,4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of N-Fmoc-D-2-pyridine-Ala (OK) , 0.25 mmol of 4-quinolinecarboxaldehyde and 0.125 mmol of 4-(tri-fluoromethanethio) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 7.5 mg of expected product are obtained. EIMS ([M+H]+ ): 509 RT = 3.47 min Example 40 : Preparation of (S)-5-pyrid-2-ylmethyl-1 -quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)-imidazolidine-2,4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of N-Fmoc-D-2-pyridine-Ala(OH) , 0.25 mmol of 4-quinolinecarboxaldehyde and 0.125 mmol of 4-(trifluoro-methanesulfonyl)aniline, in the same way as in Example 1. After purification by preparative LC-MS, 1.6 mg of expected product are obtained. EIMS ([M+H]+): 541 RT = 3.41 min Example 41 : Preparation of (R)-1-(3-hydroxypyrid-4-ylmethyl)-5-methyl-3-(4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of N-Fmoc-D-Ala (OH) , 0.25 mmol of 3-hydroxy-4-pyridinecarboxaldehyde and 0.125 mmol of 4-(trifluoro-methanethio) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 8.3 mg of expected product are obtained. EIMS ([M+H]+): 398 RT = 4.2 6 min Example 42 : Preparation of 5,5-dimethyl-1-quinol-4-ylmethyl-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione tri fluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of Fmoc-AIB- (OH) , 0.25 mmol of 4-quinolinecarboxaldehyde and 0.125 mmol of 4-(trifluoromethoxy) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 5.5 mg of expected product are obtained. EIMS ([M+H]+ ): 430 RT = 4.3 3 min Example 43 : Preparation of 5,5-dimethyl-1-quinol-4-ylmethyl-3-(4-trifluoromethylsulfanylphenyl)imidazolidine-2, 4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of Fmoc-AIB- (OH) , 0.25 mmol of 4-quinoline-carboxaldehyde, and 0.125 mmol of 4-(trifluoro-methanethio) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 9.4 mg of expected product are obtained. EIMS ([M+H]+): 446 RT = 4.58 min Example 44 : Preparation of 5,5-dimethyl-1-(3-methylpyrid-4-ylmethyl) -3- (4-trifluoromethoxyphenyl) -imidazolidine-2,4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of Fmoc-AIB- (OH) , 0.25 mmol of 3-methyl-4-pyridinecarboxaldehyde and 0.125 mmol of 4-(trifluoro-methoxy) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 5.5 mg of expected product are obtained. EIMS ([M+H]+): 394 RT = 4.06 min Example 45 : Preparation of 5,5-dimethyl-l-(3-methylpyrid-4-ylmethyl) -3- (4-trifluoromethylsulfanyl-phenyl)imidazolidine-2,4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of Fmoc-AIB-(OH), 0.25 mmol of 3-methyl-4-pyridinecarboxaldehyde and 0.125 mmol of 4-(trifluoro-methanethio) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 13.1 mg of expected product are obtained. EIMS ([M+H]+): 410 RT = 4.3 0 min Example 46 : Preparation of 5,5-dimethyl-1-(3-methylpyrid-4-ylmethyl) -3- (4-trifluoromethanesulfonyl-phenyl)imidazolidine-2,4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of Fmoc-AIB-(OH) , 0.25 mmol of 3-methyl-4-pyridinecarboxaldehyde and 0.125 mmol of 4-(trifluoro-methanesulfonyl)aniline, in the same way as in Example 1. After purification by preparative LC-MS, 9.6 mg of expected product are obtained. EIMS ([M+H]+): 442 RT = 4.18 min Example 47 : Preparation of 1- (3-hydroxypyrid-4-ylmethyl)-5,5-dimethyl-3-(4-trifluoromethoxyphenyl)-imidazolidine-2,4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of Fmoc-AIB-(OH) , 0.25 mmol of 3-hydroxy-4-pyridinecarboxaldehyde and 0.125 mmol of 4-(trifluoro-methoxy) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 6.9 mg of expected product are obtained. EIMS ( [M+H] +) : 394. RT = 4.15 min Example 48 : Preparation of 1-(3-hydroxypyrid-4-ylmethyl) -5, 5-dimethyl-3- (4-trifluoromethylsulfanyl-phenyl)imidazolidine-2,4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of Fmoc-AIB- (OH) , 0.25 mmol of 3-hydroxy-4-pyridinecarboxaldehyde and 0.125 mmol of 4-(trifluoro-methanethio) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 9.7 mg of expected product are obtained. EIMS ([M+H]+): 412 RT = 4.3 9 min Example 49 : Preparation of 1-(3-hydroxypyrid-4-ylmethyl)-5,5-dimethyl-3-(4-trifluoromethanesulfonyl-phenyl)imidazolidine-2,4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of Fmoc-AIB- (OH) , 0.25 mmol of 3-hydroxy-4-pyridinecarboxaldehyde and 0.125 mmol of 4-(trifluoro-methanesulfonyl)aniline, in the same way as in Example 1. After purification by preparative LC-MS, 15.2 mg of expected product are obtained. EIMS ([M+H]+): 444 RT = 4.3 0 min Example 50 : Preparation of 4-quinol-4-ylmethyl-6 -(4-trifluoromethoxyphenyl)-4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of Fmoc-ACPC- (OH) , 0.25 mmol of 4-quinoline-carboxaldehyde and 0.125 mmol of 4-(trifluoromethoxy)-aniline, in the same way as in Example 1. After purification by preparative LC-MS, 4.1 mg of expected product are obtained. EIMS ([M+H]+): 428 RT = 4.24 min Example 51 : Preparation of 4-(3-methylpyrid-4-ylmethyl)-6-(4-trifluoromethoxyphenyl)-4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of Fmoc-ACPC- (OH) , 0.25 mmol of 4-pyridine-carboxaldehyde and 0.125 mmol of 4-(trifluoromethoxy)-aniline, in the same way as in Example 1. After purification by preparative LC-MS, 3 mg of expected product are obtained. EIMS ( [M+H]+) : 392 RT = 3.95 min Example 52 : Preparation of 4-(3-methylpyrid-4-ylmethyl)-6-(4-trifluoromethylsulfanylphenyl)-4,6-diazaspiro[2.4]-heptane-5#7-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of Fmoc-ACPC- (OH) , 0.25 mmol of 3-methyl-4-pyridinecarboxaldehyde and 0.125 mmol of 4-(trifluoro-methanethio) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 5 mg of expected product are obtained. EIMS ([M+H]+): 408 RT = 4.24 min Example 53 : Preparation of 4-(3-methylpyrid-4-ylmethyl)-6-(4-trifluoromethanesulfonylphenyl)-4,6-diazaspiro [2.4]-heptane-5,7-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of Fmoc-ACPC-(OH) , 0.25 mmol of 3-methyl-4-pyridinecarboxaldehyde and 0.125 mmol of 4-(trifluoro-methanesulfonyl)aniline, in the same way as in Example 1. After purification by preparative LC-MS, 1.9 mg of expected product are obtained. EIMS ([M+H]+): 440 RT = 4.11 min Example 54 : Preparation of 4-(3-hydroxypyrid-4-ylmethyl)-6-(4-trifluoromethoxyphenyl)-4,6-diazaspiro-[2.4]heptane-5,7-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of Fmoc-ACPC-(OH) , 0.25 mmol of 3-hydroxy-4-pyridinecarboxaldehyde and 0.125 mmol of 4-(trifluoro-methoxy) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 5.5 mg of expected product are obtained. EIMS ([M+H]+): 394 RT = 4.04 min Example 55 : Preparation of 4-(3-hydroxypyrid-4-ylmethyl)-6-(4-trifluoromethylsulfanylphenyl)-4,6-diazaspiro[2.4]heptane-5f7-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of Fmoc-ACPC- (OH) , 0.25 mmol of 3-hydroxy-4-pyridinecarboxaldehyde and 0.125 mmol of 4-(trifluoro-methanethio) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 0.7 mg of expected product is obtained. EIMS ([M+H]+): 410 RT = 4.34 min Example 56 : Preparation of 4-(3-hydroxypyrid-4-ylmethyl)-6-(4-trifluoromethanesulfonylphenyl)-4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of Fmoc-ACPC- (OH) , 0.25 mmol of 3-hydroxy-4-pyridinecarboxaldehyde and 0.125 mmol of 4-(trifluoro-methanesulfonyl)aniline, in the same way as in Example 1. After purification by preparative LC-MS, 2.5 mg of expected product are obtained. EIMS ([M+H]+): 442 RT = 4.17 min Example 57 : Preparation of 5-methyl-l-quinol-4-ylmethyl-3- (4-trif luoromethanesulfonylphenyl) dihydropyrimidine-2,4-dione 58 8 mg (1 mmol) of Wang polystyrene resin (1.7 mmol/g) are washed with 2 x 5 ml of DMF, 1 x 5 ml of DCM and then treated with a solution of 0.49 g of N-Fmoc-3-amino-2-(R,S)-methyl-propionic acid (1.5 mmol), 0.24 g of pyridine (3 mmol) in 5 ml of DMF, immediately followed by 0.31 g of 2,6-dichlorobenzoyl chloride (dropwise addition to control the exothermicity). The reaction mixture is stirred overnight at room temperature. The mixture is filtered and the resin is then washed with 1 x 5 ml of DMF, 1 x 5 ml of DCM and 2 x 5 ml of DMF and then treated with 5 ml of a 10% solution of piperidine in DMF. The resin is then washed with 2 x 5 ml of DMF, 1 x 5 ml of DCM, 1x5 ml of DMF, 1 x 5 ml of DMF, 4 x 5 ml of DCM, 4 x 5 ml of MeOH and dried under vacuum. 0.94 g of 4-quinolinecarboxaldehyde (6 mol) in 16 ml of a 50/50 mixture of THF/TMOF is added to the resin, which is stirred overnight. The resin is then washed 3 times with 5 ml of the same THF/TMOF mixture and then treated with 12 ml of a 1M solution of sodium cyanoborohydride in THF (12 mmol) in the presence of 1.2 ml of MeOH and 0.12 ml of acetic acid. After stirring overnight at room temperature, the resin is washed with 1 x 5 ml of THF, 4x 5 ml of a 30% solution of acetic acid in DMF, 1 x 5 ml of MeOH, 1 x 5 ml of THF, 1 x 5 ml of DMF, 1 x 5 ml of THF, 1 x 5 ml of MeOH and dried under vacuum. In parallel, 0.121 g of triphosgene (0.41 mmol) in 1 ml of DCM is added dropwise to a solution of 0.281 g of 4-(trifluoromethanesulfonyl)aniline (1. 25 mmol) and 0.1 g of pyridine (1.25 mmol) in 2 ml of DCM. After stirring for 15 minutes at room temperature, the same amount of pyridine is added, followed by the resin previously prepared. The mixture is stirred overnight and then filtered. The resin is washed with 1 x 5 ml of MeOH, 1 x 5 ml of THF, 1x5 ml of MeOH, 1x5 ml of DMF, 1 x 5 ml of THF, 1 x 5 ml of MeOH and 3 x 5 ml of THF and dried under vacuum. The resin is then treated with 154 mg of DBU (1 mmol) in 5 ml of DCM and stirred overnight. Finally, the dihydrouracil is obtained by treating the resin with 5 ml of 2% solution of acetic acid in THF. After purification by preparative HPLC, 90 mg of expected product are isolated. EIMS ( [M+H]+) : 477 RT = 1.83 min (20-100% ACN/H20 gradient over 5 minutes) Example 58 : (S)-5-Methyl-l-quinol-4-ylmethyl-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione This example describes a novel preparation of Example 5 above. A mixture of 0.71 g of ethyl (S)-2-[(quinol-4-rlmethyl)amino]propanoate and. 1.42 g of 4-(trifluoro-lethanesulf anylphenyl) isocyanate in 15 ml of THF is stirred for 15 hours at room temperature under an argon itmosphere. After evaporating off the solvent under reduced pressure, 2 0 ml of dichloromethane are added. The precipitate is filtered off. The filtrate is concentrated inder reduced pressure and the residue is purified by Elash chromatography (Si02, CH2C12 and then CH2C12/MeOH, 35/5 by volume as eluent, Ar). 0.69 g of (S)-5-methyl-l-3uinol-4-ylmethyl-3-(4-trifluoromethanesulfanylphenyl)-imidazolidine-2,4-dione is isolated in the form of a tfhite powder. [a]D= -33.1° +/- 0.8° (MeOH) Mass: EI m/z = 431 M+. base peak m/z = 143 [C10H9N]+. 1H NMR spectrum (400 MHz, (CD3)2SO d6, 5 in ppm) : 1.42 (d, J = 5.5 Hz : 3H) ; 4.35 (q, J = 5.5 Hz: 1H) ; 5.08 (d, J = 17 Hz : 1H) ; 5.25 (d, J = 17 Hz : 1H) ; 7.65 (d, J = 5 Hz : 1H) ; from 7.65 to 7.75 (mt : 1H) ; 7.70 (d, J = 8.5 Hz : 2H) ; 7.83 (broad t, J = 8 Hz : 1H) ; 7.89 (d, J = 8.5 Hz : 2H) ; 8.10 (broad d, J = 8.5 Hz : 1H) ; 8.25 (broad d, J = 8.5 Hz : 1H) ; 8.90 (d, J = 5Hz : 1H). Ethyl (S)-2- [ (quinol-4-ylmethyl)amino]propanoate (P-31397-073-1) A mixture of 2 g of L-alanine ethyl ester in hydrochloride form and 1.83 ml of triethylamine in 30 ml of dichloromethane is stirred at room temperature for 10 minutes. Next, 2.05 g of quinoline-4-carbaldehyde are added. The reaction medium is stirred at room temperature for 15 hours and then concentrated under reduced pressure. 35 ml of ethanol are then added; the solution is cooled to 0°C and 0.4 9 g of sodium borohydride is then added portionwise. Stirring is continued for 15 hours at room temperature. The precipitate formed is filtered off; the filtrate is concentrated under reduced pressure. The residue is purified by flash chromatography on a column (Si02, CH2C12/MeOH/ 95/5 by volume as eluent, Ar). 0.71 g of ethyl (S)-2- [ (quinol-4-ylmethyl)amino]propanoate is obtained in the form of a pink oil. Mass: EI m/z = 258 M+. m/z = 185 [M - COOCH2CH3]+ base peak m/z = 142 [C10H8N]+ 1H NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm) : 1.22 (t, J = 7 Hz : 3H) ; 1.28 (d, J = 7 Hz : 3H) ; 2.72 (unresolved peak : 1H) ; 3.42 (mt : 1H) / from 4.00 to 4.20 (mt : 1H) ; 4.13 (q, J = 7 Hz : 2H) ; 4.27 (broad d, J = 16 Hz : 1H) / 7.55 (broad d, J = 5 Hz : 1H) ; 7.64 (ddd, J = 8.5 - 7.5 and 1 Hz : 1H) ; 7.77 (ddd, J = 8.5 -7.5 and 1 Hz : 1H) ; 8.04 (broad d, J = 8.5 Hz : 1H) ; 8.22 (broad d, J = 8.5 Hz : 1H) ; 8.86 (d, J = 5 Hz : 1H) . Example 59 : 5,5-Dimethyl-l-quinol-4-ylmethyl-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione : This example describes a novel preparation of Example 42 above. The product is prepared according to the procedure described in Example 58 with 600 mg of methyl 2-methyl-2-t(quinol-4-ylmethyl)amino]propanoate instead of ethyl (S)-2-[(quinol-4-ylmethyl)amino]propanoate used in Example 58 and 1.114 g of 4-(trifluoromethoxyphenyl) isocyanate instead of 4-(trifluoromethanesulfanylphenyl) isocyanate used in Example 58. After purification by flash chromatography on a column (Si02, CH2C12 as eluant, Ar) and then a second purification by flash chromatography on a column (Si02, 60/4 0 cyclohexane/EtOAc by volume as eluent, Ar) , 710 mg of the desired product are obtained. Mass: EI m/z = 429 M+. base peak m/z = 414 [M - CH3]+ m/z = 359 [M - C4H60]+. 1H NMR spectrum (300 MHz, (CD3)2SO d6, 8 in ppm) : 1.46 (s : 6H) ; 5.16 (s : 2H) ; 7.55 (broad d, J = 8.5 Hz : 2H) ; 7.65 (d, J = 5 Hz ; 1H) ; 7.69 (d, J = 8.5 Hz : 2H) ; 7.70 (mt : 1H) ; 7.83 (ddd, J = 8 - 7.5 and 1.5 i Hz : 1H) ; 8.09 (broad d, J = 8.5 Hz : 1H) ; 8.27 (broad d, J = 8.5 Hz : 1H) ; 8.88 (d, J = 5 Hz : 1H). Preparation of methyl 2- ( (quinol-4-ylmethyl)amino)-propanoate A mixture of 1.5 g of methyl ot-aminoisobutyrate hydrochloride and 1.4 ml of triethylamine in 30 ml of dichlorome thane is stirred at 0°C for 2 0 minutes. Next, 1 g of magnesium sulfate and 1.5 g of quinoline-4-carbaldehyde are added. Stirring is continued for 15 hours at room temperature and the mixture is then concentrated under reduced pressure. The residue is taken up in 35 ml of methanol and the solution obtained is cooled to 0°C. 0.4 g of sodium borohydride is added portionwise and stirring is continued at room temperature for 15 hours. The precipitate formed is filtered and the filtrate is concentrated under reduced pressure. The residue obtained is purified by recrystallization from diisopropyl ether. 600 mg of expected product are obtained in the form of a pink oil. Mass: DCI m/z = 259 [M+H] + m/z = 199 [M+H- HC00CH3]+ 1H NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm) : 1.36 (s : 6H) ; 2.68 (broad t, J = 7 Hz : 1H) ; 3.69 (s : 3H) ; 4.11 (d, J = 7 Hz : 2H) ; 7.60 (broad d, J = 5 Hz : 1H) ; 7.63 (ddd, J = 9 - 8.5 and 1 Hz : 1H) ; 7.76 (ddd, J = 9 - 8.5 and 1 Hz : 1H) ; 8.03 (broad d, J = 8.5 Hz : 1H) ; 8.20 (broad d, J = 8.5 Hz : 1H) ; 8.85 (d, J = 5 Hz : 1H). Example 60 : 5,5-dimethyl-1-(3-chloro-6-methoxyquinol-4-ylmethyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione The product is prepared according to the procedure described in Example 59, starting with 180 mg of methyl 2-methyl-2- [ (3-chloro-6-methoxyquinol-4-ylmethyl)amino]-propanoate instead of methyl 2-methyl-2-[(quinol-4-ylmethyl) amino] propanoate used in Example 59 and 267 mg of 4-(trifluoromethoxy)phenyl isocyanate. After purification by flash chromatography on a column (Si02, 80/20 cyclohexane/EtOAc by volume as eluent, Ar), 13 7 mg of the expected product are obtained. Mass: EI m/z = 493 M+. isotopic band of the peak monochloro m/z = 458 [M - Cl]+ base peak 1H NMR spectrum (300 MHz, (CD3)2SO d6, 8 in ppm) : 1.27 (S : 6H) ; 3.89 (s : 3H) ; 5.27 (s : 2H) ; 7.48 (dd, J = 9 and 3 Hz : 1H) ; 7.56 (broad d, J = 8.5 Hz : 2H) ; 7.68 (dt, J = 8.5 and 2 Hz : 2H) ; 7.79 (d, J = 3 Hz : 1H) ; 8.01 (d, J = 9 Hz : 1H) ; 8.80 (s : 1H). Preparation of methyl 2-methyl-2- [ (3-chloro-6- methoxyquinol-4-ylmethyl) amino] propanoate (P-31397-099-1) The product is prepared according to the procedure described in Example 59, starting with 1 g of methyl a-aminoisobutyrate hydrochloride, 1.25 g of (3-chloro-6-methoxy)quinoline-4-carbaldehyde instead of quinoline-4-carbaldehyde used in Example 59, 0.66 g of triethylamine and 250 mg of sodium borohydride. After purification by flash chromatography (Si02, 70/30 cyclohexane/EtOAc by volume as eluent, Ar), 180 mg of the expected product are obtained. Mass: EI m/z = 322 M+. isotopic band of the peak monochloro m/z = 2 63 [M-COOCH3]+ base peak isotopic band of the monochloro peak m/z = 206 [M-C5H10O2N]+ isotopic band of the monochloro peak 1H NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm) : 1.39 (s : 6H) ; 2.47 (broad t, J = 7.5 Hz : 1H) ; 3.74 (s : 3H) ; 3.98 (s : 3H) / 4 . 04 (d, J = 7,5 Hz : 2H) ; 7.46 (dd, J = 9 and 3 Hz : 1H) ; 7.66 (d, J = 3 Hz : 1H) ; 5 7.97 (d, J = 9 Hz : 1H) ; 8.71 (s : 1H). Preparation of (3-chloro-6-methoxyquinoline) -4- carbaldehyde (P-31397-097-1) A solution of 2 g of 4-bromo-3-chloro-6-methoxyquinoline in 50 ml of THF is cooled to -78°C. i 6.9 ml of a 1.6 M solution of nBuLi in dioxane are added. The solution is stirred for 2 hours at this temperature and 1.7 ml of DMF are then added. The mixture is stirred at -60°C for 2 hours 30 minutes and the reaction medium is then allowed to warm to room temperature. 2 00 ml of water are then added. The organic phase is extracted with 200 ml of ethyl acetate, washed with 5 x 200 ml of water, dried over magnesium sulfate and concentrated under reduced pressure. The residue obtained is purified by flash chromatography on a column (Si02, 8 0/20 cyclohexane/EtOAc by volume as eluent, Ar) . 1.2 g of the expected product are obtained in the form of a yellow powder. Mass: EI m/z = 221 M+. base peak, isotopic band of the monochloro m/z = 193 [M-CO] +. isotopic band of the monochloro peak m/z = 150 [M-C3H302]+ isotopic band of the monochloro peak 1H NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm) : 3.96 (s : 3H) ; 7.56 (dd, J = 9 and 3 Hz : 1H) ; 8.07 (d, J = 9 Hz : 1H) ; 8.22 (d, J = 3 Hz : 1H) ; 8.93 (s : 1H) ; 10.77 (S : 1H). Preparation of 4-bromo-3-chloro-6-methoxyquinoline is described in French patent FR 2 816 618 in Example 1. Example 61 : 5,5-Dimethyl-l-pyrid-4-ylmethyl-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione 0.764 g of 4-(trifluoromethanesulfanylphenyl) isocyanate is added to a solution of 0.726 g of methyl 2-methyl-2-[(pyrid-4-ylmethyl)amino]propanoate in 10 ml of tetrahydrofuran. The reaction medium is stirred under an argon atmosphere for about 3 days at a temperature in the region of 20°C. The reaction mixture is taken up in ethyl acetate, washed successively with water and then with saturated sodium chloride solution. The organic phase is dried over magnesium sulfate and then concentrated under reduced pressure. The residue thus obtained is purified by flash chromatography on an AIT cartridge of reference FC-50SI filled with 50 g of silica conditioned and eluted with dichloromethane at a flow rate of 10 ml per minute. The fractions between 100 and 2 80 ml are concentrated under reduced pressure, the residue obtained is taken up in ethyl ether and the insoluble material is filtered off. 700 mg of 5,5-dimethyl-l-pyrid-4-ylmethyl-3-(4-trifluoromethanesulf anylphenyl) imidazolidine-2,4-dione are thus obtained in the form of a white powder, the characteristics of which are as follows: 1H NMR spectrum (300 MHz, (CD3)2SO d6, 8 in ppm) : 1.43 (s : 6H) ; 4.66 (s : 2H) ; 7.44 (broad d, J = 6 Hz : 2H) ; 7.69 (d t, J = 8.5 and 2.5 Hz : 2H) / 7.87 (broad d, J = 8.5 Hz : 2H) ; 8.55 (dd, J = 6 and 1.5 Hz : 2H) . Mass IE m/z=395 M+. base peak m/z=380 (M-CH3)+ m/z=219 C8H4NOSF3+. m/z=92 C6H6N+ Preparation of methyl 2-methyl-2-[(pyrid-4-ylmethyl)-amino]propanoate (P-31402-151-1) 1.04 ml of triethylamine and then 0.659 g of pyridine-4-carbaldehyde are successively added to a solution of 0.945 g of methyl a-aminoisobutyrate hydrochloride in 28 ml of dichloroethane. The reaction mixture is stirred overnight at a temperature in the region of 20°C. The mixture is purified by filtration on Merck Lichroprep aminopropyl-grafted silica. The filtrate is concentrated under reduced pressure and the residue thus obtained is taken up 2 5 ml of methanol, 0.3 72 g of sodium borohydride is added. The reaction mixture is stirred for 4 8 hours at a temperature in the region of 20°C and then poured into a mixture of a normal solution of sodium hydroxide/ice. The mixture obtained is extracted three times with ethyl acetate. The organic phase is dried over magnesium sulfate and then concentrated under reduced pressure. 0.726 g of methyl 2-methyl-2-[(pyrid-4-ylmethyl)amino]propanoate is thus obtained in the form of an oil, the characteristics of which are as follows: 1H NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm) : 1.27 (s : 6H) ; 2.69 (broad t, J = 5 Hz : 1H) ; 3.64 (s : 3H) / 3.65 (d, J = 5 Hz: 2H) ; 7.35 (broad d, J = 6 Hz : 2H) ; 8.47 (dd, J = 6 and 1.5 Hz : 2H) . Mass IC m/z=209 MH+ base peak m/z=149 (M-C2H402)+ Example 62 : l-Pyrid-4-ylmethyl-3-(4-trifluoromethane-sulfanylphenyl)imidazolidine-2,4-dione 0.087 g sodium hydride is added to a solution of 0.300 g of 3- (4-trifluoromethy1sulfanylphenyl)imidazolidine-2, 4-dione in 6 ml of anhydrous dimethylformamide, under an inert atmosphere of argon at a temperature in the region of 20°C, stirring is continued at this temperature for 30 minutes, 0.152 ml of triethylamine and 0.2 74 g of 4-(bromomethyl)pyridine hydrobromide are successively added, followed by addition of ice-water 10 minutes later. The reaction mixture is placed on a cartridge 37 mm in diameter packed with 50 g of Amicon 5 0 }im octadecyl-grafted silica of ref. conditioned successively with a water/acetonitrile mixture (5/95, v/v) and then a water/acetonitrile mixture (95/5, v/v) . The elution was performed with a water/acetonitrile mixture (95/5, v/v) over 20 minutes, followed by a linear gradient from 5% to 95% of ace tonit rile over 60 minutes, at a flow rate of 10 ml/minute. The fractions between 580 and 630 ml are concentrated under reduced pressure. 0.220 g of 1-pyrid-4-ylmethyl-3- (4-trifluoromethylsulfanylphenyl)imidazol-idine-2,4-dione is thus obtained in the form of a white powder, the characteristics of which are as follows: 1H NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm) : 4.16 (s : 2H) ; 4.65 (s : 2H) ; 7.42 (broad d, J = 6 Hz : 2H) ; 7.64 (broad d, J = 8.5 Hz : 2H) ; 7.87 (broad d, J = 8.5 Hz : 2H) ; 8.57 (broad d, J = 6 Hz : 2H) . Mass IE m/z=367 M+. base peak m/z=219 C8H4NOSF3+. m/z=92 C6H6N+ The compound 3- (4-trifluoromethylsulfanylphenyl)imid-azolidine-2,4-dione is described in patent US 4 496 575. Example 63 : 5,5-Dimethyl-l-pyrid-4-ylmethyl-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione 0.042 g of sodium hydride is added to a solution of 0.150 g of 5,5-dimethyl-3-(4-trifluoromethoxyphenyl)imidazolidine-2 , 4-dione in 3 ml of anhydrous dimethylformamide, under an inert atmosphere of argon and at a temperature in the region of 20°C, stirring is continued at this temperature for 30 minutes, 0.094 ml of triethylamine and 0.132 g of 4-(bromomethyl)pyridine hydrobromide are successively added, followed by addition of ice-water 10 minutes later. The reaction mixture is placed on a cartridge 27 mm in diameter packed with 30 g of Amicon 50 /xm octadecyl-graf ted silica conditioned successively with a water/acetonitrile mixture (5/95, v/v) and then a water/acetonitrile mixture (95/5, v/v) . The elution was performed with a water/acetonitrile mixture (95/5, v/v) over 20 minutes, followed by a linear gradient from 5% to 95% of acetonitrile over 60 minutes, at a flow rate of 10 ml/minute. The fractions between 300 and 450 ml are concentrated under reduced pressure. 0.1 g of mixture is thus obtained, which is repurified on a cartridge of 37 mm in diameter packed with 50 g of Amicon 50 fim octadecyl-graf ted silica of ref. conditioned successively with a water/acetonitrile mixture (5/95, v/v) and then a water/acetonitrile mixture (95/5, v/v) . The elution was performed with a water/acetonitrile mixture (95/5, v/v) over 2 0 minutes, followed by a linear gradient from 5% to 95% of acetonitrile over 60 minutes, at a flow rate of 10 ml/minute. The fractions between 550 and 750 ml are concentrated under reduced pressure. 0 . 060 g of 5,5-dimethyl-l-pyrid-4-ylmethyl-3-(4-tri-fluoromethoxyphenyl)imidazolidine-2, 4-dione is thus obtained, the characteristics of which are as follows: 1H NMR spectrum (300 MHz, (CD3)2SO d6, 8 in ppm) : 1.42 (s : 6H) ; 4.65 (s : 2H) ; 7.44 (broad d, J = 6 Hz : 2H) ; 7.53 (broad d, J = 8.5 Hz : 2H) ; 7.64 (dt, J = 8.5 and 2.5 Hz : 2H) ; 8.54 (broad d, J = 6 Hz : 2H). Mass IE m/z=379 M+. base peak m/z=364 (M-CH3)+ m/z=203 C8H4N02F3+. m/z=92 C6H6N+ Preparation of 5,5-dimethyl-3-(4-trifluoromethoxyphenyl)-imidazolidine-2,4-dione A solution of 7.08 g of 4-trifluoromethoxyaniline in 50 ml of toluene is added over 15 minutes to a suspension of 8.7 g of diphosgene and 1 g of plant charcoal in 100 ml of toluene, at a temperature in the region of -20°C. The mixture is stirred until the temperature is in the region of 2 0°C, and then ref luxed for 3 hours. The mixture is cooled to a temperature in the region of 20°C and then filtered through Celite, 5 g of methyl a-aminoisobutyrate hydrochloride, 5 0 ml of toluene and 10 ml of triethylamine are added to the filtrate. The mixture thus obtained is refluxed for 16 hours and then cooled to a temperature in the region of 20°C. The precipitate is filtereed off and the filtrate is concentrated under reduced pressure, the residue obtained is purified by flash chromatography on a column packed with silica, conditioned and then eluted with a cyclohexane/ethyl acetate mixture (50/50, v/v) . The fractions containing the expected product are concentrated under reduced pressure, and 3.4 g of 5,5-dimethyl-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione are thus obtained, the characteristics of which are as follows: Mass IE m/z=288 M+. base peak m/z=273 (M-CH3)+ m/z=203 C8H4N02F3+. 1H NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm) : 1.42 (s : 6H) ; 7.49 (d, J = 9 Hz : 2H) ; 7.55 (d, J = 9 Hz : 2H) ; 8.63 (unresolved peak : 1H). Example 64: Preparation of 3-[4-(pentafluorothio)-phenyl]-5,5-dimethyl-l-quinolin-4-ylmethylimidazolidine-2,4-dione trifluoroacetate. The compound is prepared from 0.16 mmol of resin, 0.48 mmol of Fmoc-AIB-(OH), 1.12 mmol of 4-quinoline-carboxaldehyde and 0.4 mmol of 4-(pentafluorothio)-aniline, in the same manner as in Example 1. After purification by preparative LC-MS chromatography, 5 mg of the expected product are obtained. EIMS ( [M+H]+) : 472 Example 65: Preparation of 3-[4-(pentafluorothio)-phenyl]-5,5-dimethyl-l-pyrid-4-ylmethylimidazolidine-2,4-dione trifluoroacetate The compound is prepared from 0.16 mmol of resin, 0.48 mmol of Fmoc-AIB-(OH) , 1.12 mmol of 4-pyridine-carboxaldehyde and 0.4 mmol of 4-(pentafluorothio)-aniline, in the same manner as in Example 1. After purification by preparative LC-MS chromatography, 13.2 mg of the expected product are obtained. EIMS ( [M+H]+) : 422 Example 66: Preparation of 3-[4-(pentafluorothio)-phenyl]-l-quinolin-4-ylmethylimidazolidine-2,4-dione trifluoroacetate The compound is prepared from 0.1 mmol of resin, 0.3 mmol of N-Fmoc-Gly-(OH) , 0.5 mmol of 4-quinoline-carboxaldehyde and 0.25 mmol of 4-(pentafluorothio)-aniline, in the same manner as in Example 1. After purification by preparative LC-MS chromatography, 18 mg of the expected product are obtained. EIMS ( [M+H]+) : 444 Example 67: Preparation of 3-[4-(pentafluorothio)-phenyl]-l-pyrid-4-ylmethylimidazolidine-2,4-dione tri-fluoroacetate The compound is prepared from 0.1 mmol of resin, 0.3 mmol of N-Fmoc-Gly-(OH), 0.5 mmol of 4-quinoline-carboxaldehyde and 0.25 mmol of 4-(pentafluorothio) aniline, in the same manner as in Example 1, After purification by preparative LC-MS chromatography, 18 mg of the expected product are obtained. EIMS ( [M+H]+) : 394 Example 68: Preparation of 3-[4-(pentafluorothio)-phenyl]-l-pyrid-2-ylmethylimidazolidine-2# 4-dione tri-fluoroacetate The compound is prepared from 0.1 mmol of resin, 0.3 mmol of N-Fmoc-Gly-(OH) , 0.5 mmol of 4-quinoline-carboxaldehyde and 0.25 mmol of 4-(pentafluorothio)-aniline, in the same manner as in Example 1. After purification by preparative LC-MS chromatography, 9 mg of the expected product are obtained. EIMS ( [M+H]+) : 394 Example 69: Preparation of 3- [4-(pentafluorothio)-phenyl]-l-pyrid-3-ylmethylimidazolidine-2,4-dione tri-fluoroacetate The compound is prepared from 0.2 mmol of resin, 0.6 mmol of N-Fmoc-Gly-(OH) , 1 mmol of 4-quinoline-carboxaldehyde and 0.5 mmol of 4-(pentafluorothio)-aniline, in the same manner as in Example 1. After purification by preparative LC-MS chromatography, 42 mg of the expected product are obtained. EIMS ( [M+H] +) : 394 The 6 reaction schemes below describe the preparation of products of formula (I) according to the present invention/ especially among the products of Examples 70 to 178 that follow. Scheme 1 describes the preparation of hydantoin derivatives with amino substituents in the two positions of the pyridine ring (B2) . Procedures of Scheme 1 Step 1: (Syntheses described for X = S, analogous scheme for X = 0) . l-Isocyanato-4-trifluoromethylsulfanylbenzene (14.27 g, 65 mmol) is dissolved in 30 ml of dry CH2C12 and cooled to 0°C. 7.5 g (65 mmol) of N-ethylmorpholine are added, followed by 10 g (65 mmol) of methyl 2-amino-2-methylpropionate. The reaction is left to reach 25°C over a period of 6 hours and washed with water, and, after removal of the solvent, 21.8 g of the product methyl 2-methyl-2-[3-(4-trifluoromethyl-sulfanylphenyl)ureido]propionate 3 are isolated. Step 2: 30 g of methyl 2-methyl-2-[3-(4-trifluoromethyl-sulfanylphenyl)ureido]propionate 3 are dissolved in a mixture of 225 ml of 3N HC1 and 230 ml of dioxane, refluxed for 6 hours and, after cooling to 4°C, the product 5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl) imidazolidine-2,4-dione is isolated in the form of white crystals (24.14 g) . Step 3: 5,5-Dimethyl-3 -(4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione 3 (1 g, 3.29 mmol) is dissolved in 10 ml of DMF, 1.36 g of K2C03 (3 eq, 9.87 mmol) and 909 mg of 2-chloro-4-chloromethylpyridine (3.95 mmol, 1.2 eq) are added and the mixture is refluxed for 2 0 hours. The solvent is removed under vacuum and the residue is dissolved in CH2C12 and treated three times with active charcoal. After removal of the solvent, the product 1-(2-chloropyrid-4-ylmethyl)-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)imidazolidine-2,4-dione is obtained (3.2 g; 56%). Analytical data: MS (LC-MS): 429.05; retention time: 2.49 min. NMR: 1.4: s, 6H; 4.7: s, 2H; 7.45: m, 1H; 7.6: s, 1H; 7.7: d, 2H; 7.9: d, 2H; 8.4: m, 1H. Preparation of 2-chloro-4-chloromethylpyridine 10 g of 2-chloro-4-methylpyridine are dissolved in 3 0 ml of CH3CN and a mixture of AIBN (3 g) and NCS (30 g) is added. The resulting mixture is refluxed for 4 hours. After removal of the solvent, the crude product is purified further by distillation (boiling point: 70 °C, 20 mtorr). Step 4: General procedure for the palladium-catalyzed amination of the pyridine ring system in 1- (2-chloro-pyrid-4-ylmethyl)-5,5-dimethyl-3-(4-trifluoromethyl-sulfanylphenyl)imidazolidine-2,4-dione 100 mg (0.23 mmol) of 1-(2-chloropyrid-4-ylmethyl)-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)imidazolidine-2 , 4-dione, 20 mg of Pd(0Ac)2, 60 mg of XANTPHOS and 3 00 mg of Cs2C03 are transferred into a reaction tube with a screw stopper equipped with a rubber seal and an argon atmosphere is generated in the tube. 1.5 equivalents (0.35 mmol) of the appropriate amine or amide are dissolved in 10 ml of toluene, the solution is transferred into the reaction tube mentioned above and the resulting mixture is heated at 95°C for 6 to 10 hours depending on the reaction progress, which is monitored by LCMS. After filtration, the solvent is removed under vacuum and the crude product is further purified by chromatography on an HPLC system. Scheme 2 describes the preparation of urea and thiourea derivatives. Analytical data for N- {4- [5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazolidin-1-yl-methyl]pyrid-2-yl}acetamide: MS (LC-MS): 452.11; retention time: 1.82 min. NMR: 1.4: s, 6H; 2.05: s, 3H; 4.65: S, 2H; 7.1: m, 1H; 7.65: d, 2H; 7.85: d, 2H; 8.15: m, 1H; 8.25: m, 1H. Step 2: 500 mg (1.11 mmol) of N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazolidin-1-ylmethyl]pyrid-2-yl}acetamide are dissolved in MeOH, 1.5 mmol of NaOMe are added and the resulting mixture is refluxed for 4 hours. The solvent is removed, the residue is taken up in CH2C12/ washed twice with 10% NaHC03 solution and water, and the organic phase is evaporated off. 340 mg (75%) of 1- (2-aminopyrid-4-ylmethyl)-5,5-dimethyl-3- (4-trifluoromethylsulfanylphenyl) imidazolidine-2,4-dione are isolated in this manner. MS (LC-MS): 410.10; retention time: 1.57. NMR: 1.4: s, 6H; 4.4: s, 2H; 6.35: s, 2H; 6.4: m, 1H; 6.5: m, 1H; 7.65: d, 2H; 7.9: m, 3H. Step 3: General procedure, all the urea and thiourea derivatives are prepared in this manner. 10 0 mg of 1-(2-aminopyrid-4-ylmethyl)-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)imidazolidine-2,4-dione are dissolved in 5 ml of dioxane and 1.5 equivalents of the corresponding isocyanate or isothiocyanate are added. The reaction is stirred at slightly elevated temperature up to completion, which is monitored by LCMS. The solvent is removed, and further purification is obtained by chromatography on an HPLC system. R = alkyl, substituted alkyl, aryl, substituted aryl, alkyl-CO-, substituted alkyl-CO, aryl-CO-, substituted aryl-CO X = S or O Scheme 3 Step 1: (Syntheses described for X = S, analogous scheme for X = 0) 5,5-Dimethyl-3-(4-trifluoromethylsulfanylphenyl)imi-dazolidine-2,4-dione (1000 mg/3.29 mmol) is dissolved in 20 ml of DMF, Cs2C03 (3.21 g/9.9 mmol) and 2,6-dichloro-4-chloromethylpyridine (774 g/3.9 mmol) are added and the resulting mixture is heated at 80°C for 6 hours. The solvent is removed, the residue is dissolved in CH2C12 and washed three times with water. After evaporation of the solvent, the crude material is further purified by chromatography on an HPLC system. Step 2: General procedure for the Pd-catalyzed monoamination of 1-(2,6-dichloropyrid-4-ylmethyl)-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)imidazolid-ine-2,4-dione This step is identical to step 4 of Scheme 1, but only 1 equivalent of the corresponding amine or amide is used. Step 3: General procedure for the Pd-catalyzed bisamination of 1-(2,6-dichloropyrid-4-ylmethyl)-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)imidazolid-ine-2,4-dione This step is identical to step 4 of Scheme 1, but in this case 2.2 equivalents of the corresponding amine or amide are used. Het = aromatic or aliphatic heterocycle X = CI or Br Scheme 4: General procedure for the alkylation of 5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)imidazolid-ine-2,4-dione with aromatic or aliphatic heterocycles bearing a chloromethyl or bromomethyl substituent 5,5-Dimethyl-3-(4-trifluoromethylsulfanylphenyl)imi-dazolidine-2,4-dione (100 mg/0.33 mmol) is dissolved in 10 ml of DMF, Cs2C03 (321 mg/0.99 mmol) and 0.4 9 mmol (1.5 equivalents) of the corresponding aromatic or aliphatic heterocycle substituted with a chloromethyl or bromomethyl group is added, and the resulting mixture is heated at 80°C for 6 hours. The solvent is removed and the crude material obtained is further purified by chromatography on an HPLC system. Scheme 5 100 mg (0.23 mmol) of 1-(2-chloropyrid-4-ylmethyl)-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)imidazo-lidine-2,4-dione, 20 mg of Pd(OAc)2, 60 mg of XANTPHOS, 300 mg of Cs2C03 and 124 mg of Mo(CO)6 (2 eq) are transferred into a screw stoppered reaction tube with a rubber seal and an argon atmosphere is generated in the tube. 1.5 equivalents (0.35 mmol) of the appropriate amine and 212 mg of DBU are dissolved in 10 ml of toluene, this solution is transferred into the reaction tube mentioned above and the resulting mixture is heated at 95°C for 6 to 10 hours as a function of the reaction progress, which is monitored by LCMS. After filtration, the solvent is removed under vacuum and the crude product is further purified by chromatography on an HPLC system. Scheme 6 3 0 mg (0.05 mmol) of methyl 2-(3-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazolidin-1-ylmethyl]pyrid-2-yl}thioureido)benzoate are dissolved in 2 ml of MeOH, 0.1 mmol of NaOMe is added and the resulting mixture is stirred at room temperature overnight. After evaporating off the solvent, the crude material of 5,5-dimethyl-1-[2-(4-oxo-2-thioxo-l,4-dihydro-2H-quinazolin-3-yl)pyrid-4-ylmethyl] -3-(4-trifluoromethylsulf anylphenyl) imidazolidine-2,4-dione is further purified by chromatography on an HPLC system. Example 70: N-{4- [5,5-Dimethyl-2,4-dioxo-3-(4-tri-fluoromethylsulfanylphenyl)imidazolidin-l-ylmethyl]pyrid-2-yl}propionamide; compound with trifluoroacetic acid MS (LC-MS): 466.13, retention time: 1.83 min. NMR: 1.05: t, 3H; 1.40: S, 6H; 2.35: q, 2H; 4.65: s, 2H; 7.1: d, 1H; 7.65: d, 2H; 7.85: d, 2H; 8.15: S, 1H; 8.25: d, 1H. The synthesis is described in Scheme 1. Example 71: N-{4-[5,5-Dimethyl-2,4-dioxo-3-(4-tri-fluoromethylsulfanylphenyl) imidazolidin»l-ylmethyl]pyrid-2-yl}isobutyramide; compound with trifluoroacetic acid MS (LC-MS): 480.14, retention time: 1.93 min. NMR: 1.10: d, 6H; 1.40: s, 6H; 2 .75: s, 1H; 4.65: s, 2H; 7.15: d, 1H; 7.65: d, 2H; 7.85: d, 2H; 8.15: s, 1H; 8.25: d, 1H. The synthesis is described in Scheme 1. Example 72: N-{4- [5,5-Dimethyl-2,4-dioxo-3-(4-tri-fluoromethylsulfanylphenyl) imidazolidin-l-ylmethyl]pyrid-2-yl}-3-morpholin-4-ylpropionamide; compound with trifluoroacetic acid MS (LC-MS): 551.18, retention time: 1.54 min. NMR: 1.40: s, 6H; 2.85: m, 2H; 3.1: m, 2H; 3.4: m, 2H; 3.95: m, 2H; 4.65: s, 2H; 7.15: d, 1H; 7.65: d, 2H; 7.85: d, 2H; 8.15: s, 1H; 8.25: d, 1H. The synthesis is described in Scheme 1. Example 73: N-{4- [5,5-Dimethyl-2,4-dioxo-3-(4-tri- fluoromethylsulfanylphenyl)imidazolidin-1-ylmethyl]pyrid- 2-yl}-3-[4-(2-hydroxyethyl)piperazin-l-yl]propionamide MS (LC-MS): 594.22, retention time: 1.40 min. NMR: 1.40: s, 6H; 2.55 to 3.50: m, 12H; 4.65: S, 2H; 7.15: m, 1H; 7.65: d, 2H; 7.85: d, 2H; 8.15: S, 1H; 8.25: d, 1H. The synthesis is described in Scheme 1. Example 74: N-{4-[5,5-Dimethyl-2,4-dioxo-3-(4-tri- fluoromethylsulfanylphenyl)imidazolidin-l-ylmethyl]pyrid- 2-yl}-3-(4-methylpiperazin-l-yl)propionamide MS (LC-MS): 564.21, retention time: 1.41 min. NMR: 1.40: s, 6H; 2.55 to 3.50: m, 12H; 2.75: s, 3H; 4.65: s, 2H; 7.15: m, 1H; 7.65: d, 2H; 7.85: d, 2H; 8.15: S, 1H; 8.25: d, 1H. The synthesis is described in Scheme 1. Example 75: Cyclopropanecarboxylic acid {4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)-imidazolidin-l-ylmethyl]pyrid-2-yl}amide MS (LC-MS): 478.13, retention time: 1.99 min. NMR: 0.80: m, 4H; 1.15: t, 1H; 1.40: S, 6H; 4.65: s, 2H; 7.15: m, 1H; 7.65: d, 2H; 7.85: d, 2H; 8.15: S, 1H; 8.25: d, 1H. The synthesis is described in Scheme 1. Example 76: 5, 5-Dimethyl-l- [2- (pyrid-2-ylamino) pyrid-4-ylmethyl]-3-(4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione MS (LC-MS): 487.13, retention time: 1.85 min. NMR: 1.40: s, 6H; 4.65: s, 2H; 7.3: m, 4H; 7.65: d, 2H; 7.85: d, 2H; 8.05: s, 1H; 8.35: m, 1H. The synthesis is described in Scheme 1. Example 77: N-{4- [5,5-Dimethyl-2,4-dioxo-3-(4-tri- fluoromethylsulfanylphenyl)imidazolidin-l-ylmethyl]pyrid- 2-yl}-3-pyrrolidin-1-ylpropionamide MS (LC-MS): 535.19, retention time: 1.52 min. ' NMR: 1.40: s, 6H; 1.8: m, 2H; 2.0: m, 2H; 2.85: m, 2H; 3.0: m, 2H; 3.4: m, 2H; 3.5: m, 2H; 4.65: s, 2H; 7.2: m, 1H; 7.65: d, 2H; 7.85: d, 2H; 8.15: s, 1H; 8.40: m, 1H. The synthesis is described in Scheme 1. Example 78: 5,5-Dimethyl-1-{2-[3-(4-methylpiperazin-l-yl)propylamino]pyrid-4-ylmethyl}-3- (4-trifluoromethyl-sulfanylphenyl)imidazolidine-2,4-dione MS (LC-MS): 550.23, retention time: 1.52 min. NMR: 1.40: s, 6H; 2.6 to 3.5: m, 14H; 2.75: s, 3H; 4.65: s, 2H; 6.85: m, 1H; 6.95: m, 1H; 7.65: d, 2H; 7.9: m, 3H. The synthesis is described in Scheme 1. Example 79: 5,5-Dimethyl-1-{2-[3-(4-ethylpiperazin-l-yl)propylamine)]pyrid-4-ylmethyl}-3- (4-trifluoromethyl-sulfanylphenyl)imidazolidine-2,4-dione The synthesis is described in Scheme 1. Example 80: 1- [2- (3-Methoxyphenylamino)pyrid-4-ylmethyl]-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione MS (LC-MS): 516.14, retention time: 1.90 min. NMR: 1.40: s, 6H; 3.7: s, 3H; 4.65: s, 2H; 6.6: m, 1H; 6.9: m, 2H; 7.15: m, 1H; 7.2: m, 1H; 7.25: m, 1H; 7.65: d, 2H; 7.85: d, 2H; 8.05: s, 1H. The synthesis is described in Scheme 1. Example 81: N-{4- [5, 5-Dimethyl-2, 4-dioxo-3- (4-tariff luoromethylsulfanylphenyl) imidazolidin-l-ylmethyl]pyrid-2-yl}-3-(4-ethylpiperazin-l-yl)propionamide MS (LC-MS): 516.14, retention time: 1.90 min. NMR: 1.15: t, 3H; 1.40: S, 6H; 2.5 to 3.7: m, 14H; 4.65: s, 2H; 7.15: m, 1H; 7.65: d, 2H; 7.85: d, 2H; 8.15: s, 1H; 8.25: m, 1H. The synthesis is described in Scheme 1. Example 82: 5,5-Dimethyl-1-[2-(3-methyl-2-oxopyrrolidin-l-yl)pyrid-4-ylmethyl] -3- (4-trifluoromethyl-sulfanylphenyl)lmidazolldlne-2,4-dione; compound with trifluoroacetic acid MS (LC-MS): 492.14; retention time: 2.23 min. NMR: 1.15: d, 3H; 1.40: s, 6H; 1.60: m, 1H; 2.30: m, 1H; 2.70: m, 1H; 3 .80: m, 1H; 4.0: m, 1H; 4 .65: s, 2H; 7.15: m, 1H; 7.65: d, 2H; 7.85: d, 2H; 8.35: m, 2H. The synthesis is described in Scheme 1. Example 83 MS (LC-MS): 495.19; retention time: 1.43 min. The synthesis is described in Scheme 1. Example 84: 5,5-Dimethyl-1-[2-(4-pyrid-2-ylpiperazin-l-yl)pyrid-4-ylmethyl] -3- (4-trifluoromethylsulfanylphen-yl)imidazolidine-2,4-dione; compound with trifluoroacetic acid MS (LC-MS): 556.19; retention time: 1.56 min. The synthesis is described in Scheme 1. Example 85: N-{4- [5,5-Dimethyl-2,4-dioxo-3-(4-tri-fluoromethylsulfanylphenyl)imidazolidin-l-ylmethyl]pyrid-2-yl}-3-piperid-l-ylpropionamide; compound with trifluoroacetic acid MS (LC-MS): 549.22; retention time: 1.62 min. NMR: 1.45: s, 6H; 1.55: m, 3H; 1.80: m, 2H; 2.80: m, 4H; 3.3 to 3.5: m, 7H; 4.65: s, 2H; 7.15: m, 1H; 7.65: d, 2H; 7.85: m, 2H; 8.15: m, 1H; 8.3: m, 1H; 9.0: m, 1H. The synthesis is described in Scheme 1. Example 86: 1- [2- (3-Imidazol-l-ylpropylamino)pyrid-4-ylmethyl] -5, 5-dimethyl-3- (4-trifluoromethylsulfanyl-phenyl) imidazolidine-2,4-dione; compound with tri-fluoroacetic acid MS (LC-MS): 518.17/ retention time: 1.57 min. The synthesis is described in Scheme 1. Example 87: 1-[2-(4-Ethylpyrid-2-ylamino)pyrid-4-yl-methyl]-5,5-dimethyl-3-(4-trifluoromethylsulfanyl-phenyl)imidazolidine-2,4-dione MS (LC-MS): 515.16; retention time: 1.85 min. NMR: 1.15: t, 3H; 1.45: s, 6H; 2.7: q, 2H; 4.75: S, 2H; 7.1: broad s, 2H; 7.3: broad s 2HM; 7.65: d, 2H; 7.85: d, 2H; 8.25: s, 1H; 8.45: s, 1H. The synthesis is described in Scheme 1. Example 88: 1-[2-(6-Ethylpyrid-2-ylamino)pyrid-4-yl-methyl]-5,5-dimethyl-3-(4-trifluoromethylsulfanyl-phenyl)imidazolidine-2,4-dione MS (LC-MS): 515.16; retention time: 1.95 min. NMR: 1.15: t, 3H; 1.45: S, 6H; 2.7: q, 2H; 4.75: s, 2H; 7.1: broad s, 2H; 7.3: broad s 2HM; 7.65: d, 2H; 7.85: d, 2H; 8.25: s, 1H; 8.45: s, 1H. The synthesis is described in Scheme 1. Example 89: 5,5-Dimethyl-l-[2-(quinolin-2-ylamino)pyrid-4-ylmethyl]-3-(4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione MS (LC-MS): 537.14; retention time: 1.95 min. NMR: 1.45: s, 6H; 4.75: s, 2H; 7.4 to 7.6: m, 6H; 7.65: d, 2H; 7.85: d, 2H; 8.00: broad s, 1H; 8.50: broad s, 2H. The synthesis is described in Scheme 1. Example 90: 5,5-Dimethyl-l-[2-(4-methylpyrid-2-yl-amino)pyrid-4-ylmethyl] -3- (4-trifluoromethylsulfanyl-phenyl)imidazolidine-2,4-dione MS (LC-MS): 501.14; retention time: 1.80 min. NMR: 1.45: s, 6H; 2.4: S, 3H; 4.75: s, 2H; 7.1: m, 2H; 7.25: m, 2H; 7.65: d, 2H; 7.85: d, 2H; 8.20: broads, 1H; 8.45: broad s, 1H. The synthesis is described in Scheme 1. Example 91: 5,5-Dimethyl-1-[2-(6-methylpyrid-2-yl-amino)pyrid-4-ylmethyl] -3- (4-trifluoromethylsulfanyl-phenyl)imidazolidine-2,4-dione MS (LC-MS): 501.14; retention time: 1.85 min. NMR: 1.45: s, 6H; 2,55: s, 3H; 4.75: s, 2H; 7.1: m, 1H; 7.25: m, 2H; 7.4: s, 1H; 7.65: d, 2H; 7.85: m, 3H; 8.45: broad s, 1H. The synthesis is described in Scheme 1. Example 92: 1- [2-(3,5-Dichloropyrid-2-ylamino)pyrid-4-ylmethyl]-5,5-dimethyl-3-(4-trifluoromethylsulfanyl-phenyl)imidazolidine-2,4-dione MS (LC-MS): 555.05; retention time: 1.96 min. NMR: 1.45: s, 6H; 4.70: S, 2H; 7.1: m, 1H; 7.20: m, 1H; 7.65: d, 2H; 7.85: m, 3H; 8.30: m, 3H. The synthesis is described in Scheme 1. Example 93: 1-[2-(4,6-Dimethylpyrid-2-ylamino)pyrid-4-ylmethyl] -5, 5-dimethyl-3- (4-trif luoromethylsulfanyl- phenyl) imidazolidine-2, 4-dione F MS (LC-MS): 515.16; retention time: 2.00 min. NMR: 1.45: S; 2.35: s, 3H; 2.6: S, 3H; 6H; 4.75: s, 2H; 7.0: m, 2H; 7.35: m, 2H; 7.70: d, 2H; 7.9: dt 2H; 8.40: broad s, 1H. The synthesis is described in Scheme 1. NMR: 1.45: S; 4.70: s, 2H; 7.15: m, 1H; 7.25: m, 1H; 7.65: d, 2H; 7.9: d, 2H; 8.10: broad s, 2H; 8.40: s, 1H; 8.50: m, 2H. The synthesis is described in Scheme 1. Example 96: 5,5-Dimethyl-1-[2-(pyrid-3-ylamino)pyrid-4-ylmethyl] -3- (4-trifluoromethylsulfanylphenyl) imidazol-idine-2,4-dione MS (LC-MS): 487.13; retention time: 1.69 min. NMR: 1.45: s; 4.60: s, 2 H; 6.95: s, 1H; 7.05: s, 1H; 7.7: d, 2H; 7.8: m, 1H; 7.85: d, 2H; 8.25: s, 1H; 8.35: s, 1H; 8.45: m, 1H; 9.4: s, 1H. The synthesis is described in Scheme 1. Example 97: N-{4- [5,5-Dimethyl-2,4-dioxo-3-(4-tri- fluoromethylsulfanylphenyl)imidazolidin-l-ylmethyl]pyrid- 2-yl}-3-(2-oxoazepan-l-yl)propionamide. r- MS (LC-MS): 577.20; retention time: 2.00 min. NMR: 1.45: s, 6H; 1.5: m, 4H; 1.55: m, 2H; 2.35: m, 2H; 2.6: m, 4H; 3.3 m, 2H; 4.65: S, 2H; 7.15: S, 1H ; 7.65: d, 2H; 7.85: d, 2H; 8.1: s, 1H; 8.35: s, 1H. The synthesis is described in Scheme 1. Example 98: 3- (Benzylmethylamino)-N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazolidin-1-ylmethyl]pyrid-2-yl}propioneunide F MS (LC-MS): 585.20, retention time: 1.73 min. NMR: 1.45: s, 6H; 2.2: s, 3H; 2.95: m, 2H; 3.3: m, 1H; 4.3: m, 1H; 4.4: m, 1H; 4.65: s, 2H; 7.2: s, 1H; 7.45: m, 2H; 7.50: m, 2H; 7.65: d, 2H; 7.85: d, 2H; 8.1: m, 1H; 8.3: m, 1H. The synthesis is described in Scheme 1. Example 99: N-{4-[5,5-Dimethyl-2,4-dioxo-3-(4-tri-fluoromethylsulfanylphenyl) imidazolidin-l-ylmethyl]pyrid-2-yl}-2-pyrrolidin-l-ylacetamide MS (LC-MS): 521.17, retention time: 1.68 min. NMR: 1.45: s, 6H; 1.85: m, 2H; 2.00: m, 2H; 3.1: m, 2H; 4.25: m, 2H; 4.7: s, 2H; 7.25: m, 1H; 7.65: d, 2H; 7.85: d, 2H; 8.1: broad s, 1H; 8.3: s, 1H. The synthesis is described in Scheme 1. Example 100: N«{4- [5,5-Dimethyl-2,4-dioxo-3-(4-tri- fluoromethylsulfanylphenyl)imidazolidin-l-ylmethyl]pyrid- 2-yl}-2-(4-pyrid-2-ylpiperazin-l-yl)acetamide MS (LC-MS): 613.21, retention time: 1.60 min. NMR: 1.45: s, 6H; 3.3: broad m, 4H; 4.35: broad m, 4H; 4 .65 : s, 2H; 6.7: m, 1H; 6.9: m, 1H; 7.25: s, 1H; 7.65, m + d: 3H; 7.85: d, 2H; 8.15: m, 2H; 8.35: s, 1H. The synthesis is described in Scheme 1. Example 101: 2- [ (2-Dimethylaminoethyl)methylamino]-N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethyl-sulfanylphenyl)imida20lidin-l-ylmethyl]pyrid-2-yl}-acetamide MS (LC-MS): 552.21, retention time: 1.52 min. NMR: 1.45: s, 6H; 2.75: s, 6H; 4.65: s, 2H; 7.20: m, 1H; 7.65: d, 2H; 7.85: d, 2H; 8.15: S, 1H; 8.30: m, 1H. The synthesis is described in Scheme 1. Example 102: 3- [ (2-Dimethylaminoethyl)methylamino] -N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethyl-sulfanylphenyl) imidazolidin-l-ylmethyl]pyrid-2-yl}-propionamide MS (LC-MS): 566.23, retention time: 1.37 min. NMR: 1.45: s, 6H; 2.75: S, 6H; 2.8 to 3.4: broad m, 8H; 7.20: m, 1H; 7.65: d, 2H; 7.85: d, 2H; 8.15: s, 1H; 8.30: m, 1H. The synthesis is described in Scheme 1. Example 103: 5,5-Dimethyl-1-[2-(5-methylpyrid-2-yl-amino)pyrid-4-ylmethyl] -3- (4-trifluoromethylsulfanyl-phenyl) imidazolidine-2, 4-dione MS (LC-MS): 501.14, retention time: 1.83 min. NMR: 1.45: s, 6H; 2.3: s, 3H; 4.7: s, 2H; 7.3: m, 3H; 7.7: d, 2H; 7.9: d, 2H; 8.2: m, 1H; 8.35: m, 1H. The synthesis is described in Scheme 1. Example 104: N-{4- [5,5-Dimethyl-2,4-dioxo-3-(4-tri-fluoromethylsulfanylphenyl)imidazolidin-l-ylmethyl]pyrid-2-yl}-3,5-dimethoxybenzamide; compound with tri-fluoroacetic acid MS (LC-MS): 574.78, retention time: 2.34 min. NMR: 1.45: s, 6H; 2.3: s, 3H; 4.7: S, 2H; 6.7: s, 2H; 7.2: m, 2H; 7.25: m, 1H; 7.7: d, 2H; 7.9: d, 2H; 8.2: m, 1H; 8.3: m, 1H. The synthesis is described in Scheme 1. Example 105: 2- (Benzylmethylamino) -N-{4- [5, 5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazol-idin-l-ylmethyl]pyrid-2-yl}acetemiide; compound with trifluoroacetic acid MS (LC-MS): 574.78, retention time: 2.34 min. NMR: 1.45: s, 6H; 2.8: s, 4.0 to 4.4: m, 4H; 4.7: s, 2H; 7.2: m, 1H; 7.4: m, 2H; 7.5: m, 2H; 7.7: d, 2H; 7.9: d, 2H; 8.1: m, 1H; 8.3: m, 1H. The synthesis is described in Scheme 1. MS (LC-MS): 488.12, retention time: 1.63. NMR: 1.45: s, 6H; 4.7: s, 2H; 7.1: m, 1H; 7.6: m, 1H; 7.65: d, 2H; 7.9: d, 2H; 8.2: s, 1H; 8.3: m, 2H; 9.0: S, 1H. The synthesis is described in Scheme 1. Example 107: N-{4- [5,5-Dimethyl-2,4-dioxo-3-(4-tri- f luoromethylsulf anylphenyl) imidazolidin-1-ylmethyl] pyrid- 2-yl}-2-phenylbutyramide; compound with trifluoroacetic acid MS (LC-MS): 566.18, retention time: 2.43. NMR: 0.7: t, 3H; 1.4: s, 6H; 1.7: m, 1H; 2.05: m, 1H; 4.6: S, 2H; 7.1: S, 1H; 7.25: m, 1H; 7.3: m, 1H; 7.4: m, 2H; 7.65: d, 2H; 7.85: d, 2H; 8.15: s, 1H; 8.25: m, 1H. The synthesis is described in Scheme 1. Example 108: N-{4- [5,5-Dimethyl-2,4-dioxo-3-(4-tri-fluoromethylsulfanylphenyl)imidazolidin-l-ylmethyl]pyrid-2-yl}-3-(3-methylpiperid-l-yl)propionamide; compound with trifluoroacetic acid MS (LC-MS): 563.22, retention time: 1.62. The synthesis is described in Scheme 1. Example 109: 1- [2- (4-Methoxyphenylamino)pyrid-4-ylmeth-yl]-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione MS (LC-MS): 517.1; retention time: 1.74. NMR: 1.4: s, 6H; 4.6: s, 2H; 6.85: broad s, 1H; 7.0: m, 1H; 7.4: m, 2H; 7.6: d, 2H; 7.9: d, 2H; 8.95: S, 1H. The synthesis is described in Scheme 1. Example 110: 5,5-Dimethyl-1-[2-(2-oxopyrrolidin-l-yl)-pyrid-4-ylmethyl]-3-(4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione MS (LC-MS): 478.13; retention time: 1.83. The synthesis is described in Scheme 1. Example 111: {4-[5,5-Dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethyl]pyrid-2-yl}-pyraz ine-2-carboxamide; compound wi th tri fluoroacetic acid MS (LC-MS): 516.12; retention time: 2.42. NMR: 1.4: s, 6H; 4.7: S, 2H; 7.3: m, 1H; 7.65: d, 2H; 7.95: d, 2H; 8.3: S, 1H; 8.4: s, 1H; 8.7: s, 1H; 9.0: s, 1H; 9.4: s, 1H. The synthesis is described in Scheme 1. Example 112: N-{4- [5,5-Dimethyl-2,4-dioxo-3-(4-tri-f luoromethylsulf anylphenyl) imidazolidin-1-ylmethyl] pyrid-2-yl}-2,2-dimethylpropionamide; compound with trifluoroacetic acid MS (LC-MS): 494.16; retention time: 2.48. NMR: 1.2: S, 9H; 1.4: s, 6H; 4.7: s, 2H; 7.2: m, 1H; 7.65: d, 2H; 7.90: d, 2H; 8.1: S, 1H; 8.3: s, 1H. The synthesis is described in Scheme 1. Example 113 : Thiophene-2-carboxylic acid {4- [5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)-imidazolidin-l-ylmethyl]pyrid-2-yl}amide; compound with trifluoroacetic acid MS (LC-MS): 520.09; retention time: 2.14. NMR: 1.4: s, 6H; 4.7: S, 2H; 7.2: m, 2H; 7.65: d, 2H; 7.8: m, 3H; 8.2: s, 1H; 8.25: S, 1H; 8.4: m, 1H. The synthesis is described in Scheme 1. Example 114: N-{4- [5,5-Dimethyl-2,4-dioxo-3-(4-tri-fluoromethylsulfanylphenyl)imidazolidin-l-ylmethyl]pyrid-2-yl}-4-methylbenzamide; compound with trifluoroacetic acid MS (LC-MS): 528.16; retention time: 2.23. NMR: 1.4: s, 6H; 4.7: s, 2H; 7.2: m, 1H; 7.3: d, 2H; 7.7: d, 2H; 7.85: d, 2H; 7.95: d, 2H; 8.2: s, 1H; 8.3: s, 1H. The synthesis is described in Scheme 1. Example 115: N-{4- [5,5-Dimethyl-2,4-dioxo-3-(4-tri-fluoromethylsulfanylphenyl)imidazolidin-l-ylmethyl]pyrid-2-yl}-3 -(3,5-dimethylpiperid-1-yl)propionamide; compound with trifluoroacetic acid F MS (LC-MS): 577.23; retention time: 1.72. The synthesis is described in Scheme 1. Example 116: N-{4- [5,5-Dimethyl-2,4-dioxo-3-(4-tri-fluoroxnethylsulfanylphenyl)imidazolidin-l-ylmethyl]pyrid-2-yl}-3-(4-pyrid-2-ylpiperazin-l-yl)propionamide; compound with trifluoroacetic acid MS (LC-MS): 627.22; retention time: 1.50. NMR: 1.4: s, 6H; 2.9: m, 2H; 3.1: m, 2H; 3.4: m, 2H; 3.6: m, 2H; 4.4: m, 2H; 4.65: s, 2H; 6.7: m, 1H; 6.95: d, 1H; 7.2: m, 1H; 7.7: d, 2H; 7.9: d, 2H; 8.15: m, 2H; 8.3: m, 1H. The synthesis is described in Scheme 1. Example 117: 5,5-Dimethyl-l-[2-(5-trifluoromethylpyrid-2-ylamino)pyrid-4-ylmethyl]-3-(4-trifluoromethyl-sulfanylphenyl)imldazolidlne-2,4-dlone F MS (LC-MS): 555.51; retention time: 1.78. The synthesis is described in Scheme 1. Example 118: N-{4-[5,5-Dimethyl-2,4-dioxo-3-(4-tri- fluoromethylsulfanylphenyl)imidazolidin-1-ylmethyl]pyrid- 2-yl}-3-methoxybenzamide; compound with trifluoroacetic acid MS (LC-MS): 544.14; retention time: 2.15. The synthesis is described in Scheme 1. Example 119: 1- (3,5-Dichlorophenyl)-3-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazol-idin-l-ylmethyl]pyrid-2-yl}urea MS (LC-MS): 597.06; retention time: 2.15 min. The synthesis is described in Scheme 2. Example 120: Methyl 3- (3-{4- [5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazolidin-1-yl-methyl]pyrid-2-yl}thioureido)benzoate MS (LC-MS): 603.12; retention time: 2.81 min. The synthesis is described in Scheme 2. Example 121: l-{4- [5,5-Dimethyl-2,4-dioxo-3-(4-tri- fluoromethylsulfanylphenyl)imidazolidin-1-ylmethyl]pyrid- 2-yl}-3-phenylurea MS (LC-MS): 529.14; retention time: 2.33 min. NMR: 1.50: s, 6H; 4.65: s, 1H; 7.0: m, 2H; 7.30: m, 2H; 7.5: m, 3H; 7.65: d, 2H; 7.85: d, 2H; 8.25: d, 1H; 9.4: s, 1H. The synthesis is described in Scheme 2. Example 122: 1-(2,4-Dichlorophenyl)-3-{4-[5, 5-dimethy 1-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazol-idin-1-ylmethyl]pyrid-2-yl}urea MS (LC-MS): 597.06; retention time: 3.00 min. The synthesis is described in Scheme 2. Example 123: 1-(3-Chlorophenyl)-3-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazolidin-1-ylmethyl]pyrid-2-yl}thiourea MS (LC-MS): 579.08; retention time: 3.05 min. The synthesis is described in Scheme 2. Example 124: Methyl 2- (3-{4- [5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazolidin-1-yl-methyl]pyrid-2-yl}thioureido) benzoate MS (LC-MS): 603.12; retention time: 2.85 min. The synthesis is described in Scheme 2. Example 125: 3,5-Diacetoxy-2-acetoxymethyl-6- (3-{4- [5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanyl-phenyl) imidazolidin-1-ylmethyl]pyrid-2-yl}thioureido) -tetrahydropyran-4-yl acetate MS (LC-MS): 799.18, retention time: 2.60 min. The synthesis is described in Scheme 2. Example 126: 1-(4-Dimethylaminophenyl)-3-{4-[5,5-di-methyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)-imidazolidin-1-ylmethyl]pyrid-2-yl}thiourea MS (LC-MS): 588.16; retention time: 1.99. NMR: 1.4: s, 6H; 2.9: s, 6H; 4.7: s, 2H; 6.7: d, 2H; 7.1: m, 1H; 7.25: s, 1H; 7.4: d, 2H; 7.7: d, 2H; 7.9: d, 2H; 8.25: m, 1H. The synthesis is described in Scheme 2. Example 127: 1- (2,4-Dimethoxyphenyl)-3-{4-[5, 5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)-imidazolidin-l-ylmethyl]pyrid-2-yl}urea MS (LC-MS): 589.60; retention time: 1.98. The synthesis is described in Scheme 2. Example 128: 3- (3-{4- [5,5-Dimethyl-2,4-dioxo-3-(4-tri-f luoromethylsulf anylphenyl) imidazolidin-l-ylmethyl]pyrid- 2-yl}thioureido)benzoic acid n MS (LC-MS): 589.11; retention time: 2.30. The synthesis is described in Scheme 2. Example 129: l-{4- [5,5-Dimethyl-2,4-dioxo-3-(4-tri- f luoromethylsulf anylphenyl) imidazolidin-l-ylmethyl]pyrid- 2-yl}-3-(2-methoxyphenyl)urea MS (LC-MS): 559.15; retention time: 1.88. The synthesis is described in Scheme 2. Example 130: 1-(2-Aminopyrid-4-ylmethyl)-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl) imidazolidine-2,4-dione MS (LC-MS): 410.10; retention time: 1.57. NMR: 1.4: s, 6H; 4.6: s, 2H; 6.9: d, 1H; 7.0: s, 1H; 7.7: d, 2H; 7.85: d, 2H; 7.95: d, 1H; 8.0: broad s, 1H. The synthesis is described in Scheme 2. Example 131: 1-(2,6-Dichloropyrid-4-yl)-3-{4-[5,5-di-methyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)-imidazolidin-1-ylmethyl] pyrid-2-yl}urea MS (LC-MS): 599.42; retention time: 2.73 min. NMR: 1.40, s, 6H; 4.65 s, 2H; 7.15: m, 1H; 7.65: d, 2H; 7.85: d, 2H; 8.15: s, 1H; 8.25: m, 1H. The synthesis is described in Scheme 2. Example 132: 1- (2,6-Dichlorophenyl)-3-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazol-idin-1-ylmethyl]pyrid-2-yl}urea MS (LC-MS): 597.06; retention time: 2.44 min. The synthesis is described in Scheme 2. Example 133: 1-(2,3-Dichlorophenyl)-3-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazol-idin-l-ylmethyl]pyrid-2-yl}urea MS (LC-MS): 597.06; retention time: 2.08 min. The synthesis is described in Scheme 2. Example 134: l-{4- [5,5-Dimethyl-2,4-di oxo-3-(4-tri- fluoromethylsulfanylphenyl)imidazolidin-l-ylmethyl]pyrid- 2-yl}-3-pyrid-3-ylthiourea MS (LC-MS): 546.11; retention time: 1.89 min. The synthesis is described in Scheme 2. Example 135: 1- [2-Chloro-6-(4-methylthiazol-2-ylamino)-pyrid-4-ylmethyl]-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl) imidazolidine-2,4-dione MS (LC-MS): 541.06; retention time: 2.49 min. The synthesis is described in Scheme 3. MS (LC-MS): 535.11; retention time: 1.90 min. The synthesis is described in Scheme 3. Example 13 9: 1- [2,6-bis(3-Methoxyphenylamino)pyrid-4-ylmethyl] -5, 5-dimethyl-3- (4-trifluoromethoxyphenyl) -imidazolidine-2,4-dione; compound with trifluoroacetic acid MS (LC-MS): 621.22; retention time: 1.95 min. The synthesis is described in Scheme 3. Example 140: 1- [2, 6-bis (2,4-Dimethoxyphenylamino)pyrid-4-ylmethyl] -5, 5-dimethyl-3- (4-trif luoromethoxyphenyl) -imidazolidine-2,4-dione; compound with trifluoroacetic acid MS (LC-MS): 681.24; retention time: 1.83 min. The synthesis is described in Scheme 3. Example 141: 1- [2,6-bis (4-Methoxyphenylamino)pyrid-4-ylmethyl]-5,5-dimethyl-3-(4-trifluoromethoxyphenyl)-imidazolidine-2,4-dione; compound with trifluoroacetic acid MS (LC-MS): 621.22; retention time: 1.63 min. The synthesis is described in Scheme 3. Example 142: N-{4-[5,5-Dimethyl-2,4-dioxo-3-(4-tri-fluoromethoxyphenyl)imidazolidin-1-ylmethyl]-6-esto-butyrylaminopyrid-2-yl}isobutyramide; compound with trifluoroacetic acid MS (LC-MS): 549.22; retention time: 1.83 min. The synthesis is described in Scheme 3. Example 143: 1- [2-Chloro-6- (pyrid-4-ylamino)pyrid-4-yl-methyl]-5,5-dimethyl-3-(4-trif luoromethoxyphenyl) imida-zolldlne-2,4-dlone; compound with trifluoroacetic acid MS (LC-MS): 563.19; retention time: 2.61 min. The synthesis is described in Scheme 3. Example 144: 1- [2-Chloro-6-(pyrid-4-ylamino)pyrid-4-yl-methyl]-5,5-dimethyl-3-(4-trifluoromethylsulfanyl-phenyl)imidazolidine-2,4-dione MS (LC-MS): 521.09; retention time: 1.91 min. The synthesis is described in Scheme 3. Example 145: N-{6-Chloro-4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanyIphenyl)imidazolidin-1-yl-methyl]pyridin-2-yl}propionamide MS (LC-MS): 500.09; retention time: 2.46. The synthesis is described in Scheme 3. Example 146: N-{6-Chloro-4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazolidin-1-yl-methyl]pyrid-2-yl}acetamide MS (LC-MS): 486.90; retention time: 2.15. The synthesis is described in Scheme 3. Example 147: 1- [2-Chloro-6-(pyrid-3-ylamino)pyrid-4-yl-methyl]-5,5-dimethyl-3-(4-trifluoromethoxyphenyl)imida-zolidine-2,4-dione; compound with trifluoroacetic acid MS (LC-MS): 505.11/ retention time: 2.27. The synthesis is described in Scheme 3. Example 148: Cyclopropanecarboxylic acid {6 -Chloro-4 -[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl) imidazolidin-l-ylmethyl]pyrid-2-yl}amide MS (LC-MS): 512.09; retention time: 2.32. The synthesis is described in Scheme 3. Example 149: N-{6-Chloro-4-[5,5-dimethyl-2, 4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazolidin-1-yl-methyl]pyrid-2-yl}isobutyramide MS (LC-MS): 514.11; retention time: 1.63. The synthesis is described in Scheme 3. Example 150: 1-[2,6-bis(Pyrid-2-ylamino)pyrid-4-ylmeth-yl]-5,5-dimethyl-3-(4-trifluoromethoxyphenyl)imidazol-idine-2,4-dione; compound with trifluoroacetic acid MS (LC-MS): 563.15; retention time: 1.70 min. The synthesis is described in Scheme 3. Example 151: 1-[2-Chloro«6-(pyrid-2-ylamino)pyrid-4-yl-methyl]-5#5-dimethyl-3-(4-trifluoromethylsulfanylphenyl) imidazolidine-2# 4-dione MS (LC-MS): 521.09; retention time: 1.78 min. The synthesis is described in Scheme 3. Example 152: 5,5-Dimethyl-1-(5-phenyl[1,2,4]oxadiazol-3-ylmethyl)-3- (4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione MS (LC-MS): 462.10; retention time: 2.77 min. The synthesis is described in Scheme 4. Example 153: 1-(2-Imidazol-l-ylethyl)-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)imidazolidine-2,4-dione r MS (LC-MS): 398.10; retention time: 1.49 min. The synthesis is described in Scheme 4. Example 154: 1-[2-(4-Chlorophenyl)oxazol-5-ylmethyl]-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)imidazolidine-2, 4-dione MS (LC-MS): 495.06; retention time: 2.99 min. The synthesis is described in Scheme 4. Example 155: Preparation of l-isoquinolin-5-yl-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)imidazoli-dlne-2,4-dione 50 0 mg (2.4 mmol) of 2- (isoquinolin-5-ylamino)-2- methylpropionitrile, 1.6 mg (0.013 mmol) of benzoic acid and 526 mg (2.4 mmol) of 4- (trif luoromethylthio) phenyl isocyanate in 4 ml of chlorobenzene were re fluxed for 2 days. The resulting mixture was filtered and the filtrate was evaporated to dryness. The intermediate imine was separated out by preparative HPLC chromatography (RP 18, acetonitrile, water, 0.01% TFA) . 60 mg of the resulting product were stirred for 1 hour at 40 °C with IN hydrochloric acid. The solvent was evaporated off and the residue taken up in sodium hydrogen carbonate solution and extracted with ethyl acetate. The combined organic phases were dried and the residue remaining after evaporation was purified by flash chromatography (Si02, methylene chloride/ methanol = 98/2) leading to 3 8 mg of the desired product. M+H+ = 432. LC/MS retention time = 1.245. Example 156: 5,5-Dimethyl-l-(5-phenyloxazol-4-ylmethyl)-3-(4-trifluoromethylsulfanylphenyl)imidazolidine-2,4-dione MS (LC-MS): 461.10, retention time: 2.63 min. The synthesis is described in Scheme 4. Example 157: 5, 5-Dimethyl-1- (l-methylpiperid-3-ylmethyl) -3-(4-trifluoromethylsulfanylphenyl)imidazolidine-2,4-dione MS (LC-MS): 415.15/ retention time: 1.63. The synthesis is described in Scheme 4. Example 158: 5,5-Dimethyl-1-(l-methylpiperid-3-ylmethyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione MS (LC-MS): 499.18; Retention time: 1.39. The synthesis is described in Scheme 4. Example 159: 1-[2-(4-Chlorophenyl)thiazol-4-ylmethyl]-5, 5-dimethyl-3- (4-trifluoromethylsulfanylphenyl) imidazolidine-2, 4-dione MS (LC-MS): 511.04; retention time: 3.12. The synthesis is described in Scheme 4. Example 160: 5,5-Dimethyl-1-(l-methyl-lH-imidazol-2-yl-methyl) -3- (4-trifluoromethylsulfanylphenyl) imidazolidine-2,4-dione MS (LC-MS): 398.10; retention time: 1.53. The synthesis is described in Scheme 4. Example 161: 1-(7-Methoxy-2-oxo-2H-chromen-4-ylmethyl)-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)imid-azolidine-2,4-dione MS (LC-MS): 492.48; retention time: 1.84. The synthesis is described in Scheme 4. Example 162: 5,5-Dimethyl-l-(5-methylestoxazol-3-yl-methyl)-3-(4-trifluoromethylsulfanylphenyl)imidazolidine-2,4-dione MS (LC-MS): 500.09; retention time: 2.52. The synthesis is described in Scheme 4. Example 163: 1- [5- (4-Methoxyphenyl) [1,2,4]oxadiazol-3-ylmethyl] -5, 5-dimethyl-3- (4-trifluoromethylsulfanyl-phenyl)imidazolidine-2,4-dione MS (LC-MS): 492.11; retention time: 1.87. The synthesis is described in Scheme 4. Example 164: 1-[5-(4-Methoxyphenyl)[1,2,4]oxadiazol-3-ylmethyl] -5, 5-dimethyl-3- (4-trif luoromethoxyphenyl) -imidazolidlne-2,4-dione MS (LC-MS): 476.13; retention time: 2.03. The synthesis is described in Scheme 4. Example 165: Methyl 5-[5,5-dimethyl-2,4-dioxo-3-(4-tri-fluoromethylsulfanylphenyl)imidazolidin-1-ylmethyl]-furan-2-carboxylate MS (LC-MS): 442.42; retention time: 1.74. The synthesis is described in Scheme 4. Example 166: 1-(l-Benzyl-lH-imidazol-2-ylmethyl)-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)imidazolidine-2, 4-dione MS (LC-MS): 474.13; retention time: 2.02. The synthesis is described in Scheme 4. Example 167: 1- (4-Dimethylaminopyrimidin-2-ylmethyl) -5,5-dimethyl-3- (4-trifluoromethylsulfanylphenyl) -imidazolidine-2,4-dione , M r MS (LC-MS): 439.46; retention time: 1.91. The synthesis is described in Scheme 4. Example 168: 1- [1-(4-Methoxybenzyl)-lH-imidazol-2-yl-methyl]-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl) imidazolidine-2,4-dione MS (LC-MS): 504.14; retention time: 2.24. The synthesis is described in Scheme 4. Example 169: 5,5-Dimethyl-l-[2-(l-methylpyrrolidin-2-yl)ethyl]-3-(4-trifluoromethylsulfanylphenyl)imidazolidine-2, 4-dione MS (LC-MS): 415.15; retention time: 1.66 min. The synthesis is described in Scheme 4. Example 170: 5,5-Dimethyl-l-(2-morpholin-4-ylethyl)-3-(4-trifluoromethylsulfanylphenyl)imidazolidine-2,4-dione MS (LC-MS): 417.13; retention time: 1.62 min. The synthesis is described in Scheme 4. Example 171: 1-[5-(2-Methoxyphenyl) [1,2,4]oxadiazol-3-ylmethyl] -5,5-dimethyl-3- (4-trifluoromethylsulfanyl-phenyl) imidazolidine-2,4-dione MS (LC-MS): 492.11; retention time: 2.67 min. The synthesis is described in Scheme 4. Example 172: 5,5-Dimethyl-1-(5-methylestoxazol-3-yl-methyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione MS (LC-MS): 383.33; retention time: 1.95 min. The synthesis is described in Scheme 4. Example 173: 1-(5-tert-Butyl[1,2,4]oxadiazol-3-ylmethyl)-5,5-dimethyl-3-(4-trifluoromethylsulfanyl-phenyl)imidazolidine-2,4-dione MS (LC-MS): 442.16; retention time: 2.64 min. The synthesis is described in Scheme 4. Example 174: 4-[5,5-Dimethyl-2,4-dioxo-3-(4-trifluoro-methylsulfanylphenyl)imidazolidin-1-ylmethyl]pyridine-2-carboxylic acid 4-methylbenzylamide; compound with trifluoroacetic acid MS (LC-MS): 542.16; retention time: 2.80 min. The synthesis is described in Scheme 5. Example 175: 4- [5,5-Dimethyl-2,4-dioxo-3-(4-trifluoro-methylsulfanylphenyl)imidazolidin-1-ylmethyl]pyridine-2-carboxylic acid (2-p-tolylethyl)amide MS (LC-MS): 556.18; retention time: 2.31. The synthesis is described in Scheme 5. Example 176: 4- [5,5-Dimethyl-2,4-dioxo-3-(4-trifluoro-methylsulfanylphenyl)imidazolidin-1-ylmethyl]pyridine-2-carboxylic acid 3,4-dimethoxybenzylamide MS (LC-MS): 588.16; retention time: 1.58. The synthesis is described in Scheme 5. Example 177: 4- [5,5-Dimethyl-2,4-dioxo-3-(4-trifluoro-methylsulfanylphenyl)imidazolidin-1-ylmethyl]pyridine-2-carboxylic acid benzylamide MS (LC-MS): 528.14; retention time: 1.77. The synthesis is described in Scheme 5. Example 17 8: 5,5-Dimethyl-1-[2-(4-oxo-2-thioxo-l,4-di-hydro-2H-quinazolin-3-yl)pyrid-4-ylmethyl]-3- (4-tri-fluoromethylsulfanylphenyl)imidazolidine-2,4-dione MS (LC-MS): 571.10; retention time: 2.3. The synthesis is described in Scheme 6 The two reaction schemes below describe the synthesis of products of formula (I) according to the present invention, especially among the products of Examples 178 to 200 below. Bis(4-amino-2-chlorophenyl) disulfide 76.8 g (0.4 mol) of 1,2-dichloro-4-nitrobenzene, suspended in 120 ml of water, were heated to 90°C and treated with a solution of 62.4 g (0.8 mol) of sodium sulfide and 12.8 g (0.4 mol) of sulfur in 200 ml of water. After refluxing the mixture for 5 hours, 6 g of carbon dioxide was bubbled through the solution, followed by a regular stream of air. The pH was adjusted to 5.5, the mixture was cooled to room temperature and the resulting precipitate was collected by filtration. The crude material was recrystallized from isopropanol to give 45 g (71%) of the desired product. M+H+ = 318. LC/MS retention time = 1.526. Bis[(2-chloro-4-(4,4-dimethyl-2,5-dioxo-3-pyrid-4-yl-methylimidazolidin-1-yl)]phenyl disulfide A solution of 13.7 g (69.5 mmol) of diphosgene in 100 ml of toluene was cooled to -20°C and treated with a solution of 5.0 g (15.8 mmol) of bis (4-amino-2-chlorophenyl) disulfide. The resulting mixture was stirred for 30 minutes at room temperature, refluxed for 1 hour and then evaporated to dryness. 2.53 g (about 6.86 mmol) of this material were dissolved in THF and treated with 2.0 g (9.5 mmol) of methyl 2-methyl-2-[(pyrid-4-ylmethyl)amino]propionate. The mixture was stirred for 3 hours at room temperature, evaporated to dryness and the resulting solid was purified by flash chromatography (Si02, methylene chloride/methanol = 97/3) to give 1.8 g (37%) of the desired product. M+H+ = 722. LC/MS retention time = 1.176. Example 179: Preparation of 3- (4-tert-butylsulfanyl-3-chlorophenyl) -5, 5-dimethyl-1-pyrid-4-ylmethylimidazoli-dine-2,4-dione trifluoroacetate 200 mg (0.28 mol) of bis [ (2-chloro-4-(4,4-dimethyl-2, 5-dioxo-3-pyrid-4-ylmethylimidazolidin-l-yl)]phenyl disulfide were dissolved in 10 ml of methanol and treated with 22 mg (0.56 mmol) of sodium borohydride. After stirring for 3 0 minutes at room temperature, the mixture was evaporated to dryness. The residue was dissolved in 10 ml of sulfuric acid (75%) and added to 20 ml of sulfuric acid (75%) saturated with isobutylene. The mixture was stirred for 20 minutes at room temperature and then added cautiously to a cooled solution of sodium hydroxide in water. The alkaline aqueous phase was extracted three times with ethyl acetate, the combined organic phases were dried over sodium sulfate and the material remaining after evaporation was filtered through silica gel (methylene chloride/methanol = 95/5). The resulting crude product was purified by preparative HPLC chromatography (RP 18, acetonitrile, water, 0.01% TFA) leading to 120 mg (81%) of the desired product. M+H+ = 418. LC/MS retention time = 1.249. General procedure 1A: Preparation of 3-(3-chloro-4-alkylsulfanylphenyl)-5,5-dimethyl-l-pyrid-4-ylmethyl-imidazolidine-2,4-diones 445 mg (0.62 mol) of bis[(2-chloro-4-(4,4-dimethyl-2,5-dioxo-3-pyrid-4-ylmethylimidazolidin-l-yl)]phenyl disulfide were dissolved in 15 ml of methanol and treated with 4 9 mg (1.24 mmol) of sodium borohydride. After stirring for 30 minutes at room temperature, 1.24 mmol of the respective alkyl halide were added and the resulting mixture was refluxed for 1 hour. The solvent was removed by evaporation and the remaining crude materials were purified by preparative HPLC chromatography (RP 18, acetonitrile, water, 0.01% TFA). Example 180: Preparation of 3-(3-chloro-4-isopropyl-sulf anylphenyl) -5,5-dimethyl -1 -pyrid- 4 -ylmethylimi -dazolidine-2,4-dione Synthesized according to the general procedure 1A. M+H+ = 404. LC/MS retention time = 1.196. Example 181: Preparation of 3-(3 -chloro-4 -isobutyl-sulfanylphenyl) - 5, 5 -dimethyl-1-pyrid-4-ylmethylimi-dazolidine-2,4-dione trifluoroacetate Prepared according to the general procedure 1A. M+H+ = 418. LC/MS retention time = 1.272. Example 182: Preparation of 3- (3-chloro-4-methyl-sulfanylphenyl)-5, 5-dimethyl-1-pyrid-4-ylmethylimi -dazolidine-2,4-dione Prepared according to the general procedure 1A. M+H+ = 376. LC/MS retention time = 1.054. Example 183: Preparation of 3-[3-chloro-4-(3-methoxy-propylsulfanyl)phenyl]-5,5-dimethyl-1-pyrid-4-ylme thyl-imidazolidine-2,4-dione trifluoroacetate Prepared according to the general procedure 1A. M+H+ = 434. LC/MS retention time = 1.096. Example 184: Preparation of 3-[3-chloro-4-(2-morpholin-4-ylethylsulfanyl)phenyl]-5,5-dimethyl-l-pyrid-4-yl-methylimidazolidine-2,4-dione trifluoroacetate Prepared according to the general procedure 1A. M+H+ = 475. LC/MS retention time = 0.792 Example 185: Preparation of 3-{3-chloro-4-[2-(1-methyl-pyrrolidin-2-yl)ethylsulfanyl]phenyl}-5,5-dimethyl-1-pyrid-4-ylmethylimidazolidine-2,4-dione trifluoroacetate Prepared according to the general procedure 1A. M+H+ = 473. LC/MS retention time = 0.865. Example 186: Preparation of 3-{3-chloro-4-[3-(4-methyl-piperazin-l-yl)propylsulfanyl]phenyl}-5,5-dimethyl-1-pyrid-4-ylmethylimidazolidine-2,4-dione trifluoroacetate Prepared according to the general procedure 1A. M+H+ = 502. LC/MS retention time = 0.795. Example 187: Preparation of 3- [3-chloro-4-(3-hydroxy-propylsulfanyl)phenyl]-5,5-dimethyl-l-pyrid-4-ylmethyl-imidazolidine-2,4-dione trifluoroacetate Prepared according to the general procedure 1A. M+H+ = 420. LC/MS retention time = 0.968. Example 188: Preparation of 3-[3-chloro-4-(2-hydroxy-ethylsulfanyl)phenyl]-5, S-dimethyl-l-pyrid^-ylmethyl-imidazolidine^, 4-dione trifluoroacetate Prepared according to the general procedure 1A. M+H+ = 406. LC/MS retention time = 0.921. Example 189: Preparation of [2-chloro-4-(4,4-dimethyl-2,5-dioxo-3-pyrid-4-ylmethylimidazolidin-l-yl)phenyl-sulfanyl]acetonitrile trifluoroacetate Prepared according to the general procedure 1A. M+H+ = 401. LC/MS retention time = 0.999. 3-nitro-4-trifluoromethoxyaniline 20 g (112.9 mmol) of 4-trifluoromethoxyaniline were dissolved in 50 ml of concentrated sulfuric acid at a temperature of 0 to 5°C, and treated with 3 0 ml of a 4/1 mixture of sulfuric acid and nitric acid. The mixture was stirred for 5 hours at 0°C and then poured into an ice-water mixture and basified with 20 0 ml of concentrated aqueous ammonia solution. Extraction with EE, drying with sodium sulfate, evaporation to dryness and recrystallization from ethyl acetate/heptane gave 15.5 g (63%) of the desired product. M+H+ = 223. LC/MS retention time = 1.378. Example 190: Preparation of trifluoroacetic acid; 5,5-dimethyl-3-(3-nitro-4-trifluoromethoxyphenyl)-l-pyrid-4-ylmethylimidazolidine-2,4-dione 2.27 g (11.5 mmol) of diphosgene in 1,2-dichloro-ethane were added at -20°C to 1.0 g (4.5 mmol) of 3-nitro-4-trifluoromethoxyaniline, dissolved in 20 ml of 1,2-dichloroethane. The mixture was stirred for 1 hour while being allowed to return to room temperature, and was then heated at 50°C for 2 hours. After leaving to stand overnight, the solvent was evaporated off and the residue was taken up in dry THF and treated with 937 mg (4.5 mmol) of methyl 2-methyl-2-[(pyrid-4-ylmethyl)amino]propionate. The mixture was stirred for 2 hours at room temperature and for 1 hour at 40°C, and then evaporated to dryness, and the remaining residue was purified (RP 18, acetonitrile, water, 0.01% TFA) to give 1.15 g (61%) of the desired product. M+H+ = 425. LC/MS retention time = 1.324. Example 191: Preparation of 3- (3-amino-4-tri£luoro-methoxyphenyl) -5, 5-dimethyl- 1-pyrid-4-ylittethylimi-dazolidine-2,4-dione 9.63 g (22.7 mmol) of 5,5-dimethyl-3-(3-nitro-4-trifluoromethoxyphenyl)-l-pyrid-4-ylmethylimidazolidine-2,4-dione trifluoroacetate were dissolved in semi-concentrated hydrochloric acid, heated to reflux and treated with 30 g of zinc dust. After 1.5 hours, the mixture was cooled, filtered and extracted twice with tert-butyl methyl ether. The aqueous phase was basified with 6N sodium hydroxide and extracted- with tert-butyl methyl ether, and the combined organic phases were dried over sodium sulfate. Evaporation of the solvent gave 5.0 g (56%) of the desired product. M+H+ = 395. LC/MS retention time = 0.948. Example 192: Preparation of 5,5-dimethyl-1-pyrid-4-yl-methyl-3-[4-(2,2,2-trifluoroethoxy)phenyl]imidazolidine-2,4-dione 68 8 mg (3.6 mmol) of 2,2,2-trifluoroethoxyaniline in 30 ml of methylene chloride were added at 0°C to 356 mg (3.6 mmol) of triethylamine and a solution of 356 mg (1.2 mmol) of triphosgene in 3 0 ml of methylene chloride. The mixture was stirred overnight while being allowed to return to room temperature. Next, the solvent was evaporated off and the residue was taken up in 15 ml of THF and treated with 100 mg (0.48 mmol) of methyl 2-methyl-2 -[(pyrid-4-ylmethyl)amino] propionate and 48.5 mg (0.48 mmol) of triethylamine. The mixture was stirred for 4 hours at room temperature and for 1 hour at 50°C, and then evaporated to dryness, and the remaining residue was purified by preparative HPLC chromatography (RP 18, acetonitrile, water, 0.01% TFA) to give 67 g (36%) of the desired product. M+H+ = 394. LC/MS retention time = 1.032. Example 193: Preparation of 3-(8-chloro-3,4,4-tri-methylthiochroman-6-yl)-5,5-dimethyl-1-pyrid-4-yl-methylimidazolidine-2,4-dione 200 mg (0.28 mol) of bis[(2-chloro-4-(4,4-dimethyl-2,5-dioxo-3-pyrid-4-ylmethylimidazolidin-l-yl)]phenyl disulfide were dissolved in 10 ml of methanol and treated with 22 mg (0.56 mmol) of sodium borohydride. After stirring for 3 0 minutes at room temperature, the mixture was evaporated to dryness. The residue was dissolved in 10 ml of sulfuric acid (75%) and added to 20 ml of sulfuric acid (75%) saturated with isobutylene. The mixture was stirred for 3 0 minutes at 40°C, while a regular airstream of isobutylene was bubbled through the solution. After leaving to stand overnight, the mixture was added cautiously to a cooled solution of sodium hydroxide in water. The alkaline aqueous phase was extracted three times with ethyl acetate, the combined organic phases were dried with sodium sulfate and the material remaining after evaporation was filtered through silica gel (95/5 methylene chloride/methanol). The resulting crude product was purified by preparative HPLC chromatography (RP 18, acetonitrile, water, 0.01% TFA) to give 70 mg (56%) of the desired product. M+H+ = 444. LC/MS retention time = 1.240. Example 194: Preparation of 1-(2-chlorothiazol-5-yl-methyl)-5,5-dimethyl-3-(4-trifluoromethylsulfanyl-phenyl)imidazolidine-2,4-dione trifluoroacetate 200 mg (0.65 mmol) of 5,5-dimethyl-3-(4-trifluoromethylsulf anylphenyl)imidazolidine-2,4-dione, 115 mg (0.82 mmol) of potassium carbonate and 276 mg (1.64 mmol) of 2-chloro-5-chloromethylthiazole were dissolved in 2 ml of DMF and stirred at room temperature for 2 days. The mixture was poured into water and extracted three times with ethyl acetate, the combined organic phases were dried over sodium sulfate and the material remaining after evaporation was purified by preparative HPLC chromatography (RP 18, acetonitrile, water, 0.01% TFA) to give 143 mg (50%) of the desired product. M+H+ = 436. LC/MS retention time = 1.784. Example 195: Preparation of 3- [3-chloro-4-(propane-2-sulfonyl)phenyl]-5,5-dimethyl-1-pyrid-4-ylmethyl-imidazolidine-2,4-dione 40 mg (0.1 mmol) of 3-(3-chloro-4-isopropyl-sulfanylphenyl)-5,5-dimethyl-l-pyrid-4-ylmethylimida-zolidine-2,4-dione were dissolved in 2 ml of methylene chloride and treated with a solution of 37 mg (0.15 mmol) of m-chloroperbenzoic acid in 2 ml of methylene chloride. The reaction was monitored by TLC and stopped when the sulfoxide and the sulfone were formed in equal amounts. The mixture was evaporated to dryness and purified by flash chromatography (Si02, 98/2 methylene chloride/methanol) to give 4 mg of 3- [3-chloro-4-(propane-2-sulfonyl)phenyl]-5,5-dimethyl-1-pyrid-4-ylmethylimidazolidine-2,4-dione and 7 mg of 3- [3-chloro-4-(propane-2-sulfinyl)phenyl]-5,5-dimethyl-1-pyrid-4-ylmethylimidazolidine-2,4-dione. M+H+ = 436. LC/MS retention time = 0.970. Example 196: Preparation of 3- [3-chloro-4-(propane-2-sulf inyl) phenyl] -5, 5-dimethyl-1-pyrid-4-ylmethylimi-dazolidine-2,4-dione Prepared as described above. M+H+ = 420. LC/MS retention time = 0.932. 2-(Isoquinolin-5-ylamino)-2-methylpropionitrile: 5.0 g (34.7 mmol) of 5-aminoisoquinoline, 5.1 ml (69.4 mmol) of acetone and 945 mg (6.94 mmol) of zinc chloride were dissolved in 100 ml of acetonitrile and treated at 0°C with 6.9 g (69.4 mmol) of trimethylsilyl cyanide. The mixture was refluxed for 3 hours, the solvent was then evaporated off and the residue was taken up in 200 ml of sodium hydrogen carbonate and extracted 3 times with ethyl acetate. The combined organic phases were dried and the residue remaining after evaporation was purified by flash chromatography (Si02, 95/5 methylene chloride/methanol) to give 6.0 g (82%) of the desired product. M+H+ = 212. LC/MS retention time = 0.696. General procedure 2: Synthesis of alkylsulfanylanilines 1.1 g (8 mmol) of 4-aminothiophenol and 896 mg (8 mmol) of potassium tert-butoxide were dissolved in 10 ml of DMF and stirred for 45 minutes under an argon atmosphere. Next, 8.8 mmol of the corresponding alkyl bromide were added, the mixture was stirred for 3 hours at room temperature, poured into water and extracted with ethyl acetate. The combined organic phases were dried and evaporated. The residual product was essentially pure and could be used without further purification. 4-(3-Methoxypropylsulfanyl)phenylamine Prepared according to the general procedure 2. M+H+ = 197. LC/MS retention time = 0.777. 4-Isopropylsulfanylphenylamine Prepared according to the general procedure 2. M+H+ = 266. LC/MS retention time = 0.173. 4-[3-(4-Methylpiperazin-l-yl)propylsulfanyl]phenylamine Prepared according to the general procedure 2. M+H+ = 168. LC/MS retention time = 0.894. General procedure 3: Preparation of 3-(3-chloro-4-alkylsulfanylphenyl)-5,5-dimethyl-1-pyrid-4-ylmethyl-imidazolidine-2,4-diones 371 mg (2.3 mmol) of carbonyldiimidazole, 41 mg (0.5 mmol) of imidazole and 1.9 mmol of the respective alkylsulfanylaniline were dissolved at 0°C in 10 ml of THF and stirred for 1 hour. Next, 280 mg (1.35 mmol) of methyl 2-methyl-2- [ (pyrid-4-ylmethyl) amino] propionate dissolved in 5 ml of THF were added and the mixture was refluxed for 5 hours. The solvent was then evaporated off and the material remaining after evaporation was purified by preparative HPLC chromatography (RP 18, acetonitrile, water, 0.01% TFA). Example 197: Preparation of 5,5-dimethyl-3-(4-methyl-sulfanylphenyl)-l-pyrid-4-ylmethylimidazolidine-2,4-dione trifluoroacetate Prepared according to the general procedure 3. M+H+ = 342. LC/MS retention time = 0.942. Example 198: Preparation of 3-[4-(3-methoxypropyl-sulf anyl) phenyl] -5, 5-dimethyl-1-pyrid-4-ylme thylimi-dazolidine-2,4-dione trifluoroacetate Prepared according to the general procedure 3. M+H+ = 400. LC/MS retention time = 1.007. Example 199: Preparation of 3- (4-isopropylsulfanylphenyl) -5, 5-dimethyl-l-pyrid-4-ylmethylimidazolidine-2# 4-dione trifluoroacetate Prepared according to the general procedure 3. M+H+ = 370. LC/MS retention time = 1.096. Example 200: Preparation of 5,5-dimethyl-3-{4-[3-(4-methylpiperazin-l-yl)propylsulfanyl]phenyl}-l-pyrid-4-ylmethylimidazolidine-2,4-dione trifluoroacetate Prepared according to the general procedure 3. M+H+ = 468. LC/MS retention time = 0.689 Example 201; 5,5-Dimethyl-l-(6-methoxyquinolin-4-yl-methyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dlone 0.1 g of sodium hydride (60%) is added to a solution of 0 . 65 g of 5,5-dimethyl-3-(4-trifluoromethoxyphenyl)-imidazolidine-2,4-dione in 40 ml of anhydrous THF, under an inert atmosphere of argon at a temperature in the region of 20°C. Stirring is maintained at this temperature for 30 minutes. 0.47 g of 4-chloromethyl-6-methoxyquinoline dissolved in 10 ml of THF is added. The reaction mixture is refluxed for 16 hours. After cooling, 100 ml of water and 75 ml of ethyl acetate are added. After separation of the phases by settling, the organic phase is dried over sodium sulfate, filtered and then concentrated under reduced pressure. The brown oil obtained is purified by flash chromatography (Si02/ 50/50 EtOAc/cyclohexane by volume as eluent, Ar). The fractions containing the product are concentrated under reduced >ressure. 0 . 36 g of 5,5-dimethyl-1-(6-methoxyquinolin-4-^lmethyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-Lione is thus obtained, the characteristics of which are is follows: XH NMR spectrum (300 MHz, (CD3)2SO d6, 6 in ppm) : 1,45 [s: 6H); 3.96 (s: 3H); 5.10 (broad s: 2H); 7.46 (dd, J = ) and 3 Hz: 1H); 7.54 (d, J = 3 Hz: 1H); 7.56 (broad d, J = 9 Hz: 2H); 7.61 (d, J = 4.5 Hz: 1H); 7.68 (broad d, J = ) Hz: 2H) ; 8.00 (d, J = 9 Hz: 1H) ; 8.72 (d, J = 4.5 Hz: .H) . Mass EI m/z=459 M+. base peak m/z=213 C12H9N202+ m/z = 172 CnHi0NO+ 7he compound 5,5-dimethyl-3-(4-trifluoromethoxyphenyl)-.midazolidine-2,4-dione is prepared according to the >rocedure described in Example 63. 3reparation of 4 -chloromethyl-6-methoxyquinoline 1.16 ml of triethylamine and 0.64 ml of lethanesulfonyl chloride are successively added to a solution of 1. 2 g of 4-hydroxymethyl-6-methoxyquinoline .n 45 ml of dichloromethane, under an inert atmosphere of irgon at a temperature in the region of 20°C. Stirring is :ontinued at this temperature for 3 hours. The reaction ledium is concentrated under reduced pressure to give a jrown residue. The product is used without further mrification in the following step. XH NMR spectrum (300 MHz, (CD3)2SO d6, 6 in ppm): 3.97 [s: 3H) ; 5.30 (s: 2H) ; 7.48 (dd, J= 9 and 3 Hz: 1H) ; '.52 (d, J = 3 Hz: 1H) ; 7.62 (d, J = 4.5 Hz: 1H) ; 8.00 [d, J = 9 Hz: 1H); 8.75 (d, J = 4.5 Hz: 1H). Mass EI m/z=207 M+" m/z=172 (M - Cl)+ base peak m/z=157 (m/z=172 - CH3)+ m/z=129 (m/z=157 - CO) + Preparation of 4-hydroxymethyl-6-methoxyquinoline 17 ml of a 1M solution of LiAlH4 in THF is added dropwise to a solution of 4 g of 4-ethoxycarbonyl-6-methoxyquinoline in 100 ml of anhydrous THF, under an inert atmosphere of argon at a temperature in the region of 5°C. The reaction medium is maintained at a temperature in the region of 20 °C for 16 hours with stirring and 50 ml of water and 50 ml of ethyl acetate are added. After separation of the phases by settling, the organic phase is dried over sodium sulfate, filtered and then concentrated under reduced pressure. The foam obtained is purified by flash chromatography (Si02, EtOAc as eluent, Ar). The fractions containing the product are concentrated under reduced pressure. 0.86 g of 4-hydroxymethyl-6-methoxyquinoline is thus obtained, the characteristics of which are as follows: XH NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm): 3.93 (s: 3H) ; 5.02 (d, J = 5.5 Hz: 2H) ; 5.57 (t, J = 5.5 Hz: 1H) ; 7.30 (d, J = 3 Hz: 1H) ; 7.38 (dd, J = 9 and 3 Hz: 1H) ; 7.50 (d, J = 4.5 Hz: 1H) ; 7.92 (d, J = 9 Hz: 1H) ; 8.69 (d, J = 4.5 Hz: 1H). Mass EI, m/z=189 M+> base peak m/z=174 (M - CH3)+ m/z=160 (M - CHO)+ m/z = 146 (m/z = 174 - CO)+ m/z=117 (m/z=146 - CHO)+' Example 2 02: 5,5-Dimethyl-1-(6-hydroxyquinolin-4-yl-methyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione 6 ml of a 1M solution of boron tribromide in CH2C12 are added to a solution of 0.26 g of 5,5-dimethyl-1- (6-methoxyquinolin-4-ylmethyl)-3-(4-trifluoromethoxyphenyl) imidazolidine-2,4-dione in 40 ml of dichloro-methane, under an inert atmosphere of argon at a temperature in the region of 0°C. The reaction medium is maintained at a temperature in the region of 20°C for 16 hours with stirring. 5 ml of methanol are added dropwise. After stirring for 30 minutes at this temperature, 50 ml of water, 30 ml of CH2C12 and 10 ml of saturated NaHC03 solution are added. After separation of the phases by settling, the organic phase is dried over sodium sulfate, filtered and then concentrated under reduced pressure. The beige-colored foam obtained is purified by flash chromatography (Si02, EtOAc as eluent, Ar). The fractions containing the product are concentrated under reduced pressure. 0,17 g of 5,5-dimethyl-l-(6-hydroxyquinolin-4-ylmethyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione is thus obtained, the characteristics of which are as follows: XH NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm): 1.46 (s: 6H); 5.00 (broad S: 2H); 7.30 to 7.40 (mt: 2H); 7.51 (d, J = 4.5 Hz: 1H); 7.55 (broad d, J = 8.5 Hz: 2H); 7.69 (d, J = 8.5 Hz: 2H) ; 7.94 (d, J= 9 Hz: 1H) ; 8.64 (d, J = 4.5 Hz: 1H) ; 10.12 (unresolved complex: 1H) . Mass EI m/z=445 M+" m/z = 199 CiiH7N202+ m/z = 158 Ci0H8NO+ base peak Example 203: 5,5-Dimethyl-1-(7-methoxyquinolin-4-yl-methyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2#4-dione The product is prepared according by following the procedure described in Example 59, starting with 0.94 g of methyl 2-methyl-2-[(7-methoxyquinolin-4-ylmethyl)-amino]propanoate instead of methyl 2-methyl-2-[(quinolin-4-ylmethyl) amino] propanoate used in Example 59, and 1.7 g of 4-(trifluoromethoxyphenyl) isocyanate. After purification by flash column chromatography (Si02, 70/3 0 cyclohexane/EtOAc by volume and then 90/10 CH2Cl2/MeOH by volume as eluents, Ar) , 1.45 g of the expected product are obtained. XH NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm): 1.44 (s: 6H); 3.96 (s: 3H); 5.12 (broad S: 2H); 7.35 (dd, J = 9 and 3 Hz: 1H) ; 7.47 (d, J = 3 Hz: 1H) ; 7.49 (d, J = 4.5 Hz: 1H) ; 7.55 (broad d, J = 9 Hz: 2H) ; 7.68 (broad d, J = 9 Hz: 2H); 8.19 (d, J = 9 Hz: 1H); 8.80 (d, J = 4.5 Hz: 1H). Mass EI m/z=459 M+' base peak m/z=444 (M - CH3)+ m/z = 213 Ci2H9N202+ m/z = 172 CnHioNO+ Preparation of methyl 2-((7-methoxyquinolin-4-yl-methyl)amino)propanoate A mixture of 1.23 g of methyl a-aminoisobutyrate hydrochloride and 1.12 ml of triethylamine in 30 ml of dichloromethane is stirred at 0°C for 20 minutes. Next, 1 g of magnesium sulfate and 1.5 g of 7-methoxyquinoline-4-carbaldehyde are added. Stirring is continued for 15 hours at room temperature and the mixture is then concentrated under reduced pressure. The residue is taken up in 3 5 ml of methanol, the solut ion obtained is cooled to 0°C and 0.31 g of sodium borohydride is then added portionwise. The reaction medium is stirred at a temperature in the region of 2 0°C for 15 hours. The reaction medium is concentrated under reduced pressure. The residue obtained is taken up in 100 ml of EtOAc. The precipitate formed is filtered off and the filtrate is concentrated under reduced pressure and then purified by flash column chromatography (Si02/ EtOAc as eluent, Ar) to give 0.95 g of the expected product. XH NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm) : 1.35 (s: 6H) ; 2.63 (t, J = 7.5 Hz: 1H) ; 3.70 (s: 3H) ; 3.93 (s: 3H); 4.05 (d, J = 7.5 Hz: 2H); 7.28 (dd, J = 9 and 3 Hz: 1H) ; 7.41 (d, J = 3 Hz: 1H) ; 7.43 (d, J = 4.5 Hz: 1H); 8.12 (d, J = 9 Hz: 1H); 8.76 (d, J = 4.5 Hz: 1H) . Mass CI m/z=289 MH+ base peak m/z=229 (M - C2H402) + Preparation of 7-methoxyquinoline-4-carbaldehyde A mixture of 1.9 g of selenium oxide dissolved in 35 ml of dioxane is added dropwise to a solution of 2.7 g of 4-methyl-7-methoxyquinoline in 35 ml of dioxane preheated to 65°C. At the end of the addition, the brown suspension is heated at a temperature in the region of 80°C for 5 hours. The reaction medium is stirred for 16 hours at a temperature in the region of 20 °C. The greenish suspension is suction-filtered and then washed with EtOAc. The filtrate is concentrated under reduced pressure. The suspension obtained is crystallized from isopropyl ether to give 1.54 g of 7-methoxyquinoline-4-carbaldehyde. *H NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm): 3.99 (s: 3H) ; 7.48 (dd, J = 9 and 3 Hz: 1H) ; 7.57 (d, J = 3 Hz: 1H) ; 7.90 (d, J = 4.5 Hz: 1H) ; 8.89 (d, J = 9 Hz: 1H) ; 9.19 (d, J = 4.5 Hz: 1H) ; 10.52 (s: 1H) . Mass CI m/z = 188 MH+ base peak Preparation of 4-methyl-7-methoxyquinoline 4 g of triphenylphosphine, 5.3 g of lithium chloride, 14 ml of tetramethyltin and 2.1 g of bis(triphenylphosphine)palladium(II) chloride are added to a solution of 6 g of 4-bromo-7-methoxyquinoline in 100 ml of DMF, under an inert atmosphere of argon at a temperature in the region of 20°C. The reaction medium is heated at a temperature in the region of 12 0°C for 16 hours. After cooling, the insoluble material is filtered off. The filtrate is concentrated under reduced pressure. The residue obtained is taken up in 3 00 ml of EtOAc and 3 00 ml of water. After separation of the phases by settling, the organic phase is dried over magnesium sulfate, filtered and then concentrated under reduced pressure. The oil obtained is taken up in 300 ml of EtOAc and 300 ml of water and then acidified with hydrochloric acid to pH 1. The aqueous phase is basified with sodium hydroxide to pH 10 and then extracted with 3 00 ml of EtOAc. After separation of the phases by settling, the organic phase is dried over magnesium sulfate, filtered and then concentrated under reduced pressure to give 2.7 g of 4-methyl-7-methoxyquinoline, the characteristics of which are as follows: *H NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm): 2.65 (s: 3H) ; 3.94 (s: 3H) ; 7.23 (broad d, J = 4.5 Hz: 1H) ; 7.28 (dd, J = 9 and 3 Hz: 1H) ; 7.40 (d, J = 3 Hz: 1H); 8.01 (d, J = 9 Hz: 1H); 8.58 (d, J = 4.5 Hz: 1H). Mass EI m/z=173 M+' base peak m/z=158 (M - CH3)+ m/z=143 (M - CH20)+' m/z=130 (m/z=158 - CO)+ Preparation of 4-bromo-7-methoxyquinoline 22.74 g of 4-hydroxy-7-methoxyquinoline are added to 200 g of phosphorus oxybromide preheated to a temperature in the region of 110°C. The reaction medium is heated at this same temperature for 3 hours. The reaction medium is poured while hot into a mixture of 5 00 ml of EtOAc and 500 ml of ice-water. The medium is neutralized with potassium carbonate to pH 7. After separation of the phases by settling, the organic phase is dried over magnesium sulfate, evaporated under reduced pressure and then purified by column chromatography (Si02, 50/50 EtOAc/cyclohexane by volume as eluents, Ar) , to give 14.6 g of the expected product. XH NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm) : 3.97 (s: 3H); 7.43 (dd, J = 9 and 3 Hz: 1H); 7.49 (d, J = 3 Hz: 1H) ; 7.79 (d, J = 4.5 Hz: 1H) ; 8.06 (d, J = 9 Hz: 1H); 8.67 (d, J = 4.5 Hz: 1H). Mass EI m/z=237 M+' base peak 4-Hydroxy-7-methoxyquinoline is prepared according to the process described in: J. Am. Chem. Soc., 68, 1268, 1946. Example 204: 5,5-Dimethyl-l-(7-hydroxyquinolin-4-yl-methyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dlone A mixture of 0.89 g of 5,5-dimethyl-1-(7-methoxy-quinolin-4-ylmethyl)-3-(4-trifluoromethoxyphenyl)imi-dazolidine-2,4-dione and 5.5 g of pyridine hydrochloride is heated at a temperature in the region of 220°C for 4 hours. After cooling, 200 ml of water and 100 ml of CH2C12 are added. After separation of the phases by settling, the organic phase is dried over sodium sulfate, filtered and then concentrated under reduced pressure. The solid obtained is purified by flash chromatography (Si02, 4 0/60 EtOAc/CH2Cl2 by volume as eluent, Ar) . The fractions containing the product are concentrated under reduced pressure. 85 mg of 5,5-dimethyl-1-(7-hydroxyquinolin-4-ylmethyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione are thus obtained, the characteristics of which product are as follows: XH NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm) : 1.45 (s: 6H) ; 5.08 (broad s: 2H) ; 7.24 (dd, J = 9 and 3 Hz: 1H) ; 7.30 (d, J = 3 Hz: 1H) ; 7.38 (d, J = 4.5 Hz: 1H) ; 7.55 (broad d, J = 9 Hz: 2H) ; 7.68 (broad d, J = 9 Hz: 2H) ; 8.10 (d, J = 9 Hz: 1H) ; 8.71 (d, J = 4.5 Hz: 1H); from 9.90 to 10.50 (broad unresolved complex: 1H), Mass EI m/z=445 M+' base peak m/z=430 (M - CH3)+ m/z = 199 Cn^NaCV m/z = 158 C10H8NO+ Example 205; 5, 5-Dimethyl-l- (2-aminoquinolin-4-ylmethyl) -3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione 0.44 g of tosyl chloride is added to a solution of 0 . 8 g of 5, 5-dimethyl-l- (N-oxyquinolin-4-ylmethyl) -3- (4-trifluoromethoxyphenyl)imidazolidine-2,4-dione in 10 ml of chloroform, under an inert atmosphere of argon at a temperature in the region of 5°C. After stirring for 3 0 minutes at this same temperature, 1.5 ml of 32% aqueous ammonia are added. The temperature is allowed to rise to 20°C. The reaction medium is stirred at a temperature in the region of 20°C for 16 hours. 100 ml of water are added. After separation of the phases by settling, the organic phase is dried over sodium sulfate, filtered and then concentrated under reduced pressure. The solid obtained is purified by flash chromatography (Si02, EtOAc as eluent, Ar) . The fractions containing the product are concentrated under reduced pressure. 200 mg of 5,5-dimethyl-1-(2-aminoquinolin-4-ylmethyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione are thus obtained, the characteristics of which are as follows: XH NMR spectrum (300 MHz, (CD3)2SO d6, 6 in ppm): 1.49 (s: 6H) ; 4.96 (broad s: 2H); 6.36 (broad s: 2H)/ 6.81 (s: 1H) ; 7.23 (mt: 1H) ; 7.51 (mt: 2H) ; 7.58 (broad d, J = 9 Hz: 2H) ; 7.68 (broad d, J = 9 Hz: 2H) ; 7.91 (d, J = 8.5 Hz: 1H). Mass EI m/z=444M+' base peak m/z=429 (M - CH3)+ m/z = 198 CnH8N30+ m/z=158 C10H10N2+ Example 206: 5,5-Dimethyl-1-(N-oxyquinolin-4-ylmethyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione 0.78 g of m-chloroperbenzoic acid is added to a solution of 1. 95 g of 5,5-dimethyl-1-(quinolin-4-yl-methyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione in 200 ml of chloroform and 10 ml of methanol, under an inert atmosphere of argon at a temperature in the region of 20°C. The reaction medium is stirred at a temperature in the region of 2 0°C for 4 hours. A further 0.8 g of m-chloroperbenzoic acid is added. The reaction medium is concentrated under reduced pressure. The product is crystallized from isopropyl ether to give 1. 76 g of 5,5-dimethyl-l-(N-oxyquinolin-4-ylmethyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione, the characteristics of which are as follows: XH NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm): 1.45 (s: 6H) ; 5.09 (broad s: 2H) ; 7.55 (broad d, J = 8.5 Hz: 2H); 7.63 (d, J = 4.5 Hz: 1H); 7.68 (broad d, J = 8.5 Hz: 2H) ; 7.85 (broad t, J = 8.5 Hz: 1H) ; 7.91 (broad t, J = 8.5 Hz: 1H) ; 8.35 (broad d, J = 8.5 Hz: 1H) ; 8.56 (d, J = 4.5 Hz: 1H); 8.64 (broad d, J = 8.5 Hz: 1H). Mass ES m/z=446 MH+ base peak Example 207: 5,5-Dimethyl-1-(2»chloroquinolin-4-yl-methyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione 0.17 ml of phosphorus oxychloride is added to a solution of 4 ml of DMF and 2 ml of toluene, under an inert atmosphere of argon at a temperature in the region of 5°C. After stirring for 3 0 minutes at this same temperature, 0.4 g of 5,5-dimethyl-1-(N-oxyquinolin-4-yl-methyl)-3 -(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione in 10 ml of toluene is added. The reaction medium is stirred at a temperature in the region of 5°C for 2 and a half hours. The temperature is allowed to rise to 20°C. The reaction medium is concentrated under reduced pressure. The residue obtained is taken up in 50 ml of EtOAc and washed with saturated NaHC03 solution. After separation of the phases by settling, the organic phase is dried over sodium sulfate, filtered and then concentrated under reduced pressure. The product is crystallized from isopropyl ether to give 0.37 g of 5,5-dimethyl-1-(2-chloroquinolin-4-ylmethyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione, the characteristics of which product are as follows: XH NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm) : 1.50 (s: 6H) ; 5.17 (broad s: 2H) ; 7.56 (broad d, J = 8.5 Hz: 2H) ; 7.71 (broad d, J = 8.5 Hz: 2H) ; 7.76 (s: 1H) ; 7.76 (resolved t, J = 8 and 1.5 Hz: 1H) ; 7.89 (resolved t, J = 8 and 1.5 Hz: 1H); 8.03 (broad d, J = 8 Hz: 1H) ; 8.31 (broad d, J = 8 Hz: 1H). Mass EI m/z=463 M+' base peak m/z=448 (M - CH3)+ m/z=428 (M - Cl)+ m/z=358 (m/z=428 - C4H60)+ m/z = 217 CnH6N2OCl+ m/z=176 Ci0H7NCl+ Example 208: 5,5-Dimethyl-1-(2-chloropyrid-4-ylmethyl)-3-(4-trifluoromethoxyphenyl)lmidazolldine-2,4-dlone 0.02 8 g of sodium hydride is added to a solution of 0 .1 g of 5,5-dimethyl-3-(4-trifluoromethoxyphenyl)-imidazolidine-2,4-dione in 2 ml of anhydrous dimethylformamide, under an inert atmosphere of argon at a temperature in the region of 20°C, stirring is continued at this temperature for 30 minutes, 0.1 g of 2-chloro-4-(bromomethyl)pyridine in 2 ml of dimethyl-formamide is added, followed by addition of ice-water after reaction for 10 minutes. The reaction mixture is deposited on a cartridge 2 0 mm in diameter packed with 17 g of 50 /im octadecyl-grafted silica conditioned successively with acetonitrile and then with water. Elution was performed by gradient using a mixture (water/acetonitrile) of from 0 to 100% acetonitrile. The fractions containing the expected product are concentrated under reduced pressure. 0.13 0 g of crude product is thus obtained, and is purified by a double chromatography using a cartridge packed with 10 g of conditioned 20-40 /xm silica, and then eluted with a mixture (cyclohexane/ethyl acetate) (8/2), (v/v), at a flow rate of 5 ml/minute. The fractions between 30 and 75 ml are concentrated under reduced pressure. 0.1 g of 5,5-dimethyl-l-(2-chloropyrid-4-ylmethyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione is thus obtained in the form of a white powder, the characteristics of which are as follows: m.p. 134°C Mass EI m/z=413 M+' base peak + . m/z=398 (M - CH3)+ + m/z=203 C8H4NO2F3 m/z=167 C7H4N2OCI m/z=126 C6H5NC1+ XU NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm) : 1.44 (s: 6H) ; 4.67 (s: 2H) ; 7.50 (broad d, J = 5.5 Hz: 1H) ; 7.54 (broad d, J = 9 Hz: 2H) ; 7.61 (broad s: 1H) ; 7 .66 (broad d, J = 9 Hz: 2H) ; 8.40 (d, J = 5.5 Hz: 1H) . The compound 5,5-dimethyl-3-(4-trifluoromethoxyphenyl)-imidazolidine-2,4-dione is described in Example 63. Example 209s 5,5-Dimethyl-1-(2-ethoxypyrid-4-ylmethyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione 0.015 g of sodium hydride is added to a solution of 0 .175 g of 5,5-dimethyl-3-(4-trifluoromethoxyphenyl)-imidazolidine-2,4-dione in 2 ml of anhydrous dimethyl-formamide, under an inert atmosphere of argon at a temperature in the region of 2 0°C, stirring is continued at this temperature for 30 minutes, and a solution of 0.185 g of 2-ethoxy-4- (bromomethyl) pyridine in 2 ml of anhydrous dimethylformamide is added, followed by addition of ice-water after reaction for 10 minutes. The reaction mixture is deposited on a cartridge 3 7 mm in diameter packed with 65 g of 40-60 ^m octadecyl-grafted silica conditioned successively with a mixture (water/acetonitrile) (5/95), (v/v), and then with a mixture (water/acetonitrile) (95/5), (v/v). Elution was performed with a mixture (water/ acetonitrile), (95/5) , (v/v) for 20 minutes, followed by a linear gradient of from 5% to 95% acetonitrile over 60 minutes, at a flow rate of 10 ml/minute. The fractions between 70 0 and 760 ml are concentrated under reduced pressure. 0 .145 g of 5,5-dimethyl-l-(2-ethoxypyrid-4-ylmethyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4- dione is thus obtained, the characteristics of which are as follows: Mass EI m/z=423 M+' m/z=408 (M - CH3)+base peak m/z=395 (M - C2H4)+- m/z=203 C8H4N02F3+-XH NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm) : 1.32 (t, J = 7 Hz: 3H) ; 1.42 (s: 6H) ; 4.30 (q, J *= 7 Hz: 2H); 4.58 (broad s: 2H); 6.85 (broad s: 1H); 7.01 (broad d, J = 5.5 Hz: 1H); 7.52 (broad d, J = 8.5 Hz: 2H); 7.63 (broad d, J = 8.5 Hz: 2H) ; 8.10 (d, J = 5.5 Hz: 1H) . The compound 5,5-dimethyl-3-(4-trifluoromethoxyphenyl)-imidazolidine-2,4-dione is described in Example 63. Example 210; 5,5-Dimethyl-l-(2-ethylpyrid-4-ylmethyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione 0.009 g of sodium hydride is added to a solution of 0 . 064 g of 5,5-dimethyl-3-(4-trifluoromethoxyphenyl)~ imidazolidine-2,4-dione in 1 ml of anhydrous dimethyl- formamide, under an inert atmosphere of argon at a temperature in the region of 20°C, stirring is continued for 30 minutes at this temperature, and a solution of 0 . 062 g of 2-ethyl-4- (bromomethyl) pyridine in 0 . 5 ml of anhydrous dimethylformamide is added, followed by addition of ice-water after reaction for 10 minutes. The reaction mixture is deposited on a cartridge 27 mm in diameter packed with 25 g of 40-60 [iva octadecyl-graf ted silica conditioned successively with a mixture (water/acetonitrile) (5/95) (v/v) and then with a mixture (water/acetonitrile) (95/5) (v/v). Elution was performed with a mixture (water/ acetonitrile) (95/5) (v/v) for 2 0 minutes, followed by a linear gradient of from 5% to 95% acetonitrile over 60 minutes, at a flow rate of 10 ml/minute. The fractions between 75 0 and 7 90 ml are concentrated under reduced pressure. 0.06 g of 5,5-dimethyl-l-(2-ethylpyrid-4- ylmethyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione is thus obtained, the characteristics of which are as follows: Mass EI m/z=407 M+> base peak m/z=392 (M - CH3)+ m/z=203 C8H4N02F3+- m/z=120 C8Hi0N+ XH NMR spectrum (400 MHz, (CD3)2SO d6, 8 in ppm) : 1.27 (t, J = 7.5 Hz: 3H) ; 1.44 (s: 6H) ; 2 .75 (q, J = 7.5 Hz: 2H) ; 4.54 (s: 2H) ; 7.10 (broad d, J = 5.5 Hz: 1H); 7.15 (broad s: 1H); 7.39 (broad d, J = 8.5 Hz: 2H); 7.49 (d, J = 8.5 Hz: 2H); 8.26 (d, J = 5.5 Hz: 1H). The compound 5,5-dimethyl-3-(4-trifluoromethoxyphenyl) imidazolidine-2,4-dione is described in Example 63. Example 211: 5,5-Dimethyl-1-(2-chloropyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione 0.046 g of sodium hydride is added to a solution of 0 .175 g of 5,5-dimethyl-3-(4-trifluoromethylsulfanyl-phenyl)imidazolidine-2,4-dione in 3 ml of anhydrous dimethylformamide, under an inert atmosphere of argon at a temperature in the region of 20°C, stirring is continued at this temperature for 30 minutes, and a solution of 0.166 g of 2-chloro-4-(bromomethyl)pyridine in 2 ml of anhydrous dimethylformamide is added, followed by addition of ice-water after reaction for 10 minutes. The reaction mixture is deposited on a cartridge 37 mm in diameter packed with 65 g of 40-60 /zm octadecyl-grafted silica conditioned successively with a mixture (water/acetonitrile) (5/95) (v/v) , and then with a mixture (water/acetonitrile) (95/5) (v/v). Elution was performed with a mixture (water/ acetonitrile) (95/5) (v/v) for 20 minutes, followed by a linear gradient of from 5% to 95% acetonitrile over 60 minutes, at a flow rate of 10 ml/minute. The fractions between 740 and 7 80 ml are concentrated under reduced pressure. 0.03 g of 5,5-dimethyl-l-(2-chloropyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)-imidazolidine-2,4-dione is thus obtained in the form of a white powder, the characteristics of which are as follows: m.p. 111°C Mass CI m/z = 447 MNH4+ m/z=430 MH+ base peak XH NMR spectrum (300 MHz, (CD3)2SO d6, 8 in ppm): 1.44 (s: 6H) ; 4.67 (broad s: 2H) ; 7.49 (broad d, J = 5.5 Hz: 1H); 7.61 (broad s: 1H); 7.70 (broad d, J = 8.5 Hz: 2H); 7.88 (broad d, J = 8.5 Hz: 2H); 8.38 (d, J = 5.5 Hz: 1H). Preparation of 5, 5-dimethyl-3- (4-trifluoromethyl- sulfanylphenyl)imidazolidine-2,4-dione 5.12 ml of triethylamine and 2.8 g of methyl a-aminoisobutyrate hydrochloride are added to a solution of 4 g of 4-trifluoromethylsulfanylphenyl isocyanate in 40 ml of toluene, under an inert atmosphere of argon at a temperature in the region of 20°C. The mixture thus obtained is ref luxed for 24 hours and then cooled to a temperature in the region of 20°C. The reaction mixture is concentrated to dryness under reduced pressure and the residue obtained is taken up in ethyl ether and filtered. 5 . 3 g of 5,5-dimethyl-3-(4-trifluoromethylsulf anylphenyl) imidazolidine-2,4-dione are thus obtained, the characteristics of which are as follows: Mass CI m/z = 322 MNH4+ m/z=102 triethylamineH* base peak XU NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm): 1.44 (s: 6H); 7.62 (broad d, J= 8.5 Hz: 2H); 7.85 (broad d, J = 8.5 Hz: 2H) ; 8.72 (unresolved complex: 1H) . The insoluble material thus obtained is taken up in dichloromethane and then washed with water. 2.76 g of 5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)imida-zolidine-2,4-dione are thus obtained, and are used for the rest of the synthesis. Example 212; 5, 5-Dimethyl-l- (2-ethoxypyrid-4-ylmethyl) -3-(4-trifluoromethanesulfanylphenyl)imidazolldlne-2,4-dione 0.049 g of sodium hydride is added to a solution of 0 .185 g of 5,5-dimethyl-3-(4-trifluoromethylsulfanyl phenyl) imidazolidine-2,4-dione in 3.2 ml of anhydrous dimethylformamide, under an inert atmosphere of argon at a temperature in the region of 20°C, stirring is continued at this temperature for 3 0 minutes, and a solution of 0 .184 g of 2-ethoxy-4-(bromomethyl)pyridine in 2 ml of dimethylformamide is added, followed by addition of ice-water after reaction for 10 minutes. The reaction mixture is deposited on a cartridge 37 mm in diameter packed with 65 g of 40-60 /xm octadecyl-graf ted silica conditioned successively with a mixture (water/acetonitrile) (5/95) (v/v) and then with a mixture (water/acetonitrile) (95/5) (v/v). Elution was performed with a mixture (water/ acetonitrile) (95/5) (v/v) for 2 0 minutes, followed by a linear gradient of from 5% to 95% acetonitrile over 60 minutes, at a flow rate of 10 ml/minute. The fractions between 520 and 7 00 ml are concentrated under reduced pressure. The residue thus obtained is purified by flash chromatography using a cartridge packed with 2 g of conditioned 15-35 jxm silica, and then eluted with a mixture (eyelohexane/ethyl acetate) (9/1) (v/v). The fractions containing the expected product are concentrated under reduced pressure. 0.01 g of 5,5-di-methyl-1-(2-ethoxypyrid-4-ylmethyl)-3-(4-trifluoromethanesulf anylphenyl) imidazolidine-2,4-dione is thus obtained, the characteristics of which are as follows: Mass EI m/z = 439 M+- m/z=424 (M - CH3)+base peak m/z = 411 (M - C2H4)+-m/z = 219 C8H4NOSF3+-1H NMR spectrum (300 MHz, (CD3)2SO d6, 8 in ppm) : 1.32 (t, J = 7 Hz: 3H); 1.42 (s: 6H); 4.30 (q, J = 7 Hz: 2H); 4.58 (broad s: 2H); 6.86 (broad s: 1H); 7.01 (broad d, J = 5.5 Hz: 1H); 7.69 (broad d, J = 8.5 Hz: 2H); 7.88 (broad d, J = 8.5 Hz: 2H) ; 8.10 (broad d, J = 5,5 Hz: 1H) . The compound 5,5-dimethyl-3-(4-trifluoromethylsulfanyl-phenyl)imidazolidine-2,4-dione is described in Example 211. Example 213; 5,5-Dimethyl-1-(2-ethylpyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione 0.021 g of sodium hydride is added to a solution of 0 .13 5 g of 5,5-dimethyl-3-(4-trifluoromethylsulfanyl- phenyl)imidazolidine-2,4-dione in 2 ml of anhydrous dimethyIformamide, under an inert atmosphere of argon at a temperature in the region of 20 °C, stirring is continued at this temperature for 3 0 minutes and a solution of 0.126 g of 2-ethyl-4-(bromomethyl)pyridine in 1 ml of anhydrous dimethylformamide is added, followed by addition of ice-water after reaction for 10 minutes. The reaction mixture is deposited on a cartridge 37 mm in diameter packed with 65 g of 40-60 /xm octadecyl-grafted silica conditioned successively with a mixture (water/acetonitrile) (5/95) (v/v) and then with a mixture (water/acetonitrile) (95/5) (v/v). Elution was performed with a mixture (water/ acetonitrile) (95/5) (v/v) for 20 minutes, followed by a linear gradient of from 5% to 95% acetonitrile over 6 0 minutes, and elution with 100% acetonitrile for 10 minutes, at a flow rate of 10 ml/minute. The fractions between 800 and 880 ml are concentrated under reduced pressure. 0.12 0 g of 5,5-dimethyl-1-(2-ethylpyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)-imidazolidine-2,4-dione is thus obtained, the characteristics of which are as follows: Mass EI m/z=423 M+> base peak m/z = 408 (M - CH3) + m/z=219 C8H4NOSF3 + - m/z = 120 C8Hi0N+ lH NMR spectrum (4 0 0 MHz, (CD3)2SC d6, 8 in ppm) : 1.23 (t, J = 7.5 Hz: 3H) ; 1.42 (s: 6H) / 2.75 (q, J = 7.5 Hz: 2H) ; 4.62 (broad s: 2H) ; 7.25 (broad d, J = 5.5 Hz: 1H) ; 7.30 (broad S: 1H) ; 7.70 (d, J = 8.5 Hz: 2H) ; 7.88 (d, J = 8.5 Hz: 2H); 8.43 (d, J = 5.5 Hz: 1H). The compound 5,5-dimethyl-3-(4-trifluoromethylsulfanyl-phenyl)imidazolidine-2,4-dione is described in Example 211. Example 214; 5,5-Dimethyl-1-(2-bromopyrid-4-ylmethyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione 0.023 g of sodium hydride is added to a solution of 0 . 081 g of 5,5-dimethyl-3-(4-trifluoromethoxyphenyl)-imidazolidine-2,4-dione in 2 ml of anhydrous dimethyl-formamide, under an inert atmosphere of argon at a temperature in the region of 2 0°C, stirring is continued at this temperature for 35 minutes, and a solution of 0.071 g of 2-bromo-4- (bromomethyl)pyridine in 1 ml of anhydrous dimethylformamide is added, followed by addition of ice-water after reaction for 15 minutes. The reaction mixture is deposited on a cartridge 16 mm in diameter packed with 5 g of 40-60 /zm octadecyl-graf ted silica conditioned successively with a mixture (water/acetonitrile) (5/95) (v/v) and then with a mixture (water/acetonitrile) (95/5) (v/v). Elution was performed by a linear gradient of from 5% to 95% acetonitrile over 30 minutes, followed by a mixture (water/acetonitrile) (5/95) (v/v) for 10 minutes, at a flow rate of 10 ml/minute. The fractions between 90 and 100 ml are concentrated under reduced pressure. 0.015 g of 5,5-dimethyl-1-(2-bromopyrid-4-ylmethyl)-3-(4- trifluoromethoxyphenyl)imidazolidine-2,4-dione is thus obtained in the form of a white foam, the characteristics of which are as follows: Mass EI m/z=457 M+- base peak m/z=442 (M - CH3)+ m/z = 211 C7H4N2OBr+ m/z = 203 C8H4N02F3+- m/z=170 C6H5NBr+ XH NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm) : 1.44 (s: 6H) ; 4.67 (broad s: 2H) ; 7.52 (broad d, J = 5.5 Hz: 1H); 7.54 (broad d, J = 9 Hz: 2H); 7.66 (broad d, J = 9 Hz: 2H) ; 7.75 (broad s: 1H) ; 8.37 (d, J = 5.5 Hz: 1H) . The compound 5,5-dimethyl-3-(4-trifluoromethoxyphenyl) imidazolidine-2,4-dione is described in Example 63. Example 215; 5, 5-Dimethyl-l- (2-f luoropyrid-4-ylmethyl) -3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione 0.025 g of sodium hydride is added to a solution of 0 . 096 g of 5,5-dimethyl-3-(4-trifluoromethylsulfanyl-phenyl)imidazolidine-2,4-dione in 2 ml of anhydrous dimethylformamide, under an inert atmosphere of argon at a temperature in the region of 20°C, stirring is continued at this temperature for 25 minutes, and a solution of 0 . 060 g of 2-fluoro-4-(bromomethyl)pyridine in 1 ml of anhydrous dimethylformamide is added, followed by addition of ice-water after reaction for 15 minutes. The reaction mixture is deposited on a cartridge 16 mm in diameter packed with 5 g of 40-60 /im octadecyl-grafted silica conditioned successively with a mixture (water/acetonitrile) (5/95) (v/v) and then with a mixture (water/acetonitrile) (95/5) (v/v). Elution was performed by a linear gradient of from 5% to 95% acetonitrile over 30 minutes, followed by a mixture (water/acetonitrile) (5/95) (v/v) for 10 minutes, at a flow rate of 5 ml/minute. The fractions between 105 and 125 ml are concentrated under reduced pressure. 0.069 g of 5,5-dimethyl-1-(2-fluoropyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione is thus obtained in the form of a white solid, the characteristics of which are as follows: m.p.: 82°C Mass EI m/z=413 M+' base peak m/z=398 (M - CH3)+ m/z = 219 C8H4NOSF3+* m/z = 151 C7H4N2OF+ m/z = 110 C6H5NF+ *H NMR spectrum (300 MHz, (CD3)2SO d6, 6 in ppm) : 1.45 (s: 6H); 4.72 (broad s: 2H); 7.29 (broad s: 1H) ; 7.43 (broad d, J = 5.5 Hz: 1H) ; 7.71 (broad d, J = 8.5 Hz: 2H); 7.89 (broad d, J = 8.5 Hz: 2H) ; 8.23 (d, J = 5.5 Hz: 1H). The compound 5,5-dimethyl-3-(4- trifluoromethylsulfanylphenyl)imidazolidine-2,4-dione is described in Example 211. Example 216; 5,5-Dimethyl-1-(2-cyanopyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione 0.037 g of sodium hydride is added to a solution of 0 .13 9 g of 5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl) imidazolidine-2,4-dione in 4 ml of anhydrous dimethylformamide, under an inert atmosphere of argon at a temperature in the region of 2 0°C, stirring is continued at this temperature for 3 0 minutes, and a solution of 0.090 g of 2-cyano-4-(bromomethyl)pyridine in 1 ml of anhydrous dimethylformamide is added, followed by addition of ice-water after reaction for 15 minutes. The reaction mixture is deposited on a cartridge 20 mm in diameter packed with 10 g of 40-60 ^m octadecyl-grafted silica conditioned successively with a mixture (water/acetonitrile) (5/95) (v/v) and then with a mixture (water/acetonitrile) (95/5) (v/v). Elution was performed by a linear gradient of from 5% to 95% acetonitrile over 30 minutes, followed by a mixture (water/acetonitrile) (5/95) (v/v) for 10 minutes, at a flow rate of 5 ml/minute. The fractions between 210 and 230 ml are concentrated under reduced pressure. 0.1 g of 5,5-dimethyl-1-(2-cyanopyrid-4-ylmethyl)-3-(4- trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione is thus obtained in solid form, the characteristics of which are as follows: m.p.: 148°C Mass EI m/z=420 M+" base peak m/z = 405 (M - CH3) + m/z=219 C8H4NOSF3+' m/z = 158 C8H4N30+ m/z=117 C7H5N2+ *H NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm) : 1.44 (s: 6H) ; 4.74 (broad S: 2H) ; 7.72 (broad d, J = 9 Hz: 2H) ; 7.81 (dd, J = 5.5 and 2 Hz: 1H) ; 7.89 (broad d, J = 9 Hz; 2H); 8.15 (broad s: 1H); 8.72 (broad d, J = 5.5 Hz: 1H). The compound 5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl) imidazolidine-2,4-dione is described in Example 211. Example 217; 5, 5-Dimethyl-1- (2-hydroxycarbonylpyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2, 4-dione A solution of 0.09 g of 5,5-dimethyl-l-(2-cyanopyrid-4-ylmethyl)-3-(4- trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione in 5 ml of 5N hydrochloric acid is refluxed for about 16 hours. The reaction mixture is concentrated under reduced pressure and the crude product thus obtained is purified by flash chromatography using a cartridge 20 mm in diameter packed with 10 g of conditioned 20-40 /im silica, and then eluted with a mixture (dichloromethane/methanol) (9/1) (v/v) at a flow rate of 8 ml/minute. The fractions between 4 0 and 200 ml are concentrated under reduced pressure. 0.06 g of 5,5-dimethyl-l-(2-hydroxy-carbonylpyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl) imidazolidine-2,4-dione is thus obtained, the characteristics of which are as follows: Mass EI m/z=439 M+" m/z=395 (M - C0NH2)+base peak m/z = 219 C8H4NOSF3+" m/z = 185 C7H9N202S+ XH NMR spectrum (300 MHz, (CD3)2SO d6, 8 in ppm) : 1.45 (s: 6H) ; 4.76 (broad S: 2H) ; 7.70 (d, J = 8.5 Hz: 2H); 7.72 (mt: 1H); 7.89 (d, J = 8.5 Hz: 2H); 8.12 (broad s: 1H); 8.68 (d, J = 5.5 Hz: 1H). Example 218; 5,5-Dimethyl-l-[2-(methylamino)carbonyl-pyrid-4-ylmethyl] -3- (4-trifluoromethanesulfanylphenyl) -imidazolidine-2,4-dione 0.025 g of methylamine hydrochloride, 0.005 g of hydroxybenzotriazole hydrate, 0.105 ml of triethylamine and 72 mg of 1-(3-dimethylaminopropyl)-3-ethylcarbodi-imide hydrochloride are successively added to a solution of 0.055 g of 5,5-dimethyl-l-(2-hydroxycarbonylpyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl) imidazolidine-2,4-dione in 2 ml of dichloromethane, under an inert atmosphere of argon at a temperature in the region of 20°C, and stirring is continued at this temperature for about 16 hours. The reaction mixture is washed with water and the organic phase is dried over magnesium sulfate, filtered and then concentrated under reduced pressure. The crude product thus obtained is purified by flash chromatography using a cartridge 16 mm in diameter packed with 5 g of conditioned 2 0-40 /im silica, and then eluted with a mixture (dichloromethane/methanol) (95/05) (v/v) at a flow rate of 10 ml per minute. The fractions containing the expected product are concentrated under reduced pressure. 0.013 g of 5,5-dimethyl-1-[2-(methylamino)carbonylpyrid-4-ylmethyl] -3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione is thus obtained in the form of a white powder, the characteristics of which are as follows: Mass EI m/z=452 M+" m/z=395 (M - C2H3ON)+ base peak m/z=219 C8H4NOSF3+' m/z = 148 C8H8N20+ XH NMR spectrum (300 MHz, (CD3)2SO d6, 8 in ppm) : 1.44 (s: 6H); 2.85 (d, J = 5 Hz; 3H); 4.76 (broad s: 2H) ; 7.67 (dd, J = 5 and 2 Hz: 1H); 7.70 (broad d, J = 8.5 Hz: 2H); 7.89 (broad d, J = 8.5 Hz: 2H); 8.10 (broad s: 1H); 8.60 (d, J = 5 Hz: 1H)/ 8.75 (broad q, J = 5 Hz: 1H). Example 219 : 5, 5-Dimethyl -1 - (2-aminocarbonylpyrid-4 -yl-methyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2, 4-dione A solution of 0.04 g of 5,5-dimethyl-1-(2-cyanopyrid-4-ylmethyl)-3-(4- trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione in 1 ml of 98% sulfuric acid is maintained at 40°C for 3 0 minutes. The mixture is taken up in 15 ml of ice-water and then neutralized with normal sodium hydroxide solution. The solution thus obtained is extracted with 100 ml of ethyl acetate. The organic phase is dried over magnesium sulfate, filtered and then concentrated under reduced pressure, and the crude product thus obtained is purified by flash chromatography using a cartridge 16 mm in diameter packed with 5 g of conditioned 20-40 /xm silica, and then eluted with dichloromethane at a flow rate of 10 ml per minute. The fractions containing the expected product are concentrated under reduced pressure. 0 . 017 g of 5,5-dimethyl-l-(2-aminocarbonylpyrid-4-yl-methyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolid-ine-2,4-dione is thus obtained in the form of an amorphous white powder, the characteristics of which are as follows: Mass EI m/z=438 M+' base peak m/z=423 (M - CH3)+ m/z=393 (M - CH3N0) + m/z = 219 C8H4NOSF3+- m/z = 135 C7H7N20+ *H NMR spectrum (300 MHz, (CD3)2SO d6, S in ppm) : 1.44 (s: 6H) ; 4.76 (broad s: 2H) ; from 7.60 to 7.70 (mt: 2H) ; 7.71 (broad d, J = 8.5 Hz: 2H) ; 7.89 (broad d, J = 8.5 Hz: 2H) ; 8.11 (broad S: 2H) ; 8.60 (d, J= 5.5 Hz: 1H) . Example 220t 5,5-Dimethyl-l-(2-morpholinopyrid-4-yl-methyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione A sealed 2.5 ml tube containing 0.05 g of 5,5-dimethyl-1-(2-chloropyrid-4-ylmethyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione, 0 . 5 ml of dimethylformamide, 0.034 g of potassium carbonate and 0.021 ml of morpholine is placed in a Personal Chemistry Emrys Optimiser microwave oven. The mixture is irradiated with magnetic stirring at 210°C for about 50 minutes. The reaction mixture is deposited on a Bond Elut Varian reference 1225-6053 cartridge containing 2 g of SCX phase conditioned with dimethylformamide. Washing with methanol is performed, followed by elution with 2M ammoniacal methanol. The ammoniacal fractions are concentrated to dryness under reduced pressure. The residue thus obtained is purified by flash chromatography using a cartridge 16 mm in diameter packed with 2 g of conditioned 15-35 /xm silica, and then eluted with a mixture (cyclohexane/ethyl acetate) (8/2) (v/v) at a flow rate of 10 ml/minute. The fractions between 160 and 260 ml are concentrated to dryness under reduced pressure. 0.01 g of 5,5-dimethyl-l-(2-morpholinopyrid-4-ylmethyl)-3-(4-trifluoromethoxy-phenyl)imidazolidine-2,4-dione is thus obtained in the form of a powder, the characteristics of which are as follows: Mass EI m/z = 464 M+" m/z=433 (M - CH30)+ base peak m/z = 419 (M - C2H50) + m/z = 407 (M - C3H50) + m/z = 379 (M - C4H5NO) + m/z = 203 C8H4N02F3+* m/z=176 Ci0Hi2N2O+- XH NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm) : 1.42 (s: 6H) ; 3.44 (broad t, J - 5 Hz: 4H) ; 3.72 (broad t, J = 5 Hz: 4H); 4.53 (broad s: 2H) ; 6.75 (broad d, J = 5.5 Hz: 1H); 6.85 (broad s: 1H); 7.54 (broad d, J = 8.5 Hz: 2H) ; 7.64 (d, J = 8.5 Hz: 2H) ; 8.10 (d, J = 5.5 Hz: 1H). Example 221; 5,5-Dimethyl-l-(2-morpholinopyrid-4-yl-methyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2, 4-dione A sealed 2.5 ml tube containing 0.05 g of 5,5-dimethyl-1-(2-chloropyrid-4-ylmethyl)-3-(4- trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione and 0.5 ml of morpholine is placed in a Personal Chemistry Emrys Optimiser microwave oven. The mixture is irradiated with magnetic stirring at 160°C for about 70 minutes. The reaction mixture is purified by preparative LC/MS. The fractions containing the expected product are concentrated to dryness under reduced pressure. The residue thus obtained is taken up in methanol and then deposited on a Bond Elut Varian reference 1225-6053 cartridge containing 2 g of SCX phase conditioned with methanol. Washing with methanol is performed, followed by elution with 2M ammoniacal methanol. The ammoniacal fractions are concentrated to dryness under reduced pressure. 0 . 03 g of 5,5-dimethyl-l-(2-morpholinopyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2, 4-dione is thus obtained in the form of a powder, the characteristics of which are as follows: Mass EI m/z=480 M+' m/z=449 (M - CH30)+ base peak m/z = 435 (M - C2H50) + +. m/z=423 (M - C3H50) + .+. m/z = 219 C8H4NOSF3 m/z = 176 Ci0Hi2N2O' XH NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm) : 1.42 (s: 6H) ; 3.45 (broad t, J = 5 Hz: 4H); 3.71 (broad t, J = 5 Hz: 4H); 4.54 (broad S: 2H); 6.75 (broad d, J = 5.5 Hz: 1H); 6.84 (broad s: 1H); 7.68 (broad d, J = 8.5 Hz: 2H) ; 7.88 (d, J = 8.5 Hz: 2H) ; 8.09 (d, J = 5.5 Hz: 1H). Example 222: 5,5-Dimethyl-l-(2-dimethylaminopyrid-4-yl-methyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2, 4-dione A sealed 2.5 ml tube containing 0.05 g of 5,5-dimethyl-1-(2-chloropyrid-4-ylmethyl)-3-(4- trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione, 0.4 ml of isopropylamine and 0.1 ml of dimethylformamide is placed in a Personal Chemistry Emrys Optimiser microwave oven. The mixture is irradiated with magnetic stirring at 14 0°C for about 13 0 minutes. The reaction mixture is purified by preparative LC/MS. The fractions containing the expected product are concentrated to dryness under reduced pressure. The residue thus obtained is taken up in methanol and then deposited on a Bond Elut Varian reference 1225-6053 cartridge containing 2 g of SCX phase conditioned with methanol. Washing with methanol is performed, followed by elution with 2M ammoniacal methanol. The ammoniacal fractions are concentrated to dryness under reduced pressure. 0.013 g of 5,5-dimethyl-l-(2-dimethylaminopyrid-4-ylmethyl)-3- (4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione is thus obtained in the form of a powder, the characteristics of which are as follows: Mass CI m/z=439 MH+ base peak XH NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm) : 1.42 (s: 6H) / 3.03 (s: 6H) ; 4.53 (broad s: 2H) ; 6.62 (broad d, J = 5.5 Hz: 1H) ; 6.65 (broad s: 1H) ; 7.68 (broad d, J = 8.5 Hz: 2H); 7.87 (d, J = 8.5 Hz: 2H); 8.03 (d, J = 5.5 Hz: 1H). Example 223 : 5,5-Dimethyl-1 - (2 -methylaminopyrid-4 -yl -methyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2, 4-dione A sealed 2.5 ml tube containing 0.1 g of 5,5-dimethyl-1-(2-chloropyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione, 0.5 ml of N-methyl-2-pyrrolidone, 0.016 mg of methylamine hydrochloride and 0.064 ml of triethylamine is placed in a Personal Chemistry Emrys Optimiser microwave oven. The mixture is irradiated with magnetic stirring at 180°C for about 80 minutes. The reaction mixture is purified by preparative LC/MS. The fractions containing the expected product are concentrated to dryness under reduced pressure. The residue thus obtained is taken up in methanol and then deposited on a Bond Elut Varian reference 1225-6054 cartridge containing 3 g of SCX phase conditioned with methanol. Washing with methanol is performed, followed by elution with 2M ammoniacal methanol. The ammoniacal fractions are concentrated to dryness under reduced pressure. The residue thus obtained is purified by flash chromatography using a cartridge 16 mm in diameter packed with 2 g of conditioned 15-35 /zm silica, and then eluted with dichloromethane at a flow rate of 5 ml/minute. The fractions containing the expected product are concentrated to dryness under reduced pressure. 0.021 g of 5,5-dimethyl-1-(2-methylaminopyrid-4-ylmethyl)-3-(4- trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione is thus obtained in the form of an amorphous white powder, the characteristics of which are as follows: Mass EI m/z=424 M+' base peak m/z = 396 (M - CH2N) + m/z=219 C8H4NOSF3+- m/z = 120 C7H8N2+' 1H NMR spectrum (300 MHz, (CD3)2SO d6, 8 in ppm) : 1.42 (s: 6H); 2.77 (d, J = 5 Hz: 3H); 4.48 (broad S: 2H) ; 6.42 (mt: 1H) ; 6.46 (broad s: 1H) ; 6.52 (broad d, J = 5.5 Hz: 1H); 7.69 (broad d, J = 8.5 Hz: 2H); 7.89 (broad d, J = 8.5 Hz: 2H); 7.94 (d, J = 5.5 Hz: 1H). Example 224: 5,5-Dimethyl-1-(2-cyclohexylaminopyrid-4 -ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2, 4-dione A sealed 2.5 ml tube containing 0.1 g of 5,5-dimethyl-1-(2-chloropyrid-4-ylmethyl)-3-(4- trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione, 0.2 ml of N-methyl-2-pyrrolidone and 0.4 ml of cyclohexylamine is placed in a Personal Chemistry Emrys Optimiser microwave oven. The mixture is irradiated with magnetic stirring at 2 00°C for about 50 minutes. The reaction mixture is purified by preparative LC/MS. The fractions containing the expected product are concentrated to dryness under reduced pressure. The residue thus obtained is taken up in methanol and then deposited on a Bond Elut Varian reference 1225-6054 cartridge containing 3 g of SCX phase conditioned with methanol. Washing with methanol is performed, followed by elution with 2M ammoniacal methanol. The ammoniacal fractions are concentrated to dryness under reduced pressure. The residue thus obtained is purified by flash chromatography using a cartridge 16 mm in diameter packed with 2 g of conditioned 15-35 /xm silica, and then eluted with dichloromethane at a flow rate of 5 ml/minute. The fractions between 15 and 45 ml are concentrated under reduced pressure. 0 . 017 g of 5,5-dimethyl-l-(2-cyclohexylaminopyrid-4-ylmethyl)-3-(4- trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione is thus obtained in the form of an amorphous powder, the characteristics of which are as follows: Mass EI m/z=492 M+- m/z=449 (M - C3H7 m/z=435 (M - C3H7 m/z=410 (M - C6Hi m/z=219 C8H4NOSF3H m/z=175 CnH15N2+ m/z=98 C6H12N+ XH NMR spectrum (400 MHz, (CD3)2SO d6, 5 in ppm) : from 1.10 to 1.40 (mt: 5H) ; 1.43 (s: 6H) ; from 1.55 to 2.0 0 (mt: 5H); 3.67 (mt: 1H); 4.45 (s: 2H); 6.2 8 (d, J = 8 Hz: 1H); 6.44 (broad s: 1H); 6.46 (broad d, J = 5.5 Hz: 1H); 7.68 (broad d, J = 9 Hz: 2H) ; from 7.85 to 7.95 (mt: 3H) . Example 225: 5,5-Dimethyl-1-(2-isopropylaminopyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)imidazo-lidine-2,4-dione A sealed 2.5 ml tube containing 0.1 g of 5,5-dimethyl-1-(2-chloropyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione, 0.2 ml of N-methyl-2-pyrrolidone and 0.4 ml of isopropylamine is placed in a Personal Chemistry Emrys Optimiser microwave oven. The mixture is irradiated with magnetic stirring at 200°C for about 70 minutes. The reaction mixture is purified by preparative LC/MS. The fractions containing the expected product are concentrated to dryness under reduced pressure. The residue thus obtained is taken up in methanol and then deposited on a Bond Elut Varian reference 1225-6027 cartridge containing 5 g of SCX phase conditioned with methanol. Washing with methanol is performed, followed by elution with 2M ammoniacal methanol. The ammoniacal fractions are concentrated to dryness under reduced pressure. The residue thus obtained is purified by flash chromatography using a cartridge 16 mm in diameter packed with 2 g of conditioned 15-35 fim silica, and then eluted with dichloromethane at a flow rate of 5 ml/minute. The fractions between 10 and 35 ml are concentrated to dryness under reduced pressure. 0.008 g of 5,5-dimethyl-1-(2-isopropylaminopyrid-4-ylmethyl)-3-(4- trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione is thus obtained in the form of an amorphous powder, the characteristics of which are as follows: Mass EI m/z = 452 M+* m/z=437 (M - CH3)+base peak m/z = 410 (M - C3H6)+- m/z = 219 C8H4NOSF3+' m/z=134 C8H10N2+- m/z = 58 C3H8N+ lK NMR spectrum (3 00 MHz, (CD3)2SO d6, 5 in ppm) : 1.13 (d, J = 6.5 Hz: 6H) ; 1.42 (s: 6H) ; 3.98 (mt : 1H) ; 4.45 (broad s: 2H) ; 6.27 (broad d, J = 7.5 Hz: 1H); 6.42 (broad s: 1H) ; 6.46 (broad d, J = 5.5 Hz: 1H) ; 7.68 (broad d, J = 8 Hz: 2H); 7.88 (broad d, J = 8 Hz: 2H) ; 7.90 (d, J = 5.5 Hz: 1H). Example 226: 5,5-Dimethyl-l-(2-piperidinopyrid-4-yl-methyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolid-ine-2,4-dione A sealed 2.5 ml tube containing 0.1 g of 5,5-dimethyl-1-(2-chloropyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione, 0.2 ml of N-methyl-2-pyrrolidone and 0.4 ml of piperidine is placed in a Personal Chemistry Emrys Optimiser microwave oven. The mixture is irradiated with magnetic stirring at 200°C for about 30 minutes. The reaction mixture is purified by preparative LC/MS. The fractions containing the expected product are concentrated to dryness under reduced pressure. The residue thus obtained is taken up in methanol and then deposited on a Bond Elut Varian reference 1225-6027 cartridge containing 5 g of SCX phase conditioned with methanol. Washing with methanol is performed, followed by elution with 2M ammoniacal methanol. The ammoniacal fractions are concentrated to dryness under reduced pressure. The residue thus obtained is purified by flash chromatography using a cartridge 16 mm in diameter packed with 2 g of conditioned 15-35 fim silica, and then eluted with dichloromethane, at a flow rate of 5 ml/minute. The fractions between 10 and 30 ml are concentrated to dryness under reduced pressure. 0.07 g of 5,5-dimethyl-1-(2-piperidinopyrid-4-ylmethyl)-3-(4- trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione is thus obtained in the form of an amorphous powder, the characteristics of which are as follows: Mass EI m/z=478 M+" base peak m/z = 449 (M - C2H5) + m/z = 422 (M - C4H8)+' m/z=395 (M - C5H9N)+ m/z=219 C8H4NOSF3+- m/z = 161 C10H13N2+ m/z=84 C5Hi0N+ XH NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm) : 1.42 (s: 6H); from 1.45 to 1.65 (mt: 6H); 3.52 (broad t, J = 5 Hz: 4H) ; 4.52 (broad S: 2H) ; 6.64 (broad d, J = 5.5 Hz: 1H) ; 6.83 (broad s: 1H) ; 7.68 (d, J = 8.5 Hz: 2H); 7.88 (d, J = 8.5 Hz: 2H); 8.04 (d, J = 5.5 Hz: 1H). Example 227; 5,5-Dimethyl-l-[2-(4-methylpiperazino)pyrid-4-ylmethyl]-3-(4-trifluoromethanesulfanylphenyl)-imidazolidine-2,4-dione A sealed 2.5 ml tube containing 0.1 g of 5,5-dimethyl-1-(2-chloropyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione, 0.2 ml of N-methyl-2-pyrrolidone and 0.4 ml of N-methylpiperazine is placed in a Personal Chemistry Emrys Dptimiser microwave oven. The mixture is irradiated with magnetic stirring at 200°C for about 3 0 minutes. The reaction mixture is purified by preparative LC/MS. The fractions containing the expected product are concentrated to dryness under reduced pressure. The residue thus obtained is taken up in methanol and then deposited on a Bond Elut Varian reference 1225-6027 cartridge containing 5 g of SCX phase conditioned with methanol. Washing with methanol is performed, followed by slution with 2M ammoniacal methanol. The ammoniacal fractions are concentrated to dryness under reduced pressure. The residue thus obtained is purified by flash chromatography using a cartridge 16 mm in diameter packed with 2 g of conditioned 15-35 /zm silica, and then eluted with dichloromethane, at a flow rate of 5 ml/minute. The fractions between 105 and 135 ml are concentrated to dryness under reduced pressure. 0.028 g of 5,5-dimethyl-1-[2-(4-methylpiperazino)pyrid-4-ylmethyl]-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione is thus obtained in the form of an amorphous powder, the characteristics of which are as follows: Mass EI m/z=493 M+- m/z=423 (M - C4H8N)+- base peak m/z = 219 C8H4NOSF3+- m/z = 176 C10H14N3+ 1H NMR spectrum (300 MHz, (CD3)2SO d6, 8 in ppm) : 1.42 (s: 6H) ; 2.23 (s: 3H) ; 2.40 (broad t, J = 5 Hz: 4H); 3.50 (broad t, J = 5 Hz: 4H) ; 4.53 (broad s: 2H) ; 6.70 (broad d, J = 5.5 Hz: 1H); 6.85 (broad s: 1H); 7.69 (d, J = 8.5 Hz: 2H) ; 7.88 (d, J = 8.5 Hz: 2H) ; 8.07 (d, J = 5.5 Hz: 1H) . Example 228: 5,5-Dimethyl-1-(2-phenylaminopyrid-4-yl-methyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2, 4-dione A sealed 2.5 ml tube containing 0.1 g of 5,5-dimethyl-1-(2-chloropyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione, 0.2 ml of N-methyl-2-pyrrolidone and 0.4 ml of aniline is placed in a Personal Chemistry Emrys Optimiser microwave oven. The mixture is irradiated with magnetic stirring at 2 0 0 ° C for about 3 0 minutes. The react ion mixture is purified by preparative LC/MS. The fractions containing the expected product are concentrated to dryness under reduced pressure. The residue thus obtained is taken up in methanol and then deposited on a Bond Elut Varian reference 1225-6027 cartridge containing 5 g of SCX phase conditioned with methanol. Washing with methanol is performed, followed by elution with 2M ammoniacal methanol. The ammoniacal fractions are concentrated to dryness under reduced pressure. The residue thus obtained is purified by flash chromatography using a cartridge 16 mm in diameter packed with 2 g of conditioned 15-35 /xm silica, and then eluted with dichloromethane, at a flow rate of 5 ml/minute. The fractions between 40 and 85 ml are concentrated to dryness under reduced pressure. 0 . 082 g of 5,5-dimethyl-1-(2-phenylaminopyrid-4-ylmethyl)-3-(4-tri- fluoromethanesulfanylphenyl)imidazolidine-2,4-dione is ■thus obtained in the form of an amorphous powder, the characteristics of which are as follows: Mass EI m/z=486 M+" m/z=485 (M - H)+ base peak m/z=417 (M - CF3) + m/z = 182 Ci2H10N2+-XH NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm) : 1.46 (s: 6H) ; 4.55 (broad s: 2H) ; 6.80 (broad d, J = 5.5 Hz: 1H) ; 6.84 (broad s: 1H) ; 6.88 (broad t, J = 7.5 Hz: 1H) ; 7.25 (dd, J = 8 and 7.5 Hz: 2H) ; 7.67 (broad d, J = 8 Hz: 2H); 7.69 (d, J = 8.5 Hz: 2H); 7.88 (broad d, J = 8.5 Hz: 2H); 8.01 (d, J = 5.5 Hz: 1H); 9.01 (broad S: 1H) . Example 229; 5,5-Dimethyl-1-[2-(4-piperazino)pyrid-4-ylmethyl]-3-(4-trifluoromethanesulfanylphenyl)-imidazolidine-2,4-dione A sealed 2.5 ml tube containing 0.1 g of 5,5-dimethyl-1-(2-chloropyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione, 0.6 ml of N-methyl-2-pyrrolidone and 0.123 g of piperazine is placed in a Personal Chemistry Emrys Optimiser microwave oven. The mixture is irradiated with magnetic stirring at 200°C for about 30 minutes. The reaction mixture is purified by preparative LC/MS. The fractions containing the expected product are concentrated to dryness under reduced pressure. The residue thus obtained is taken up in methanol and then deposited on a Bond Elut Varian reference 1225-6027 cartridge containing 5 g of SCX phase conditioned with methanol. Washing with methanol is performed, followed by elution with 2M ammoniacal methanol. The ammoniacal fractions are concentrated to dryness under reduced pressure. The residue thus obtained is purified by flash chromatography using a cartridge 16 mm in diameter packed with 2 g of conditioned 15-35 /xm silica, and then eluted with dichloromethane, at a flow rate of 5 ml/minute. The fractions between 45 and 110 ml are concentrated to dryness under reduced pressure. 0.042 g of 5,5-dimethyl-1-[2-(4-piperazino)pyrid-4-ylmethyl] -3-(4- trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione is thus obtained in the form of an amorphous powder, the characteristics of which are as follows: Mass CI m/z=480 MH+ base peak *H NMR spectrum (300 MHz, (CD3)2SO d6, 8 in ppm) : 1.43 (s: 6H) ; 2.79 (broad t, J = 5 Hz: 4H) ; 3.41 (broad t, J = 5 Hz: 4H); 4.52 (broad s: 2H); 6.69 (broad d, J = 5.5 Hz: 1H) ; 6.82 (broad s: 1H) ; 7.69 (broad d, J = 8.5 Hz: 2H) ; 7.88 (d, J = 8.5 Hz: 2H) ; 8.06 (d, J = 5.5 Hz: 1H) . Example 230: 5,5-Dimethyl-l-(2-ethylaminopyrid-4-yl-methyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2, 4-dione A sealed 2.5 ml tube containing 0.1 g of 5,5-dimethyl-1-(2-chloropyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione, 0.5 ml of N-methyl-2-pyrrolidone, 0.019 g of ethylamine hydrochloride and 0.064 ml of triethylamine is placed in a Personal Chemistry Emrys Optimiser microwave oven. The mixture is irradiated with magnetic stirring at 200°C for about 120 minutes. The reaction mixture is purified by preparative LC/MS. The fractions containing the expected product are concentrated to dryness under reduced pressure. The residue thus obtained is taken up in methanol and then deposited on a Bond Elut Varian reference 1225-6027 cartridge containing 5 g of SCX phase conditioned with methanol. Washing with methanol is performed, followed by elution with 2M ammoniacal methanol. The ammoniacal fractions are concentrated to dryness under reduced pressure. The residue thus obtained is purified by flash chromatography using a cartridge 16 mm in diameter packed with 2 g of conditioned 15-35 /im silica, and then eluted with dichloromethane, at a flow rate of 5 ml/minute. The fractions between 280 and 300 ml are concentrated to dryness under reduced pressure. 0 . 033 g of 5, 5-dimethyl-l- (2-ethylaminopyrid-4-ylmethyl) -3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione is thus obtained in the form of an amorphous powder, the characteristics of which are as follows: m.p. = 136°C Mass EI m/z = 438 M+" m/z=423 (M - CH3)+base peak m/z = 395 (M - C2H5N) + m/z = 369 (M - CF3) + m/z=121 C7H9N2+' m/z = 44 C2H6N+ XH NMR spectrum (300 MHz, (CD3)2SO d6, 8 in ppm) : 1.14 (t, J = 7 Hz: 3H); 1.44 (s: 6H); 3.26 (mt: 2H); 4.47 (broad s: 2H) ; 6.40 (broad t, J = 5.5 Hz: 1H) ; 6.45 (broad s: 1H) ; 6.50 (broad d, J = 5.5 Hz: 1H) ; 7.69 (broad d, J = 8.5 Hz: 2H) ; 7.89 (broad d, J = 8.5 Hz: 2H); 7.92 (d, J = 5.5 Hz: 1H). Example 231: 5,5-Dimethyl-1-(2-benzylaminopyrid-4-yl-methyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2, 4-dione A sealed 2.5 ml tube containing 0.1 g of 5,5-dimethyl-1-(2-chloropyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione, 0.2 ml of N-methyl-2-pyrrolidone and 0.4 ml of benzylamine is placed in a Personal Chemistry Emrys Optimiser microwave oven. The mixture is irradiated with magnet ic st irring at 2 0 0 ° C for about 3 0 minutes. The reaction mixture is purified by preparative LC/MS. The fractions containing the expected product are concentrated to dryness under reduced pressure. The residue thus obtained is taken up in methanol and then deposited on a Bond Elut Varian reference 1225-6027 cartridge containing 5 g of SCX phase conditioned with methanol. Washing with methanol is performed, followed by elution with 2M ammoniacal methanol. The ammoniacal fractions are concentrated to dryness under reduced pressure. The residue thus obtained is purified by flash chromatography using a cartridge 16 mm in diameter packed with 2 g of conditioned 15-35 /xm silica, and then eluted with dichloromethane, at a flow rate of 5 ml/minute. The fractions between 10 and 50 ml are concentrated to dryness under reduced pressure. 0.035 g of 5,5-dimethyl-1-(2-benzylaminopyrid-4-ylmethyl)-3-(4- trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione is thus obtained in the form of an amorphous powder, the characteristics of which are as follows: m.p. 144°C Mass EI m/z=500 M+' base peak m/z = 431 (M - CF3) + m/z=196 Ci3Hi2N2+' m/z = 106 C7H8N+ m/z=91 C7H7+ 1H NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm) : 1.39 (s: 6H) ; 4.47 (broad s: 2H) ; 4.48 (d, J = 6 Hz: 2H) ; 6.51 (broad S: 1H) ; 6.54 (broad d, J = 5.5 Hz: 1H) ; 7.02 (broad t, J = 6 Hz: 1H); from 7.15 to 7.35 (mt: 5H); 7.68 (broad d, J = 8.5 Hz: 2H); 7.89 (d, J = 8.5 Hz: 2H); 7.92 (d, J = 5.5 Hz: 1H). Example 232; 5,5-Dimethyl-l-[2-(4-methoxybenzylamino)-pyrid-4-ylmethyl]-3-(4-trifluoromethanesulfanylphenyl)-imidazolidine-2,4-dione A sealed 2.5 ml tube containing 0.1 g of 5,5-dimethyl-1-(2-chloropyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione, 0.2 ml of N-methyl-2-pyrrolidone and 0.4 ml of para-methoxybenzylamine is placed in a Personal Chemistry Emrys Optimiser microwave oven. The mixture is irradiated with magnetic stirring at 200°C for about 30 minutes. The reaction mixture is purified by preparative LC/MS. The fractions containing the expected product are concentrated to dryness under reduced pressure. The residue thus obtained is taken up in methanol and then deposited on a Bond Elut Varian reference 1225-6027 cartridge containing 5 g of SCX phase conditioned with methanol. Washing with methanol is performed, followed by elution with 2M ammoniacal methanol. The ammoniacal fractions are concentrated to dryness under reduced pressure. The residue thus obtained is purified by flash chromatography using a cartridge 16 mm in diameter packed with 2 g of conditioned 15-35 /xm silica, and then eluted with dichloromethane, at a flow rate of 5 ml/minute. The fractions between 5 and 55 ml are concentrated to dryness under reduced pressure. 0.035 g of 5,5-dimethyl-1-[2-(4-methoxybenzylamino)pyrid-4-ylmethyl] -3-(4- trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione is thus obtained in the form of an amorphous powder, the characteristics of which are as follows: Mass EI m/z=530 M+- m/z = 461 (M - CF3) + m/z=136 C8Hi0NO+ m/z=121 C8H90+ base peak XH NMR spectrum (300 MHz, (CD3)2SO d6, 8 in ppm) : 1.39 (s: 6H) ; 3.72 (s: 3H) ; 4.39 (d, J = 5.5 Hz: 2H) ; 4.46 (broad s: 2H) ; 6.48 (broad s: 1H); 6.53 (broad d, J = 5.5 Hz: 1H) ; 6.87 (broad d, J = 8.5 Hz: 2H) ; 6.93 (t, J = 5.5 Hz: 1H) ; 7.25 (broad d, J = 8.5 Hz: 2H) ; 7.68 (broad d, J = 8.5 Hz: 2H) ; 7.89 (broad d, J = 8.5 Hz: 2H) ; 7.92 (d, J = 5.5 Hz: 1H) . Example 233; 5,5-Dimethyl-1-(2-aminopyrid-4-ylmethyl)-3-(4-tri fluoromethanesulfanylphenyl)imidazolIdine-2,4-dione. 0.5 ml of trif luoroacetic acid is added to a solution of 0.035 g of 5,5-dimethyl-l-[2-(4-methoxybenzylamino)pyrid-4-ylmethyl] -3-(4- trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione in 0.5 ml of dichloromethane at a temperature in the region of 2 0 ° C, and s t irr ing is cont inued at this same temperature for 5 hours. The reaction mixture is purified by preparative LC/MS. The fractions containing the expected product are concentrated to dryness under reduced pressure. The residue thus obtained is taken up in methanol and then placed on a Bond Elut Varian reference 1225-6027 cartridge containing 5 g of SCX phase conditioned with methanol. Washing with methanol is performed, followed by elution with 2M ammoniacal methanol. The ammoniacal fractions are concentrated to dryness under reduced pressure. 0.015 g of 5,5-dimethyl-1-(2-aminopyrid-4-ylmethyl) -3-(4- trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione is thus obtained in the form of a powder, the characteristics of which are as follows: m.p.: 161°C Mass EI m/z=410 M+* base peak m/z=395 (M - CH3)+ m/z = 219 C8H4NOSF3+' m/z = 148 C7H6N30+ m/z=107 C6H7N2+ lH NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm) : 1.43 (s: 6H) ; 4.46 (broad s: 2H) ; 5.86 (broad s: 2H) ; 6.46 (broad s: 1H); 6.53 (broad d, J = 5.5 Hz: 1H); 7.69 (broad d, J = 8.5 Hz: 2H); 7.84 (d, J = 5.5 Hz: 1H); 7.89 (broad d, J = 8.5 Hz: 2H). Example 234; 5# 5-Dimethyl-1-(2-acetamidopyrid-4-yl-methyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2, 4-dione A solution of 0.050 g of 5,5-dimethyl-1-(2-aminopyrid-4-ylmethyl)-3-(4- trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione in 5 ml of acetic anhydride is stirred under an inert atmosphere of argon for 24 hours at a temperature in the region of 8 0°C. The reaction mixture is purified by preparative LC/MS. The fractions containing the expected product are concentrated to dryness under reduced pressure. The residue thus obtained is taken up in methanol and then placed on a Bond Elut Varian reference 1225-6027 cartridge containing 5 g of SCX phase conditioned with methanol. Washing with methanol is performed, followed by elution with 2M ammoniacal methanol. The ammoniacal fractions are concentrated to dryness under reduced pressure. 0.006 g of 5,5-dimethyl-1-(2-acetamidopyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione is thus obtained in the form of a powder, the characteristics of which are as follows: Mass EI m/z = 452 M+- m/z=410 (M » C2H20)+-base peak m/z=395 (m/z=410 - CH3)+ m/z = 219 C8H4NOSF3+' m/z=150 C8Hi0N2O+- m/z=107 C6H7N2+ m/z=43 C2H30+ XR NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm) : 1.44 (broad s: 6H) ; 2.11 (s: 3H) ; 4.65 (broad s: 2H) ; 7.15 (broad d, J = 5.5 Hz: 1H); 7.68 (broad d, J = 8.5 Hz: 2H) ; 7.89 (broad d, J = 8.5 Hz: 2H) ; 8.14 (broad s: 1H) ; 8.27 (d, J = 5.5 Hz: 1H) ; 10.49 (unresolved complex: 1H). Example 235: 5,5-Dimethyl-1-(2-tert-butoxycarbonyl-aminopyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanyl-phenyl)imidazolidine-2,4-dione 0 . 05 g of 5,5-dimethyl-l-(2-aminopyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione is added portionwise to a solution of 0.029 g of di-tert-butyl dicarbonate in 0.65 ml of tert-butyl alcohol, under an inert atmosphere of argon at a temperature in the region of 20 °C, and stirring is continued at this temperature for 24 hours. The reaction mixture is concentrated to dryness under reduced pressure. The residue thus obtained is purified by flash chromatography using a cartridge 16 mm in diameter packed with 5 g of conditioned 20-40 /an silica, and then eluted with a mixture (cyclohexane/ethyl acetate) (8/2) (v/v). The fractions between 260 and 400 ml are concentrated under reduced pressure. 0.035 g of 5,5-dimethyl-l-(2-tert-butoxycarbonylaminopyrid-4-ylmethyl)-3- (4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione is thus obtained, the characteristics of which are as follows: Mass CI m/z=511 MH+ base peak XH NMR spectrum (300 MHz, (CD3)2SO d6, 8 in ppm) : 1.43 (s: 6H) ; 1.4 9 (s: 9H) ; 4.6 3 (broad s: 2H) ; 7.0 8 (broad dd, J = 5.5 and 1.5 Hz: 1H) ; 7.68 (broad d, J = 9 Hz: 2H); 7.84 (broad s: 1H); 7.87 (broad d, J = 9 Hz: 2H); 8.19 (d, J = 5.5 Hz: 1H); 9.73 (broad s: 1H). Example 236: 5, 5-Dimethyl-1- (2-methylsulfonylaminopyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)-imidazolidine-2,4-dione 0.010 ml of methanesulfonyl chloride is added to a solution of 0.050 g of 5,5-dimethyl-l-(2-aminopyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2, 4-dione in 0.4 ml of pyridine, under an inert atmosphere of argon at a temperature in the region of 2 0°C, and stirring is continued at this temperature for 2 hours. The reaction mixture is poured into 50 ml of saturated sodium bicarbonate solution and then extracted with 2x50 ml of ethyl acetate. The organic phase is dried over magnesium sulfate, filtered and then concentrated to dryness under reduced pressure. 0 . 020 g of 5,5-dimethyl-1-(2-methylsulfonylaminopyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione is thus obtained in the form of a white powder, the characteristics of which are as follows: m.p.: 208°C Mass EI m/z=488 M+* base peak m/z=473 (M - CH3)+ m/z = 409 (M - S02CH3) + m/z = 219 C8H4NOSF3+- m/z = 185 C7H9N202S+ NOVEL CYCLIC UREA DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE OF THE SAME AS KINASE INHIBITORS The present invention relates to nbvel cyclic urea derivatives, to a process for preparing them, to their use as medicinal products, to pharmaceutical compositions containing them and to the pharmaceutical use of such derivatives for preventing and treating, complaints that may be modulated by inhibiting the activity of protein kinases. The present invention relates to novel cyclic urea derivatives that have inhibitory effects on protein kinases. The products of the present invention may thus be used especially for preventing or treating complaints capable of being modulated by inhibiting the activity of protein kinases. The inhibition and regulation of protein kinases especially constitute a powerful new mechanism of action for treating a large number of solid tumors. Such complaints that the products of the present patent application can treat are thus most particularly solid tumors. Such protein kinases belong especially to the following group: EGFR, Fak, FLK-1, FGFR1, FGFR2, FGFR3, FGFR4, FGFR5, flt-1, IGF-IR, KDR, PLK,PDGFR, tie2, VEGFR, AKT, Raf. The protein kinase IGF1-R (Insulin Growth Factor-1 Receptor) is particularly indicated. The protein kinase FAK is also indicated. The protein kinase AKT is also indicated. The present invention thus relates particularly to novel inhibitors of the IGF-IR receptor that may be used for oncology treatments. The present invention also relates to novel FAK receptor inhibitors that may be used for oncology treatments. The present invention also relates to novel AKT receptor inhibitors that may be used for oncology treatments. Cancer remains a disease for which the existing treatments are clearly insufficient. Certain protein kinases, especially including IGF-1R (Insulin Growth Factor 1 Receptor) , play an important role in many cancers. The inhibition of such protein kinases is potentially important in the chemotherapy of cancers, especially for suppressing the growth or survival of tumors. The present invention thus relates to the identification of novel products that inhibit such protein kinases. Protein kinases participate in signaling events that control the activation, growth and differentiation of cells in response either to extracellular mediators or to changes in the environment. In general, these kinases belong to two groups: those that preferentially phosphorylate serine and/or threonine residues and those that preferentially phosphorylate tyrosine residues [S.K. Hanks and T. Hunter, FASEB. J., 1995, 9, pages 576-596] . The serine/threonine kinases are, for example, the isoforms of the protein kinases C [A.C. Newton, J. Biol. Chem., 1995, 270, pages 28495-28498] and a group of cycline-dependent kinases, for instance cdc2 [J. Pines, Trends in Biochemical Sciences, 1995, 18, pages 195-197]. Tyrosine kinases comprise growth factor receptors, for instance the epidermal growth factor (EGF) receptor [S. Iwashita and M. Kobayashi, Cellular Signalling, 1992, 4, pages 12 3-132], and cytosol kinases, for instance p56tck, p59fYn and ZAP-70 and the kinases csk [C. Chan et. al., Ann. Rev. Immunol., 1994, 12, pages 555-592]. Abnormally high levels of kinase protein activity have been implicated in many diseases, resulting from abnormal cellular functions. This may arise either directly or indirectly from a dysfunction in the mechanisms for controlling the kinase activity, linked, for example, to a mutation, an overexpression or an inappropriate activation of the enzyme, or an over- or underproduction of cytokines or of growth factors, also involved in the transduction of the signals upstream or downstream of the kinases. In all these cases, a selective inhibition of the action of the kinases offers hope of a beneficial effect. The type 1 receptor for in the insulin-like growth factor (IGF-I-R) is a transmembrane receptor with tyrosine kinase activity which binds firstly to IGFI, but also to IGFI I and to insulin with lower affinity. The binding of IGFI to its receptor results in oligomerization of the receptor, the activation of tyrosine kinase, intermolecular autophosphorylation and the phosphorylation of cell substrates (main substrates: IRS1 and She) . The receptor activated by its ligand induces mitogenic activity in normal cells. However, IGF-I-R plays an important role in "abnormal" growth. Several clinical reports underline the important role of the IGF-1 route in the development of human cancers: IGF-I-R is often found overexpressed in many types of tumor (breast, colon, lung, sarcoma, etc.) and its presence is often associated with a more aggressive phenotype. High concentrations of circulating IGFI are strongly correlated with a risk of prostate cancer, lung cancer and breast cancer. Furthermore, it has been widely documented that IGF-I-R is necessary for establishing and maintaining the transformed phenotype in vitro as in vivo [Baserga R, Exp. Cell. Res., 1999, 253, pages 1-6]. The kinase activity of IGF-I-R is essential for the transformation activity of several oncogenes: EGFR, PDGFR, the large T antigen of the SV40 virus, activated Ras, Raf, and v-Src. The expression of IGF-I-R in normal fibroblasts induces a neoplastic phenotype, which may then result in the formation of a tumor in vivo. The expression of IGF-I-R plays an important role in substrate-independent growth. IGF-I-R has also been shown to be a protector in chemotherapy-induced and radiation-induced apoptosis, and cytokine-induced apoptosis. Furthermore, the inhibition of endogenous IGF-I-R with a negative dominant, the formation of a triple helix or the expression of an antisense sequence brings about suppression of the transforming activity in vitro and reduction of tumor growth in animal models. Among the kinases for which a modulation of the activity is desired, FAK (Focal Adhesion Kinase) is also a preferred kinase. FAK is a cytoplasmic tyrosine kinase that plays an important role in tranducing the signal transmitted by the integrins, a family of heterodimeric receptors of cellular adhesion. FAK and the integrins are colocalized in perimembrane structures known as adhesion plaques. It has been shown in many cell types that the activation of FAK and its phosphorylation on tyrosine residues and in particular its autophosphorylation on tyrosine 397 were lependent on the binding of the integrins to their extracellular ligands and thus induced during cellular idhesion [Kornberg L, and al. J. Biol. Chem. 267(33) : 13439-442 (1992)]. The autophosphorylation on tyrosine -97 of FAK represents a binding site for another tyrosine :inase, Src, via its SH2 domain [Schaller et al. Mol. 'ell. Biol. 14 : 1680-1688 1994 ; Xing et al. Mol. Cell. iol. 5 : 413-421 1994] . Src can then phosphorylate FAK n tyrosine 925, thus recruiting the adapter protein Grb2 and inducing in certain cells activation of the ras and MAP kinase pathway involved in controlling cellular proliferation [Schlaepfer et al. Nature ; 372 : 786-791 1994; Schlaepfer et al. Prog. Biophy. Mol. Biol. 71: 435-478 1999 ; Schlaepfer and Hunter, J. Biol. Chem. 272: 13189-13195 1997]. The activation of FAK can thus induce the jun Nonterminal kinase (JNK) signaling pathway and result in the progression of the cells to the Gl phase of the cellular cycle [Oktay et al., J. Cell. Biol.145: 1461-1469 1999]. Phosphatidylinositol-3-OH kinase (PI3-kinase) also binds to FAK on tyros ine 3 97 and thi s interact ion might be necessary for the activation of PI3-kinase [Chen and Guan, Proc. Nat. Acad. Sci. USA. 91: 10148-10152 1994/ Ling et al. J. Cell. Biochem. 73: 533-544 1999]. The FAK/Src complex phosphorylates various substrates, for instance paxillin and pl3 0CAS in fibroblasts [Vuori et al. Mol. Cell. Biol. 16: 2606-2613 1996]. The results of numerous studies support the hypothesis that FAK inhibitors might be useful in treating cancer. Studies have suggested that FAK might play an important role in in vitro cell proliferation and/or survival. For example, in CHO cells, certain authors have demonstrated that the overexpression of pi 2 5 FAK induces an acceleration of the Gl to S transition, suggesting that pl25FAK promotes cellular proliferation [Zhao J.-H et al. J. Cell Biol. 143: 1997-2008 1998]. Other authors have shown that tumor cells treated with FAK antisense oligonucleotides lose their adhesion and go into apoptosis (Xu et al, Cell Growth Differ. 4: 413-418 1996) . It has also been demonstrated that FAK promotes the migration of cells in vitro. Thus, fibroblasts that are deficient for the expression of FAK ("knockout" mice for FAK) show a rounded morphology and deficiencies in cell migration in response to chimiotactic signals, and these defects are suppressed by reexpression of FAK [DJ. Sieg et al. , J. Cell Science. 112: 2677-91 1999] . The overexpression of the C-terminal domain of FAK (FRNK) blocks the stretching of adherent cells and reduces cellular migration in vitro [Richardson A. and Parsons J.T. Nature. 380: 538-540 1996], The overexpression of FAK in CHO or COS cells or in human astrocytoma cells promotes migration of the cells. The involvement of FAK in promoting the proliferation and migration of cells in numerous cell types in vitro suggests the potential role of FAK in neoplastic processes. A recent study has effectively demonstrated the increase in the proliferation of tumor cells in vivo after induction of the expression of FAK in human astrocytoma cells [Cary L.A. et al. J. Cell Sci. 109: 1787-94 1996; Wang D et al. J. Cell Sci. 113: 4221-4230 2000] . Furthermore, immunohistochemical studies on human biopsies have demonstrated that FAK is overexpressed in prostate cancer, breast cancer, thyroid cancer, cancer of the colon, melanoma, brain cancer and lung cancer, the level of expression of FAK being directly correlated to the tumors having the most aggressive phenotype [Weiner TM, et al. Lancet. 342 (8878): 1024-1025 1993; Owens et al. Cancer Research. 55: 2752-2755 1995; Maung K. et al. Oncogene 18: 6824-6828 1999; Wang D et al. J. Cell Sci. 113: 4221-4230 2000]. Protein kinase AKT (also known as PKB) and phosphoinositide 3-kinase (PI3K) are involved in a cell signaling pathway that transmits signals from growth factors activating membrane receptors. This transduction pathway is involved in numerous cellular functions: regulation of apoptosis, control of transcription and translation, glucose metabolism, angiogenesis and mitochondrial integrity. First identified as an important component of insulin-dependent signaling pathways regulating metabolic responses, serine/threonine kinase AKT was then identified as a mediator playing a key role in survival induced with growth factors. It has been shown that AKT can inhibit death by apoptosis induced by various stimuli, in a certain number of cell types and tumor cells. In accordance with these findings, it has been shown that AKT can, by phosphorylation of given serine residues, inactivate BAD, GSK3(3, caspase-9, and Forkhead transcription factor, and can activate IKKalpha and e-NOS. It is interesting to note that the protein BAD is found hyper-phosphorylated in 11 human tumor cell lines out of 41 studied. Furthermore, it has been shown that hypoxia modulates the induction of VEGF in cells transformed with Ha-ras by activating the PI3K/AKT pathway and by involving the binding sequence of the HIF-1 (hypoxia inducible factor-1) transcription factor known as HRE for nhypoxy-responsive element". AKT plays a very important role in cancer pathologies. The amplification and/or overexpression of AKT has been reported in many human tumors, for instance gastric carcinoma (amplification of AKT1), ovary carcinoma, breast carcinoma or pancreatic carcinoma (amplification and overexpression of AKT2) and breast carcinomas deficient in estrogen receptors, and also androgen-independent prostate carcinomas (overexpression of AKT3). Furthermore, AKT is constitutively activated in all the PTEN (-/-) tumors, the PTEN phosphatase being deleted or inactivated by mutations in many types of tumors, for instance carcinomas of the ovary, of the prostate, of the endometrium, glioblastomas and melanomas. AKT is also involved in the oncogenic activation of bcr-abl (references: Khawaja A. , Nature 1999, 401, 33-34; Cardone et al. Nature 1998, 282, 1318-1321; Kitada S. et al., Am J Pathol 1998 Jan; 152(1): 51-61; Mazure NM et al. Blood 1997, 90, 3322-3331; Zhong H. et al. Cancer Res. 2000, 60, 1541-1545). One subject of the present invention is thus the products of general formula (I) : in which p represents an integer from 0 to 2, R and Rl, which may be identical or different, represent 0 or NH, R2 and R3, which may be identical or different, represent hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl and heteroaryl which are optionally substituted, or alternatively R2 and R3 form, together with the carbon atom to which they are attached, a carbocyclic or heterocyclic radical, these radicals being 3 - to 10 - membered and the heterocyclic radical containing one or more hetero atoms chosen from 0, S, N and NR7, all these radicals optionally being substituted, Al represents a single bond, an alkyl radical or an allyl or propynyl radical, Y and Yl, which may be identical or different, are such that one from among Y and Yl is chosen from 0CF3, -0-CF2-CHF2, -0-CHF2, -0-CH2-CF3, S02NR5R6, SF5 and -S(0)n-alkyl and the other from among Y and Yl is chosen from these same values and in addition from the following values: hydrogen, halogen, hydroxyl, alkoxy, nitro, CN, NR5R6, optionally substituted alkyl, optionally substituted aryl and heteroaryl, CF3, O-alkenyl, O-alkynyl, O-cycloalkyl, S(O)n-alkenyl, S(0)n-alkynyl, S(0)n-cycloalkyl, free, salified or esterified carboxyl and CONR5R6, or alternatively the phenyl radical forms with its substituents Y and Yl the following radicals: with p representing the integer 2, 3 or 4, the radical thus formed being optionally substituted with one or more alkyl radicals that are themselves optionally substituted, R5 and R6, which may be identical or different, are chosen from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl and heteroaryl, which are optionally substituted, or alternatively R5 and R6 form, with the nitrogen atom to which they are attached, a 3- to 10-membered heterocyclic radical containing one or more hetero atoms chosen from 0, S, N and NR7, which is optionally substituted, A2, which may be identical to or different from Al, represents the values of Al and CO and S02, B2 represents a saturated or unsaturated monocyclic or bicyclic heterocyclic radical containing 1 or more identical or different hetero atoms chosen from 0, S, N and NR7, optionally substituted with one or more identical or different substitutents chosen from the values of Y2, R7 represents a hydrogen atom or an alkyl, cycloalkyl, phenyl, acyl, S(0)2Alk, S(0)2Aryl, S(0)2heteroaryl or S(0)2NR5R6 radical, Y2 represents hydrogen, halogen, hydroxyl, cyano, alkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aryl, heteroaryl, -0-alkenyl, -0-alkynyl, -O-cycloalkyl, -S(O)n-alkyl, -S(0)n-alkenyl, -S(0)n-alkynyl, S(0)n-cycloalkyl, C00R13, -0C0R13, NR5R6, CONR5R6, S(0)n-NR5R6, -NR10-CO-R13, -NR10-SO2-R13, NH-S02-NR5R6, -NR10-CO-NR5R6, -NR10-CS-NR5R6, -NR10-C00R13, all these radicals optionally being substituted, all the alkyl, alkenyl, alkynyl and alkoxy radicals above being linear or branched and containing not more than 6 carbon atoms, all the cycloalkyl and heterocycloalkyl radicals above containing not more than 7 carbon atoms, all the aryl and heteroaryl radicals above containing not more than 10 carbon atoms, all the carbocyclic and heterocyclic alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl and heteroaryl radicals above, and also the ring formed by R5 and R6 with the atom to which they are attached, optionally being substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and cyano, hydroxyl, alkoxy, CF3, nitro, aryl, heteroaryl, -C(=0)-0R9, -C(=0)-R8, -NR11R12, -C(=0)- NR11R12, -N(R10)-C(=0)-R8, -N(R10)-C(=0)-0R9, N(R10)-C(=0)-NR11R12, -N(R10)-S(0)n- R8, -S(0)n-R8, -N(R10) -S (0) n-NRHR12 or -S (0) n-NRHR12 radicals, all the aryl and heteroaryl radicals above furthermore being optionally substituted with one or more radicals chosen from alkyl, alkoxy and alkylenedioxy radicals, all the cyclic radicals above, and also the ring formed by R5 and R6 with the atom to which they are attached, being moreover optionally substituted with one or more radicals chosen from oxo and thioxo, n represents an integer from 0 to 2, R8 represents alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl, R9 represents the values of R8 and hydrogen, RIO represents hydrogen or alkyl, Rll and R12, which may be identical or different, represent hydrogen, C3-C6 cycloalkyl, C1-C4 alkyl and phenyl, optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and cyano, hydroxyl, alkoxy, CF3, nitro, phenyl and free, salified, esterified or amidated carboxyl radicals, or alternatively Rll and R12 form, with the nitrogen atom to which they are attached, a 5- to 7-membered cyclic radical containing one or more hetero atoms chosen from 0, S, N and NR7 and preferably a cyclic amine, R13, which may be identical to or different than R5 or R6, being chosen from the values of R5 or R6, it being understood that the products of formula (I) are as defined below from a) to d): a) when p represents the integer 0, R represents oxygen, Rl represents oxygen, Al represents a single bond or alkyl, Y and Yl, which may be identical or different, are such that at least one represents 0CF3 or Salk, A2 represents a single bond or alkyl and B2 represents an optionally substituted heterocyclic radical, then R2 and R3 do not represent one hydrogen and the other imidazolylalkyl, b) when p represents the integer 0, R and Rl represent oxygen, Al represents a single bond or alkyl, Y and Yl, which may be identical or different, are such that at least one represents 0CF3, SOAlk, S (0)2alk or S02NH2, A2 represents CH2 and B2 represents an optionally substituted heterocyclic radical, then R2 and R3 do not represent one hydrogen and the other an alkyl chain optionally interrupted with 0, S or Nalk always substituted with a hydroxamate -CO-NHOH c) when p represents the integer 0, R and Rl represent oxygen, Al represents a single bond or alkyl, Y and Yl, which may be identical or different, are such that at least one represents S (0)nAlk, A2 represents a single bond and B2 represents an optionally substituted 5- or 6-membered aromatic heterocyclic radical, then R2 and R3 are not chosen from hydrogen, alkyl, arylalkyl, aryl and heteroaryl, d) when p represents an integer from 0 to 2, R and Rl represent oxygen, Al represents a single bond, Y and Yl, which may be identical or different, are such that one represents S02Alk or S02NH2 and the other represents NR5R6, A2 represents a single bond or alkylene and B2 represents an optionally substituted 5- to 10-membered heterocyclic radical, then R2 and R3 do not both represent hydrogen, said products of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (I) . A subject of the present invention is thus the products of general formula (I) as defined above in which p represents an integer from 0 to 2, R and Rl, which may be identical or different, represent 0 or NH, R2 and R3, which may be identical or different, represent hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl and heteroaryl which are optionally substituted, or alternatively R2 and R3 form, together with the carbon atom to which they are attached, a carbocyclic or heterocyclic radical, these radicals being 3- to 10- membered and the heterocyclic radical containing one or more hetero atoms chosen from 0, S, N and NR7, all these radicals optionally being substituted, Al represents a single bond, an alkyl radical or an allyl or propynyl radical, Y and Yl, which may be identical or different, are such that one from among Y and Yl is chosen from 0CF3, S (0)nCF3, S(0)nAlk, S02CHF2, S02CF2CF3 and S02NR5R6 and the other from among Y and Yl is chosen from these same values and in addition from the following values: hydrogen, halogen, hydroxyl, alkoxy, NR5R6, optionally substituted alkyl, optionally substituted aryl and heteroaryl, CF3 , 0-allyl, O-propynyl, O-cycloalkyl, S(0)n-allyl, S(0)n-propynyl, S(0)n-cycloalkyl, free, salified or esterified carboxyl and CONR5R6 in which R5 and R6, which may be identical or different, are chosen from hydrogen, alkyl, alkenyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl and heteroaryl, which are optionally substituted, or alternatively R5 and R6 form, with the nitrogen atom to which they are attached, a 3- to 10-membered heterocyclic radical containing one or more hetero atoms chosen from 0, S, N and NR7, which is optionally substituted, A2, which may be identical to or different from Al, represents the values of Al and CO and S02, B2 represents a saturated or unsaturated heterocyclic radical containing 1 or more identical or different hetero atoms chosen from 0, S, N and NR7, optionally substituted with one or more identical or different substitutents chosen from the values of Y2, R7 represents a hydrogen atom or an alkyl, cycloalkyl, phenyl, aryl, S(0)2alk, S(0)2aryl, S(0)2heteroaryl or S(0)2NRSR6 radical, Y2 represents hydrogen, halogen, hydroxyl, alkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, 0-allyl, O-propynyl, O-cycloalkyl, S(O)n-alkyl, S(O)n-allyl, S(O)n-propynyl, S (0)n-cycloalkyl, C00R9, 0C0R8, NR5R6, CONR5R6, S(0)n-R5R6, NHC0R8, NH-S(0)nR8 or NH-S(0)nCF3 or NH-S02-NR5R6, all these radicals being optionally substituted, all the alkyl, alkenyl, alkynyl and alkoxy radicals above being linear or branched and containing not more than 6 carbon atoms, all the cycloalkyl and heterocycloalkyl radicals above containing not more than 7 carbon atoms, all the aryl and heteroaryl radicals above containing not more than 10 carbon atoms, all the carbocyclic and heterocyclic alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl and heteroaryl radicals above optionally being substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and cyano, hydroxyl, alkoxy, CF3, nitro, aryl, heteroaryl, -C(=0)-0R9, -C(=0)-R8, -NR11R12, -C(=0)-NR11R12, -N(R10)-C(=0)-R8, -N(R10)-C(=0)-OR9, N(R10)-C(=0)-NR11R12, -N(R10)-S(0)n- R8, -S(0)n-R8, -N(R10) -S (0) n-NRHR12 or -S (0) n-NRHR12 radicals, all the aryl and heteroaryl radicals above furthermore being optionally substituted with one or more radicals chosen from alkyl and alkylenedioxy radicals, n represents an integer from 0 to 2, R8 represents alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl, R9 represents the values of R8 and hydrogen, RIO represents hydrogen or alkyl, Rll and R12, which may be identical or different, represent hydrogen, C3-C6 cycloalkyl, C1-C4 alkyl and phenyl, optionally substituted with one or. more radicals, which may be identical or different, chosen from halogen atoms and cyano, hydroxyl, alkoxy, CF3, nitro, phenyl and free, salified, esterified or amidated carboxyl radicals, or alternatively Rll and R12 form, with the nitrogen atom to which they are attached, a 5- to 7-membered cyclic radical containing one or more hetero atoms chosen from 0, S, N and NR7 and preferably a cyclic amine, it being understood that the products of formula (I) are as defined below from a) to d): a) when p represents the integer 0, R represents oxygen, Rl represents oxygen, Al represents a single bond or alkyl, Y and Yl, which may be identical or different, are such that at least one represents 0CF3 or Salk, A2 represents a single bond or alkyl and B2 represents an optionally substituted heterocyclic radical, then R2 and R3 do not represent one hydrogen and the other imidazolylalkyl, b) when p represents the integer 0, R and Rl represent oxygen, Al represents a single . bond or alkyl, Y and Yl, which may be identical or different, are such that at least one represents 0CF3, SOAlk, S (0)2alk or S02NH2, A2 represents CH2 and B2 represents an optionally substituted heterocyclic radical, then R2 and R3 do not represent one hydrogen and the other an alkyl chain optionally interrupted with 0, S or Nalk always substituted with a hydroxamate -CO-NHOH c) when p represents the integer 0, R and Rl represent oxygen, Al represents a single bond or alkyl, Y and Yl, which may be identical or different, are such that at least one represents S(0)nAlk, A2 represents a single bond and B2 represents an optionally substituted 5- or 6-membered aromatic heterocyclic radical, then R2 and R3 are not chosen from hydrogen, alkyl, arylalkyl, aryl and heteroaryl, d) when p represents an integer from 0 to 2, R and Rl represent oxygen, Al represents a single bond, Y and Yl, which may be identical or different, are such that one represents S02Alk or S02NH2 and the other represents NR5R6, A2 represents a single bond or alkylene and B2 represents an optionally substituted 5- to 10-membered heterocyclic radical, then R2 and R3 do not both represent hydrogen, said products of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (I) . One subject of the present invention is thus the products of general formula (I) as defined above in which p represents an integer from 0 to 2, R and Rl, which may be identical or different, represent 0 or NH, R2 and R3, which may be identical or different, represent hydrogen, alkyl, alkenyl, cycloalkyl, phenyl and heteroaryl, which are optionally substituted, or alternatively R2 and R3 form, together with the carbon atom to which they are attached, a carbocyclic or heterocyclic radical, these radicals being from 3- to 10-membered and the heterocyclic radical containing one or more hetero atoms chosen from 0, S, N and NR7, all these radicals being optionally substituted, Al represents a single bond, an alkyl radical or an allyl or propynyl radical, Y and Yl, which may be identical or different, are such that one from among Y and Yl is chosen from 0CF3, S(0)nCF3, S(0)nAlk, S02CHF2, S02CF2CF3 and S02NR5R6 and the other from among Y and Yl is chosen from these same values and in addition from the following values: hydrogen, halogen, hydroxyl, alkoxy, NR5R6, optionally substituted alkyl and phenyl, and optionally substituted pyrazolyl and pyridyl, with R5 and R6, which may be identical or different, chosen from hydrogen, alkyl, alkenyl, cycloalkyl, heterocycloalkyl, phenyl and heteroaryl, which are optionally substituted, or alternatively R5 and R6 form, with the nitrogen atom to which they are attached, a 3- to 10-membered heterocyclic radical containing one or more hetero atoms chosen from 0, S, N and NR7, which are optionally substituted, A2, which may be identical to or different than Al, represents the values of Al and CO and S02, B2 represents a saturated or unsaturated heterocyclic radical containing one or more identical or different hetero atoms chosen from 0, S, N and NR7, optionally substituted with one or more identical or different substituents chosen from the values of Y2, R7 represents a hydrogen atom or an alkyl, cycloalkyl or phenyl radical, Y2 represents hydrogen, halogen, hydroxyl, alkyl, alkoxy, cycloalkyl, heterocycloalkyl, phenyl, heteroaryl, O-cycloalkyl, S(0)n-alk, S (0)n-cycloalkyl, C00R9, 0C0R8, NR5R6, CONR5R6, S(0)n-R5R6, NHC0R8 and NH-S(0)nR8, all these radicals being optionally substituted, all the above alkyl, alkenyl, alkynyl and alkoxy radicals being linear or branched and containing up to 6 carbon atoms, all the above cycloalkyl and heterocycloalkyl radicals containing up to 7 carbon atoms, all the above aryl and heteroaryl radicals containing up to 10 carbon atoms, all the above alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, carbocyclic and heterocyclic radicals being optionally substituted with one or more identical or different radicals chosen from halogen atoms and cyano, hydroxyl, alkoxy, CF3, nitro, phenyl, heteroaryl, -C(=0)-0R9, -C(=0)-R8, -NR11R12, -C(=0)-NR11R12, -N(R10)-C(=0)-R8, -N(R10)-C(=0)-0R9, N(R10)-C(=0)-NR11R12, -N(R10)- S(0)n-R8, -S(0)n-R8, -N(R10) -S (O) n-NRHR12 and -S(0)n- NR11R12, all the aryl and heteroaryl radicals above moreover being optionally substituted with one or more radicals chosen from alkyl and alkylenedioxy radicals, n represents an integer from 0 to 2, R8 represents alkyl, cycloalkyl, cycioalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, phenyl and phenylalkyl, R9 represents the values of R8 and hydrogen, RIO represents hydrogen or alkyl, Rll and R12, which may be identical or different, represent hydrogen, C1-C4 alkyl and phenyl, optionally substituted with one or more identical or different radicals chosen from halogen atoms and hydroxyl, alkoxy, CF3, nitro, phenyl and free, salified, esterified or amidated carboxyl radicals, or alternatively Rll and R12 form, with the nitrogen atom to which they are attached, a 5- to 7-membered cyclic radical containing one or more hetero atoms chosen from 0, S, N and NR7 and preferably a cyclic amine, it being understood that the products of formula (I) are as defined below from a) to d): a) when p represents the integer 0, R represents Oxygen, Rl represents Oxygen, Al represents a single bond or alkyl, Y and Yl, which may be identical or different, are such that at least one represents 0CF3 or Salk, A2 represents a single bond or alkyl and B2 represents an optionally substituted heterocyclic radical, then R2 and R3 do not represent a hydrogen for one and imidazolylalkyl for the other, b) when p represents the integer 0, R and Rl represent Oxygen, Al represents a single bond or alkyl, Y and Yl, which may be identical or different, are such that at least one represents OCF3, SOAlk, S(O)2alk or S02NH2, A2 represents CH2 and B2 represents an optionally substituted heterocyclic radical, then R2 and R3 do not represent a hydrogen atom for one and, for the other, an alkyl chain optionally interrupted with 0, S, Nalk always substituted with a hydroxamate -CO-NHOH, c) when p represents the integer 0, R and Rl represent Oxygen, Al represents a single bond or alkyl, Y and Yl, which may be identical or different, are such that at least one represents S(0)nAlk, A2 represents a single bond and B2 represents an optionally substituted 5- or 6-membered aromatic heterocyclic radical, then R2 and R3 are not chosen from hydrogen, alkyl, arylalkyl, aryl and heteroaryl, d) when p represents an integer from 0 to 2, R and Rl represent oxygen, Al represents a single bond, Y and Yl, which may be identical or different, are such that one represents S02Alk or S02NH2 and the other represents NR5R6, A2 represents a single bond or alkylene and B2 represents an optionally substituted 5- to 10-membered heterocyclic radical, then R2 and R3 do not both represent hydrogen, said products of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (I) . One subject of the present invention is thus the products of formula (I) as defined above in which Y and Yl, which may be identical or different, are such that one from among Y and Yl is chosen from 0CF3, -0-CF2-CHF2, -0-CHF2, -0-CH2-CF3, S(0)nCF3, -S-CF2-CF2-CF3, -S(0)n-Alk, -S-Alk-0-Alk, -S-Alk-OH, -S-Alk-CN, -S-Alk-heterocycloalkyl, -S02CHF2, -S02CF2CF3, -S02NR5R6 and -SF5, with Alk representing an alkyl radical containing from 1 to 4 carbon atoms, and the other from among Y and Yl is chosen from the following values: hydrogen, halogen, nitro, NR5R6, free or esterified carboxyl and CONR5R6, or alternatively the phenyl radical forms with its substituents Y and Yl one of the following radicals: the radical thus formed being optionally substituted with one or more alkyl radicals that are themselves optionally substituted, the other substituents on said products of formula (I) being chosen from the values defined in claim 1 and it being understood that: a) when p represents the integer 0, R represents oxygen, Rl represents Oxygen, Al represents a single bond or alkyl, Y and Yl, which may be identical or different, are such that one represents hydrogen and the other represents OCF3 or Salk, A2 represents a single bond or alkyl and B2 represents an optionally substituted heterocyclic radical, then R2 and R3 do not represent hydrogen for one and imidazolylalkyl for the other, b) when p represents the integer 0, R and Rl represent Oxygen, Al represents a single bond or alkyl, Y and Yl, which may be identical or different, are such that one represents hydrogen and the other represents 0CF3, SOAlk, S(0)2alk or S02NH2, A2 represents CH2 and B2 represents an optionally substituted heterocyclic radical, then R2 and R3 do not represent hydrogen for one and, for the other, an alkyl chain optionally interrupted with O, S, Nalk always substituted with a hydroxamate-CO-NHOH, c) when p represents the integer 0, R and Rl represent Oxygen, Al represents a single bond or alkyl, Y and Yl, which may be identical or different, are such that one represents hydrogen and the other represents S(0)nAlk, A2 represents a single bond and B2 represents an optionally substituted 5- or 6-membered aromatic heterocyclic radical, then R2 and R3 are not chosen from hydrogen, alkyl, arylalkyl, aryl and heteroaryl, said products of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (I) . A subject of the present invention is thus the products of general formula (I) as defined above in which one from among Y and Yl represents a hydrogen atom and the other is chosen from 0CF3, S(0)nCF3, S(0)nAlk, S02CHF2, S02CF2CF3 and S02NR5R6, the other substituents of said products of formula (I) being chosen from the values defined above, it being understood that: a) when p represents the integer 0, R represents oxygen, Rl represents oxygen, Al represents a single bond or alkyl, Y and Yl, which may be identical or different, are such that one represents hydrogen and the other represents 0CF3 or Salk, A2 represents a single bond or alkyl and B2 represents an optionally substituted heterocyclic radical, then R2 and R3 do not represent one hydrogen and the other imidazolylalkyl, b) when p represents the integer 0, R and Rl represent oxygen, Al represents a single bond or alkyl, Y and Yl, which may be identical or different, are such that one represents hydrogen and the other represents 0CF3, SOAlk, S(0)2alk or S02NH2, A2 represents CH2 and B2 represents an optionally substituted heterocyclic radical, then R2 and R3 do not represent one hydrogen and the other an alkyl chain optionally interrupted with 0, S or Nalk always substituted with a hydroxamate -CO-NHOH c) when p represents the integer 0, R and Rl represent oxygen, Al represents a single bond or alkyl, Y and Yl, which may be identical or different, are such that one represents hydrogen and the other represents S(0)nAlk, A2 represents a single bond and B2 represents an optionally substituted 5- or 6-membered aromatic heterocyclic radical, then R2 and R3 are not chosen from hydrogen, alkyl, arylalkyl, aryl and heteroaryl, said products of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (I) . A subject of the present invention is thus the products of general formula (I) as defined above in which one from among Y and Yl represents a hydrogen atom and the other is chosen from S(0)nCF3, SOAlk, S(0)2Alk, S02CHF2, S02CF2CF3 and S02NR5R6, the other substituents of said products of formula (I) being chosen from the values defined above and it being understood that the products of formula (I) are as defined below in a) and b): a) when p represents the integer 0, R and Rl represent. oxygen, Al represents a single bond or alkyl, Y and Yl, which may be identical or different, are such that one represents hydrogen and the other represents SOAlk, S(0)2alk or S02NH2, A2 represents CH2 and B2 represents an optionally substituted heterocyclic radical, then R2 and R3 do not represent one hydrogen and the other an alkyl chain optionally interrupted with O, S or Nalk always substituted with a hydroxamate -CO-NHOH b) when p represents the integer 0, R and Rl represent oxygen, Al represents a single bond or alkyl, Y and Yl, which may be identical or different, are such that one represents hydrogen and the other represents SOAlk or S(0)2Alk, A2 represents a single bond and B2 represents an optionally substituted 5- or 6-membered aromatic heterocyclic radical, then R2 and R3 are not chosen from hydrogen, alkyl, arylalkyl, aryl and heteroaryl, said products of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (I) . A subject of the present invention is thus the products of general formula (I) as defined above in which one from among Y and Yl represents a hydrogen atom and the other is chosen from S(0)nCF3, S02CHF2, S02CF2CF3 and S02NR5R6, the other substituents of said products of formula (I) being chosen from the values defined above and it being understood that when p represents the integer 0, R and Rl represent oxygen, Al represents a single bond or alkyl, Y and Yl, which may be identical or different, are such that one represents hydrogen and the other represents S02NH2, A2 represents CH2 and B2 represents an optionally substituted heterocyclic radical, then R2 and R3 do not represent one hydrogen and the other an alkyl chain optionally interrupted by 0, S or Nalk, always substituted with a hydroxamate -CO-NHOH said products of formula (I) being in any possible racemic, enantiomeric and diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (I) . In the products of formula (I) and subsequently, the terms indicated have the following meanings: the term "Hal", "Halo" or halogen denotes fluorine, chlorine, bromine or iodine atoms, - the term "alkyl", "alk", "Alk" or "ALK" denotes a linear or branched radical containing not more than 12 carbon atoms, chosen from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, sec-pentyl, tert-pentyl, neopentyl, hexyl, isohexyl, sec-hexyl, tert-hexyl, heptyl, octyl, nonyl, decyl, undecyl and dodecyl radicals, and also the linear or branched positional isomers thereof. Mention is made more particularly of alkyl radicals containing not more than 6 carbon atoms, and especially methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, linear or branched pentyl and linear or branched hexyl radicals. - the term "alkenyl radical" denotes a linear or branched radical containing not more than 12 carbon atoms and preferably 4 carbon atoms, chosen, for example, from the following values: ethenyl or vinyl, propenyl or allyl, 1-propenyl, n-butenyl, i-butenyl, 3-methyl-2- butenyl, n-pentenyl, hexenyl, heptenyl, octenyl, cyclohexylbutenyl and decenyl, and also the linear or branched positional isomerers thereof. Among the alkenyl values that may be mentioned particularly are the values allyl or butenyl. - the term "alkynyl radical" denotes a linear or branched radical containing not more than 12 carbon atoms and preferably 4 carbon atoms, chosen, for example, from the following values: ethynyl, propynyl or propargyl, butynyl, n-butynyl, i-butynyl, 3-methyl-2-butynyl, pentynyl or hexynyl, and also the linear or branched positional isomers thereof. Among the alkynyl values that are mentioned more particularly is the propargyl value. the term "alkoxy radical" denotes a linear or branched radical containing not more than 12 carbon atoms and preferably 6 carbon atoms chosen, for example, from methoxy, ethoxy, propoxy, isopropoxy, linear, secondary or tertiary butoxy, pentoxy, hexoxy and heptoxy radicals, and also the linear or branched positional isomers thereof, - the term "alkoxycarbonyl radical" or alkyl-O-CO-denotes a linear or branched radical containing not more than 12 carbon atoms, in which the alkyl radical has the meaning given above: examples that may be mentioned include methoxycarbonyl and ethoxycarbonyl radicals, - the term "alkylenedioxy radical" or -O-alkylene-0-denotes a linear or branched radical containing not more than 12 carbon atoms, in which the alkylene radical has the meaning given above: examples that may be mentioned include methylenedioxy and ethylenedioxy radicals, - the term "alkylsulfinyl" or alkyl-SO- denotes a linear or branched radical containing not more than 12 carbon atoms, in which the alkyl radical has the meaning given above and preferably contains 4 carbon atoms, - the term "alkylsulfonyl" or alkyl-S02- denotes a linear or branched radical containing not more than 12 carbon atoms, in which the alkyl radical has the meaning given above and preferably contains 4 carbon atoms, - the term "alkylsulfonylcarbamoyl" or alkyl-S02-NH-C(=0)- denotes a linear or branched radical containing not more than 12 carbon atoms, in which the alkyl radical has the meaning given above and preferably contains 4 carbon atoms, - the term "alkylthio" or alkyl-S- denotes a linear or branched radical containing not more than 12 carbon atoms and especially represents methylthio, ethylthio, isopropylthio and heptylthio radicals, - the term "cycloalkyl radical" denotes a 3- to 10-membered monocyclic or bicyclic carbocyclic radical and especially denotes cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl radicals, - the term "-0-cycloalkyl radical" denotes a radical in which the cycloalkyl radical has the meaning given above, - the term "cycloalkenyl radical" denotes a 3- to 10-membered monocyclic or bicyclic nonaromatic carbocyclic radical containing at least one double bond, and especially denotes cyclobutenyl, cyclopentenyl and cyclohexenyl radicals, the term "cycloalkylalkyl radical" denotes a radical in which cycloalkyl and alkyl are chosen from the values indicated above: this radical thus denotes, for example, cyclopropylmethyl, cyclopentylmethyl, cyclo-hexylmethyl and cycloheptylmethyl radicals, - the term "acyl radical" or r-CO- denotes a linear or branched radical containing not more than 12 carbon atoms, in which the radical r represents a hydrogen atom or an alkyl, cycloalkyl, cycloalkenyl, cycloalkyl, heterocycloalkyl or aryl radical, these radicals having the values indicated above and being optionally substituted as indicated: examples that are mentioned include the formyl, acetyl, propionyl, butyryl or benzoyl radical, or alternatively valeryl, hexanoyl, acryloyl, crotonoyl or carbamoyl, - the term "acyloxy radical" means acyl-O- radicals in which acyl has the meaning given above: examples that are mentioned include acetoxy or propionyloxy radicals, the term "acylamino radical" means acyl-NH-radicals in which acyl has the meaning given above, the term "aryl radical" denotes unsaturated monocyclic radicals or unsaturated radicals consisting of fused carbocyclic rings. Examples of such aryl radicals that may be mentioned include phenyl or naphthyl radicals. Mention is made more particularly of the phenyl radical. - the term "arylalkyl" means radicals resulting from the combination of the optionally substituted alkyl radicals mentioned above and the optionally substituted aryl radicals also mentioned above: examples that are mentioned include benzyl, phenylethyl, 2-phenethyl, triphenylmethyl or naphthalenemethyl radicals, the term "heterocyclic radical" denotes a saturated carbocyclic radical (heterocycloalkyl) or unsaturated carbocyclic radical (heteroaryl) which is at least 6-membered, interrupted with one or more hetero atoms, which may be identical or different, chosen from oxygen, nitrogen and sulfur atoms. Heterocycloalkyl radicals that may especially be ment ioned include dioxolane, dioxane, dithiolane, thiooxolane, thiooxane, oxiranyl, oxolanyl, dioxolanyl, piperazinyl, piperidyl, pyrrolidyl, imidazolidinyl, pyrazolidinyl, morpholinyl, or tetrahydrofuryl, tetrahydrothienyl, chromanyl, dihydrobenzofuranyl, indolinyl, piperidyl, perhydropyranyl, pyrindolinyl, tetrahydroquinolyl, tetrahydroisoquinolyl and thioazolidinyl radicals, all these radicals being optionally substituted. Among the heterocycloalkyl radicals that may especially be mentioned are optionally substituted piperazinyl, optionally substituted piperidyl, optionally substituted pyrrolidinyl, imidazolidinyl, pyrazolidinyl, morpholinyl and thioazolidinyl radicals and thioazolidinyl radicals: mention may be made even more particularly of optionally substituted morpholinyl, pyrrolidinyl and piperazinyl radicals; the term "heterocycloalkylalkyl radical" means radicals in which the heterocycloalkyl and alkyl residues have the above meanings; - among the 5-membered heteroaryl radicals that may be mentioned are furyl radicals such as 2-furyl, thienyl radicals such as 2-thienyl and 3-thienyl, and pyrrolyl, diazolyl, thiazolyl, thiadiazolyl, thiatriazolyl, isothiazolyl, oxazolyl, oxadiazolyl, 3 - or 4-isoxazolyl, imidazolyl, pyrazolyl and isoxazolyl radicals. Among the 6-membered heteroaryl radicals that may especially be mentioned are pyridyl radicals such as 2-pyridyl, 3-pyridyl and 4-pyridyl, and pyrimidyl, pyrimidinyl, pyridazinyl, pyrazinyl and tetrazolyl radicals; - as fused heteroaryl radicals containing at least one hetero atom chosen from sulfur, nitrogen and oxygen, examples that may be mentioned include benzothienyl such as 3-benzothienyl, benzofuryl, benzofuranyl, benzopyrrolyl, benzimidazolyl, benzoxazolyl, thionaphthyl, indolyl, purinyl, quinolyl, isoquinolyl and naphthyridinyl. Among the fused heteroaryl radicals that may be mentioned more particularly are benzothienyl, benzofuranyl, indolyl, quinolyl, benzimidazolyl, benzothiazolyl, furyl, imidazolyl, indolizinyl, isoxazolyl, isoquinolyl, isothiazolyl, oxadiazolyl, pyrazinyl, pyridazinyl, pyrazolyl, pyridyl, pyrimidinyl, pyrrolyl, quinazolinyl, 1,3,4-thiadiazolyl, thiazolyl and thienyl radicals and triazolyl groups, these radicals optionally being substituted as indicated for the heteroaryl radicals/ - the term "cyclic amine" denotes a 3- to 8-membered cycloalkyl radical in which one carbon atom is replaced i with a nitrogen atom, the cycloalkyl radical having the meaning given above and also possibly containing one or more other hetero atoms chosen from 0, S, S02, N and NR7 with R7 as defined above; examples of such cyclic amines that may be mentioned include pyrrolidyl, piperidyl, morpholinyl, piperazinyl, indolinyl, pyrindolinyl and tetrahydroquinolyl radicals. The term "patient" denotes human beings, but also other mammals. The term "prodrug" denotes a product that may be converted in vivo via metabolic mechanisms (such as hydrolysis) into a product of formula (I) . For example, an ester of a product of formula (I) containing a hydroxyl group may be converted by hydrolysis in vivo into its parent molecule. Alternatively, an ester of a product of formula (I) containing a carboxyl group may be converted by in vivo hydrolysis into its parent molecule. Examples of esters of the products of formula (I) containing a hydroxyl group that may be mentioned include the acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylenebis-P-hydroxynaphthoates, gentisates, isethionates, di-p-tolyltartrates, methanesulfonates, ethanesulfonates, benzenesulfonates, p-toluenesulfonates, cyclohexylsulfamates and quinates. Esters of products of formula (I) that are particularly useful, containing a hydroxyl group, may be prepared from acid residues such as those described by Bundgaard et. al. , J. Med. Chem. , 1989, 32, page 2503-2507: these esters especially include substituted (aminomethyl)benzoates, dialkylaminomethylbenzoates in which the two alkyl groups may be linked together or may be interrupted with an oxygen atom or with an optionally substituted nitrogen atom, ie. an alkylated nitrogen atom, or alternatively (morpholinomethyl)benzoates, eg. 3- or 4-(morpholinomethyl)benzoates, and (4-alkyl-piperazin-l-yl)benzoates, eg. 3- or 4-(4-alkylpiperazin-1-yl)benzoates. The carboxyl radical(s) of the products of formula (I) may be salified or esterified with various groups known to those skilled in the art, among which nonlimiting examples that may be mentioned include the following compounds: - among the salification compounds, mineral bases such as, for example, one equivalent of sodium, potassium, lithium, calcium, magnesium or ammonium, or organic bases such as, for example, methylamine, propylamine, trimethylamine, diethylamine, triethylamine, N,N-dimethylethanolamine, tris(hydroxymethyl)amino-methane, ethanolamine, pyridine, picoline, dicyclohexylamine, morpholine, benzylamine, procaine, lysine, arginine, histidine or N-methylglucamine, - among the esterification compounds, alkyl radicals to form alkoxycarbonyl groups such as, for example, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl or benzyloxycarbonyl, these alkyl radicals possibly being substituted with radicals chosen, for example, from halogen atoms and hydroxyl, alkoxy, acyl, acyloxy, alkylthio, amino or aryl radicals, such as, for example, in chloromethyl, hydroxypropyl, methoxymethyl, propionyloxymethyl, methylthiomethyl, dimethylaminoethyl, benzyl or phenethyl groups. The term "esterified carboxyl" means, for example, radicals such as alkyloxycarbonyl radicals, for example methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butyl or tert-butyloxycarbonyl, cyclobutyloxycarbonyl, cyclopentyloxycarbonyl or cyclohexyloxycarbonyl. Mention may also be made of radicals formed with readily cleavable ester residues, such as methoxymethyl or ethoxymethyl radicals; acyloxyalkyl radicals such as pivaloyloxymethyl, pivaloyloxyethyl, acetoxymethyl or acetoxyethyl/ alkyloxycarbonyloxyalkyl radicals such as methoxycarbonyloxy methyl or ethyl radicals, and isopropyloxycarbonyloxy methyl or ethyl radicals. A list of such ester radicals may be found, for example, in European patent EP 0 034 536. The term "amidated carboxyl" means radicals of the type -CONR5R6 as defined above: also intended are the radicals NCOR6R7 in which the radicals R6 and R7, which may be identical or different, represent a hydrogen atom or an alkyl radical containing from 1 to 4 carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl radicals and especially amino, alkylamino and dialkylamino radicals. The term "alkylamino radical" means linear or branched methylamino, ethylamino, propylamino or butylamino radicals. Alkyl radicals containing not more than 4 carbon atoms are preferred, the alkyl radicals possibly being chosen from the alkyl radicals mentioned above. The term Mialkylamino radical" means, for example, dimethylamino, diethylamino and methylthylamino radicals. As previously, alkyl radicals containing not more than 4 carbon atoms, chosen from the list indicated above, are preferred. The radicals NR5R6 or NR6R7 may also represent a heterocycle which may or may not comprise an additional hetero atom. Mention may be made of pyrrolyl, imidazolyl, indolyl, piperidyl, morpholinyl and piperazinyl radicals. The piperidyl, morpholinyl and piperazinyl radicals are preferred. The term "salified carboxyl" means the salts formed, for example, with one equivalent of sodium, potassium, lithium, calcium, magnesium or ammonium. Mention may also be made of the salts formed with organic bases such as methylamine, propylamine, trimethylamine, diethylamine and triethylamine. The sodium salt is preferred. When the products of formula (I) comprise an amino radical that may be salified with an acid, it is clearly understood that these acid salts also form part of the invention. Mention may be made of the salts obtained, for example, with hydrochloric acid or methanesulfonic acid. The addition salts with mineral or organic acids of the products of formula (I) may be, for example, the salts formed with hydrochloric acid, hydrobromic acid, hydriodic acid, nitric acid, sulfuric acid, phosphoric acid, propionic acid, acetic acid, trifluoroacetic acid, formic acid, benzoic acid, maleic acid, fumaric acid, succinic acid, tartaric acid, citric acid, oxalic acid, glyoxylic acid, aspartic acid, ascorbic acid, alkylmonosulfonic acids such as, for example, methanesulfonic acid, ethanesulfonic acid or propanesulfonic acid, alkyldisulfonic acids such as, for example, methanedisulfonic acid or a,p-ethanedisulfonic acid, arylmonosulfonic acids such as benzenesulfonic acid, and aryldisulfonic acids. It may be recalled that stereoisomerism may be defined in its broad sense as the isomerism of compounds having the same structural formulae but whose various groups are arranged differently in space, especially such as in monosubstituted cyclohexanes whose substituent may be in an axial or equatorial position, and the various possible rotational conformations of ethane derivatives. However, there is another type of stereoisomerism, due to the different spatial arrangements of fixed substituents, either on double bonds or on rings, which is often referred to as geometrical isomerism or cis-trans isomerism. The term "stereoisomer" is used in the present patent application in its broadest sense and thus relates to all the compounds indicated above. A subject of the invention is especially the products of formula (I) as defined above in which one from among Y and Yl represents a hydrogen atom and the other is chosen from S(0)nCF3, S02CHF2 and S02CF2CF3, the other substituents of said products of formula (I) being chosen from the values defined above, said products of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (I). A subject of the invention is especially the products of formula (I) as defined above such that all the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclo-alkyl, aryl or heteroaryl radicals defined above are optionally substituted with one or more radicals, which may be identical or different, chosen from halogen, cyano, hydroxyl, alkoxy, CF3, nitro, phenyl, carboxyl which is free, salified, esterified with an alkyl radical or amidated with a radical NRllaR12a, -C(=0)-R9a, -NRllaR12a, -C(=0)-NRllaR12a, -N(R10a)-C(=0)-R9a, -N(R10a)-C(=0)-OR8a, N(R10a)-C(=0)-NRllaR12a, -N(R10a)- S(0)n-R9a, -S(0)n-R9a, -N(R10a)-S(0)n-NRllaR12a or -S(0)n-NRllaR12a, all the aryl and heteroaryl radicals above furthermore being optionally substituted with an ethylenedioxy radical, R8a represents hydrogen, alkyl, alkenyl, phenyl, phenylalkyl, heteroaryl or heteroarylalkyl, R9a represents alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, phenyl, phenylalkyl, heteroaryl or heteroarylalkyl, RlOa represents hydrogen or alkyl, Rlla and R12a, which may be identical or different represent hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, phenyl, phenylalkyl, optionally substituted with one or more substituents, which may be identical or different, chosen from halogen, hydroxyl, C1-C4 alkyl or C1-C4 alkoxy, or alternatively Rlla and R12a form, with the nitrogen atom to which they are attached, a cyclic radical chosen from pyrrolidyl, piperidyl, piperazinyl, morpholinyl, indolinyl, pyrindolinyl, tetrahydroquinolyl, thiazolidinyl and naphthyridyl, said products of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (I). A subject of the invention is especially the products of formula (I) as defined above in such that p represents the integer 0, the other substituents of said products of formula (I) each having any one of the values defined above. A subject of the invention is especially the products of formula (I) as defined above such that p l represents the integer 1, the other substituents of said products of formula (I) having any one of the values defined above. A subject of the invention is especially the products of formula (I) as defined above such that p represents the integer 2, the other substituents of said products of formula (I) having the values defined in the present invention. A subject of the invention is especially the products of formula (I) as defined above such that Rl represents 0, the other substituents of said products of formula (I) having any one of the values defined above. A subject of the invention is especially the products of formula (I) as defined above such that R represents 0, the other substituents of said products of formula (I) having any one of the values defined above. A subject of the invention is especially the products of formula (I) as defined above such that R2 and R3, which may be identical or different, represent hydrogen, alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, phenyl, phenylalkyl, heterocycloalkyl, heterocyclo-alkylalkyl, heteroaryl and heteroarylalkyl, which are optionally substituted, or alternatively R2 and R3 form, together with the carbon atom to which they are attached, a carbocyclic or heterocyclic radical, these radicals being 3- to 10-membered and the heterocyclic radical containing one or more hetero atoms chosen from 0, S, N and NR7b, all these radicals being optionally substituted, all the above radicals being optionally substituted with one or more radicals chosen from halogen, cyano, hydroxyl, alkyl and alkoxy containing 1 to 4 carbon atoms, CF3, nitro, phenyl, carboxy which is free, salified, esterified with an alkyl radical or amidated with a radical NRllbR12b, -C(=0)-R9b, -NRllbR12b and -C(=0)-NRllbR12b, R7b represents a hydrogen atom, an alkyl radical or a phenyl radical, R9 represents hydrogen, alkyl, cycloalkyl, cycloalkyl- alkyl or phenyl, Rllb and R12b, which may be identical or different, represent hydrogen, alkyl, cycloalkyl or phenyl, or alternatively Rllb and R12b form, with the nitrogen atom to which they are attached, an optionally substituted piperazinyl radical, the other substituents of said products of formula (I) having any one of the values defined above. A subject of the invention is especially the products of formula (I) as defined above such that R2 and R3, which may be identical or different, are chosen from hydrogen, alkyl, phenylalkyl, pyridylalkyl and benzo-thienylalkyl, which are optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, alkyl and alkoxy radicals containing from one to 4 carbon atoms, or alternatively R2 and R3 form, together with the carbon atom to which they are attached, a 3- to 6-membered cycloalkyl or heterocycloalkyl radical containing a nitrogen atom, the other substituents of said products of formula (I) having any one of the values defined above. A subject of the invention is especially the products of formula (I) as defined above such that R2 and R3, which may be identical or different, are chosen from hydrogen, alkyl, hydroxyalkyl, phenylalkyl, hydroxy-phenylalkyl, pyridylalkyl, benzothienylalkyl or thienylbenzothienylalkyl, or alternatively R2 and R3 form, together with the carbon atom to which they are attached, a cycloalkyl radical containing from 3 to 6 carbon atoms or an azetidinyl, pyrrolidyl or piperidyl radical, the other substituents of said products of formula (I) having any one of the values defined above. A subject of the invention is especially the products of formula (I) as defined above such that R2 and R3, which may be identical or different, are chosen from hydrogen, alkyl, hydroxyalkyl, phenylalkyl and hydroxy-phenylalkyl, or alternatively R2 and R3 form, together with the carbon atom to which they are attached, a cycloalkyl radical containing from 3 to 6 carbon atoms. A subject of the invention is especially the products of formula (I) as defined above such that one from among R2 and R3 is chosen from hydrogen and a 1 ky 1, and the other from among R2 and R3 is chosen from all the values of R2 and R3, or alternatively R2 and R3 form, together with the carbon atom to which they are attached, a cycloalkyl radical containing from 3 to 6 carbon atoms, the other substituents of said products of formula (I) having any one of the values defined above. A subject of the invention is especially the products of formula (I) as defined above such that R2 and R3, which may be identical or different, represent hydrogen and alkyl, or alternatively R2 and R3 form, together with the carbon atom to which they are attached, a cycloalkyl radical containing from 3 to 6 carbon atoms, the other substituents of said products of formula (I) having any one of the values defined above. A subject of the invention is especially the products of formula (I) as defined above such that R2 and R3, which may be identical or different, represent hydrogen and CH3, or alternatively R2 and R3 form, together with the carbon atom to which they are attached, a cyclopropyl radical, the other substituents of said products of formula (I) having any one of the values defined above. A subject of the invention is especially the products of formula (I) as defined above such that Al represents a single bond and A2 is chosen from a single bond, a linear or branched alkyl radical containing not more than 6 carbon atoms and allyl, propynyl, C-0 and S02 radicals, the other substituents of said products of formula (I) having any one of the values defined above. A subject of the invention is especially the products of formula (I) as defined in the present invention such that Al represents a single bond and A2 is chosen from a single bond or alkyl, allyl, propynyl, C=0 and S02 radicals, the other substituents of said products of formula (I) having the values defined above. One subject of the invention is especially the products of formula (I) as defined above such that Al represents a single bond and A2 is chosen from alkyl, allyl, propynyl, C=0 and S02 radicals, the other substituents of said products of formula (I) having any one of the values defined above. A subject of the invention is especially the products of formula (I) as defined above such that Al represents a single bond and A2 represents un alkyl or C=0 radical, the other substituents of said products of formula (I) having any one of the values defined above. A subject of the invention is especially the products of formula (I) as defined above such that Al represents a single bond and A2 represents C=0, -CH2-CH2-or -CH2, the other substituents of said products of formula (I) having any one of the values defined above. A subject of the invention is especially the products of formula (I) as defined above such that Al represents a single bond and A2 represents -CH2, the other substituents of said products of formula (I) having any one of the values defined above. A subject of the invention is especially the products of formula (I) as defined above in which Y and Yl are such that one represents a hydrogen atom, a halogen atom or an amino radical and the other is chosen i from -0CF3, -0-CF2-CHF2, -0-CHF2, -0-CH2-CF3, -SF5, -S (0)n-CF3, -S (0)n-Alk, -S02CHF2 , S02CF2CF3, -S02NH2, -S-CF2-CF2-CF3, -S-Alk-0-Alk, -S-Alk-OH, -S-Alk-CN, -S-Alk-morpholino, -S-Alk-pyrrolidinyl and -S-Alk-piperazinyl, the morpholino, pyrrolidinyl and piperazinyl radicals being optionally substituted with Alk, with Alk representing an alkyl radical containing from 1 to 4 carbon atoms, the other substituents of said products of formula (I) being chosen from the values defined in the present invention. A subject of the invention is especially the products of formula (I) as defined above such that Y represents a hydrogen atom and Yl is chosen from -0CF3, S(0)n-CF3, S(0)n-CH3, S02CHF2 and S02NH2, the other substituents of said products of formula (I) having any one of the values defined above. A subject of the invention is especially the products of formula (I) as defined above such that Y represents a hydrogen atom and Yl is chosen from -0CF3, S(0)n-CF3 and S02CHF2, the other substituents of said products of formula (I) having any one of the values defined above. A subject of the invention is especially the products of formula (I) as defined above such that Y represents a hydrogen atom and Yl is chosen from -0CF3 and S(0)n-CF3, the other substituents of said products of formula (I) having any one of the values defined above. A subject of the invention is especially the products of formula (I) as defined above such that Y represents a hydrogen atom and Yl is chosen from -0CF3, S-CF3 and S (0)2-CF3, the other substituents of said products of formula (I) having any one of the values defined above. One subject of the invention is especially the products of formula (I) as defined above in which B2 represents a monocyclic or bicyclic heteroaryl radical chosen from pyridyl, pyrimidinyl, quinolyl, azaindolyl, lH-pyrrolo[2,3-b]pyridinyl, quinazolyl, thiazolyl, imidazolyl, pyrazolyl, furazanyl, isoxazolyl, morpholinyl, pyrrolidinyl, furyl, piperidyl, thienyl, chromenyl, oxochromenyl, indolyl, pyrrolyl, purinyl, benzoxazinyl, benzimidazolyl and benzofuranyl radicals, these radicals being optionally substituted with one or more radicals chosen from the values of Y2, the other substituents of said products of formula (I) having the values defined for the products of formula (I). A subject of the invention is especially the products of formula (I) as defined above such that B2 represents a heteroaryl radical chosen from 3- or 4-pyridyl, 3 - or 4-quinolyl, imidazolyl, thiazolyl, indolyl, pyrazolyl, pyrrolyl, pyrimidyl, purinyl, benzoxazinyl, benzimidazolyl and benzofuranyl radicals, these radicals being optionally substituted with one or more radicals chosen from the values of Y2, the other substituents of said products of formula (I) having any one of the values defined above. A subject of the invention is especially the products of formula (I) as defined above such that B2 represents a heteroaryl radical chosen from 4-pyridyl, 4-quinolyl, imidazolyl, thiazolyl, pyrazolyl, pyrrolyl, pyrimidyl and purinyl radicals, these radicals being optionally substituted with one or more radicals chosen from the values of Y2, the other substituents of said products of formula (I) having any one of the values defined above. In particular in the products of formula (I), B2 represents a heteroaryl radical chosen from 3- or 4-pyridyl, pyrimidinyl, 3 - or 4-quinolyl, azaindolyl, quinazolyl, thiazolyl, imidazolyl, pyrazolyl, furazanyl and isoxazolyl radicals, these radicals being optionally substituted with one or more radicals chosen from the values of Y2, the other substituents on said products of formula (I) having the values defined in the present invention. In particular in the products of formula (I) , B2 represents a heteroaryl radical chosen from 3- or 4-pyridyl, pyrimidinyl, 3- or 4-quinolyl, azaindolyl and quinazolyl radicals, these radicals being optionally substituted with one or more radicals chosen from the values of Y2, the other substituents on said products of formula (I) having the values defined in the present invention. A subject of the invention is the products of formula (I) as defined in the present invention such that B2 represents the 4-pyridyl and 4-quinolyl, 1H-pyrrolo[2,3-b]pyridine-4-yl radicals, optionally substituted with one or more radicals chosen from the values of Y2 defined in the present invention, the other substituents of said products of formula (I) having any one of the values defined in the present invention. In particular in the products of formula (I) of the present invention, Y2 may represent the 2-amino-4-pyridyl radical in which the amino radical is optionally substituted as indicated for the radical NR5R6 as defined above or below and in the experimental section, the other substituents on said products of formula (I) possibly taking the values as defined in the present invention for said substituents. In particular, the products of formula (I) of the present invention are such that Y2 represents hydrogen, halogen, hydroxyl, cyano, alkyl, alkoxy, phenyl, COOH, COOAlk, CONR5R6, NR5R6, -NR10-COOR6, -NR10-CO-R6, -NR10-CS-NR5R6, -NR10-CO-NR5R6 or -NR10-SO2-R6, all these radicals being optionally substituted, R5 and R6, which may be identical or different, are chosen from hydrogen, alkyl, cycloalkyl, phenyl and 5- or 6-membered heteroaryl radicals containing 1 to 3 hetero atoms chosen from 0, N and S, all these radicals being optionally substituted, or alternatively R5 and R6 form, with the nitrogen atom to which they are attached, an optionally substituted pyrrolidinyl, piperidyl, piperazinyl, morpholinyl or quinazolinyl radical, RIO represents hydrogen or alkyl, all the above alkyl, alkoxy, cycloalkyl and phenyl radicals, and also the ring formed by R5 and R6 with the atom to which they are attached, being optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and the following radicals: cyano; hydroxyl; alkyl; alkoxy; 0CF3; CF3; S(0)n-CF3; nitro; oxo; thioxo; OCOAlk; phenyl, itself optionally substituted with one or more radicals chosen from halogen atoms and alkyl and alkoxy radicals; -OCOAlk; NH2, NHAlk, N(Alk)2, N(alk)(phenylalkyl), N(Alk)(aminoalkyl), N(Alk)(alkylaminoalkyl), N(Alk)(dialkylaminoalkyl); carboxyl, free or esterified with an alkyl radical, all the above phenyl radicals moreover being optionally substituted with an alkylenedioxy radical, all the above alkyl radicals moreover being optionally substituted with one or more saturated or partially unsaturated, 4- to 7-membered heterocyclic radicals containing at least one nitrogen atom N and also 0 to 2 other hetero atoms chosen from 0, N and S, all the pyrrolidinyl and quinazolinyl radicals above moreover being optionally substituted with oxo or thioxo, all the above alkyl and alkoxy radicals being linear or branched and containing up to 6 carbon atoms, all the above cycloalkyl radicals containing up to 7 carbon atoms, the other substituents on said products of formula (I) having the values defined above. In particular, R5 and R6 may represent the following heteroaryl radicals: pyridyl, pyrazinyl, pyrimidinyl, thienyl, thiazolyl and oxazolyl, all these radicals being optionally substituted. In particular in the products of formula (I) of the present invention, the alkyl radicals may be substituted with heterocyclic radicals chosen from the following radicals: thiomorpholin-4-yl, thiazolidin-3-yl, azetidin-1-yl, piperazinyl, imidazolyl, morpholinyl, pyrrolidinyl, piperidyl and azepanyl radicals, all these radicals being optionally substituted as indicated above and especially with one or more radicals chosen from alkyl, hydroxyalkyl, oxo, pyridyl and phenyl optionally substituted with one or more radicals chosen from halogen atoms and alkyl, hydroxyl, alkoxy, CN, carboxyl or amino radicals, which are themselves optionally substituted. Mention may be made, for example, of piperazinyl radicals optionally substituted with Alk, Alk-OH, pyridyl or phenyl, itself optionally substituted with one or more radicals chosen from halogen atoms and alkyl, hydroxyl, alkoxy, CN, carboxyl and amino radicals, which are themselves optionally substituted; piperidyl optionally substituted with one or two Alk; azepanyl optionally substituted with oxo. One subject of the present invention is the products of formula (I) as defined above such that Y2 represents hydrogen, halogen, hydroxyl, cyano, alkyl, alkoxy, phenyl, CONR5R6, NR5R6, -NR10-COOH, -NRlO-COOAlk, -NR10-CO-R6, -NR10-CS-NR5R6, -NR10-CO-NR5R6 or -NR10-S02-R6, R5 and R6, which may be identical or different, are chosen from hydrogen; alkyl; cycloalkyl/ phenyl; pyrimidinyl; thienyl; pyridyl; quinolyl; thiazolyl optionally substituted with one or two halogen atoms; pyran optionally substituted with one or more OCOAlk; phenyl substituted with one or more radicals chosen from halogen atoms and alkyl, alkoxy, amino, alkylamino, dialkylamino and carboxyl which is free or esterified with an alkyl radical; alkyl substituted with phenyl, which is itself optionally substituted with one or more radicals chosen from halogen atoms, alkyl, alkoxy, amino, alkylamino, dialkylamino and carboxyl, which is free or esterified with an alkyl radical; alkyl substituted with piperazinyl, which is itself optionally substituted with one or more radicals chosen from Alk, Alk-OH and pyridyl; alkyl substituted with imidazolyl; alkyl substituted with one or more radicals chosen from NH2, NHAlk, N(Alk)2, N(alk)(phenylalkyl), N(Alk)(aminoalkyl), N(Alk)(alkyl-aminoalkyl) and N(Alk)(dialkylaminoalkyl); alkyl substituted with morpholinyl, which is optionally substituted with one or two Alk; alkyl substituted with pyrrolidinyl; alkyl substituted with piperidyl, which is itself optionally substituted with one or two Alk; alkyl substituted with thiomorpholinyl; alkyl substituted with azetidinyl; alkyl substituted with azepanyl, which is itself optionally substituted with oxo, or alternatively R5 and R6 form, with the nitrogen atom to which they are attached, a pyrrolidinyl; piperidyl; piperazinyl; morpholinyl; or quinazolinyl radical, all these radicals being optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and alkyl, hydroxy1 and alkoxy radicals and phenyl, which is itself optionally substituted with one or more radicals chosen from halogen atoms and alkyl and alkoxy radicals, the pyrrolidinyl and quinazolinyl radicals moreover being optionally substituted with oxo or thioxo, the piperazinyl radical itself being optionally substituted with one or more radicals chosen from Alk, Alk-OH and pyridyl, RIO represents hydrogen or alkyl, all the above alkyl or Alk and alkoxy radicals being linear or branched and containing up to 6 carbon atoms, all the above cycloalkyl radicals containing up to 7 carbon atoms, all the phenyl radicals moreover being optionally substituted with a radical chosen from CF3, -0CF3, nitro and alkylenedioxy, the other substituents on said products of formula (I) having any of the values defined above. Among the preferred structures of the present invention, mention may be made of the products of formula (1) whose three structures are given below, in which the values of NR14R15 are chosen from the values of NR5R6 and the values of the Alkyl, Aryl and Heteroaryl radicals are chosen from the values of the alkyl, aryl and heteroaryl radicals as defined above and optionally substituted as defined in the present invention. A subject of the invention is especially the products of formula (I) as defined above such that B2 represents 4-pyridyl and 4-quinolyl radicals, optionally substituted with one or more radicals chosen from the values of Y2, the other substituents on said products of formula (I) having any of the values defined above. A subject of the invention is especially the products of formula (I) as defined above such that Y2 represents VI, halogen, hydroxyl, -C(=NH)NH2, 0V1, 0-C0-V1, C00V1, C0V1, C0-NV1V2, -NV1V2, -NH-C0-V1, -NH-C00-V1, -NH-NH-C0-V1, -NV1-C0-NV1V2, -NV1-C0-NHV1, -NH-C0-NHV1, -NH-S02-NHV1 and -NH-S02-V1, in which VI and V2, which may be identical or different, represent a hydrogen atom, an alkyl, cycloalkyl or phenyl radical or a heterocyclic radical such as pyridyl, pyrazolyl, imidazolyl, dihydroimidazolyl, tetrazolyl, norpholinyl, piperazinyl, piperazinylalkyl, alkylpiperazinyl, phenylpiperazinyl, thienyle, furanyl, piperidyl, methylpiperidyl, pyridyl, pyrrolidyl and pyrrolidylalkyl, all the alkyl, phenyl and heterocyclic radicals being optionally substituted with one or more radicals chosen :rom halogen atoms and hydroxyl, alkyl, alkoxy, CF3, NH2, JHalk, N(alk)2 radicals and a phenyl radical, itself optionally substituted with one or more substituents rhosen from halogen atoms and hydroxyl or alkoxy radicals, all the phenyl and heterocyclic radicals above furthermore being optionally substituted with one or more alkyl radicals, the phenyl radicals furthermore being optionally substituted with NR5R6 in which R5 and R6 are as defined above, the other substituents of said products of formula (I) having any one of the values defined above. A subject of the invention is especially the products of formula (I) as defined above such that Y2 represents hydrogen, halogen, alkyl, cycloalkyl, hydroxyl, alkoxy, carboxyl which is free or esterified with an alkyl or phenyl radical, NH2, NHalk, N(alk)2 and phenyl, all the alkyl, alkoxy and phenyl radicals being optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, C1-C4 alkyl, C1-C4 alkoxy, CF3, NH2, NHalk and N(alk)2 radicals and a phenyl radical, which is itself optionally substituted with one or more substituents chosen from halogen atoms and hydroxyl or alkoxy radicals, all the phenyl radicals furthermore being optionally substituted with one or more C1-C4 alkyl radicals and optionally substituted with NR5R6 in which R5 and R6 are as defined above, the other substituents of said products of formula (I) having any one of the values defined above. A subject of the invention is especially the products of formula (I) as defined above such that Y2 represents hydrogen, F, CI, CH3, CH2CH3, OH, 0CH3, NH2, NHAlk and phenyl optionally substituted with NR5R6 in which R5 and R6 are as defined above, the other substituents of said products of formula (I) having any one of the values defined above. A subject of the invention is especially the products of formula (I) as defined above such that B2 represents 4-pyridyl and 4-quinolyl radicals substituted with one or two radicals chosen from F, CI, OH and 0CH3, the other substituents of said products of formula (I) having any one of the values defined above. In certain products of formula (I) of the present invention, the following group: In the products of formula (I) of the present invention, R2 and R3 may especially form together a cycloalkyl or heterocycloalkyl radical, or alternatively, identical or different, may especially represent hydrogen and methyl radicals. Products of formula (I) as defined above corresponding to formula (CI): in which YC and Y1C are such that one represents a hydrogen atom, a halogen atom or an amino radical and the other is chosen from -0CF3, -0-CF2-CHF2, -0-CHF2, -0-CH2-CF3 , -SF5, -S (0)n-CF3 , -S(0)n-Alk, -S02CHF2, S02CF2CF3, -S02NH2, -S-CF2-CF2-CF3, -S-Alk-0-Alk, -S-Alk-OH, -S-Alk-CN, -S-Alk-morpholino, -S-Alk-pyrrolidinyl and -S-Alk-piperazinyl, the morpholino, pyrrolidinyl and piperazinyl radicals being optionally substituted with Alk, with Alk representing an alkyl radical containing from 1 to 4 carbon atoms, or the phenyl radical forms with its substituents YC and Y1C one of the following two radicals: R2C and R3C, which may be identical or different, represent hydrogen or optionally substituted alkyl, or alternatively R2C and R3C form, together with the carbon atom to which they are attached, a C3-C10 eyeloalkyl or heterocycloalkyl radical, A2C represents a single bond or CH2, B2C represents pyridyl, pyrimidinyl, quinolyl, azaindolyl, quinazolyl, thiazolyl, imidazolyl, pyrazolyl, furazanyl, isoxazolyl, morpholinyl, pyrrolidinyl, furyl, piperidyl, chromenyl, oxochromenyl, quinazolyl, thienyl, indolyl, pyrrolyl, purinyl, benzoxazinyl, benzimidazolyl and benzofuranyl radicals, optionally substituted with one or more radicals chosen from the values of Y2A, Y2CA represents hydrogen, halogen, hydroxyl, cyano, alkyl, alkoxy, phenyl, COOH, COOAlk, CONR5R6, NR5R6, -NR10-COOH, -NR10-COOAlk, -NR10-CO-R6, -NR10-CS-NR5R6, -NR10-CO-NR5R6 or -NR10-SO2-R6, all these radicals being optionally substituted, R5 and R6, which may be identical or different, are chosen from hydrogen, alkyl, cycloalkyl, phenyl, pyrimidinyl, thienyl, pyridyl, quinolyl, thiazolyl and pyran, all these radicals being optionally substituted, or alternatively R5 and R6 form, with the nitrogen atom to which they are attached, an optionally substituted pyrrolidinyl, piperidyl, piperazinyl, morpholinyl or quinazolinyl radical, RIO represents hydrogen or alkyl, all the above alkyl, Alk or ALK, alkoxy, cycloalkyl and phenyl radicals, and also the ring formed by R5 and R6 with the atom to which they are attached, being optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and cyano; hydroxyl; alkyl; alkoxy; 0CF3; CF3; S(0)n-CF3; nitro; oxo; thioxo; OCOAlk; phenyl, itself optionally substituted with one or more radicals chosen from halogen atoms and alkyl and alkoxy radicals; -OCOAlk; NH2, NHAlk, N(Alk)2, N(alk) (phenylalkyl) , N(Alk) (aminoalkyl) , N(Alk) (alkylaminoalkyl) , N(Alk) (dialkylaminoalkyl); carboxyl, which is free or ester if ied with an alkyl radical, all the above phenyl radicals moreover being optionally substituted with an alkylenedioxy radical, all the above alkyl radicals moreover being optionally substituted with one or more radicals chosen from the following radicals: piperazinyl, which is itself optionally substituted with Alk, Alk-OH and pyridyl; imidazolyl; morpholinyl; pyrrolidinyl; piperidyl, which is itself optionally substituted with one or two alk; azepanyl, optionally substituted with oxo, all the pyrrolidinyl and quinazolinyl radicals above moreover being optionally substituted with oxo or thioxo, all the above alkyl and alkoxy radicals being linear or branched and containing up to 6 carbon atoms, all the above cycloalkyl radicals containing up to 7 carbon atoms, n represents an integer from 0 to 2, said products of formula (CI) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (CI) . In particular in the products of formula (I), the radical below that may be formed by phenyl with its substituents Y and Yl: A subject of the present invention is especially the products of formula (I) as defined above and corresponding to formula (IA) : in which: Y1A represents -0CF3, S(0)n-CF3 and S02CHF2, B2a represents 4-quinolyl and 4-pyridyl radicals optionally substituted with one or more radicals chosen from the values of Y2A, Y2A has the meaning given above for Y2, R2A and R3A, which may be identical or different, represent hydrogen or optionally substituted alkyl, or alternatively R2A and R3A form, together with the carbon atom to which they are attached, a C3-C10 cycloalkyl or heterocycloalkyl radical, all the alkyl and phenyl radicals being optionally substituted with one or more radicals chosen from halogen, OH, alk, Oalk, 0CF3, S(0)n-CF3, CF3, NH2, NHAlk and N(alk)2, n represents an integer fom 0 to 2, said products of formula (IA) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (IA) . A subject of the present invention is especially the products of formula (IA) as defined above in which Y1A, B2a, R2A and R3A have the meanings given above and Y2A represents halogen, -OH, -alk, Oalk, -Oacyl, -NR5AR6A, -C02H, -C02alk, -CO-NR5AR6A, -S(0)n-CF3, -NH-S(0)n-CF3 or phenyl radicals, alk representing a linear or branched alkyl radical containing not more than 6 carbon atoms, all the alkyl, alkoxy and phenyl radicals being optionally substituted, R5A and R6A, which may be identical or different, represent hydrogen, alkyl, cycloalkyl or phenyl, the alkyl and phenyl radicals being optionally substituted, or alternatively R5A and R6A form, with the nitrogen atom to which they are attached, a cyclic radical chosen from pyrrolidyl, piperidyl, piperazinyl, morpholinyl, indolinyl, pyrindolinyl, tetrahydroquinolyl and azetidinyl radicals, all the alkyl, alkoxy and phenyl radicals being optionally substituted with one or more radicals chosen from halogen, OH, alk, Oalk, 0CF3, S(0)n-CF3, CF3, NH2, NHAlk and N(alk)2, n represents an integer from 0 to 2, said products of formula (IA) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (IA) . A subject of the present invention is especially the products of formula (IA) as defined above in which: Y1A represents -0CF3, SCF3 or S(0)2-CF3, B2a represents a 4-quinolyl or 4-pyridyl radical optionally substituted with one or two radicals chosen from halogen, -OH, alk, -Oalk, -C02H, -C02alk, -NR5AR6A, -CF3, -0CF3 and optionally substituted phenyl, R5A and R6A, which may be identical or different, represent hydrogen, alkyl, cycloalkyl or phenyl, the alkyl and phenyl radicals being optionally substituted, or alternatively R5A and R6A form, with the nitrogen atom to which they are attached, a cyclic radical chosen from pyrrolidyl, piperidyl, piperazinyl, morpholinyl, piperazinyl and azetidinyl radicals, R2A and R3A, which may be identical or different, represent hydrogen or optionally substituted alkyl, or alternatively R2A and R3A form, together with the carbon atom to which they are attached, a C3-C6 cycloalkyl or heterocycloalkyl radical, all the alkyl and phenyl radicals being optionally substituted with one or more radicals chosen from halogen, OH, alk, Oalk, 0CF3, S (0) n-CF3, CF3, NH2, NHalk and N(alk)2, said products of formula (IA) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (IA) . A subject of the present invention is especially the products of formula (IA) as defined above corresponding to formule (IA) in which: Y1A represents -0CF3, SCF3 or S(0)2-CF3, B2a represents a 4-quinolyl or 4-pyridyl radical optionally substituted with one or two radicals chosen from halogen, -OH, alk and -Oalk, R2A and R3A, which may be identical or different, represent hydrogen and linear or branched alkyl containing not more than 4 carbon atoms optionally substituted with a hydroxyl radical, or alternatively R2A and R3A form, together with the carbon atom to which they are attached, a C3-C6 cycloalkyl radical, said products of formula (IA) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (IA). A subject of the present invention is especially the products of formula (IA) as defined above corresponding to formula (IA) in which Yla represents 0CF3, SCF3 or S(0)2CF3 and R2A and R3A, which may be identical or different, represent hydrogen and CH3, or alternatively R2A and R3A form, together with the carbon atom to which they are attached, a cyclopropyl radical, the other substituents having any one of the values defined above, said products of formula (IA) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (IA) . A subject of the present invention is also the products of formula (I) as defined above corresponding to formula (IB): in which R2, R3, Al, Y, Yl, A2, B2 and Y2 have the meanings given above said products of formula (IB) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (IB) . A subject of the present invention is also the products of formula (IB) as defined above in which Yl represents 0CF3, SCF3 or S (0) 2CF3 and R2 and R3, which may be identical or different, represent hydrogen and CH3 or, alternatively R2 and R3 form, together with the carbon atom to which they are attached, a cyclopropyl radical, the other substituents having any of the values given above, said products of formula (IB) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (IB). Among the products of the invention that are preferred, mentioned may be made more specifically of the products of formula (I) as defined above, the names of which are below: (S)-5-methyl-l-quinol-4-ylmethyl-3-(4-trifluoromethane-sulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate (S)-5-methyl-l-pyrid-4-ylmethyl-3-(4-trifluoromethane-sulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate (S)-5-methyl-l-quinol-4-ylmethyl-3-(4-trifluoromethyl-sulfanylphenyl)imidazolidine-2,4-dione trifluoroacetate - 5,5-dimethyl-l-quinol-4-ylmethyl-3-(4-trifluoromethane-sulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate (R)-5-methyl-l-quinol-4-ylmethyl-3-(4-trifluoromethane-sulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate (R)-5-methyl-l-quinol-4-ylmethyl-3-(4-trifluoromethyl-sulfanylphenyl)imidazolidine-2,4-dione trifluoroacetate (R)-5-methyl-l-pyrid-4-ylmethyl-3-(4-trifluoromethane-sulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate (R)-5-methyl-l-(3-methylpyrid-4-ylmethyl)-3-(4-tri-fluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate (R)-4-methyl-3-quinol-4-ylmethyl-5-thioxo-l-(4-tri-fluoromethylsulfanylphenyl)imidazolidin-2-one trifluoroacetate (R)-5-isopropyl-l-quinol-4-ylmethyl-3-(4-trifluoro-methylsulfanylphenyl)imidazolidine-2,4-dione trifluoroacetate (R)-5-isopropyl-l-quinol-4-ylmethyl-3-(4-trifluoro-methanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate (R)-5-(4-hydroxy-benzyl)-l-quinol-4-ylmethyl-3- (4-tri-fluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate (R)-5-(4-hydroxy-benzyl)-l-pyrid-4-ylmethyl-3-(4-tri-fluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate (R)-5-(1-hydroxy-ethyl)-l-quinol-4-ylmethyl-3-(4-tri-fluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate 4-quinol-4-ylmethyl-6-(4-trifluoromethylsulfanylphenyl) -4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate 4-quinol-4-ylmethyl-6-(4-trifluoromethanesulfonylphenyl) -4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate - 4-pyrid-4-ylmethyl-6-(4-trifluoromethylsulfanylphenyl)- 4,6-diazaspiro [2.4]heptane-5,7-dione trifluoroacetate 4-pyrid-4-ylmethyl-6-(4-trifluoromethanesulfonylphenyl) -4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate (R)-1-(3-hydroxypyrid-4-ylmethyl)-5-methyl-3-(4-tri-fluoromethylsulfanylphenyl)imidazolidine-2,4-dione trifluoroacetate - 5,5-dimethyl-l-quinol-4-ylmethyl-3-(4-trifluoromethoxy- phenyl)imidazolidine-2,4-dione trifluoroacetate 5,5-dimethyl-l-quinol-4-ylmethyl-3-(4-trifluoromethylsulf anylphenyl) imidazolidine-2,4-dione trifluoroacetate 5,5-dimethyl-l-(3-methylpyrid-4-ylmethyl)-3- (4-tri-fluoromethoxyphenyl)imidazolidine-2,4-dione trifluoroacetate 5,5-dimethyl-1-(3-methylpyrid-4-ylmethyl)-3-(4-tri-fluoromethylsulfanylphenyl)imidazolidine-2,4-dione trifluoroacetate 5,5-dimethyl-1-(3-methylpyrid-4-ylmethyl)-3- (4-tri-fluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate 1-(3-hydroxypyrid-4-ylmethyl)-5,5-dimethyl-3-(4-tri-fluoromethoxyphenyl)imidazolidine-2,4-dione trifluoroacetate 1-(3-hydroxypyrid-4-ylmethyl)-5,5-dimethyl-3-(4-tri-fluoromethylsulfanylphenyl)imidazolidine-2,4-dione trifluoroacetate 1-(3-hydroxypyrid-4-ylmethyl)-5,5-dimethyl-3-(4-tri-fluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate 4-quinol-4-ylmethyl-6-(4-trifluoromethoxyphenyl)-4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate 4-(3-methylpyrid-4-ylmethyl)-6-(4-trifluoromethylsulf-anylphenyl)-4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate 4-(3-hydroxypyrid-4-ylmethyl)-6-(4-trifluoromethoxyphenyl) -4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate, - 4-(3-hydroxypyrid-4-ylmethyl)-6-(4-trifluoromethylsulf-anylphenyl)-4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate 4-(3-hydroxypyrid-4-ylmethyl)-6-(4-trifluoromethanesulf onylphenyl) -4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate, said products of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (I) . Among the preferred products of the invention, mention may be made most particularly of the products of formula (I) as defined above, the names of which are given below: cyclopropanecarboxylic acid {4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazolidin-1-ylmethyl]pyridin-2-yl}amide trifluoroacetate; 5,5-dimethyl-l- [2-(pyrid-2-ylamino)pyridin-4-ylmethyl]-3-(4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione; compound with trifluoroacetic acid; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}isobutyramide; compound with trifluoroacetic acid; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}propionamide; compound with trifluoroacetic acid; 1-(2-aminopyridin-4-ylmethyl)-5,5-dimethyl-3- (4-trifluoromethylsulfanylphenyl)imidazolidine-2,4-dione hydrochloride; pyridine-2-carboxylic acid {4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazolidin-1-ylmethyl] pyridin-2-yl}amide trifluoroacetate; N-{4- [5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}-3-piperidin-l-ylpropionamide trifluoroacetate; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}-3-[4-(2-hydroxyethyl)piperazin-l-yl]propionamide trifluoroacetate; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}-3-morpholin-4-ylpropionamide trifluoroacetate; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}-3-pyrrolidin-1-ylpropionamide trifluoroacetate; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}-3-(4-methylpiperazin-l-yl)propionamide trifluoroacetate; l-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}-3-phenylurea; 1- [2- (6-ethylpyridin-2-ylamino)pyridin-4-ylmethyl] -5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione; 5,5-dimethyl-l-[2-(4-methylpyridin-2-ylamino)-pyridin-4-ylmethyl]-3-(4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione; 5,5-dimethyl-l- [2-(6-methylpyridin-2-ylamino)-pyridin-4-ylmethyl]-3-(4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione; 1-[2-(4,6-dimethylpyridin-2-ylamino)pyridin-4-ylmethyl]-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl) imidazolidine-2,4-dione; 1-[2-(3,5-dichloropyridin-2-ylamino)pyridin-4-ylmethyl]-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl) imidazolidine-2,4-dione; 5,5-dimethyl-l-[2-(pyridin-4-ylamino)pyridin-4-ylmethyl]-3- (4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione; 5,5-dimethyl-l-[2-(pyridin-3-ylamino)pyridin-4-ylmethyl]-3-(4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}-3-(2-oxoazepan-1-yl)propionamide; 3-(benzylmethylamino)-N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazolidin-1-ylmethyl]pyridin-2-yl}propionamide; 4,5-diacetoxy-6-acetoxymethyl-2-(3-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)- imidazolidin-1-ylmethyl]pyridin-2-yl}thioureidoacetic acid; 5,5-dimethyl-1-[2-(5-methylpyridin-2-ylamino)-pyridin-4-ylmethyl]-3-(4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethyl-sulfanylphenyl)imidazolidin-1-ylmethyl]pyridin-2-yl}-3,5-dimethoxybenzamide trifluoroacetate; 5,5-dimethyl-1-[2-(pyrazin-2-ylamino)pyridin-4-ylmethyl]-3-(4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione trifluoroacetate; N-{4- [5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}-3-(3-methylpiperidin-l-yl)propionamide trifluoroacetate; N-{4- [5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}-3-(3,5-dimethylpiperidin-1-yl)propionamide trifluoroacetate; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}-3-methoxybenzamide trifluoroacetate; pyrazine-2-carboxylic acid {4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazolidin-1-ylmethyl]pyridin-2-yl}amide trifluoroacetate; thiophene-2-carboxylic acid {4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazolidin-1-ylmethyl]pyridin-2-yl}amide trifluoroacetate; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}-4-methylbenzamide; compound with trifluoroacetic acid; l-isoquinolin-5-yl-5,5-dimethyl-3-(4-trifluoromethylsulf anylphenyl) imidazolidine-2,4-dione; 3-(4-acetylpiperazin-l-yl)-N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazolidin-1-ylmethyl]pyridin-2-yl}propionamide; 3-[4-(2-diethylaminoethyl)piperazin-l-yl]-N-{4- [5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl) imidazolidin-l-ylmethyl]pyridin-2-yl}propionamide; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}-3-(2,6-dimethylmorpholin-4-yl)propionamide; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}-3-(4-pyrrolidin-l-ylpiperid-l-yl)propionamide; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}-2-(4-pyrrolidin-1-ylpiperidin-l-yl)acetamide; 5,5-dimethyl-1-[2-(4-methylpyridin-3-ylamino)-pyridin-4-ylmethyl] -3- (4-trif luoromethylsulf anylphenyl) -imidazolidine-2,4-dione; 5,5-dimethyl-l-[2-(6-morpholin-4-ylpyridin-3-ylamino)pyridin-4-ylmethyl]-3-(4-trifluoromethylsulf anylphenyl) imidazolidine-2,4-dione; 1-[2-(2,6-dimethylpyridin-3-ylamino)pyridin-4-ylmethyl]-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl) imidazolidine-2,4-dione; methyl 5-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethyl]pyridin-2-ylamino}pyridine-2-carboxylate; 1-[2-(2,6-dimethoxypyridin-3-ylamino)pyridin-4-ylmethyl]-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl) imidazolidine-2,4-dione; 1-[2-(6-fluoropyridin-3-ylamino)pyridin-4-ylmethyl]-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl) imidazolidine-2,4-dione; 1-[2-(6-methoxypyridin-3-ylamino)pyridin-4-ylmethyl]-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl) imidazolidine-2,4-dione, said products of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (I). A subject of the present invention is also a process for preparing the products of general formula (I) as defined above, characterized in that: either a product of formula (II) : in which Y' and Yl' have the meanings given above for Y and Yl, respectively, in which the optional reactive functions are optionally protected and R has the meaning given above, is reacted in the presence of a tertiary base with a product of formula (III) : in which X represents -A2'-B2'-Y2' or hydrogen, and A2' , B2' , Y2' , R2' and R3' have the meanings given above, respectively, for A2', B2', Y2', R2' and R3' in which the optional reactive functions are optionally protected above, to obtain a product of formula (IV) : in which Y' , Yl', X, R, R2' and R3' have the meanings given above, which products of formula (IV) are, if necessary or if desired, subjected to any one or more of the following reactions, in any order: a) reaction for removal of any protecting groups that may be borne by Y', Yl', R, R2' and R3' and X when X represents -A2'-B2'-Y2'; b) reaction for hydrolysis of the >C=NH group to a ketone function c) action on the products of formula (IV) in which X represents a hydrogen atom, and after optional hydrolysis of the >C=NH group to a ketone function of a reagent of formula Hal-A2 '-B2 '-Y2 ' in which A2 ' , B2 ' and Y2 ' have the meanings given above and Hal represents a halogen atom, to obtain products of formula (Ii): in which Y', Yl', R2' , R3' , A2' , B2' and Y2' have the meanings given above, followed, if desired, by the action on these products of an agent for removing any protecting groups that may be borne by Y', Yl', R2' , R3' , A2', B2' and Y2' or, where appropriatel the action of an esterification, amidification or salification agent, or the product of formula (II) defined above is reacted in the presence of a tertiary base with a product of formula (III') : in which R2' and R3' have the meanings given above and Q represents either an alkali metal atom, for example sodium, or an alkyl radical containing from 1 to 6 carbon atoms, to obtain a product of formula (IVa): in which Y' , Yl' , R, R2' , R3' and X have the meanings given above, which product, if desired, is subjected to any one or more of the following reactions, in any order: a) reaction for removal of the possible protecting groups that may be borne by X; b) action on the products of formula (IVa), in which X represents a hydrogen atom, of a reagent of formula Hal-A2'-B2'-Y2' in which A2' , B2' and Y2' have the meanings given above and Hal represents a halogen atom, to obtain products of formula (Iii): in which Y' , Yl' , R, Rl, R2', R3' and A2' , B2' and Y2' have the meanings given above, followed, if desired, by the action on these products of an agent for removing any protecting groups that may be borne by Y' , Yl', R2', R3' , A2', B2' and Y2' or, where appropriate, the action of an esterification, amidification or salification agent, or a reagent of formula Hal-A2'-B2'-Y2', in which A2' , B2' , Y2' and Hal have the meanings given above, is reacted with a product of formula (IV) : in which Y' , Yl' , R2' and R3' have the meanings given above, to obtain a product of formula (IV"): in which Y', Yl' , R2', R3 ' , A2' , B2' and Y2' have the meanings given above, which product of formula (IV") is, if necessary or if desired, subjected to a reaction for removal of any protecting groups that may be borne by -A2'-B2'-Y2', followed, where appropriate, by the action of an esterification, amidation or salification agent. It may be noted that, depending on the values Y' , Yl', R2', R3', A2', B2' and Y2', the products of formulae (IV), (Ii) , (IVa), (Iii) and (IV') may be products of formula (I) and that, to obtain products or other products of formula (I), these products may be subjected if desired, and necessary, to one or more of the following conversion reactions, in any order: a) a reaction for esterification of an acid function, b) a reaction for saponification of an ester function to an acid function, c) a reaction for oxidation of an alkylthio group to the corresponding sulfoxide or sulfone group, d) a reaction for conversion of a ketone function to an oxime function, e) a reaction for reducing a free or esterified carboxyl function to an alcohol function, f) a reaction for conversion of an alkoxy function to a hydroxyl function, or alternatively of a hydroxyl function to an alkoxy function, g) a reaction for oxidation of an alcohol function to an aldehyde, acid or ketone function, h) a reaction for conversion of a nitrile radical to a tetrazolyl, i) a reaction for reduction of nitro compounds to amino compounds, j) a reaction for removal of the protecting groups that may be borne by the protected reactive functions, k) a reaction for salification with a mineral or organic acid or with a base to obtain the corresponding salt, 1) a reaction for resolution of the racemic forms to resolved products, said products of formula (I) thus obtained being in any possible racemic, enantiomeric or diastereoisomeric isomer form. It may be noted that such reactions for converting substituents into other substituents may also be performed on the starting materials, and also on the intermediates as defined above before continuing the synthesis according to the reactions indicated in the process described above. The various reactive functions that may be borne by certain compounds of the reactions defined above may, if necessary, be protected: these are, for example, hydroxyl, acyl, free carboxyl or amino and monoalkylamino radicals, which may be protected with the appropriate protecting groups. The following nonexhaustive list of examples of protection of reaction functions may be mentioned: - the hydroxyl groups may be protected, for example, with alkyl radicals such as tert-butyl, trimethylsilyl, tert-butyldimethylsilyl, methoxymethyl, tetrahydropyranyl, benzyl or acetyl, - the amino groups may be protected, for example, with acetyl, trityl, benzyl, tert-butoxycarbonyl, benzyloxycarbonyl, phthalimido radicals or other radicals known in peptide chemistry, - the acyl groups such as the formyl group may be protected, for example, in the form of cyclic or noncyclic ketals or thioketals such as dimethyl or diethylketal or ethylene dioxyketal, or diethylthioketal or ethylenedithioketal, - the acid functions of the products described above may be, if desired, amidated with a primary or secondary amine, for example in methylene chloride in the presence, for example, of 1-ethyl-3-(dimethylaminopropyl)carbo-diimide hydrochloride at room temperature: - the acid functions may be protected, for example, in i the form of esters formed with readily cleavable esters such as benzyl esters or tert-butyl esters, or esters known in peptide chemistry. These reactions a) to k) indicated above may be performed, for example, as indicated below. a) The products described above may, if desired, undergo, on the possible carboxyl functions, esterification reactions that may be performed according to the usual methods known to those skilled in the art. b) The possible conversions of ester functions into an acid function of the products described above may be, if desired, performed under the usual conditions known to those skilled in the art, especially by acid or alkaline hydrolysis, for example with sodium hydroxide or potassium hydroxide in alcoholic medium such as, for example, in methanol, or alternatively with hydrochloric acid or sulfuric acid. c) the possible alkylthio groups in the products described above, in which the alkyl radical is optionally substituted with one or more halogen atoms, especially fluorine, may, if desired, be converted into the corresponding sulfoxide or sulfone functions under the usual conditions known to those skilled in the art such as, for example, with peracids such as, for example, peracetic acid or meta-chloroperbenzoic acid, or alternatively with ozone, oxone or sodium periodate in a solvent such as, for example, methylene chloride or dioxane at room temperature. The production of the sulfoxide function may be promoted with an equimolar mixture of the product containing an alkylthio group and the reagent such as, especially, a peracid. The production of the sulfone function may be promoted with a mixture of the product containing an alkylthio group with an excess of the reagent such as, especially, a peracid. d) The reaction for conversion of a ketone function into an oxime may be performed under the usual conditions known to those skilled in the art, such as, especially, a reaction in the presence of an optionally O-substituted hydroxylamine in an alcohol such as, for example, ethanol, at room temperature or with heating. e) The possible free or esterified carboxyl functions of the products described above may be, if desired, reduced to an alcohol function by the methods known to those skilled in the art: the possible esterified carboxyl functions may be, if desired, reduced to an alcohol function by the methods known to those skilled in the art and especially with lithium aluminum hydride in a solvent such as, for example, tetrahydrofuran or dioxane or ethyl ether. The possible free carboxyl functions of the products described above may be, if desired, reduced to an alcohol function especially with boron hydride. f) The possible alkoxy functions such as, especially, methoxy, in the products described above, may be, if desired, converted into a hydroxyl function under the usual conditions known to those skilled in the art, for example with boron tribromide in a solvent such as, for example, methylene chloride, with pyridine hydrobromide or hydrochloride or with hydrobromic acid or hydrochloric acid in water or trifluoroacetic acid at reflux. g) The possible alcohol functions of the products described above may be, if desired, converted into an aldehyde or acid function by oxidation under the usual conditions known to those skilled in the art, such as, for example, by the action of manganese oxide to obtain the aldehydes, or of Jones' reagent to access the acids. h) The possible nitrile functions of the products described above may be, if desired, converted into tetrazolyl under the usual conditions known to those skilled in the art, such as, for example, by cycloaddition of a metal azide such as, for example, sodium azide or a trialkyltin azide on the nitrile function, as indicated in the method described in the article referenced as follows: J. Organometallic Chemistry., 33, 337 (1971) KOZIMA S. et al. It may be noted that the reaction for conversion of a carbamate into urea and especially of a sulfonylcarbamate into sulfonylurea may be performed, for example, at the reflux point of a solvent such as, for example, toluene, in the presence of the appropriate amine. It is understood that the reactions described above may be performed as indicated or alternatively, where appropriate, according to other common methods known to those skilled in the art. i) The removal of protecting groups such as, for example, those indicated above may be performed under the usual conditions known to those skilled in the art, especially via an acid hydrolysis performed with an acid such as hydrochloric acid, benzenesulfonic acid or para-toluenesulfonic acid, formic acid or trifluoroacetic acid, or alternatively via a catalytic hydrogenation. The phthalimido group may be removed with hydrazine. A list of various protecting groups that may be used will be found, for example, in patent BF 2 499 995. j) The products described above may, if desired, be subjected to salification reactions, for example with a mineral or organic acid or with a mineral or organic base according to the usual methods known to those skilled in the art. k) The possible optically active forms of the products described above may be prepared by resolving the racemic mixtures according to the usual methods known to those skilled in the art. The reaction of the products of formula (II) with the products of formula (III) is preferably performed in an organic solvent such as tetrahydrofuran or dichloroethane, but ethyl ether or isopropyl ether may also be used. The process is optionally performed in the presence of a tertiary base such as triethylamine or alternatively pyridine or methylethylpyridine. The possible reactive functions that are optionally protected in the product of formula (III), (IVa) or (IV") are the hydroxyl or amino functions. Usual protecting groups are used to protect these functions. Examples that may be mentioned include the following protecting groups for the amino radical: tert-butyl, tert-amyl, trichloroacetyl, chloroacetyl, benzhydryl, trityl, formyl, benzyloxycarbonyl. Protecting groups for the hydroxyl radical that may be mentioned include radicals such as formyl, chloroacetyl, tetrahydropyranyl, trimethylsilyl and tert-butyldimethylsilyl. It is clearly understood that the above list is not limiting and that other protecting groups, which are known, for example, in peptide chemistry, may be used. A list of such protecting groups is found, for example, in French patent 2 499 995, the content of which is incorporated herein by reference. The possible reactions for removal of the protecting groups are performed as indicated in said patent 2 4 99 995. The preferred method of removal is acid hydrolysis with acids chosen from hydrochloric acid, benzenesulfonic acid or para-toluenesulfonic acid, formic acid or trifluoroacetic acid. Hydrochloric acid is preferred. The possible reaction for hydrolysis of the >C=NH group to a ketone group is also preferably performed using an acid such as aqueous hydrochloric acid, for example at reflux. The action on the products of formula (IV), (IVa) or (IV) of the reagent of formula Hal-A2'-B2'-Y2' is performed in the presence of a strong base such as sodium hydride or potassium hydride. The process may be performed by phase-transfer reaction in the presence of quaternary ammonium salts such as tert-butylammonium. An example of removal of the tert-butyldimethylsilyl group using hydrochloric acid is given below in the examples. - The possible esterification of a free OH radical is performed under standard conditions. An acid or a functional derivative, for example an anhydride such as acetic anhydride in the presence of a base such as pyridine may be used, for example. The possible esterification or salification of a COOH group is performed under the standard conditions known to those skilled in the art. - The possible amidation of a COOH radical is performed under standard conditions. A primary or secondary amine may be used on a functional derivative of the acid, for example a symmetrical or mixed anhydride. A subject of the present invention is also a process for preparing the products of formula (I"): in which Y' , Yl' , Al, R, Rl, R2' and R3' have the meanings given above, characterized in that a product of formula (V): in which Al, Yl' and Y2' have the above meanings and Hal represents a halogen atom, is reacted with a product of formula (VI): in which R, Rl, R2' , R3' and X have the above meanings, the reaction being performed in the presence of a catalyst and optionally a solvent. As regards the products of formula (V) , the term "Hal" preferably denotes a chlorine atom, but may also represent a bromine or iodine atom. A subject of the invention is, more specifically, a process as defined above in which the catalyst is a metal in native or oxidized form or a base. The catalyst used may be a metal in native form, in metal oxide form or alternatively in the form of metal salts. The catalyst may also be a base. When the catalyst used is a metal, this metal may be copper or nickel. The metal salts may be a chloride or an acetate. It may be noted that when Al represents a single bond, a catalyst may be used. When Al represents alkyl, it is then an alkylation, which may be performed especially in the presence of a reagent such as a base. When the catalyst is a base, this base may be, for example, sodium hydroxide or potassium hydroxide and, if desired, dimethyl sulfoxide may be added to the reaction medium. A subject of the invention is, more specifically, a process as defined above in which the catalyst is chosen from cuprous oxide, cupric oxide, copper in native form and a base such as sodium hydroxide or potassium hydroxide. The copper in native form used as catalyst is preferably in the form of powder. A subject of the invention is particularly a process as defined above in which the catalyst is cuprous oxide. The solvent used is preferably chosen from high-boiling ethers such as, for example, phenyl oxide, diglyme, triglyme and dimethyl sulfoxide, but may also be, for example, a high-boiling oil such as paraffin or liquid petroleum jelly. It may be noted that, especially when Al represents a single bond, in the reaction of a product of formula (V) with a product of formula (VI) as defined above, palladium or a salt thereof as described, for example, in the following articles, or a copper salt with a ligand, for instance a 1,2-diaminocyclohexane derivative, may also be used as catalyst: Buchwald S .L. , J. AM. CHEM. SOC, 2002, 6043 and Buchwald S.L., J. AM. CHEM. SOC, 2001, 7727. A subject of the invention is, more particularly, a process as defined above, characterized in that the process is performed in the presence of a solvent of ether type such as phenyl ether, diglyme, triglyme, dimethyl sulfoxide, toluene or dioxane. A subject of the invention is, most particularly, a process as defined above in which the solvent used is phenyl ether or triglyme. The process for preparing the desired product, defined above, may be performed under pressure or at atmospheric pressure, preferably at elevated temperature. A subject of the invention is thus a process as defined above, characterized in that the reaction is performed at a temperature above 100°C and preferably above 150°C. A subject of the invention is, more specifically, a process as defined above, characterized in that the reaction is performed for more than 2 hours. A subject of the invention is, very specifically, a process as defined above, characterized in that the reaction is performed in the presence of cuprous oxide, in triglyme, at a temperature of greater than or equal to 200°C and for more than 3 hours. The products that are the subject of the present invention have advantageous pharmacological properties: it has been found that they especially have inhibitory properties on protein kinases. Among these protein kinases, mention may be made especially of IGF1R. FAK may also be mentioned. AKT may also be mentioned. Tests given in the experimental section below illustrate the inhibitory activity of products of the present invention with respect to such protein kinases. These properties thus make the products of general formula (I) of the present invention usable as medicinal products for treating malignant tumors. The products of formula (I) may also be used in the veterinary field. A subject of the invention is thus, as medicinal products, pharmaceutically acceptable products of general formula (I). A subject of the invention is, particularly, the use as medicinal products of the products whose names are below: (S)-5-methyl-l-quinol-4-ylmethyl-3-(4-trifluoromethane-sulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate (S)-5-methyl-l-pyrid-4-ylmethyl-3-(4-trifluoromethane-sulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate (S)-5-methyl-l-quinol-4-ylmethyl-3-(4-trifluoromethyl-sulfanylphenyl)imidazolidine-2,4-dione trifluoroacetate - 5,5-dimethyl-l-quinol-4-ylmethyl-3-(4-trifluoromethane- sulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate (R)-5-methyl-l-quinol-4-ylmethyl-3-(4-trifluoromethane-sulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate - (R)-5-methyl-l-quinol-4-ylmethyl-3-(4-trifluoromethyl-sulfanylphenyl)imidazolidine-2,4-dione trifluoroacetate - (R)-5-methyl-l-pyrid-4-ylmethyl-3-(4-trifluoromethane-sulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate - (R)-5-methyl-l-(3-methylpyrid-4-ylmethyl)-3- (4-tri-fluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate - (R)-4-methyl-3-quinol-4-ylmethyl-5-thioxo-l- (4-tri-fluoromethylsulfanylphenyl)imidazolidin-2-one trifluoroacetate - (R)-5-isopropyl-l-quinol-4-ylmethyl-3-(4-trifluoro- methylsulfanylphenyl)imidazolidine-2,4-dione trifluoroacetate - (R)-5-isopropyl-l-quinol-4-ylmethyl-3-(4-trifluoro- methanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate - (R)-5-(4-hydroxy-benzyl)-l-quinol-4-ylmethyl-3-(4-tri- fluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate - (R) -5-(4-hydroxy-benzyl)-l-pyrid-4-ylmethyl-3- (4-tri-fluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate - (R)-5-(1-hydroxy-ethyl)-l-quinol-4-ylmethyl-3-(4-tri-fluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate - 4-quinol-4-ylmethyl-6-(4-trifluoromethylsulfanylphenyl) -4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate - 4-quinol-4-ylmethyl-6-(4-trifluoromethanesulfonyl phenyl) -4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate - 4-pyrid-4-ylmethyl-6-(4-trifluoromethylsulfanylphenyl)- 4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate - 4-pyrid-4-ylmethyl-6-(4-trifluoromethanesulfonyl- phenyl)-4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate - (R)-1-(3-hydroxypyrid-4-ylmethyl)-5-methyl-3-(4-tri fluoromethylsulf anylphenyl) imidazolidine-2,4-dione trifluoroacetate - 5,5-dimethyl-l-quinol-4-ylmethyl-3-(4-trifluoromethoxy- phenyl)imidazolidine-2,4-dione trifluoroacetate 5,5-dimethyl-l-quinol-4-ylmethyl-3-(4-trifluoromethylsulf anylphenyl) imidazolidine-2,4-dione trifluoroacetate - 5, 5-dimethyl-1-(3-methylpyrid-4-ylmethyl)-3- (4-tri- fluoromethoxyphenyl)imidazolidine-2,4-dione trifluoroacetate - 5,5-dimethyl-l-(3-methylpyrid-4-ylmethyl)-3-(4-trifluoromethylsulf anylphenyl) imidazolidine-2,4-dione trifluoroacetate - 5,5-dimethyl-l-(3-methylpyrid-4-ylmethyl) -3-(4-tri-fluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate - 1-(3-hydroxypyrid-4-ylmethyl)-5,5-dimethyl-3-(4-tri-fluoromethoxyphenyl)imidazolidine-2,4-dione trifluoroacetate - 1-(3-hydroxypyrid-4-ylmethyl)-5,5-dimethyl-3-(4-tri-fluoromethylsulfanylphenyl)imidazolidine-2,4-dione trifluoroacetate - 1-(3-hydroxypyrid~4-ylmethyl)-5,5-dimethyl-3-(4-tri-fluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate - 4-quinol-4-ylmethyl-6-(4-trifluoromethoxyphenyl)-4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate 4-(3-methylpyrid-4-ylmethyl)-6-(4-trifluoromethylsulf-anylphenyl)-4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate - 4-(3-hydroxypyrid-4-ylmethyl)-6-(4-trifluoromethoxy phenyl) -4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate, - 4-(3-hydroxypyrid-4-ylmethyl)-6-(4-trifluoromethylsulf- anylphenyl)-4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate - 4-(3-hydroxypyrid-4-ylmethyl)-6-(4-trifluoromethane sulfonylphenyl) -4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate, said products of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the pharmaceutically acceptable addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (I). One subject of the invention is particularly the application, as medicinal products, of the products whose names are given below: cyclopropanecarboxylic acid {4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazolidin-1-ylmethyl]pyridin-2-yl}amide trifluoroacetate; 5,5-dimethyl-l-[2-(pyrid-2-ylamino)pyridin-4-ylmethyl]-3-(4-trifluoromethylsulfanylphenyl)- imidazolidine-2,4-dione; compound with trifluoroacetic acid; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl) imidazolidin-l-ylmethyl]pyridin-2-yl}isobutyramide; compound with trifluoroacetic acid; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}propionamide; compound with trifluoroacetic acid; 1-(2-aminopyridin-4-ylmethyl)-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)imidazolidine-2,4-dione hydrochloride; pyridine-2-carboxylic acid {4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazolidin-1-ylmethyl]pyridin-2-yl}amide trifluoroacetate; N-{4- [5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}-3-piperidin-l-ylpropionamide trifluoroacetate; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}-3-[4-(2-hydroxyethyl)piperazin-l-yl]propionamide trifluoroacetate; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}-3-morpholin-4-ylpropionamide trifluoroacetate; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}-3-pyrrolidin-1-ylpropionamide trifluoroacetate; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}-3-(4-methylpiperazin-l-yl)propionamide trifluoroacetate; 1-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}-3-phenylurea; 1- [2- (6-ethylpyridin-2-ylamino)pyridin-4-ylmethyl] -5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione; 5,5-dimethyl-l-[2-(4-methylpyridin-2-ylamino)-pyridin-4-ylmethyl]-3-(4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione; 5,5-dimethyl-l-[2-(6-methylpyridin-2-ylamino)-pyridin-4-ylmethyl]-3-(4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione; 1-[2- (4,6-dimethylpyridin-2-ylamino)pyridin-4-ylmethyl]-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl) imidazolidine-2,4-dione; 1-[2-(3,5-dichloropyridin-2-ylamino)pyridin-4-ylmethyl]-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl) imidazolidine-2,4-dione; 5,5-dimethyl-l- [2-(pyridin-4-ylamino)pyridin-4-ylmethyl]-3-(4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione; 5,5-dimethyl-l-[2-(pyridin-3-ylamino)pyridin-4-ylmethyl]-3-(4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-l-ylmethyl]pyridin-2-yl}-3-(2-oxoazepan-l-yl)propionamide; 3-(benzylmethylamino)-N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazolidin-l-ylmethyl] pyridin-2-yl}propionamide; 4,5-diacetoxy-6-acetoxymethyl-2-(3-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)-imidazolidin-l-ylmethyl]pyridin-2-yl}thioureidoacetic acid; 5,5-dimethyl-l-[2-(5-methylpyridin-2-ylamino)-pyridin-4-ylmethyl] -3- (4-trifluoromethylsulfanylphenyl) -imidazolidine-2,4-dione; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-l-ylmethyl]pyridin-2-yl}-3,5-iimethoxybenzamide trifluoroacetate; 5,5-dimethyl-l-[2-(pyrazin-2-ylamino)pyridin-4-ylmethyl]-3-(4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione trifluoroacetate; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-l-ylmethyl]pyridin-2-yl}-3-(3-methylpiperidin-l-yl)propionamide trifluoroacetate; N-{4- [5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}-3-(3,5-dimethylpiperidin-l-yl)propionamide trifluoroacetate; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethyl] pyridin-2-yl}-3-methoxybenzamide trifluoroacetate; pyrazine-2-carboxylic acid {4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazolidin-1-ylmethyl]pyridin-2-yl}amide trifluoroacetate; thiophene-2-carboxylic acid {4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazolidin-1-ylmethyl]pyridin-2-yljamide trifluoroacetate; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}-4-methylbenzamide; compound with trifluoroacetic acid; l-isoquinolin-5-yl-5,5-dimethyl-3-(4-trifluoromethylsulf anylphenyl) imidazolidine-2,4-dione; 3-(4-acetylpiperazin-l-yl)-N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazolidin-1-ylmethyl]pyridin-2-yl}propionamide; 3-[4-(2-diethylaminoethyl)piperazin-l-yl]-N-{4- [5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl) imidazolidin-1-ylmethyl] pyridin-2-yl}propionamide; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethyl]pyridin-2-yl}-3-(2, 6-dimethylmorpholin-4-yl)propionamide; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethylJpyridin-2-yl}-3-(4-pyrrolidin-l-ylpiperid-l-yl)propionamide; N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethyl-sulfanylphenyl)imidazolidin-1-ylmethyl]pyridin-2-yl}-2-(4-pyrrolidin-1-ylpiperidin-l-yl)acetamide; 5,5-dimethyl-1-[2-(4-methylpyridin-3-ylamino)-pyridin-4-ylmethyl]-3-(4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione; 5,5-dimethyl-1-[2-(6-morpholin-4-ylpyridin-3-ylamino)pyridin-4-ylmethyl]-3-(4-trifluoromethylsulfanylphenyl) imidazolidine-2,4-dione; 1-[2-(2,6-dimethylpyridin-3-ylamino)pyridin-4-ylmethyl]-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl) imidazolidine-2,4-dione; methyl 5-{4- [5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl) imidazolidin-1-ylmethyl]pyridin-2-ylamino}pyridine-2-carboxylate; 1-[2 -(2,6-dimethoxypyridin-3-ylamino)pyridin-4-ylmethyl] -5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl) imidazolidine-2,4-dione; 1- [2- (6-fluoropyridin-3-ylamino)pyridin-4-ylmethyl]-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl) imidazolidine-2,4-dione; 1-[2-(6-methoxypyridin-3-ylamino)pyridin-4-ylmethyl] -5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl) imidazolidine-2,4-dione, said products of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with pharmaceutically acceptable mineral and organic bases of said products of formula (I). The products may be administered parenterally, orally, perlingually, rectally or topically. A subject of the invention is also pharmaceutical compositions, characterized in that they contain as active principle at least one of the medicinal products of general formula (I). These compositions may be in the form of injectable solutions or suspensions, tablets, coated tablets, capsules, syrups, suppositories, creams, ointments and lotions. These pharmaceutical forms are prepared according to the usual methods. The active principle may be incorporated into excipients usually used in these compositions, such as aqueous or nonaqueous vehicles, talc, gum arabic, lactose, starch, magnesium stearate, cocoa butter, fatty substances of animal or plant origin, paraffin derivatives, glycols, various wetting, dispersing or emulsifying agents, and preserving agents. The usual dose, which varies according to the individual treated and the complaint under consideration, may be, for example, from 10 mg to 5 00 mg per day orally in man. The present invention thus relates to the use of products of formula (I) as defined above or of pharmaceutically acceptable salts of said products of formula (I) for the preparation of medicinal products for inhibiting the activity of protein kinases and especially of a protein kinase. The present invention thus relates to the use of products of formula (I) as defined above or of pharmaceutically acceptable salts of said products of i formula (I) in which the protein kinase is a protein tyrosine kinase. The present invention thus relates to the use of products of formula (I) as defined above or of pharmaceutically acceptable salts of said products of formula (I) in which the protein kinase is chosen from the following group: EGFR, Fak, FLK-1, FGFR1, FGFR2, FGFR3, FGFR4, FGFR5, flt-1, IGF-1R, KDR, PDGFR, tie2, VEGFR, AKT, Raf. The present invention thus relates particularly to the use of products of formula (I) as defined above or of pharmaceutically acceptable salts of said products of formula (I) in which the protein kinase is IGF1R. The present invention also relates to the use of products of formula (I) as defined above or of pharmaceutically acceptable salts of said products of formula (I) in which the protein kinase is FAK. The present invention also relates to the use of products of formula (I) as defined above or of pharmaceutically acceptable salts of said products of formula (I) in which the protein kinase is AKT. The present invention also relates to the use of products of formula (I) as defined above or of pharmaceutically acceptable salts of said products of formula (I) in which the protein kinase is in a cell culture, and also to this use in a mammal. The present invention thus relates to the use of products of formula (I) as defined above or of pharmaceutically acceptable salts of said products of formula (I) for the preparation of a medicinal product for preventing or treating a disease characterized by deregulation of the activity of a protein kinase and especially such a disease in a mammal. The present invention relates to the use of products of formula (I) as defined above or of pharmaceutically acceptable salts of said products of formula (I) for the preparation of a medicinal product for preventing or treating a disease belonging to the following group: disorders of blood vessel proliferation, fibrotic disorders, disorders of mesangial cell proliferation, metabolic disorders, allergies, asthma, thrombosis, diseases of the nervous system, retinopathy, psoriasis, rheumatoic arthritis, diabetes, muscle degeneration, oncology diseases and cancer. The present invention thus relates to the use of products of formula (I) as defined above or of pharmaceutically acceptable salts of said products of formula (I) for the preparation of a medicinal product for treating oncology diseases. The present invention relates particularly to the use of products of formula (I) as defined above or of pharmaceutically acceptable salts of said products of formula (I) for the preparation of a medicinal product for treating cancers. Among these cancers, the present invention is most particularly of interest in the treatment of solid tumors and the treatment of cancers that are resistant to cytotoxic agents. Among these cancers, the present invention relates most particularly to the treatment of breast cancer, stomach cancer, cancer of the colon, lung cancer, cancer of the ovaries, cancer of the uterus, brain cancer, cancer of the kidney, cancer of the larynx, cancer of the lymphatic system, cancer of the thyroid, cancer of the urogenital tract, cancer of the tract including the seminal vesicle and prostate, bone cancer, cancer of the pancreas and melanomas. The present invention is even more particularly of interest in treating breast cancer, cancer of the colon and lung cancer. The present invention also relates to the use of products of formula (I) as defined above or of pharmaceutically acceptable salts of said products of formula (I) for the preparation of a medicinal product for cancer chemotherapy. As medicinal products according to the present invention for cancer chemotherapy, the products of formula (I) according to the present invention may be used alone or in combination with chemotherapy or radiotherapy or alternatively in combination with other therapeutic agents. The present invention thus relates especially to the pharmaceutical compositions as defined above, also containing active principles of other chemotherapy medicinal products for combating cancer. Such therapeutic agents may be antitumor agents commonly used. As examples of known inhibitors of protein kinases, mention may be made especially of butyrolactone, flavopiridol, 2- (2-hydroxyethylamino)-6-benzylamino-9-methylpurine, olomucine, Glivec and Iressa. The products of formula (I) according to the present invention may thus also be advantageously used in combination with antiproliferative agents: as examples of such antiproliferative agents, but without, however, being limited to this list, mention may be made of aromatase inhibitors, antiestrogens, the topoisomerase I inhibitors, the topoisomerase II inhibitors, microtubule-active agents, alkylating agents, histone deacetylase inhibitors, farnesyl transferase inhibitors, COX-2 inhibitors, MMP inhibitors, mTOR inhibitors, antineoplastic antimetabolites, platinum compounds, compounds that reduce the activity of protein kinases and also anti-angiogenic compounds, gonadorelin agonists, antiandrogens, bengamides, biphophonates and trastuzumab. Examples that may thus be mentioned include anti-microtubule agents, for instance taxoids, vinca alkaloids, alkylating agents such as cyclophosphamide, DNA-intercalating agents, for instance cis-platinum, agents that are interactive on topoisomerase, for instance camptothecin and derivatives, anthracyclines, for instance adriamycin, antimetabolites, for instance 5-fluorouracil and derivatives, and the like. The present invention thus relates to products of formula (I) as protein kinase inhibitors, said products of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with pharmaceutically acceptable mineral and organic acids or with pharmaceutically acceptable mineral and organic bases of said products of formula (I), and also the prodrugs thereof. The present invention relates particularly to products of formula (I) as defined above, as IGF1R inhibitors. The present invention also relates to products of formula (I) as defined above as FAK inhibitors. The present invention also relates to products of formula (I) as defined above as AKT inhibitors. The present invention relates more particularly to the products of formula (IA) as defined above as IGF1R inhibitors. The products of formula (I) according to the present invention may be prepared by application or adaptation of known methods and especially of the methods described in the literature such as, for example, those described by R.C. Larock in: Comprehensive Organic Transformations, VCH publishers, 198 9. In the reactions described below, it may be necessary to protect reactive functional groups such as, for example, hydroxyl, amino, imino, thio or carboxyl groups, when these groups are desired in the final product but when their participation is not desired in the reactions for synthesizing the products of formula (I) . Conventional protecting groups may be used in accordance with the usual standard practices, for instance those described, for example, by T.W. Greene and P.G.M. Wuts in "Protective Groups in Organic Chemistry" John Wiley and Sons, 1991. The products of formula (II) used at the start of the invention may be obtained by the action of phosgene when X represents an oxygen atom, or of thiophosgene when K represents a sulfur atom, on the corresponding amine of formula (A) , i.e. the aminophenyl derivative bearing the substituents Y and Yl' as defined above. A product of this type is also described in French patent 2 329 276. The products of formula (III) or (III') are known or may be prepared from the corresponding cyanohydrin according to the process described in the publication: J. Am. Chem. Soc. (1953), 75, 4841. The products of formula (III) may be obtained by the action of a product of formula Y2-B2-A2-Hal on 2-cyano-2-aminopropane under the conditions stated above for the action of Y2-B2-A2-Hal on the products of formula (IV) . An example of a preparation of this type is described in the reference: - Jilek et al. Collect. Czech. Chem. Comm. 54 (8) 2248 (1989). The products of formula (IV) are described in French patent 2 329 276. The starting materials of formulae (V) and (VI), on which a process that is the subject of the invention is performed, to obtain the products of formula (I) , are known and commercially available or may be prepared according to methods known to those skilled in the art. The preparation of products of formula (VI) is described especially in the following publications: - Zhur. Preklad. Khim. 28, 969-75 (1955) (CA 50, 4881a, 1956) - Tetrahedron 43, 1753 (1987) - J. Org. Chem. 52, 2407 (1987) - Zh. Org. Khim. 21, 2006 (1985) - J. Fluor. Chem. 17, 345 (1981) or in: - German patent DRP 637 318 (1935) - European patent EP 0 13 0 875 - Japanese patent JP 81 121 524. The products of formula (VI) that are hydantoin derivatives are widely used and cited in the literature, for instance in the following articles: - J. Pharm. Pharmacol., 67, Vol. 19(4), p. 209-16 (1967) - Khim. Farm. Zh., 67, Vol. 1 (5) p. 51-2 - German patent 2 217 914 - European patent 0 091 596 - J. Chem. Soc. Perkin. Trans. 1, p. 219-21 (1974). The products of formula (I) of the present patent application as defined above, for which p represents the integer 0 and which thus constitute hydantoin derivatives, may be synthesized according to the process indicated above and especially according to the general scheme below which describes this synthesis on a solid support. The protocol that follows this scheme gives the operating conditions for such a synthesis on solid support of the products of formula (I) of the present patent application. The experimental section below more particularly gives an illustration of such a synthesis on a solid support according to the above protocol with the preparation of Examples 1 to 56 of the present patent application. Such a synthesis may be performed according to the general protocol below. Rink resin, protected with an Fmoc group, is deprotected with a 20% solution of piperidine in DMF. The resulting amine resin is coupled with an amino acid protected with an Fmoc group, in the presence of iiisopropylaminecarbodiimide (DIC) and hydroxybenzo-:riazole (HOBt). The supported N-Fmoc amino acid is then ieprotected with a 20% solution of piperidine in DMF. The free amine is reacted with an aldehyde dissolved in a 50/5 0 mixture of THF and triethyl orthoformate (TEOF) to jive a Schiff's base, which is reduced with sodium :yanoborohydride. The resulting amine is coupled with an .socyanate or an isothiocyanate to give the corresponding irea or thiourea. When the isocyanate is not commercially ivailable, it may be prepared from the corresponding amine by reaction with 1/3 equivalent of triphosgene in the presence of 2 equivalents of pyridine. The product is then cleaved with a 95% trifluoroacetic acid/water mixture. The urea thus released cyclizes to give the expected hydantoinine. In certain cases, the cleavage solution must be heated to 80 °C to obtain complete cyclization. The products of formula (I) of the present patent application as defined above, for which p represents the integer 1 and which thus constitute dihydrouracil derivatives, may be synthesized according to the process indicated above and especially according to the general scheme below which describes this synthesis on a solid support. The protocol that follows this scheme gives the operating conditions for such a synthesis of the products of formula (I) of the present patent application on a solid support. The experimental section below more particularly gives an illustration of such a synthesis on a solid support according to the above protocol with the preparation of Example 5 of the present patent application. For the synthesis of the dihydrouracils on a solid support, the protocol that follows may be used. Wang polystyrene resin (1.7 mmol/g) is used, for example, which resin is treated with a mixture of p-amino acid, 2,6-dichlorobenzoyl chloride and pyridine in DMF. After washing the resin is treated with a 10% solution of piperidine in DMF. The resulting free amine is reacted with an aldehyde in a mixture of THF/trimethyl orthoformate (TMOF). The resulting Schiff's base is reduced with sodium cyanoborohydride in a mixture of methanol, THF and acetic acid. The secondary amine obtained is acylated with phosgene and the resulting carbomoyl chloride is treated with a primary amine to give the corresponding urea. Cyclization to the dihydrouracil and cleavage of the final product are performed by treating with a strong base such as diazabicycloundecene (DBU). The products of formula (I) of the present patent application may thus be synthesized on a solid support as described above or in liquid phase according to the process indicated below: the experimental section of the present patent application gives an illustration of such a liquid-phase synthesis with the preparation of Examples 57 to 62. For this liquid-phase synthetic process, two routes A and B may be performed, each involving two steps. Route A: step a: the alkylation of the amino ester may be performed by reductive amination with an aromatic or heterocyclic aldehyde according to the general process described in Advanced Organic Reaction, March, third edition, page 798-800. In particular, the formation of the Schiff's base (intermediate) may be performed using an amino ester optionally in salt form, an aldehyde and optionally a dehydrating agent (for example magnesium sulfate) in a solvent, for instance dichloromethane or dichloroethane, at a temperature of between 0°C and the reflux point of the solvent. The imine formed may be isolated. The imine formed is reduced with a metal hydride, for instance sodium borohydride, in a solvent, for instance an alcohol (for example ethanol or methanol), at a temperature of between 0°C and the reflux point of the solvent. step b: the amino ester obtained is coupled with an isocyanate in a solvent, for instance THF or dichloromethane, with or without the presence of a base (for example triethylamine) or an acid (for example trifluoroacetic acid), at a temperature of between 0°C and the reflux point of the solvent. When the isocyanates are not commercially available, they are prepared from the corresponding amines and triphosgene or diphosgene or phosgene in the presence of a base (for example pyridine or triethylamine) according to the general procedure described in Advanced Organic Reaction, March, third edition, page 370. Route B: step a: the formation of the isocyanate may be performed by coupling an aromatic or heterocyclic amine with diphosgene in the presence of activated plant charcoal, in a solvent, for instance toluene, at a temperature of between -40°C and the reflux point of the solvent. The isocyanate formed is not isolated, and may react with the amino ester or its salt in the same solvent in the presence of a base, for instance triethylamine, at a temperature of between 0°C and the reflux point of the solvent, to give the 3-arylimidazolidine-2,4-dione derivative. step b: the coupling of this derivative with an alkyl halide is performed in the presence of a base, for instance potassium tert-butoxide or sodium hydride, in a solvent, for instance THF or DMF, at a temperature of between 0°C and the reflux point of the solvent. The products of formula (I) of the present patent application that constitute examples 201 to 2 07 of the present patent application were prepared as indicated below in the experimental section and as indicated in the schemes that follow: in these schemes, example I represents example 201, example II represents example 202, example III represents example 203, example IV represents example 204, example V represents example 205, example VI represents example 206 and example VII represents example 207. The synthesis of the products of formula (I) of the present patent application that constitute the products of examples 208 to 243 was performed using route B. The alkyl halide may be prepared from the corresponding carboxylic acids. The ethyl carboxylates were prepared by esterification of the carboxylic acids in ethanol in the presence of sulfuric acid, repeating the conditions described in Synthesis 2000, 1138. The reduction of the ethyl carboxylates to alcohol was performed in ethanol in the presence of sodium borohydride, repeating the conditions described in Synthesis 2000, 1665. The conversion of the alcohols thus obtained into alkyl halides was performed using dibromotriphenylphosphorane as halogenating agent, repeating the conditions described in J. Heterocyclic Chem., 30, 631 (1993). The alkyl halides may also be prepared by f ree-radical bromination of the corresponding methylenes in the presence of N-bromosuccinimide and benzoyl peroxide in carbon tetrachloride, repeating the conditions described in J. Heterocyclic Chem., 30, 631 (1993). Thus, we functionalized the pyridine nucleus in position 2 with a bromine or fluorine atom or alternatively with a nitrile group. The latter compound will also allow us to prepare various carbonyl compounds. The acidic hydrolysis of the nitrile in the presence of sulfuric acid, repeating the conditions described in J. Med. Chem. 1991, 34, 281-290, led to the carboxamide in dimeric form. Hydrolysis of the nitrile under milder conditions allowed us to obtain the expected carboxamide. Acidic hydrolysis of the nitrile in the presence of 5N hydrochloric acid, repeating the conditions described in J. Heterocyclic Chem. , 30, 631 (1993) , led to the corresponding carboxylic acid. The amide may be prepared from the carboxylic acid using 1- (3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride as coupling agent in dichloromethane, repeating the conditions described in J. Am. Chem. Soc. , 95, 875, (1973) . Various amine analogs were obtained by nucleophilic substitution of the chlorointermediate with amines under irradiation in a microwave oven, based on the conditions described in Tetrahedron 2002, 58, 1125. The amino analog was obtained by deprotection of the p-methoxybenzylamine group in the presence of trifluoroacetic acid, based on the conditions described in J. Chem. Soc., Perkin Trans. 1, 2002, 428-433. This amino derivative allowed access to other chemical functions, for instance the amide function, the carbamate function or the sulfonamide function. The acetamido derivative was obtained by acylation of the amine derivative in the presence of acetic anhydride, based on the conditions described in Tetrahedron Lett. 2002, 43, 3121. We also prepared the methyl and tert-butyl carbamates on the basis of the conditions described in J. Heterocyclic Chem., 22, 313 (1985) and in J. Org. Chem. 2002, 67, 4965. The amine derivative was also sulfonylated with mesyl chloride, based on the conditions described in J. Med. Chem., 1985, 28, 824. The above conditions were also used for the synthesis of compounds containing a disubstituted phenyl group. The hydantoin containing a pyridine nucleus disubstituted in position -2,6 with a bromine atom was prepared using the above conditions, starting with 2,6-dibromo-4-(hydroxymethyl)pyridine described in Synthesis 2000, 1665. The products may be purified as follows: Purification by LC/MS The products may be purified by LC/MS using a Waters FractionLynx system composed of a Waters model 600 gradient pump, a Waters model 515 regeneration pump, a Waters Reagent Manager dilution pump, a Waters model 2700 autoinjector, two Rheodyne model LabPro valves, a Waters model 996 diode array detector, a Waters model ZMD mass spectrometer and a Gilson model 2 04 fraction collector. The system was controlled by the Waters FractionLynx software. The separation was performed alternatively on two Waters Symmetry columns (C1Q, 5 /xM, 19x50 mm, catalog reference 186000210), one column undergoing regeneration with a 95/5 (v/v) water/acetonitrile mixture containing 0.07% (v/v) of trifluoroacetic acid, while the other column was being used for separation. The elution of the columns was performed using a linear gradient of from 5% to 95% of acetonitrile containing 0.07% (v/v) of trif luoroacetic acid in water, at a flow rate of 10 mL/min. At the outlet of the separation column, a thousandth of the effluent is separated with an LC Packing Accurate, diluted with methyl alcohol at a flow rate of 0.5 mL/min and conveyed to the detectors, in a proportion of 75% to the diode array detector, and the remaining 25% to the mass spectrometer. The rest of the effluent (999/1000) is conveyed to the fraction collector, where the flow is discarded as long as the mass of the expected product is not detected by the FractionLynx software. The molecular formulae of the expected products are supplied to the FractionLynx software, which triggers the collection of the product when the detected mass signal corresponds to the ion [M+H]+ and/or to the [M+Na]+. In certain cases, depending on the analytical LC/MS results, when a strong ion corresponding to [M+2H]++ was detected, the value corresponding to half of the calculated molecular mass (MW/2) is also supplied to the FractionLynx software. Under these conditions, the collection is also triggered when the signal for the mass of the ion [M+2H]++ and/or [M+Na+H]++ is detected. The products were collected in tared glass tubes. After collection, the solvents were evaporated of f, in a Savant AES 2 00 0 or Genevac HT8 centrifugal evaporator and the product masses were determined by weighing the tubes after evaporation of the solvents. The LC/MS analyses were performed on a Micromass model LCT machine connected to an HP 1100 machine. The abundance of the products was measured using an HP G1315A diode array detector over a 200-600 nm wavelength range and a Sedex 65 light scattering detector. The mass spectra were acquired over a range from 180 to 800. The data were analyzed using the Micromass MassLynx software. The separation was performed on a Hypersil BDS CI8, 3 /zm column (50 x 4.6 mm) , eluting with a linear gradient of from 5% to 90% of acetonitrile containing 0.05% (v/v) of trifluoroacetic acid (TFA) in water containing 0.05% (v/v) of TFA, over 3.5 min at a flow rate of 1 mL/min. The total analysis time, including the column re-equilibration time, is 7 minutes. The products of Examples 244 to 255 of the present invention were prepared as indicated in the experimental section and according to the general synthetic route of the scheme below: The products of Examples 256 to 2 63 of the present invention were prepared according to reaction Schemes 1 and 2 indicated below in which the figures 1 to 8 correspond, respectively, to Examples 256 to 263: the products of Examples 256 to 261 (i.e. products 1 to 6) were prepared according to Scheme 1 and the two thiohydantoin compounds of Examples 262 and 263 (i.e. products 7 and 8) were prepared according to Scheme 2. The nit ro compound i s prepared by nit rat ion of methyl 2-trifluoromethoxybenzoate by nitration (fuming > nitric acid), while controlling the temperature, according to the conditions described in the PCT patent Int. Appl. (2000), 564: WO 0069810. The corresponding amine is prepared by reduction of i the nitro function in the presence of SnCl2 in ethanol according to the same patent. The isocyanate is prepared by reaction of diphosgene dissolved in toluene at -20°C under the known usual conditions. The isocyanate is reacted with the quinoline derivative prepared according to the known methods in order to prepare the desired hydantoin. The acid is obtained by saponification using 2N sodium hydroxide in THF at 60°C. The amide is prepared by coupling of the desired amine using EDCI as coupling agent (standard coupling conditions). The alcohol is obtained by reduction of the ester in THF in the presence of LiAlH4. The halo derivatives R = CI and R = Br are prepared from commercial anilines according to the same synthetic scheme. The examples whose preparation follows illustrate the present invention without, however, limiting it Example 1 : preparation of (S)-5-methyl-l-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazol-idine-2,4-dione trifluoroacetate 2 g (1.02 mmol) of Polystyrene AM RAM (Rink resin) (0.51 mmol/g) are suspended in 20 ml of DMF in a 50 ml syringe fitted with a sinter. After agitation for 10 minutes, the DMF is filtered and replaced with 10 ml of a 2 0% solution of piperidine in DMF. After agitation for one hour at room temperature, the solution is filtered and the resin washed successively with 3 x 10 ml of DMF, 2 x 10 ml of methanol and 3 x 10 ml of DMF. A solution of 0.94 g of Fmoc-Ala(OH) (3 mmol), 0.41 g of HOBt (3 mmol) and 0.48 ml of DIC (3 mmol) in 10 ml of DMF is added to the resin. The syringe is agitated overnight at room temperature and the resin is then washed successively with 5 x 10 ml of DMF, 3 x 10 ml of MeOH and 5 x 10 ml of DCM. Next, 10 ml of a 20% solution of piperidine in DMF are introduced into the syringe. After agitation for 1 hour, the solution is filtered and the resin washed with 5 x 10 ml of DMF, 2 x 10 ml of MeOH, 3 x 10 ml of DCM and 3 x 10 ml of THF. Next, a solution of 0.79 g of quinoline-4-carboxaldehyde (5.1 mmol) in 10 ml of a 50/50 THF/TEOF mixture is added to the resin. After agitation overnight at room temperature, the solution is filtered and the resin washed with 10 x 10 ml of THF. 0.63 g of sodium cyanoborohydride in a mixture of 1.5 ml of MeOH, 3.5 ml of dichloroethane and 0.1 ml of acetic acid is then added to the resin. The resin is agitated overnight and then, after filtration, washed with 10 x 10 ml of DCM, 3 x 10 ml of MeOH and 5 x 10 ml of DCM. In parallel, a solution of 0.563 g of 4-(trifluoro-methanesulfonyl)aniline (2.5 mmol) is treated with 0.25 g of triphosgene (0.83 mmol), followed by 0.23 ml of pyridine (2.5 mmol) at 0°C under nitrogen. After the temperature has warmed gradually to room temperature, the reaction is stirred for 2 hours and a further 0.23 ml of pyridine in 1 ml of DMF is added to the mixture. The solution obtained is transferred into the syringe, which is agitated for 2 hours. The solution is then filtered and the resin washed with 5 x 10 ml of DCM, 3 x 10 ml of MeOH and 5 x 10 ml of DCM. Finally, the resin is treated with 5 ml of a 95% solution of trif luoroacetic acid in water. The mixture is agitated for 2 hours and then filtered. The resin is washed with 2 ml of MeOH, followed by 2 ml of DCM. The combined filtrates are evaporated under vacuum. 2 80 mg of crude product are thus obtained. After purification by preparative LC-MS, 240 mg (overall yield = 41%) of expected product are isolated in the form of a white solid. EIMS ( [M+H]+ : 464 Retention time (RT) = 3.12 min (YMC basic S5 column; 2-85% ACN/H20 gradient over 7 min) 1H NMR (300 MHz) (CDC13): 1.59(d, 3H); 4.11(t, 1H); 5.01 and 5.55(AB, 2H); 7.70 (d, 1H); 7.89(m, 1H); 7.99(m, 3H); 8.15(m, 2H); 8.3 0(d, 1H), 8.50(d, 1H); 9.22(d, 1H). Example 2 s Preparation of (S)-4-methyl-3 -quinol-4-ylmethyl-5-thioxo-l-(4-trifluoromethanesulfonylphenyl)-imldazolidin-2-one trifluoroacetate Resin 3, 0.036 mmol, prepared according to Example 1, is used for the preparation of the compound. 33 mg of thiocarbonyldiimidazole (0.18 mmol) are added to a solution of 41 mg of 4- (trif luoromethane-sulfonyl)aniline (0.18 mmol) in 3 ml of DCM. The reaction mixture is stirred for 2 hours at room temperature and then added directly to the resin. After stirring for 2 hours, the solution is filtered and the resin is then washed with 5 x 2 ml of DCM, 3 x 5 ml of MeOH and 5x2 ml of DCM. Finally, 2 ml of a 95% solution of TFA in water are added to the resin. After stirring for 2 hours, the mixture is filtered and the resin washed with 1 ml of MeOH and 1 ml of DCM. The combined filtrates are heated at 60°C for 2 hours and then concentrated under vacuum. After purification by preparative LC-MS, 1.8 mg of expected product are isolated. EIMS [(M+H]+): 480 RT= 4.72 min (YMC basic S5 column; 2-85% ACN/H20 gradient over 7 min) Example 3 : Preparation of (S)-5-methyl-l-pyrid-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazol-idine-2,4-dione trifluoroacetate The compound is prepared from 0.025 mmol of resin, 0.075 mmol of N-Fmoc-L-Ala (OH) , 0 .125 mmol of 4-pyridinecarboxaldehyde and 0.0625 mmol of 4-(trifluoro-methanesulfonyl)aniline, in the same way as in Example 1. After purification by preparative LC-MS, 5.6 mg of expected product are obtained. EIMS ([M+H]+): 414 RT = 2.72 min Example 4 : Preparation of (S)-5-methyl-1-pyrid-4-ylmethyl-3-(4-trifluoromethylsulfanylphenyl)imidazol-idine-2,4-dione trifluoroacetate The compound is prepared from 0.025 mmol of resin, 0.075 mmol of N-Fmoc-L-Ala (OH) , 0.125 mmol of 4-pyridinecarboxaldehyde and 0.0625 mmol of 4-(trifluoro-methanethio) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 1.3 mg of expected product are obtained. EIMS ([M+H]+): 382 RT = 2.83 min Example 5 : Preparation of (S)-5-methyl-l-quinol-4-ylmethyl-3-(4-trifluoromethylsulfanylphenyl)imidazol-idine-2,4-dione trifluoroacetate The compound is prepared from 0.02 5 mmol of resin, 0,075 mmol of N-Fmoc-L-Ala (OH) , 0.125 mmol of 4-quinolinecarboxaldehyde and 0.0625 mmol of 4- (trif luoromethanethio) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 0.6 mg of expected product is obtained. EIMS ([M+H]+): 432 RT = 3.14 min Example 6 : Preparation of l-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate The compound is prepared from 4 mmol of resin, 12 mmol of N-Fmoc-Gly (OH) , 20 mmol of 4-quinoline-carboxaldehyde, and 10 mmol of 4-(trifluoromethane-sulfonyl) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 1 g of expected product is obtained. EIMS ([M+H]+): 450 RT = 3.20 min Example 7 : Preparation of 5,5-dimethyl-l-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2, 4-dione trifluoroacetate The compound is prepared from 0.25 mmol of resin, 0.75 mmol of Fmoc-AIB- (OH) , 1.25 mmol of 4-quinoline-carboxaldehyde and 0.625 mmol of 4-(trifluoromethane-sulfonyl) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 22 mg of expected product are obtained. EIMS ([M+H]+): 478 RT = 4.26 min Example 8 : Preparation of (R) -5-methyl-l-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2, 4-dione trifluoroacetate The compound is prepared from 0.04 mmol of resin, 0.12 mmol of N-Fmoc-D-Ala (OH) , 0.20 mmol of 4-quinoline-carboxaldehyde and 0.10 mmol of 4-(trifluoromethane- sulfonyl) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 10 mg of expected product are obtained. EIMS ([M+H]+ ) : 464 RT = 4.3 6 min Example 9 : Preparation of (R)-5-methyl-l-quinol-4-ylmethyl-3-(4-trifluoromethylsulfanylphenyl)imidazol-idine-2,4-dione trifluoroacetate The compound is prepared from 0.04 mmol of resin, 0.12 mmol of N-Fmoc-D-Ala (OH) , 0.20 mmol of 4-quinoline-carboxaldehyde and 0.10 mmol of 4-(trifluoromethanethio) -aniline, in the same way as in Example 1. After purification by preparative LC-MS, 11 mg of expected product are obtained. EIMS ( [M+H]+) : 432 RT = 4.50 min Example 10 : Preparation of (R)-5-methyl-l-pyrid-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazol-idine-2,4-dione trifluoroacetate The compound is prepared from 0.28 mmol of resin, 0.84 mmol of N-Fmoc-D-Ala (OH) , 1.4 mmol of 4-pyridine-carboxaldehyde and 0.70 mmol of 4-(trifluoromethane-sulfonyl) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 105 mg of expected product are obtained. EIMS ([M+H]+ ): 414 RT = 2.40 min Example 11 : Preparation of (R)-5-methyl-l-pyrid-4-ylmethyl-3-(4-trifluoromethylsulfanylphenyl)imidazol-idine-2,4-dione trifluoroacetate The compound is prepared from 0.28 mmol of resin, 0.84 mmol of N-Fmoc-D-Ala (OH) , 1.4 mmol of 4-pyridine-carboxaldehyde and 0.70 mmol of 4-(trifluoromethanethio) -aniline, in the same way as in Example 1. After purification by preparative LC-MS, 91 mg of expected product are obtained. EIMS ([M+H]+): 382 RT = 2.52 min Example 12 : Preparation of (S)-5-methyl-1-(3- methylpyrid-4-ylmethyl)-3-(4-trifluoromethylsulfanyl- phenyl)imidazolidine-2,4-dione trifluoroacetate The compound is prepared from 0.04 mmol of resin, 0.12 mmol of N-Fmoc-L-Ala (OH) , 0.20 mmol of 3-methyl-4-pyridinecarboxaldehyde and 0.10 mmol of 4-(trifluoro-methanethio) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 17 mg of expected product are obtained. EIMS ([M+H]+): 396 RT = 4.2 0 min Example 13 : Preparation of (S)-5-methyl-l-(3-methylpyrid-4-ylmethyl)-3-(4-trifluoromethanesulfonyl-phenyl)imidazolidine-2,4-dione trifluoroacetate The compound is prepared from 0.04 mmol of resin, 0.12 mmol of N-Fmoc-L-Ala (OH) , 0.20 mmol of 3-methyl-4-pyridinecarboxaldehyde, and 0.10 mmol of 4- (trifluoro-methanesulfonyl)aniline, in the same way as in Example 1. After purification by preparative LC-MS, 16 mg of expected product are obtained. EIMS ([M+H]+): 428 RT = 4.07 min Example 14 : Preparation of (S)-4-methyl-3-pyrid-4-ylmethyl-5-thioxo-l-(4-trifluoromethylsulfanylphenyl)-imidazolidin-2-one trifluoroacetate The compound is prepared from 0.04 mmol of resin, 0.12 mmol. of N-Fmoc-L-Ala (OH) , 0.20 mmol of 4-pyridine-carboxaldehyde and 0.10 mmol of 4-(trifluoromethanethio) -aniline, in the same way as in Example 2. After purification by preparative LC-MS, 1.7 mg of expected product are obtained. EIMS ([M+H]+ ): 398 RT = 4.51 min Example 15 : Preparation of (S)-4-methyl-3-pyrid-4-ylmethyl-5-thioxo-l-(4-trifluoromethanesulfonylphenyl)-imidazolidin-2-one trifluoroacetate The compound is prepared from 0.04 mmol of resin, 0.12 mmol of N-Fmoc-L-Ala (OH) , 0.20 mmol of 4-pyridinecarboxaldehyde and 0.10 mmol of 4- (trifluoromethane-sulfonyl) aniline, in the same way as in Example 2. After purification by preparative LC-MS, 2.2 mg of expected product are obtained. EIMS ([M+H]+): 430 RT = 4.34 min Example 16 : Preparation of (R)-4-methyl-3-(3 -methylpyrid-4-ylmethyl)-5-thioxo-l-(4-trifluoromethyl-sulfanylphenyl)imidazolidin-2-one trifluoroacetate The compound is prepared from 0.04 mmol of resin, 0.12 mmol of N-Fmoc-D-Ala (OH) , 0.20 mmol of 3-methyl-4-pyridinecarboxaldehyde and 0.10 mmol of 4-(trifluoro-methanethio) aniline, in the same way as in Example 2. After purification by preparative LC-MS, 1.9 mg of expected product are obtained. EIMS ([M+H]+): 412 RT = 4.60 min Example 17 : Preparation of (R)-4-methyl-3-(3-methylpyrid-4-ylmethyl)-5-thioxo-l-(4-trifluoromethyl-sulfonylphenyl)imidazolidin-2-one trifluoroacetate The compound is prepared from 0.04 mmol of resin, 0.12 mmol of N-Fmoc-D-Ala (OH) , 0.20 mmol of 3-methyl-4-pyridinecarboxaldehyde and 0.10 mmol of 4-(trifluoro-methanesulfonyl)aniline, in the same way as in Example 2. After purification by preparative LC-MS, 4.5 mg of expected product are obtained. EIMS ([M+H]+): 444 RT = 4.41 min Example 18 : Preparation of (R)-5-methyl-l-(3-methylpyrid-4-ylmethyl) -3- (4-trifluoromethylsulfanyl-phenyl)imidazolidine-2,4-dione trifluoroacetate The compound is prepared from 0.04 mmol of resin, 0.12 mmol of N-Fmoc-D-Ala (OH) , 0.20 mmol of 3-methyl-4-pyridinecarboxaldehyde and 0.10 mmol of 4-(trifluoro-methanethio) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 14 mg of expected product are obtained. EIMS ([M+H]+): 396 RT = 4.22 min Example 19 : Preparation of (R)-5-methyl-l-(3-methylpyrid-4-ylmethyl)-3-(4-trifluoromethanesulfonyl-phenyl)imidazolidine-2,4-dione trifluoroacetate The compound is prepared from 0.04 mmol of resin, 0.12 mmol of N-Fmoc-D-Ala (OH) , 0.20 mmol of 3-methyl-4-pyridinecarboxaldehyde and 0.10 mmol of 4-(trifluoro-methanesulfonyl)aniline, in the same way as in Example 1. After purification by preparative LC-MS, 6.3 mg of expected product are obtained. EIMS ([M+H]+): 428 RT = 4.10 min Example 20 : Preparation of (R)-4-methyl-3-quinol-4-ylmethyl-5-thioxo-l- (4-trifluoromethylsulfanyIphenyl) -imidazolidin-2-one trifluoroacetate The compound is prepared from 0.04 mmol of resin, 0.12 mmol of N-Fmoc-D-Ala (OH) , 0.20 mmol of 4-qinoline-carboxaldehyde and 0.10 mmol of 4-(trifluoromethanethio) -aniline, in the same way as in Example 2. After purification by preparative LC-MS, 0.4 mg of expected product is obtained. EIMS ([M+H]+): 448 RT = 4.89 min Example 21 : Preparation of (R)-5-isopropyl-l-quinol-4-ylmethyl-3-(4-trifluoromethylsulfanylphenyl)imidazolidine-2, 4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of N-Fmoc-D-Val (OH) , 0.25 mmol of 4-quinoline-carboxaldehyde and 0.12 5 mmol of 4-(trifluoromethane- thio) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 0.3 mg of expected product is obtained. RT = 4.01 min EIMS ([M+H]+ ): 460 Example 22 : Preparation of (R)-5-isopropyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazol-idine-2,4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of N-Fmoc-D-Val (OH) , 0.25 mmol of 4-quinoline-carboxaldehyde and 0.125 mmol of 4-(trifluoromethane-sulfonyl) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 1 mg of expected product is obtained. EIMS ( [M+H]+) : 492 RT = 3.91 min Example 23 : Preparation of (R)-5-Benzyl-l-quinol-4-ylmethyl-3-(4-trifluoromethylsulfanylphenyl)imidazol-idine-2,4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of N-Fmoc-D-Phe (OH) , 0.25 mmol of 4-quinoline-carboxaldehyde and 0.125 mmol of 4-(trifluoromethane-thio) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 8.9 mg of expected product are obtained. EIMS ([M+H]+): 508 RT = 4.11 min Example 24 : Preparation of (R)-5-Benzyl-l-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazol-idine-2,4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of N-Fmoc-D-Phe (OH) , 0.25 mmol of 4-quinoline-carboxaldehyde and 0.125 mmol of 4-(trifluoromethane-sulfonyl)aniline, in the same way as in Example 1. After purification by preparative LC-MS, 5.9 mg of expected product are obtained. EIMS ([M+H]+) : 540 RT = 4,01 min Example 25 : Preparation of (R)-5-Benzyl-l-pyrid-4- ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazol- idine-2,4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of N-Fmoc-D-Phe (OH) , 0.25 mmol of 4-pyridine-carboxaldehyde and 0.12 5 mmol of 4-(trifluoromethane-sulfonyl) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 11.1 mg of expected product are obtained. EIMS ([M+H]+): 490 RT = 3.76 min Example 26 : Preparation of (R)-5-isobutyl-l-quinol-4-ylmethyl-3- (4-trif luoromethanesulfonylphenyl) imidazol-idine-2,4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of N-Fmoc-D-Leu (OH) , 0.25 mmol of 4-quinoline-carboxaldehyde and 0.125 mmol of 4-(trifluoromethane-sulfonyl) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 5.9 mg of expected product are obtained. RT = 4,02 min EIMS ([M+H]+): 506 Example 27 : Preparation of (R)-5-(4-hydroxy-benzyl)-1-quinol-4-ylmethyl-3- (4-trifluoromethylsulfanylphenyl) -imidazolidine-2,4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of N-Fmoc-D-Tyr (OH) , 0.25 mmol of 4-quinoline-carboxaldehyde and 0.125 mmol of 4-(trifluoromethane-thio) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 5.1 mg of expected product are obtained. EIMS ([M+H]+ ): 524 RT = 3.75 min Example 28 : Preparation of (R)-5-(4-hydroxy-benzyl)-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)-imidazolidine-2,4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of N-Fmoc-D-Tyr (OH) , 0.25 mmol of 4-quinoline-carboxaldehyde and 0.125 mmol of 4-(trifluoromethane-sulfonyl) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 1.8 mg of expected product are obtained. EIMS ([M+H]+): 556 RT = 3.66 min Example 2 9 : Preparation of (R)-5-(4-hydroxy-benzyl)-1-pyrid-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)-imidazolidine-2,4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of N-Fmoc-D-Tyr (OH) , 0.25 mmol of 4-pyridine-carboxaldehyde and 0.125 mmol of 4-(trifluoromethane-sulfonyl) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 0.7 mg of expected product is obtained. EIMS ([M+H]+): 506 RT = 3.48 min Example 3 0 : Preparation of (R)-5-(1-hydroxy-ethyl)-1-quinol-4-ylmethyl-3-(4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of N-Fmoc-D-Thr (OH) , 0.25 mmol of 4-quinoline-carboxaldehyde and 0.125 mmol of 4-(trifluoromethane-thio) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 4.2 mg of expected product are obtained. EIMS ([M+H]+): 462 RT = 3.52 min Example 31 : Preparation of (R)-5-(1-hydroxy-ethyl)-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)-imldazolidlne-2,4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of N-Fmoc-D-Thr (OH) , 0.25 mmol of 4-quinoline-carboxaldehyde and 0.125 mmol of 4-(trifluoromethane-sulfonyl) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 3.4 mg of expected product are obtained. EIMS ([M+H]+): 494 RT = 3.43 min Example 32 : Preparation of 4-quinol-4-ylmethyl-6-(4-trifluoromethylsulfanylphenyl)-4,6-diazaspiro[2.4]hept-ane-5,7-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of Fmoc-ACPC-(OH) , 0.25 mmol of 4-quinoline-carboxaldehyde and 0.125mmol of 4-(trifluoromethane-thio) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 7.5 mg of expected product are obtained. EIMS ([M+H]+): 444 RT = 3.68 min Example 33 : Preparation of 4-quinol-4-ylmethyl-6-(4-trifluoromethanesulfonylphenyl)-4,6-diazaspiro [2.4]-heptane-5,7-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of Fmoc-ACPC- (OH) , 0.25 mmol of 4-quinoline-carboxaldehyde and 0.125 mmol of 4-(trifluoromethane-sulfonyl) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 3.8 mg of expected product are obtained. EIMS ( [M+H]+) : 476 RT = 3.60 min Example 34 : Preparation of 4-pyrid-4-ylmethyl-6-(4-trifluoromethylsulfanylphenyl)-4,6-diazaspiro[2.4]hept-ane-5,7-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of Fmoc-ACPC- (OH) , 0.25 mmol of 4-pyridine-carboxaldehyde and 0.125 mmol of 4-(trifluoromethane-thio) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 1.7 mg of expected product are obtained. EIMS ([M+H]+): 394 RT = 3.43 min Example 35 : Preparation of 4-pyrid-4-ylmethyl-6-(4-trifluoromethanesulfonylphenyl)-4,6-diazaspiro [2.4]hept-ane-5,7-dione trifluoroacetate, The compound is prepared from 0.05 mmol of resin, 0.15 mmol of Fmoc-ACPC- (OH) , 0.25 mmol of 4-pyridine-carboxaldehyde, and 0.125 mmol of 4-(trifluoromethane-sulfonyl) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 1.4 mg of expected product are obtained. EIMS ([M+H]+): 426 RT = 3.3 5 min Example 36 : Preparation of (R)-5-benzo[b]thiophen-3-ylmethyl-l-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl) imidazolidine-2,4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of N-Fmoc-D-benzothienylAla(OH), 0.25 mmol of 4-quinolinecarboxaldehyde and 0 .125 mmol of 4-(trifluoro-methanesulfonyl)aniline, in the same way as in Example 1. After purification by preparative LC-MS, 5 mg of expected product are obtained. EIMS ([M+H]+ ): 596 RT = 4.12 min Example 37 : Preparation of (R)-5-benzo[b]thiophen-3-ylmethyl-l-pyrid-4-ylmethyl-3-(4-trifluoromethyl-sulfanylphenyl)imidazolidine-2,4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of N-Fmoc-D-benzothienylAla (OH) , 0.25 mmol of 4-pyridinecarboxaldehyde and 0.125 mmol of 4-(trifluoro-methanethio) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 1.4 mg of expected product are obtained. EIMS ([M+H]+): 514 RT = 3.35 min Example 38 : Preparation of (R)-5-benzo[b]thiophen-3-ylmethyl-1-pyrid-4-ylmethyl-3 -(4-tri fluoromethanesulf-onylphenyl)imidazolidine-2,4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of N-Fmoc-D-benzothienylAla (OH) , 0.25 mmol of 4-pyridinecarboxaldehyde and 0.125 mmol of 4-(trifluoromethanesulf onyl)aniline, in the same way as in Example 1. After purification by preparative LC-MS, 8.5 mg of expected product are obtained. EIMS ([M+H]+): 546 RT = 3.90 min Example 39 : Preparation of (S)-5-pyrid-2-ylmethyl-1-quinol-4-ylmethyl-3- (4-trifluoromethylsulfanylphenyl) -imidazolidine-2,4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of N-Fmoc-D-2-pyridine-Ala (OK) , 0.25 mmol of 4-quinolinecarboxaldehyde and 0.125 mmol of 4-(tri-fluoromethanethio) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 7.5 mg of expected product are obtained. EIMS ([M+H]+ ): 509 RT = 3.47 min Example 40 : Preparation of (S)-5-pyrid-2-ylmethyl-1 -quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)-imidazolidine-2,4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of N-Fmoc-D-2-pyridine-Ala(OH) , 0.25 mmol of 4-quinolinecarboxaldehyde and 0.125 mmol of 4-(trifluoro-methanesulfonyl)aniline, in the same way as in Example 1. After purification by preparative LC-MS, 1.6 mg of expected product are obtained. EIMS ([M+H]+): 541 RT = 3.41 min Example 41 : Preparation of (R)-1-(3-hydroxypyrid-4-ylmethyl)-5-methyl-3-(4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of N-Fmoc-D-Ala (OH) , 0.25 mmol of 3-hydroxy-4-pyridinecarboxaldehyde and 0.125 mmol of 4-(trifluoro-methanethio) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 8.3 mg of expected product are obtained. EIMS ([M+H]+): 398 RT = 4.2 6 min Example 42 : Preparation of 5,5-dimethyl-1-quinol-4-ylmethyl-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione tri fluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of Fmoc-AIB- (OH) , 0.25 mmol of 4-quinolinecarboxaldehyde and 0.125 mmol of 4-(trifluoromethoxy) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 5.5 mg of expected product are obtained. EIMS ([M+H]+ ): 430 RT = 4.3 3 min Example 43 : Preparation of 5,5-dimethyl-1-quinol-4-ylmethyl-3-(4-trifluoromethylsulfanylphenyl)imidazolidine-2, 4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of Fmoc-AIB- (OH) , 0.25 mmol of 4-quinoline-carboxaldehyde, and 0.125 mmol of 4-(trifluoro-methanethio) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 9.4 mg of expected product are obtained. EIMS ([M+H]+): 446 RT = 4.58 min Example 44 : Preparation of 5,5-dimethyl-1-(3-methylpyrid-4-ylmethyl) -3- (4-trifluoromethoxyphenyl) -imidazolidine-2,4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of Fmoc-AIB- (OH) , 0.25 mmol of 3-methyl-4-pyridinecarboxaldehyde and 0.125 mmol of 4-(trifluoro-methoxy) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 5.5 mg of expected product are obtained. EIMS ([M+H]+): 394 RT = 4.06 min Example 45 : Preparation of 5,5-dimethyl-l-(3-methylpyrid-4-ylmethyl) -3- (4-trifluoromethylsulfanyl-phenyl)imidazolidine-2,4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of Fmoc-AIB-(OH), 0.25 mmol of 3-methyl-4-pyridinecarboxaldehyde and 0.125 mmol of 4-(trifluoro-methanethio) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 13.1 mg of expected product are obtained. EIMS ([M+H]+): 410 RT = 4.3 0 min Example 46 : Preparation of 5,5-dimethyl-1-(3-methylpyrid-4-ylmethyl) -3- (4-trifluoromethanesulfonyl-phenyl)imidazolidine-2,4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of Fmoc-AIB-(OH) , 0.25 mmol of 3-methyl-4-pyridinecarboxaldehyde and 0.125 mmol of 4-(trifluoro-methanesulfonyl)aniline, in the same way as in Example 1. After purification by preparative LC-MS, 9.6 mg of expected product are obtained. EIMS ([M+H]+): 442 RT = 4.18 min Example 47 : Preparation of 1- (3-hydroxypyrid-4-ylmethyl)-5,5-dimethyl-3-(4-trifluoromethoxyphenyl)-imidazolidine-2,4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of Fmoc-AIB-(OH) , 0.25 mmol of 3-hydroxy-4-pyridinecarboxaldehyde and 0.125 mmol of 4-(trifluoro-methoxy) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 6.9 mg of expected product are obtained. EIMS ( [M+H] +) : 394. RT = 4.15 min Example 48 : Preparation of 1-(3-hydroxypyrid-4-ylmethyl) -5, 5-dimethyl-3- (4-trifluoromethylsulfanyl-phenyl)imidazolidine-2,4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of Fmoc-AIB- (OH) , 0.25 mmol of 3-hydroxy-4-pyridinecarboxaldehyde and 0.125 mmol of 4-(trifluoro-methanethio) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 9.7 mg of expected product are obtained. EIMS ([M+H]+): 412 RT = 4.3 9 min Example 49 : Preparation of 1-(3-hydroxypyrid-4-ylmethyl)-5,5-dimethyl-3-(4-trifluoromethanesulfonyl-phenyl)imidazolidine-2,4-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of Fmoc-AIB- (OH) , 0.25 mmol of 3-hydroxy-4-pyridinecarboxaldehyde and 0.125 mmol of 4-(trifluoro-methanesulfonyl)aniline, in the same way as in Example 1. After purification by preparative LC-MS, 15.2 mg of expected product are obtained. EIMS ([M+H]+): 444 RT = 4.3 0 min Example 50 : Preparation of 4-quinol-4-ylmethyl-6 -(4-trifluoromethoxyphenyl)-4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of Fmoc-ACPC- (OH) , 0.25 mmol of 4-quinoline-carboxaldehyde and 0.125 mmol of 4-(trifluoromethoxy)-aniline, in the same way as in Example 1. After purification by preparative LC-MS, 4.1 mg of expected product are obtained. EIMS ([M+H]+): 428 RT = 4.24 min Example 51 : Preparation of 4-(3-methylpyrid-4-ylmethyl)-6-(4-trifluoromethoxyphenyl)-4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of Fmoc-ACPC- (OH) , 0.25 mmol of 4-pyridine-carboxaldehyde and 0.125 mmol of 4-(trifluoromethoxy)-aniline, in the same way as in Example 1. After purification by preparative LC-MS, 3 mg of expected product are obtained. EIMS ( [M+H]+) : 392 RT = 3.95 min Example 52 : Preparation of 4-(3-methylpyrid-4-ylmethyl)-6-(4-trifluoromethylsulfanylphenyl)-4,6-diazaspiro[2.4]-heptane-5#7-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of Fmoc-ACPC- (OH) , 0.25 mmol of 3-methyl-4-pyridinecarboxaldehyde and 0.125 mmol of 4-(trifluoro-methanethio) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 5 mg of expected product are obtained. EIMS ([M+H]+): 408 RT = 4.24 min Example 53 : Preparation of 4-(3-methylpyrid-4-ylmethyl)-6-(4-trifluoromethanesulfonylphenyl)-4,6-diazaspiro [2.4]-heptane-5,7-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of Fmoc-ACPC-(OH) , 0.25 mmol of 3-methyl-4-pyridinecarboxaldehyde and 0.125 mmol of 4-(trifluoro-methanesulfonyl)aniline, in the same way as in Example 1. After purification by preparative LC-MS, 1.9 mg of expected product are obtained. EIMS ([M+H]+): 440 RT = 4.11 min Example 54 : Preparation of 4-(3-hydroxypyrid-4-ylmethyl)-6-(4-trifluoromethoxyphenyl)-4,6-diazaspiro-[2.4]heptane-5,7-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of Fmoc-ACPC-(OH) , 0.25 mmol of 3-hydroxy-4-pyridinecarboxaldehyde and 0.125 mmol of 4-(trifluoro-methoxy) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 5.5 mg of expected product are obtained. EIMS ([M+H]+): 394 RT = 4.04 min Example 55 : Preparation of 4-(3-hydroxypyrid-4-ylmethyl)-6-(4-trifluoromethylsulfanylphenyl)-4,6-diazaspiro[2.4]heptane-5f7-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of Fmoc-ACPC- (OH) , 0.25 mmol of 3-hydroxy-4-pyridinecarboxaldehyde and 0.125 mmol of 4-(trifluoro-methanethio) aniline, in the same way as in Example 1. After purification by preparative LC-MS, 0.7 mg of expected product is obtained. EIMS ([M+H]+): 410 RT = 4.34 min Example 56 : Preparation of 4-(3-hydroxypyrid-4-ylmethyl)-6-(4-trifluoromethanesulfonylphenyl)-4,6-diazaspiro[2.4]heptane-5,7-dione trifluoroacetate The compound is prepared from 0.05 mmol of resin, 0.15 mmol of Fmoc-ACPC- (OH) , 0.25 mmol of 3-hydroxy-4-pyridinecarboxaldehyde and 0.125 mmol of 4-(trifluoro-methanesulfonyl)aniline, in the same way as in Example 1. After purification by preparative LC-MS, 2.5 mg of expected product are obtained. EIMS ([M+H]+): 442 RT = 4.17 min Example 57 : Preparation of 5-methyl-l-quinol-4-ylmethyl-3- (4-trif luoromethanesulfonylphenyl) dihydropyrimidine-2,4-dione 58 8 mg (1 mmol) of Wang polystyrene resin (1.7 mmol/g) are washed with 2 x 5 ml of DMF, 1 x 5 ml of DCM and then treated with a solution of 0.49 g of N-Fmoc-3-amino-2-(R,S)-methyl-propionic acid (1.5 mmol), 0.24 g of pyridine (3 mmol) in 5 ml of DMF, immediately followed by 0.31 g of 2,6-dichlorobenzoyl chloride (dropwise addition to control the exothermicity). The reaction mixture is stirred overnight at room temperature. The mixture is filtered and the resin is then washed with 1 x 5 ml of DMF, 1 x 5 ml of DCM and 2 x 5 ml of DMF and then treated with 5 ml of a 10% solution of piperidine in DMF. The resin is then washed with 2 x 5 ml of DMF, 1 x 5 ml of DCM, 1x5 ml of DMF, 1 x 5 ml of DMF, 4 x 5 ml of DCM, 4 x 5 ml of MeOH and dried under vacuum. 0.94 g of 4-quinolinecarboxaldehyde (6 mol) in 16 ml of a 50/50 mixture of THF/TMOF is added to the resin, which is stirred overnight. The resin is then washed 3 times with 5 ml of the same THF/TMOF mixture and then treated with 12 ml of a 1M solution of sodium cyanoborohydride in THF (12 mmol) in the presence of 1.2 ml of MeOH and 0.12 ml of acetic acid. After stirring overnight at room temperature, the resin is washed with 1 x 5 ml of THF, 4x 5 ml of a 30% solution of acetic acid in DMF, 1 x 5 ml of MeOH, 1 x 5 ml of THF, 1 x 5 ml of DMF, 1 x 5 ml of THF, 1 x 5 ml of MeOH and dried under vacuum. In parallel, 0.121 g of triphosgene (0.41 mmol) in 1 ml of DCM is added dropwise to a solution of 0.281 g of 4-(trifluoromethanesulfonyl)aniline (1. 25 mmol) and 0.1 g of pyridine (1.25 mmol) in 2 ml of DCM. After stirring for 15 minutes at room temperature, the same amount of pyridine is added, followed by the resin previously prepared. The mixture is stirred overnight and then filtered. The resin is washed with 1 x 5 ml of MeOH, 1 x 5 ml of THF, 1x5 ml of MeOH, 1x5 ml of DMF, 1 x 5 ml of THF, 1 x 5 ml of MeOH and 3 x 5 ml of THF and dried under vacuum. The resin is then treated with 154 mg of DBU (1 mmol) in 5 ml of DCM and stirred overnight. Finally, the dihydrouracil is obtained by treating the resin with 5 ml of 2% solution of acetic acid in THF. After purification by preparative HPLC, 90 mg of expected product are isolated. EIMS ( [M+H]+) : 477 RT = 1.83 min (20-100% ACN/H20 gradient over 5 minutes) Example 58 : (S)-5-Methyl-l-quinol-4-ylmethyl-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione This example describes a novel preparation of Example 5 above. A mixture of 0.71 g of ethyl (S)-2-[(quinol-4-rlmethyl)amino]propanoate and. 1.42 g of 4-(trifluoro-lethanesulf anylphenyl) isocyanate in 15 ml of THF is stirred for 15 hours at room temperature under an argon itmosphere. After evaporating off the solvent under reduced pressure, 2 0 ml of dichloromethane are added. The precipitate is filtered off. The filtrate is concentrated inder reduced pressure and the residue is purified by Elash chromatography (Si02, CH2C12 and then CH2C12/MeOH, 35/5 by volume as eluent, Ar). 0.69 g of (S)-5-methyl-l-3uinol-4-ylmethyl-3-(4-trifluoromethanesulfanylphenyl)-imidazolidine-2,4-dione is isolated in the form of a tfhite powder. [a]D= -33.1° +/- 0.8° (MeOH) Mass: EI m/z = 431 M+. base peak m/z = 143 [C10H9N]+. 1H NMR spectrum (400 MHz, (CD3)2SO d6, 5 in ppm) : 1.42 (d, J = 5.5 Hz : 3H) ; 4.35 (q, J = 5.5 Hz: 1H) ; 5.08 (d, J = 17 Hz : 1H) ; 5.25 (d, J = 17 Hz : 1H) ; 7.65 (d, J = 5 Hz : 1H) ; from 7.65 to 7.75 (mt : 1H) ; 7.70 (d, J = 8.5 Hz : 2H) ; 7.83 (broad t, J = 8 Hz : 1H) ; 7.89 (d, J = 8.5 Hz : 2H) ; 8.10 (broad d, J = 8.5 Hz : 1H) ; 8.25 (broad d, J = 8.5 Hz : 1H) ; 8.90 (d, J = 5Hz : 1H). Ethyl (S)-2- [ (quinol-4-ylmethyl)amino]propanoate (P-31397-073-1) A mixture of 2 g of L-alanine ethyl ester in hydrochloride form and 1.83 ml of triethylamine in 30 ml of dichloromethane is stirred at room temperature for 10 minutes. Next, 2.05 g of quinoline-4-carbaldehyde are added. The reaction medium is stirred at room temperature for 15 hours and then concentrated under reduced pressure. 35 ml of ethanol are then added; the solution is cooled to 0°C and 0.4 9 g of sodium borohydride is then added portionwise. Stirring is continued for 15 hours at room temperature. The precipitate formed is filtered off; the filtrate is concentrated under reduced pressure. The residue is purified by flash chromatography on a column (Si02, CH2C12/MeOH/ 95/5 by volume as eluent, Ar). 0.71 g of ethyl (S)-2- [ (quinol-4-ylmethyl)amino]propanoate is obtained in the form of a pink oil. Mass: EI m/z = 258 M+. m/z = 185 [M - COOCH2CH3]+ base peak m/z = 142 [C10H8N]+ 1H NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm) : 1.22 (t, J = 7 Hz : 3H) ; 1.28 (d, J = 7 Hz : 3H) ; 2.72 (unresolved peak : 1H) ; 3.42 (mt : 1H) / from 4.00 to 4.20 (mt : 1H) ; 4.13 (q, J = 7 Hz : 2H) ; 4.27 (broad d, J = 16 Hz : 1H) / 7.55 (broad d, J = 5 Hz : 1H) ; 7.64 (ddd, J = 8.5 - 7.5 and 1 Hz : 1H) ; 7.77 (ddd, J = 8.5 -7.5 and 1 Hz : 1H) ; 8.04 (broad d, J = 8.5 Hz : 1H) ; 8.22 (broad d, J = 8.5 Hz : 1H) ; 8.86 (d, J = 5 Hz : 1H) . Example 59 : 5,5-Dimethyl-l-quinol-4-ylmethyl-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione : This example describes a novel preparation of Example 42 above. The product is prepared according to the procedure described in Example 58 with 600 mg of methyl 2-methyl-2-t(quinol-4-ylmethyl)amino]propanoate instead of ethyl (S)-2-[(quinol-4-ylmethyl)amino]propanoate used in Example 58 and 1.114 g of 4-(trifluoromethoxyphenyl) isocyanate instead of 4-(trifluoromethanesulfanylphenyl) isocyanate used in Example 58. After purification by flash chromatography on a column (Si02, CH2C12 as eluant, Ar) and then a second purification by flash chromatography on a column (Si02, 60/4 0 cyclohexane/EtOAc by volume as eluent, Ar) , 710 mg of the desired product are obtained. Mass: EI m/z = 429 M+. base peak m/z = 414 [M - CH3]+ m/z = 359 [M - C4H60]+. 1H NMR spectrum (300 MHz, (CD3)2SO d6, 8 in ppm) : 1.46 (s : 6H) ; 5.16 (s : 2H) ; 7.55 (broad d, J = 8.5 Hz : 2H) ; 7.65 (d, J = 5 Hz ; 1H) ; 7.69 (d, J = 8.5 Hz : 2H) ; 7.70 (mt : 1H) ; 7.83 (ddd, J = 8 - 7.5 and 1.5 i Hz : 1H) ; 8.09 (broad d, J = 8.5 Hz : 1H) ; 8.27 (broad d, J = 8.5 Hz : 1H) ; 8.88 (d, J = 5 Hz : 1H). Preparation of methyl 2- ( (quinol-4-ylmethyl)amino)-propanoate A mixture of 1.5 g of methyl ot-aminoisobutyrate hydrochloride and 1.4 ml of triethylamine in 30 ml of dichlorome thane is stirred at 0°C for 2 0 minutes. Next, 1 g of magnesium sulfate and 1.5 g of quinoline-4-carbaldehyde are added. Stirring is continued for 15 hours at room temperature and the mixture is then concentrated under reduced pressure. The residue is taken up in 35 ml of methanol and the solution obtained is cooled to 0°C. 0.4 g of sodium borohydride is added portionwise and stirring is continued at room temperature for 15 hours. The precipitate formed is filtered and the filtrate is concentrated under reduced pressure. The residue obtained is purified by recrystallization from diisopropyl ether. 600 mg of expected product are obtained in the form of a pink oil. Mass: DCI m/z = 259 [M+H] + m/z = 199 [M+H- HC00CH3]+ 1H NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm) : 1.36 (s : 6H) ; 2.68 (broad t, J = 7 Hz : 1H) ; 3.69 (s : 3H) ; 4.11 (d, J = 7 Hz : 2H) ; 7.60 (broad d, J = 5 Hz : 1H) ; 7.63 (ddd, J = 9 - 8.5 and 1 Hz : 1H) ; 7.76 (ddd, J = 9 - 8.5 and 1 Hz : 1H) ; 8.03 (broad d, J = 8.5 Hz : 1H) ; 8.20 (broad d, J = 8.5 Hz : 1H) ; 8.85 (d, J = 5 Hz : 1H). Example 60 : 5,5-dimethyl-1-(3-chloro-6-methoxyquinol-4-ylmethyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione The product is prepared according to the procedure described in Example 59, starting with 180 mg of methyl 2-methyl-2- [ (3-chloro-6-methoxyquinol-4-ylmethyl)amino]-propanoate instead of methyl 2-methyl-2-[(quinol-4-ylmethyl) amino] propanoate used in Example 59 and 267 mg of 4-(trifluoromethoxy)phenyl isocyanate. After purification by flash chromatography on a column (Si02, 80/20 cyclohexane/EtOAc by volume as eluent, Ar), 13 7 mg of the expected product are obtained. Mass: EI m/z = 493 M+. isotopic band of the peak monochloro m/z = 458 [M - Cl]+ base peak 1H NMR spectrum (300 MHz, (CD3)2SO d6, 8 in ppm) : 1.27 (S : 6H) ; 3.89 (s : 3H) ; 5.27 (s : 2H) ; 7.48 (dd, J = 9 and 3 Hz : 1H) ; 7.56 (broad d, J = 8.5 Hz : 2H) ; 7.68 (dt, J = 8.5 and 2 Hz : 2H) ; 7.79 (d, J = 3 Hz : 1H) ; 8.01 (d, J = 9 Hz : 1H) ; 8.80 (s : 1H). Preparation of methyl 2-methyl-2- [ (3-chloro-6- methoxyquinol-4-ylmethyl) amino] propanoate (P-31397-099-1) The product is prepared according to the procedure described in Example 59, starting with 1 g of methyl a-aminoisobutyrate hydrochloride, 1.25 g of (3-chloro-6-methoxy)quinoline-4-carbaldehyde instead of quinoline-4-carbaldehyde used in Example 59, 0.66 g of triethylamine and 250 mg of sodium borohydride. After purification by flash chromatography (Si02, 70/30 cyclohexane/EtOAc by volume as eluent, Ar), 180 mg of the expected product are obtained. Mass: EI m/z = 322 M+. isotopic band of the peak monochloro m/z = 2 63 [M-COOCH3]+ base peak isotopic band of the monochloro peak m/z = 206 [M-C5H10O2N]+ isotopic band of the monochloro peak 1H NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm) : 1.39 (s : 6H) ; 2.47 (broad t, J = 7.5 Hz : 1H) ; 3.74 (s : 3H) ; 3.98 (s : 3H) / 4 . 04 (d, J = 7,5 Hz : 2H) ; 7.46 (dd, J = 9 and 3 Hz : 1H) ; 7.66 (d, J = 3 Hz : 1H) ; 5 7.97 (d, J = 9 Hz : 1H) ; 8.71 (s : 1H). Preparation of (3-chloro-6-methoxyquinoline) -4- carbaldehyde (P-31397-097-1) A solution of 2 g of 4-bromo-3-chloro-6-methoxyquinoline in 50 ml of THF is cooled to -78°C. i 6.9 ml of a 1.6 M solution of nBuLi in dioxane are added. The solution is stirred for 2 hours at this temperature and 1.7 ml of DMF are then added. The mixture is stirred at -60°C for 2 hours 30 minutes and the reaction medium is then allowed to warm to room temperature. 2 00 ml of water are then added. The organic phase is extracted with 200 ml of ethyl acetate, washed with 5 x 200 ml of water, dried over magnesium sulfate and concentrated under reduced pressure. The residue obtained is purified by flash chromatography on a column (Si02, 8 0/20 cyclohexane/EtOAc by volume as eluent, Ar) . 1.2 g of the expected product are obtained in the form of a yellow powder. Mass: EI m/z = 221 M+. base peak, isotopic band of the monochloro m/z = 193 [M-CO] +. isotopic band of the monochloro peak m/z = 150 [M-C3H302]+ isotopic band of the monochloro peak 1H NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm) : 3.96 (s : 3H) ; 7.56 (dd, J = 9 and 3 Hz : 1H) ; 8.07 (d, J = 9 Hz : 1H) ; 8.22 (d, J = 3 Hz : 1H) ; 8.93 (s : 1H) ; 10.77 (S : 1H). Preparation of 4-bromo-3-chloro-6-methoxyquinoline is described in French patent FR 2 816 618 in Example 1. Example 61 : 5,5-Dimethyl-l-pyrid-4-ylmethyl-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione 0.764 g of 4-(trifluoromethanesulfanylphenyl) isocyanate is added to a solution of 0.726 g of methyl 2-methyl-2-[(pyrid-4-ylmethyl)amino]propanoate in 10 ml of tetrahydrofuran. The reaction medium is stirred under an argon atmosphere for about 3 days at a temperature in the region of 20°C. The reaction mixture is taken up in ethyl acetate, washed successively with water and then with saturated sodium chloride solution. The organic phase is dried over magnesium sulfate and then concentrated under reduced pressure. The residue thus obtained is purified by flash chromatography on an AIT cartridge of reference FC-50SI filled with 50 g of silica conditioned and eluted with dichloromethane at a flow rate of 10 ml per minute. The fractions between 100 and 2 80 ml are concentrated under reduced pressure, the residue obtained is taken up in ethyl ether and the insoluble material is filtered off. 700 mg of 5,5-dimethyl-l-pyrid-4-ylmethyl-3-(4-trifluoromethanesulf anylphenyl) imidazolidine-2,4-dione are thus obtained in the form of a white powder, the characteristics of which are as follows: 1H NMR spectrum (300 MHz, (CD3)2SO d6, 8 in ppm) : 1.43 (s : 6H) ; 4.66 (s : 2H) ; 7.44 (broad d, J = 6 Hz : 2H) ; 7.69 (d t, J = 8.5 and 2.5 Hz : 2H) / 7.87 (broad d, J = 8.5 Hz : 2H) ; 8.55 (dd, J = 6 and 1.5 Hz : 2H) . Mass IE m/z=395 M+. base peak m/z=380 (M-CH3)+ m/z=219 C8H4NOSF3+. m/z=92 C6H6N+ Preparation of methyl 2-methyl-2-[(pyrid-4-ylmethyl)-amino]propanoate (P-31402-151-1) 1.04 ml of triethylamine and then 0.659 g of pyridine-4-carbaldehyde are successively added to a solution of 0.945 g of methyl a-aminoisobutyrate hydrochloride in 28 ml of dichloroethane. The reaction mixture is stirred overnight at a temperature in the region of 20°C. The mixture is purified by filtration on Merck Lichroprep aminopropyl-grafted silica. The filtrate is concentrated under reduced pressure and the residue thus obtained is taken up 2 5 ml of methanol, 0.3 72 g of sodium borohydride is added. The reaction mixture is stirred for 4 8 hours at a temperature in the region of 20°C and then poured into a mixture of a normal solution of sodium hydroxide/ice. The mixture obtained is extracted three times with ethyl acetate. The organic phase is dried over magnesium sulfate and then concentrated under reduced pressure. 0.726 g of methyl 2-methyl-2-[(pyrid-4-ylmethyl)amino]propanoate is thus obtained in the form of an oil, the characteristics of which are as follows: 1H NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm) : 1.27 (s : 6H) ; 2.69 (broad t, J = 5 Hz : 1H) ; 3.64 (s : 3H) / 3.65 (d, J = 5 Hz: 2H) ; 7.35 (broad d, J = 6 Hz : 2H) ; 8.47 (dd, J = 6 and 1.5 Hz : 2H) . Mass IC m/z=209 MH+ base peak m/z=149 (M-C2H402)+ Example 62 : l-Pyrid-4-ylmethyl-3-(4-trifluoromethane-sulfanylphenyl)imidazolidine-2,4-dione 0.087 g sodium hydride is added to a solution of 0.300 g of 3- (4-trifluoromethy1sulfanylphenyl)imidazolidine-2, 4-dione in 6 ml of anhydrous dimethylformamide, under an inert atmosphere of argon at a temperature in the region of 20°C, stirring is continued at this temperature for 30 minutes, 0.152 ml of triethylamine and 0.2 74 g of 4-(bromomethyl)pyridine hydrobromide are successively added, followed by addition of ice-water 10 minutes later. The reaction mixture is placed on a cartridge 37 mm in diameter packed with 50 g of Amicon 5 0 }im octadecyl-grafted silica of ref. conditioned successively with a water/acetonitrile mixture (5/95, v/v) and then a water/acetonitrile mixture (95/5, v/v) . The elution was performed with a water/acetonitrile mixture (95/5, v/v) over 20 minutes, followed by a linear gradient from 5% to 95% of ace tonit rile over 60 minutes, at a flow rate of 10 ml/minute. The fractions between 580 and 630 ml are concentrated under reduced pressure. 0.220 g of 1-pyrid-4-ylmethyl-3- (4-trifluoromethylsulfanylphenyl)imidazol-idine-2,4-dione is thus obtained in the form of a white powder, the characteristics of which are as follows: 1H NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm) : 4.16 (s : 2H) ; 4.65 (s : 2H) ; 7.42 (broad d, J = 6 Hz : 2H) ; 7.64 (broad d, J = 8.5 Hz : 2H) ; 7.87 (broad d, J = 8.5 Hz : 2H) ; 8.57 (broad d, J = 6 Hz : 2H) . Mass IE m/z=367 M+. base peak m/z=219 C8H4NOSF3+. m/z=92 C6H6N+ The compound 3- (4-trifluoromethylsulfanylphenyl)imid-azolidine-2,4-dione is described in patent US 4 496 575. Example 63 : 5,5-Dimethyl-l-pyrid-4-ylmethyl-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione 0.042 g of sodium hydride is added to a solution of 0.150 g of 5,5-dimethyl-3-(4-trifluoromethoxyphenyl)imidazolidine-2 , 4-dione in 3 ml of anhydrous dimethylformamide, under an inert atmosphere of argon and at a temperature in the region of 20°C, stirring is continued at this temperature for 30 minutes, 0.094 ml of triethylamine and 0.132 g of 4-(bromomethyl)pyridine hydrobromide are successively added, followed by addition of ice-water 10 minutes later. The reaction mixture is placed on a cartridge 27 mm in diameter packed with 30 g of Amicon 50 /xm octadecyl-graf ted silica conditioned successively with a water/acetonitrile mixture (5/95, v/v) and then a water/acetonitrile mixture (95/5, v/v) . The elution was performed with a water/acetonitrile mixture (95/5, v/v) over 20 minutes, followed by a linear gradient from 5% to 95% of acetonitrile over 60 minutes, at a flow rate of 10 ml/minute. The fractions between 300 and 450 ml are concentrated under reduced pressure. 0.1 g of mixture is thus obtained, which is repurified on a cartridge of 37 mm in diameter packed with 50 g of Amicon 50 fim octadecyl-graf ted silica of ref. conditioned successively with a water/acetonitrile mixture (5/95, v/v) and then a water/acetonitrile mixture (95/5, v/v) . The elution was performed with a water/acetonitrile mixture (95/5, v/v) over 2 0 minutes, followed by a linear gradient from 5% to 95% of acetonitrile over 60 minutes, at a flow rate of 10 ml/minute. The fractions between 550 and 750 ml are concentrated under reduced pressure. 0 . 060 g of 5,5-dimethyl-l-pyrid-4-ylmethyl-3-(4-tri-fluoromethoxyphenyl)imidazolidine-2, 4-dione is thus obtained, the characteristics of which are as follows: 1H NMR spectrum (300 MHz, (CD3)2SO d6, 8 in ppm) : 1.42 (s : 6H) ; 4.65 (s : 2H) ; 7.44 (broad d, J = 6 Hz : 2H) ; 7.53 (broad d, J = 8.5 Hz : 2H) ; 7.64 (dt, J = 8.5 and 2.5 Hz : 2H) ; 8.54 (broad d, J = 6 Hz : 2H). Mass IE m/z=379 M+. base peak m/z=364 (M-CH3)+ m/z=203 C8H4N02F3+. m/z=92 C6H6N+ Preparation of 5,5-dimethyl-3-(4-trifluoromethoxyphenyl)-imidazolidine-2,4-dione A solution of 7.08 g of 4-trifluoromethoxyaniline in 50 ml of toluene is added over 15 minutes to a suspension of 8.7 g of diphosgene and 1 g of plant charcoal in 100 ml of toluene, at a temperature in the region of -20°C. The mixture is stirred until the temperature is in the region of 2 0°C, and then ref luxed for 3 hours. The mixture is cooled to a temperature in the region of 20°C and then filtered through Celite, 5 g of methyl a-aminoisobutyrate hydrochloride, 5 0 ml of toluene and 10 ml of triethylamine are added to the filtrate. The mixture thus obtained is refluxed for 16 hours and then cooled to a temperature in the region of 20°C. The precipitate is filtereed off and the filtrate is concentrated under reduced pressure, the residue obtained is purified by flash chromatography on a column packed with silica, conditioned and then eluted with a cyclohexane/ethyl acetate mixture (50/50, v/v) . The fractions containing the expected product are concentrated under reduced pressure, and 3.4 g of 5,5-dimethyl-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione are thus obtained, the characteristics of which are as follows: Mass IE m/z=288 M+. base peak m/z=273 (M-CH3)+ m/z=203 C8H4N02F3+. 1H NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm) : 1.42 (s : 6H) ; 7.49 (d, J = 9 Hz : 2H) ; 7.55 (d, J = 9 Hz : 2H) ; 8.63 (unresolved peak : 1H). Example 64: Preparation of 3-[4-(pentafluorothio)-phenyl]-5,5-dimethyl-l-quinolin-4-ylmethylimidazolidine-2,4-dione trifluoroacetate. The compound is prepared from 0.16 mmol of resin, 0.48 mmol of Fmoc-AIB-(OH), 1.12 mmol of 4-quinoline-carboxaldehyde and 0.4 mmol of 4-(pentafluorothio)-aniline, in the same manner as in Example 1. After purification by preparative LC-MS chromatography, 5 mg of the expected product are obtained. EIMS ( [M+H]+) : 472 Example 65: Preparation of 3-[4-(pentafluorothio)-phenyl]-5,5-dimethyl-l-pyrid-4-ylmethylimidazolidine-2,4-dione trifluoroacetate The compound is prepared from 0.16 mmol of resin, 0.48 mmol of Fmoc-AIB-(OH) , 1.12 mmol of 4-pyridine-carboxaldehyde and 0.4 mmol of 4-(pentafluorothio)-aniline, in the same manner as in Example 1. After purification by preparative LC-MS chromatography, 13.2 mg of the expected product are obtained. EIMS ( [M+H]+) : 422 Example 66: Preparation of 3-[4-(pentafluorothio)-phenyl]-l-quinolin-4-ylmethylimidazolidine-2,4-dione trifluoroacetate The compound is prepared from 0.1 mmol of resin, 0.3 mmol of N-Fmoc-Gly-(OH) , 0.5 mmol of 4-quinoline-carboxaldehyde and 0.25 mmol of 4-(pentafluorothio)-aniline, in the same manner as in Example 1. After purification by preparative LC-MS chromatography, 18 mg of the expected product are obtained. EIMS ( [M+H]+) : 444 Example 67: Preparation of 3-[4-(pentafluorothio)-phenyl]-l-pyrid-4-ylmethylimidazolidine-2,4-dione tri-fluoroacetate The compound is prepared from 0.1 mmol of resin, 0.3 mmol of N-Fmoc-Gly-(OH), 0.5 mmol of 4-quinoline-carboxaldehyde and 0.25 mmol of 4-(pentafluorothio) aniline, in the same manner as in Example 1, After purification by preparative LC-MS chromatography, 18 mg of the expected product are obtained. EIMS ( [M+H]+) : 394 Example 68: Preparation of 3-[4-(pentafluorothio)-phenyl]-l-pyrid-2-ylmethylimidazolidine-2# 4-dione tri-fluoroacetate The compound is prepared from 0.1 mmol of resin, 0.3 mmol of N-Fmoc-Gly-(OH) , 0.5 mmol of 4-quinoline-carboxaldehyde and 0.25 mmol of 4-(pentafluorothio)-aniline, in the same manner as in Example 1. After purification by preparative LC-MS chromatography, 9 mg of the expected product are obtained. EIMS ( [M+H]+) : 394 Example 69: Preparation of 3- [4-(pentafluorothio)-phenyl]-l-pyrid-3-ylmethylimidazolidine-2,4-dione tri-fluoroacetate The compound is prepared from 0.2 mmol of resin, 0.6 mmol of N-Fmoc-Gly-(OH) , 1 mmol of 4-quinoline-carboxaldehyde and 0.5 mmol of 4-(pentafluorothio)-aniline, in the same manner as in Example 1. After purification by preparative LC-MS chromatography, 42 mg of the expected product are obtained. EIMS ( [M+H] +) : 394 The 6 reaction schemes below describe the preparation of products of formula (I) according to the present invention/ especially among the products of Examples 70 to 178 that follow. Scheme 1 describes the preparation of hydantoin derivatives with amino substituents in the two positions of the pyridine ring (B2) . Procedures of Scheme 1 Step 1: (Syntheses described for X = S, analogous scheme for X = 0) . l-Isocyanato-4-trifluoromethylsulfanylbenzene (14.27 g, 65 mmol) is dissolved in 30 ml of dry CH2C12 and cooled to 0°C. 7.5 g (65 mmol) of N-ethylmorpholine are added, followed by 10 g (65 mmol) of methyl 2-amino-2-methylpropionate. The reaction is left to reach 25°C over a period of 6 hours and washed with water, and, after removal of the solvent, 21.8 g of the product methyl 2-methyl-2-[3-(4-trifluoromethyl-sulfanylphenyl)ureido]propionate 3 are isolated. Step 2: 30 g of methyl 2-methyl-2-[3-(4-trifluoromethyl-sulfanylphenyl)ureido]propionate 3 are dissolved in a mixture of 225 ml of 3N HC1 and 230 ml of dioxane, refluxed for 6 hours and, after cooling to 4°C, the product 5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl) imidazolidine-2,4-dione is isolated in the form of white crystals (24.14 g) . Step 3: 5,5-Dimethyl-3 -(4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione 3 (1 g, 3.29 mmol) is dissolved in 10 ml of DMF, 1.36 g of K2C03 (3 eq, 9.87 mmol) and 909 mg of 2-chloro-4-chloromethylpyridine (3.95 mmol, 1.2 eq) are added and the mixture is refluxed for 2 0 hours. The solvent is removed under vacuum and the residue is dissolved in CH2C12 and treated three times with active charcoal. After removal of the solvent, the product 1-(2-chloropyrid-4-ylmethyl)-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)imidazolidine-2,4-dione is obtained (3.2 g; 56%). Analytical data: MS (LC-MS): 429.05; retention time: 2.49 min. NMR: 1.4: s, 6H; 4.7: s, 2H; 7.45: m, 1H; 7.6: s, 1H; 7.7: d, 2H; 7.9: d, 2H; 8.4: m, 1H. Preparation of 2-chloro-4-chloromethylpyridine 10 g of 2-chloro-4-methylpyridine are dissolved in 3 0 ml of CH3CN and a mixture of AIBN (3 g) and NCS (30 g) is added. The resulting mixture is refluxed for 4 hours. After removal of the solvent, the crude product is purified further by distillation (boiling point: 70 °C, 20 mtorr). Step 4: General procedure for the palladium-catalyzed amination of the pyridine ring system in 1- (2-chloro-pyrid-4-ylmethyl)-5,5-dimethyl-3-(4-trifluoromethyl-sulfanylphenyl)imidazolidine-2,4-dione 100 mg (0.23 mmol) of 1-(2-chloropyrid-4-ylmethyl)-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)imidazolidine-2 , 4-dione, 20 mg of Pd(0Ac)2, 60 mg of XANTPHOS and 3 00 mg of Cs2C03 are transferred into a reaction tube with a screw stopper equipped with a rubber seal and an argon atmosphere is generated in the tube. 1.5 equivalents (0.35 mmol) of the appropriate amine or amide are dissolved in 10 ml of toluene, the solution is transferred into the reaction tube mentioned above and the resulting mixture is heated at 95°C for 6 to 10 hours depending on the reaction progress, which is monitored by LCMS. After filtration, the solvent is removed under vacuum and the crude product is further purified by chromatography on an HPLC system. Scheme 2 describes the preparation of urea and thiourea derivatives. Analytical data for N- {4- [5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazolidin-1-yl-methyl]pyrid-2-yl}acetamide: MS (LC-MS): 452.11; retention time: 1.82 min. NMR: 1.4: s, 6H; 2.05: s, 3H; 4.65: S, 2H; 7.1: m, 1H; 7.65: d, 2H; 7.85: d, 2H; 8.15: m, 1H; 8.25: m, 1H. Step 2: 500 mg (1.11 mmol) of N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazolidin-1-ylmethyl]pyrid-2-yl}acetamide are dissolved in MeOH, 1.5 mmol of NaOMe are added and the resulting mixture is refluxed for 4 hours. The solvent is removed, the residue is taken up in CH2C12/ washed twice with 10% NaHC03 solution and water, and the organic phase is evaporated off. 340 mg (75%) of 1- (2-aminopyrid-4-ylmethyl)-5,5-dimethyl-3- (4-trifluoromethylsulfanylphenyl) imidazolidine-2,4-dione are isolated in this manner. MS (LC-MS): 410.10; retention time: 1.57. NMR: 1.4: s, 6H; 4.4: s, 2H; 6.35: s, 2H; 6.4: m, 1H; 6.5: m, 1H; 7.65: d, 2H; 7.9: m, 3H. Step 3: General procedure, all the urea and thiourea derivatives are prepared in this manner. 10 0 mg of 1-(2-aminopyrid-4-ylmethyl)-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)imidazolidine-2,4-dione are dissolved in 5 ml of dioxane and 1.5 equivalents of the corresponding isocyanate or isothiocyanate are added. The reaction is stirred at slightly elevated temperature up to completion, which is monitored by LCMS. The solvent is removed, and further purification is obtained by chromatography on an HPLC system. R = alkyl, substituted alkyl, aryl, substituted aryl, alkyl-CO-, substituted alkyl-CO, aryl-CO-, substituted aryl-CO X = S or O Scheme 3 Step 1: (Syntheses described for X = S, analogous scheme for X = 0) 5,5-Dimethyl-3-(4-trifluoromethylsulfanylphenyl)imi-dazolidine-2,4-dione (1000 mg/3.29 mmol) is dissolved in 20 ml of DMF, Cs2C03 (3.21 g/9.9 mmol) and 2,6-dichloro-4-chloromethylpyridine (774 g/3.9 mmol) are added and the resulting mixture is heated at 80°C for 6 hours. The solvent is removed, the residue is dissolved in CH2C12 and washed three times with water. After evaporation of the solvent, the crude material is further purified by chromatography on an HPLC system. Step 2: General procedure for the Pd-catalyzed monoamination of 1-(2,6-dichloropyrid-4-ylmethyl)-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)imidazolid-ine-2,4-dione This step is identical to step 4 of Scheme 1, but only 1 equivalent of the corresponding amine or amide is used. Step 3: General procedure for the Pd-catalyzed bisamination of 1-(2,6-dichloropyrid-4-ylmethyl)-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)imidazolid-ine-2,4-dione This step is identical to step 4 of Scheme 1, but in this case 2.2 equivalents of the corresponding amine or amide are used. Het = aromatic or aliphatic heterocycle X = CI or Br Scheme 4: General procedure for the alkylation of 5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)imidazolid-ine-2,4-dione with aromatic or aliphatic heterocycles bearing a chloromethyl or bromomethyl substituent 5,5-Dimethyl-3-(4-trifluoromethylsulfanylphenyl)imi-dazolidine-2,4-dione (100 mg/0.33 mmol) is dissolved in 10 ml of DMF, Cs2C03 (321 mg/0.99 mmol) and 0.4 9 mmol (1.5 equivalents) of the corresponding aromatic or aliphatic heterocycle substituted with a chloromethyl or bromomethyl group is added, and the resulting mixture is heated at 80°C for 6 hours. The solvent is removed and the crude material obtained is further purified by chromatography on an HPLC system. Scheme 5 100 mg (0.23 mmol) of 1-(2-chloropyrid-4-ylmethyl)-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)imidazo-lidine-2,4-dione, 20 mg of Pd(OAc)2, 60 mg of XANTPHOS, 300 mg of Cs2C03 and 124 mg of Mo(CO)6 (2 eq) are transferred into a screw stoppered reaction tube with a rubber seal and an argon atmosphere is generated in the tube. 1.5 equivalents (0.35 mmol) of the appropriate amine and 212 mg of DBU are dissolved in 10 ml of toluene, this solution is transferred into the reaction tube mentioned above and the resulting mixture is heated at 95°C for 6 to 10 hours as a function of the reaction progress, which is monitored by LCMS. After filtration, the solvent is removed under vacuum and the crude product is further purified by chromatography on an HPLC system. Scheme 6 3 0 mg (0.05 mmol) of methyl 2-(3-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazolidin-1-ylmethyl]pyrid-2-yl}thioureido)benzoate are dissolved in 2 ml of MeOH, 0.1 mmol of NaOMe is added and the resulting mixture is stirred at room temperature overnight. After evaporating off the solvent, the crude material of 5,5-dimethyl-1-[2-(4-oxo-2-thioxo-l,4-dihydro-2H-quinazolin-3-yl)pyrid-4-ylmethyl] -3-(4-trifluoromethylsulf anylphenyl) imidazolidine-2,4-dione is further purified by chromatography on an HPLC system. Example 70: N-{4- [5,5-Dimethyl-2,4-dioxo-3-(4-tri-fluoromethylsulfanylphenyl)imidazolidin-l-ylmethyl]pyrid-2-yl}propionamide; compound with trifluoroacetic acid MS (LC-MS): 466.13, retention time: 1.83 min. NMR: 1.05: t, 3H; 1.40: S, 6H; 2.35: q, 2H; 4.65: s, 2H; 7.1: d, 1H; 7.65: d, 2H; 7.85: d, 2H; 8.15: S, 1H; 8.25: d, 1H. The synthesis is described in Scheme 1. Example 71: N-{4-[5,5-Dimethyl-2,4-dioxo-3-(4-tri-fluoromethylsulfanylphenyl) imidazolidin»l-ylmethyl]pyrid-2-yl}isobutyramide; compound with trifluoroacetic acid MS (LC-MS): 480.14, retention time: 1.93 min. NMR: 1.10: d, 6H; 1.40: s, 6H; 2 .75: s, 1H; 4.65: s, 2H; 7.15: d, 1H; 7.65: d, 2H; 7.85: d, 2H; 8.15: s, 1H; 8.25: d, 1H. The synthesis is described in Scheme 1. Example 72: N-{4- [5,5-Dimethyl-2,4-dioxo-3-(4-tri-fluoromethylsulfanylphenyl) imidazolidin-l-ylmethyl]pyrid-2-yl}-3-morpholin-4-ylpropionamide; compound with trifluoroacetic acid MS (LC-MS): 551.18, retention time: 1.54 min. NMR: 1.40: s, 6H; 2.85: m, 2H; 3.1: m, 2H; 3.4: m, 2H; 3.95: m, 2H; 4.65: s, 2H; 7.15: d, 1H; 7.65: d, 2H; 7.85: d, 2H; 8.15: s, 1H; 8.25: d, 1H. The synthesis is described in Scheme 1. Example 73: N-{4- [5,5-Dimethyl-2,4-dioxo-3-(4-tri- fluoromethylsulfanylphenyl)imidazolidin-1-ylmethyl]pyrid- 2-yl}-3-[4-(2-hydroxyethyl)piperazin-l-yl]propionamide MS (LC-MS): 594.22, retention time: 1.40 min. NMR: 1.40: s, 6H; 2.55 to 3.50: m, 12H; 4.65: S, 2H; 7.15: m, 1H; 7.65: d, 2H; 7.85: d, 2H; 8.15: S, 1H; 8.25: d, 1H. The synthesis is described in Scheme 1. Example 74: N-{4-[5,5-Dimethyl-2,4-dioxo-3-(4-tri- fluoromethylsulfanylphenyl)imidazolidin-l-ylmethyl]pyrid- 2-yl}-3-(4-methylpiperazin-l-yl)propionamide MS (LC-MS): 564.21, retention time: 1.41 min. NMR: 1.40: s, 6H; 2.55 to 3.50: m, 12H; 2.75: s, 3H; 4.65: s, 2H; 7.15: m, 1H; 7.65: d, 2H; 7.85: d, 2H; 8.15: S, 1H; 8.25: d, 1H. The synthesis is described in Scheme 1. Example 75: Cyclopropanecarboxylic acid {4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)-imidazolidin-l-ylmethyl]pyrid-2-yl}amide MS (LC-MS): 478.13, retention time: 1.99 min. NMR: 0.80: m, 4H; 1.15: t, 1H; 1.40: S, 6H; 4.65: s, 2H; 7.15: m, 1H; 7.65: d, 2H; 7.85: d, 2H; 8.15: S, 1H; 8.25: d, 1H. The synthesis is described in Scheme 1. Example 76: 5, 5-Dimethyl-l- [2- (pyrid-2-ylamino) pyrid-4-ylmethyl]-3-(4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione MS (LC-MS): 487.13, retention time: 1.85 min. NMR: 1.40: s, 6H; 4.65: s, 2H; 7.3: m, 4H; 7.65: d, 2H; 7.85: d, 2H; 8.05: s, 1H; 8.35: m, 1H. The synthesis is described in Scheme 1. Example 77: N-{4- [5,5-Dimethyl-2,4-dioxo-3-(4-tri- fluoromethylsulfanylphenyl)imidazolidin-l-ylmethyl]pyrid- 2-yl}-3-pyrrolidin-1-ylpropionamide MS (LC-MS): 535.19, retention time: 1.52 min. ' NMR: 1.40: s, 6H; 1.8: m, 2H; 2.0: m, 2H; 2.85: m, 2H; 3.0: m, 2H; 3.4: m, 2H; 3.5: m, 2H; 4.65: s, 2H; 7.2: m, 1H; 7.65: d, 2H; 7.85: d, 2H; 8.15: s, 1H; 8.40: m, 1H. The synthesis is described in Scheme 1. Example 78: 5,5-Dimethyl-1-{2-[3-(4-methylpiperazin-l-yl)propylamino]pyrid-4-ylmethyl}-3- (4-trifluoromethyl-sulfanylphenyl)imidazolidine-2,4-dione MS (LC-MS): 550.23, retention time: 1.52 min. NMR: 1.40: s, 6H; 2.6 to 3.5: m, 14H; 2.75: s, 3H; 4.65: s, 2H; 6.85: m, 1H; 6.95: m, 1H; 7.65: d, 2H; 7.9: m, 3H. The synthesis is described in Scheme 1. Example 79: 5,5-Dimethyl-1-{2-[3-(4-ethylpiperazin-l-yl)propylamine)]pyrid-4-ylmethyl}-3- (4-trifluoromethyl-sulfanylphenyl)imidazolidine-2,4-dione The synthesis is described in Scheme 1. Example 80: 1- [2- (3-Methoxyphenylamino)pyrid-4-ylmethyl]-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione MS (LC-MS): 516.14, retention time: 1.90 min. NMR: 1.40: s, 6H; 3.7: s, 3H; 4.65: s, 2H; 6.6: m, 1H; 6.9: m, 2H; 7.15: m, 1H; 7.2: m, 1H; 7.25: m, 1H; 7.65: d, 2H; 7.85: d, 2H; 8.05: s, 1H. The synthesis is described in Scheme 1. Example 81: N-{4- [5, 5-Dimethyl-2, 4-dioxo-3- (4-tariff luoromethylsulfanylphenyl) imidazolidin-l-ylmethyl]pyrid-2-yl}-3-(4-ethylpiperazin-l-yl)propionamide MS (LC-MS): 516.14, retention time: 1.90 min. NMR: 1.15: t, 3H; 1.40: S, 6H; 2.5 to 3.7: m, 14H; 4.65: s, 2H; 7.15: m, 1H; 7.65: d, 2H; 7.85: d, 2H; 8.15: s, 1H; 8.25: m, 1H. The synthesis is described in Scheme 1. Example 82: 5,5-Dimethyl-1-[2-(3-methyl-2-oxopyrrolidin-l-yl)pyrid-4-ylmethyl] -3- (4-trifluoromethyl-sulfanylphenyl)lmidazolldlne-2,4-dione; compound with trifluoroacetic acid MS (LC-MS): 492.14; retention time: 2.23 min. NMR: 1.15: d, 3H; 1.40: s, 6H; 1.60: m, 1H; 2.30: m, 1H; 2.70: m, 1H; 3 .80: m, 1H; 4.0: m, 1H; 4 .65: s, 2H; 7.15: m, 1H; 7.65: d, 2H; 7.85: d, 2H; 8.35: m, 2H. The synthesis is described in Scheme 1. Example 83 MS (LC-MS): 495.19; retention time: 1.43 min. The synthesis is described in Scheme 1. Example 84: 5,5-Dimethyl-1-[2-(4-pyrid-2-ylpiperazin-l-yl)pyrid-4-ylmethyl] -3- (4-trifluoromethylsulfanylphen-yl)imidazolidine-2,4-dione; compound with trifluoroacetic acid MS (LC-MS): 556.19; retention time: 1.56 min. The synthesis is described in Scheme 1. Example 85: N-{4- [5,5-Dimethyl-2,4-dioxo-3-(4-tri-fluoromethylsulfanylphenyl)imidazolidin-l-ylmethyl]pyrid-2-yl}-3-piperid-l-ylpropionamide; compound with trifluoroacetic acid MS (LC-MS): 549.22; retention time: 1.62 min. NMR: 1.45: s, 6H; 1.55: m, 3H; 1.80: m, 2H; 2.80: m, 4H; 3.3 to 3.5: m, 7H; 4.65: s, 2H; 7.15: m, 1H; 7.65: d, 2H; 7.85: m, 2H; 8.15: m, 1H; 8.3: m, 1H; 9.0: m, 1H. The synthesis is described in Scheme 1. Example 86: 1- [2- (3-Imidazol-l-ylpropylamino)pyrid-4-ylmethyl] -5, 5-dimethyl-3- (4-trifluoromethylsulfanyl-phenyl) imidazolidine-2,4-dione; compound with tri-fluoroacetic acid MS (LC-MS): 518.17/ retention time: 1.57 min. The synthesis is described in Scheme 1. Example 87: 1-[2-(4-Ethylpyrid-2-ylamino)pyrid-4-yl-methyl]-5,5-dimethyl-3-(4-trifluoromethylsulfanyl-phenyl)imidazolidine-2,4-dione MS (LC-MS): 515.16; retention time: 1.85 min. NMR: 1.15: t, 3H; 1.45: s, 6H; 2.7: q, 2H; 4.75: S, 2H; 7.1: broad s, 2H; 7.3: broad s 2HM; 7.65: d, 2H; 7.85: d, 2H; 8.25: s, 1H; 8.45: s, 1H. The synthesis is described in Scheme 1. Example 88: 1-[2-(6-Ethylpyrid-2-ylamino)pyrid-4-yl-methyl]-5,5-dimethyl-3-(4-trifluoromethylsulfanyl-phenyl)imidazolidine-2,4-dione MS (LC-MS): 515.16; retention time: 1.95 min. NMR: 1.15: t, 3H; 1.45: S, 6H; 2.7: q, 2H; 4.75: s, 2H; 7.1: broad s, 2H; 7.3: broad s 2HM; 7.65: d, 2H; 7.85: d, 2H; 8.25: s, 1H; 8.45: s, 1H. The synthesis is described in Scheme 1. Example 89: 5,5-Dimethyl-l-[2-(quinolin-2-ylamino)pyrid-4-ylmethyl]-3-(4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione MS (LC-MS): 537.14; retention time: 1.95 min. NMR: 1.45: s, 6H; 4.75: s, 2H; 7.4 to 7.6: m, 6H; 7.65: d, 2H; 7.85: d, 2H; 8.00: broad s, 1H; 8.50: broad s, 2H. The synthesis is described in Scheme 1. Example 90: 5,5-Dimethyl-l-[2-(4-methylpyrid-2-yl-amino)pyrid-4-ylmethyl] -3- (4-trifluoromethylsulfanyl-phenyl)imidazolidine-2,4-dione MS (LC-MS): 501.14; retention time: 1.80 min. NMR: 1.45: s, 6H; 2.4: S, 3H; 4.75: s, 2H; 7.1: m, 2H; 7.25: m, 2H; 7.65: d, 2H; 7.85: d, 2H; 8.20: broads, 1H; 8.45: broad s, 1H. The synthesis is described in Scheme 1. Example 91: 5,5-Dimethyl-1-[2-(6-methylpyrid-2-yl-amino)pyrid-4-ylmethyl] -3- (4-trifluoromethylsulfanyl-phenyl)imidazolidine-2,4-dione MS (LC-MS): 501.14; retention time: 1.85 min. NMR: 1.45: s, 6H; 2,55: s, 3H; 4.75: s, 2H; 7.1: m, 1H; 7.25: m, 2H; 7.4: s, 1H; 7.65: d, 2H; 7.85: m, 3H; 8.45: broad s, 1H. The synthesis is described in Scheme 1. Example 92: 1- [2-(3,5-Dichloropyrid-2-ylamino)pyrid-4-ylmethyl]-5,5-dimethyl-3-(4-trifluoromethylsulfanyl-phenyl)imidazolidine-2,4-dione MS (LC-MS): 555.05; retention time: 1.96 min. NMR: 1.45: s, 6H; 4.70: S, 2H; 7.1: m, 1H; 7.20: m, 1H; 7.65: d, 2H; 7.85: m, 3H; 8.30: m, 3H. The synthesis is described in Scheme 1. Example 93: 1-[2-(4,6-Dimethylpyrid-2-ylamino)pyrid-4-ylmethyl] -5, 5-dimethyl-3- (4-trif luoromethylsulfanyl- phenyl) imidazolidine-2, 4-dione F MS (LC-MS): 515.16; retention time: 2.00 min. NMR: 1.45: S; 2.35: s, 3H; 2.6: S, 3H; 6H; 4.75: s, 2H; 7.0: m, 2H; 7.35: m, 2H; 7.70: d, 2H; 7.9: dt 2H; 8.40: broad s, 1H. The synthesis is described in Scheme 1. NMR: 1.45: S; 4.70: s, 2H; 7.15: m, 1H; 7.25: m, 1H; 7.65: d, 2H; 7.9: d, 2H; 8.10: broad s, 2H; 8.40: s, 1H; 8.50: m, 2H. The synthesis is described in Scheme 1. Example 96: 5,5-Dimethyl-1-[2-(pyrid-3-ylamino)pyrid-4-ylmethyl] -3- (4-trifluoromethylsulfanylphenyl) imidazol-idine-2,4-dione MS (LC-MS): 487.13; retention time: 1.69 min. NMR: 1.45: s; 4.60: s, 2 H; 6.95: s, 1H; 7.05: s, 1H; 7.7: d, 2H; 7.8: m, 1H; 7.85: d, 2H; 8.25: s, 1H; 8.35: s, 1H; 8.45: m, 1H; 9.4: s, 1H. The synthesis is described in Scheme 1. Example 97: N-{4- [5,5-Dimethyl-2,4-dioxo-3-(4-tri- fluoromethylsulfanylphenyl)imidazolidin-l-ylmethyl]pyrid- 2-yl}-3-(2-oxoazepan-l-yl)propionamide. r- MS (LC-MS): 577.20; retention time: 2.00 min. NMR: 1.45: s, 6H; 1.5: m, 4H; 1.55: m, 2H; 2.35: m, 2H; 2.6: m, 4H; 3.3 m, 2H; 4.65: S, 2H; 7.15: S, 1H ; 7.65: d, 2H; 7.85: d, 2H; 8.1: s, 1H; 8.35: s, 1H. The synthesis is described in Scheme 1. Example 98: 3- (Benzylmethylamino)-N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazolidin-1-ylmethyl]pyrid-2-yl}propioneunide F MS (LC-MS): 585.20, retention time: 1.73 min. NMR: 1.45: s, 6H; 2.2: s, 3H; 2.95: m, 2H; 3.3: m, 1H; 4.3: m, 1H; 4.4: m, 1H; 4.65: s, 2H; 7.2: s, 1H; 7.45: m, 2H; 7.50: m, 2H; 7.65: d, 2H; 7.85: d, 2H; 8.1: m, 1H; 8.3: m, 1H. The synthesis is described in Scheme 1. Example 99: N-{4-[5,5-Dimethyl-2,4-dioxo-3-(4-tri-fluoromethylsulfanylphenyl) imidazolidin-l-ylmethyl]pyrid-2-yl}-2-pyrrolidin-l-ylacetamide MS (LC-MS): 521.17, retention time: 1.68 min. NMR: 1.45: s, 6H; 1.85: m, 2H; 2.00: m, 2H; 3.1: m, 2H; 4.25: m, 2H; 4.7: s, 2H; 7.25: m, 1H; 7.65: d, 2H; 7.85: d, 2H; 8.1: broad s, 1H; 8.3: s, 1H. The synthesis is described in Scheme 1. Example 100: N«{4- [5,5-Dimethyl-2,4-dioxo-3-(4-tri- fluoromethylsulfanylphenyl)imidazolidin-l-ylmethyl]pyrid- 2-yl}-2-(4-pyrid-2-ylpiperazin-l-yl)acetamide MS (LC-MS): 613.21, retention time: 1.60 min. NMR: 1.45: s, 6H; 3.3: broad m, 4H; 4.35: broad m, 4H; 4 .65 : s, 2H; 6.7: m, 1H; 6.9: m, 1H; 7.25: s, 1H; 7.65, m + d: 3H; 7.85: d, 2H; 8.15: m, 2H; 8.35: s, 1H. The synthesis is described in Scheme 1. Example 101: 2- [ (2-Dimethylaminoethyl)methylamino]-N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethyl-sulfanylphenyl)imida20lidin-l-ylmethyl]pyrid-2-yl}-acetamide MS (LC-MS): 552.21, retention time: 1.52 min. NMR: 1.45: s, 6H; 2.75: s, 6H; 4.65: s, 2H; 7.20: m, 1H; 7.65: d, 2H; 7.85: d, 2H; 8.15: S, 1H; 8.30: m, 1H. The synthesis is described in Scheme 1. Example 102: 3- [ (2-Dimethylaminoethyl)methylamino] -N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethyl-sulfanylphenyl) imidazolidin-l-ylmethyl]pyrid-2-yl}-propionamide MS (LC-MS): 566.23, retention time: 1.37 min. NMR: 1.45: s, 6H; 2.75: S, 6H; 2.8 to 3.4: broad m, 8H; 7.20: m, 1H; 7.65: d, 2H; 7.85: d, 2H; 8.15: s, 1H; 8.30: m, 1H. The synthesis is described in Scheme 1. Example 103: 5,5-Dimethyl-1-[2-(5-methylpyrid-2-yl-amino)pyrid-4-ylmethyl] -3- (4-trifluoromethylsulfanyl-phenyl) imidazolidine-2, 4-dione MS (LC-MS): 501.14, retention time: 1.83 min. NMR: 1.45: s, 6H; 2.3: s, 3H; 4.7: s, 2H; 7.3: m, 3H; 7.7: d, 2H; 7.9: d, 2H; 8.2: m, 1H; 8.35: m, 1H. The synthesis is described in Scheme 1. Example 104: N-{4- [5,5-Dimethyl-2,4-dioxo-3-(4-tri-fluoromethylsulfanylphenyl)imidazolidin-l-ylmethyl]pyrid-2-yl}-3,5-dimethoxybenzamide; compound with tri-fluoroacetic acid MS (LC-MS): 574.78, retention time: 2.34 min. NMR: 1.45: s, 6H; 2.3: s, 3H; 4.7: S, 2H; 6.7: s, 2H; 7.2: m, 2H; 7.25: m, 1H; 7.7: d, 2H; 7.9: d, 2H; 8.2: m, 1H; 8.3: m, 1H. The synthesis is described in Scheme 1. Example 105: 2- (Benzylmethylamino) -N-{4- [5, 5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazol-idin-l-ylmethyl]pyrid-2-yl}acetemiide; compound with trifluoroacetic acid MS (LC-MS): 574.78, retention time: 2.34 min. NMR: 1.45: s, 6H; 2.8: s, 4.0 to 4.4: m, 4H; 4.7: s, 2H; 7.2: m, 1H; 7.4: m, 2H; 7.5: m, 2H; 7.7: d, 2H; 7.9: d, 2H; 8.1: m, 1H; 8.3: m, 1H. The synthesis is described in Scheme 1. MS (LC-MS): 488.12, retention time: 1.63. NMR: 1.45: s, 6H; 4.7: s, 2H; 7.1: m, 1H; 7.6: m, 1H; 7.65: d, 2H; 7.9: d, 2H; 8.2: s, 1H; 8.3: m, 2H; 9.0: S, 1H. The synthesis is described in Scheme 1. Example 107: N-{4- [5,5-Dimethyl-2,4-dioxo-3-(4-tri- f luoromethylsulf anylphenyl) imidazolidin-1-ylmethyl] pyrid- 2-yl}-2-phenylbutyramide; compound with trifluoroacetic acid MS (LC-MS): 566.18, retention time: 2.43. NMR: 0.7: t, 3H; 1.4: s, 6H; 1.7: m, 1H; 2.05: m, 1H; 4.6: S, 2H; 7.1: S, 1H; 7.25: m, 1H; 7.3: m, 1H; 7.4: m, 2H; 7.65: d, 2H; 7.85: d, 2H; 8.15: s, 1H; 8.25: m, 1H. The synthesis is described in Scheme 1. Example 108: N-{4- [5,5-Dimethyl-2,4-dioxo-3-(4-tri-fluoromethylsulfanylphenyl)imidazolidin-l-ylmethyl]pyrid-2-yl}-3-(3-methylpiperid-l-yl)propionamide; compound with trifluoroacetic acid MS (LC-MS): 563.22, retention time: 1.62. The synthesis is described in Scheme 1. Example 109: 1- [2- (4-Methoxyphenylamino)pyrid-4-ylmeth-yl]-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione MS (LC-MS): 517.1; retention time: 1.74. NMR: 1.4: s, 6H; 4.6: s, 2H; 6.85: broad s, 1H; 7.0: m, 1H; 7.4: m, 2H; 7.6: d, 2H; 7.9: d, 2H; 8.95: S, 1H. The synthesis is described in Scheme 1. Example 110: 5,5-Dimethyl-1-[2-(2-oxopyrrolidin-l-yl)-pyrid-4-ylmethyl]-3-(4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione MS (LC-MS): 478.13; retention time: 1.83. The synthesis is described in Scheme 1. Example 111: {4-[5,5-Dimethyl-2,4-dioxo-3-(4-trifluoromethylsulf anylphenyl) imidazolidin-1-ylmethyl]pyrid-2-yl}-pyraz ine-2-carboxamide; compound wi th tri fluoroacetic acid MS (LC-MS): 516.12; retention time: 2.42. NMR: 1.4: s, 6H; 4.7: S, 2H; 7.3: m, 1H; 7.65: d, 2H; 7.95: d, 2H; 8.3: S, 1H; 8.4: s, 1H; 8.7: s, 1H; 9.0: s, 1H; 9.4: s, 1H. The synthesis is described in Scheme 1. Example 112: N-{4- [5,5-Dimethyl-2,4-dioxo-3-(4-tri-f luoromethylsulf anylphenyl) imidazolidin-1-ylmethyl] pyrid-2-yl}-2,2-dimethylpropionamide; compound with trifluoroacetic acid MS (LC-MS): 494.16; retention time: 2.48. NMR: 1.2: S, 9H; 1.4: s, 6H; 4.7: s, 2H; 7.2: m, 1H; 7.65: d, 2H; 7.90: d, 2H; 8.1: S, 1H; 8.3: s, 1H. The synthesis is described in Scheme 1. Example 113 : Thiophene-2-carboxylic acid {4- [5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)-imidazolidin-l-ylmethyl]pyrid-2-yl}amide; compound with trifluoroacetic acid MS (LC-MS): 520.09; retention time: 2.14. NMR: 1.4: s, 6H; 4.7: S, 2H; 7.2: m, 2H; 7.65: d, 2H; 7.8: m, 3H; 8.2: s, 1H; 8.25: S, 1H; 8.4: m, 1H. The synthesis is described in Scheme 1. Example 114: N-{4- [5,5-Dimethyl-2,4-dioxo-3-(4-tri-fluoromethylsulfanylphenyl)imidazolidin-l-ylmethyl]pyrid-2-yl}-4-methylbenzamide; compound with trifluoroacetic acid MS (LC-MS): 528.16; retention time: 2.23. NMR: 1.4: s, 6H; 4.7: s, 2H; 7.2: m, 1H; 7.3: d, 2H; 7.7: d, 2H; 7.85: d, 2H; 7.95: d, 2H; 8.2: s, 1H; 8.3: s, 1H. The synthesis is described in Scheme 1. Example 115: N-{4- [5,5-Dimethyl-2,4-dioxo-3-(4-tri-fluoromethylsulfanylphenyl)imidazolidin-l-ylmethyl]pyrid-2-yl}-3 -(3,5-dimethylpiperid-1-yl)propionamide; compound with trifluoroacetic acid F MS (LC-MS): 577.23; retention time: 1.72. The synthesis is described in Scheme 1. Example 116: N-{4- [5,5-Dimethyl-2,4-dioxo-3-(4-tri-fluoroxnethylsulfanylphenyl)imidazolidin-l-ylmethyl]pyrid-2-yl}-3-(4-pyrid-2-ylpiperazin-l-yl)propionamide; compound with trifluoroacetic acid MS (LC-MS): 627.22; retention time: 1.50. NMR: 1.4: s, 6H; 2.9: m, 2H; 3.1: m, 2H; 3.4: m, 2H; 3.6: m, 2H; 4.4: m, 2H; 4.65: s, 2H; 6.7: m, 1H; 6.95: d, 1H; 7.2: m, 1H; 7.7: d, 2H; 7.9: d, 2H; 8.15: m, 2H; 8.3: m, 1H. The synthesis is described in Scheme 1. Example 117: 5,5-Dimethyl-l-[2-(5-trifluoromethylpyrid-2-ylamino)pyrid-4-ylmethyl]-3-(4-trifluoromethyl-sulfanylphenyl)imldazolidlne-2,4-dlone F MS (LC-MS): 555.51; retention time: 1.78. The synthesis is described in Scheme 1. Example 118: N-{4-[5,5-Dimethyl-2,4-dioxo-3-(4-tri- fluoromethylsulfanylphenyl)imidazolidin-1-ylmethyl]pyrid- 2-yl}-3-methoxybenzamide; compound with trifluoroacetic acid MS (LC-MS): 544.14; retention time: 2.15. The synthesis is described in Scheme 1. Example 119: 1- (3,5-Dichlorophenyl)-3-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazol-idin-l-ylmethyl]pyrid-2-yl}urea MS (LC-MS): 597.06; retention time: 2.15 min. The synthesis is described in Scheme 2. Example 120: Methyl 3- (3-{4- [5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazolidin-1-yl-methyl]pyrid-2-yl}thioureido)benzoate MS (LC-MS): 603.12; retention time: 2.81 min. The synthesis is described in Scheme 2. Example 121: l-{4- [5,5-Dimethyl-2,4-dioxo-3-(4-tri- fluoromethylsulfanylphenyl)imidazolidin-1-ylmethyl]pyrid- 2-yl}-3-phenylurea MS (LC-MS): 529.14; retention time: 2.33 min. NMR: 1.50: s, 6H; 4.65: s, 1H; 7.0: m, 2H; 7.30: m, 2H; 7.5: m, 3H; 7.65: d, 2H; 7.85: d, 2H; 8.25: d, 1H; 9.4: s, 1H. The synthesis is described in Scheme 2. Example 122: 1-(2,4-Dichlorophenyl)-3-{4-[5, 5-dimethy 1-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazol-idin-1-ylmethyl]pyrid-2-yl}urea MS (LC-MS): 597.06; retention time: 3.00 min. The synthesis is described in Scheme 2. Example 123: 1-(3-Chlorophenyl)-3-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazolidin-1-ylmethyl]pyrid-2-yl}thiourea MS (LC-MS): 579.08; retention time: 3.05 min. The synthesis is described in Scheme 2. Example 124: Methyl 2- (3-{4- [5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazolidin-1-yl-methyl]pyrid-2-yl}thioureido) benzoate MS (LC-MS): 603.12; retention time: 2.85 min. The synthesis is described in Scheme 2. Example 125: 3,5-Diacetoxy-2-acetoxymethyl-6- (3-{4- [5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanyl-phenyl) imidazolidin-1-ylmethyl]pyrid-2-yl}thioureido) -tetrahydropyran-4-yl acetate MS (LC-MS): 799.18, retention time: 2.60 min. The synthesis is described in Scheme 2. Example 126: 1-(4-Dimethylaminophenyl)-3-{4-[5,5-di-methyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)-imidazolidin-1-ylmethyl]pyrid-2-yl}thiourea MS (LC-MS): 588.16; retention time: 1.99. NMR: 1.4: s, 6H; 2.9: s, 6H; 4.7: s, 2H; 6.7: d, 2H; 7.1: m, 1H; 7.25: s, 1H; 7.4: d, 2H; 7.7: d, 2H; 7.9: d, 2H; 8.25: m, 1H. The synthesis is described in Scheme 2. Example 127: 1- (2,4-Dimethoxyphenyl)-3-{4-[5, 5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)-imidazolidin-l-ylmethyl]pyrid-2-yl}urea MS (LC-MS): 589.60; retention time: 1.98. The synthesis is described in Scheme 2. Example 128: 3- (3-{4- [5,5-Dimethyl-2,4-dioxo-3-(4-tri-f luoromethylsulf anylphenyl) imidazolidin-l-ylmethyl]pyrid- 2-yl}thioureido)benzoic acid n MS (LC-MS): 589.11; retention time: 2.30. The synthesis is described in Scheme 2. Example 129: l-{4- [5,5-Dimethyl-2,4-dioxo-3-(4-tri- f luoromethylsulf anylphenyl) imidazolidin-l-ylmethyl]pyrid- 2-yl}-3-(2-methoxyphenyl)urea MS (LC-MS): 559.15; retention time: 1.88. The synthesis is described in Scheme 2. Example 130: 1-(2-Aminopyrid-4-ylmethyl)-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl) imidazolidine-2,4-dione MS (LC-MS): 410.10; retention time: 1.57. NMR: 1.4: s, 6H; 4.6: s, 2H; 6.9: d, 1H; 7.0: s, 1H; 7.7: d, 2H; 7.85: d, 2H; 7.95: d, 1H; 8.0: broad s, 1H. The synthesis is described in Scheme 2. Example 131: 1-(2,6-Dichloropyrid-4-yl)-3-{4-[5,5-di-methyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)-imidazolidin-1-ylmethyl] pyrid-2-yl}urea MS (LC-MS): 599.42; retention time: 2.73 min. NMR: 1.40, s, 6H; 4.65 s, 2H; 7.15: m, 1H; 7.65: d, 2H; 7.85: d, 2H; 8.15: s, 1H; 8.25: m, 1H. The synthesis is described in Scheme 2. Example 132: 1- (2,6-Dichlorophenyl)-3-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazol-idin-1-ylmethyl]pyrid-2-yl}urea MS (LC-MS): 597.06; retention time: 2.44 min. The synthesis is described in Scheme 2. Example 133: 1-(2,3-Dichlorophenyl)-3-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazol-idin-l-ylmethyl]pyrid-2-yl}urea MS (LC-MS): 597.06; retention time: 2.08 min. The synthesis is described in Scheme 2. Example 134: l-{4- [5,5-Dimethyl-2,4-di oxo-3-(4-tri- fluoromethylsulfanylphenyl)imidazolidin-l-ylmethyl]pyrid- 2-yl}-3-pyrid-3-ylthiourea MS (LC-MS): 546.11; retention time: 1.89 min. The synthesis is described in Scheme 2. Example 135: 1- [2-Chloro-6-(4-methylthiazol-2-ylamino)-pyrid-4-ylmethyl]-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl) imidazolidine-2,4-dione MS (LC-MS): 541.06; retention time: 2.49 min. The synthesis is described in Scheme 3. MS (LC-MS): 535.11; retention time: 1.90 min. The synthesis is described in Scheme 3. Example 13 9: 1- [2,6-bis(3-Methoxyphenylamino)pyrid-4-ylmethyl] -5, 5-dimethyl-3- (4-trifluoromethoxyphenyl) -imidazolidine-2,4-dione; compound with trifluoroacetic acid MS (LC-MS): 621.22; retention time: 1.95 min. The synthesis is described in Scheme 3. Example 140: 1- [2, 6-bis (2,4-Dimethoxyphenylamino)pyrid-4-ylmethyl] -5, 5-dimethyl-3- (4-trif luoromethoxyphenyl) -imidazolidine-2,4-dione; compound with trifluoroacetic acid MS (LC-MS): 681.24; retention time: 1.83 min. The synthesis is described in Scheme 3. Example 141: 1- [2,6-bis (4-Methoxyphenylamino)pyrid-4-ylmethyl]-5,5-dimethyl-3-(4-trifluoromethoxyphenyl)-imidazolidine-2,4-dione; compound with trifluoroacetic acid MS (LC-MS): 621.22; retention time: 1.63 min. The synthesis is described in Scheme 3. Example 142: N-{4-[5,5-Dimethyl-2,4-dioxo-3-(4-tri-fluoromethoxyphenyl)imidazolidin-1-ylmethyl]-6-esto-butyrylaminopyrid-2-yl}isobutyramide; compound with trifluoroacetic acid MS (LC-MS): 549.22; retention time: 1.83 min. The synthesis is described in Scheme 3. Example 143: 1- [2-Chloro-6- (pyrid-4-ylamino)pyrid-4-yl-methyl]-5,5-dimethyl-3-(4-trif luoromethoxyphenyl) imida-zolldlne-2,4-dlone; compound with trifluoroacetic acid MS (LC-MS): 563.19; retention time: 2.61 min. The synthesis is described in Scheme 3. Example 144: 1- [2-Chloro-6-(pyrid-4-ylamino)pyrid-4-yl-methyl]-5,5-dimethyl-3-(4-trifluoromethylsulfanyl-phenyl)imidazolidine-2,4-dione MS (LC-MS): 521.09; retention time: 1.91 min. The synthesis is described in Scheme 3. Example 145: N-{6-Chloro-4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanyIphenyl)imidazolidin-1-yl-methyl]pyridin-2-yl}propionamide MS (LC-MS): 500.09; retention time: 2.46. The synthesis is described in Scheme 3. Example 146: N-{6-Chloro-4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazolidin-1-yl-methyl]pyrid-2-yl}acetamide MS (LC-MS): 486.90; retention time: 2.15. The synthesis is described in Scheme 3. Example 147: 1- [2-Chloro-6-(pyrid-3-ylamino)pyrid-4-yl-methyl]-5,5-dimethyl-3-(4-trifluoromethoxyphenyl)imida-zolidine-2,4-dione; compound with trifluoroacetic acid MS (LC-MS): 505.11/ retention time: 2.27. The synthesis is described in Scheme 3. Example 148: Cyclopropanecarboxylic acid {6 -Chloro-4 -[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl) imidazolidin-l-ylmethyl]pyrid-2-yl}amide MS (LC-MS): 512.09; retention time: 2.32. The synthesis is described in Scheme 3. Example 149: N-{6-Chloro-4-[5,5-dimethyl-2, 4-dioxo-3-(4-trifluoromethylsulfanylphenyl)imidazolidin-1-yl-methyl]pyrid-2-yl}isobutyramide MS (LC-MS): 514.11; retention time: 1.63. The synthesis is described in Scheme 3. Example 150: 1-[2,6-bis(Pyrid-2-ylamino)pyrid-4-ylmeth-yl]-5,5-dimethyl-3-(4-trifluoromethoxyphenyl)imidazol-idine-2,4-dione; compound with trifluoroacetic acid MS (LC-MS): 563.15; retention time: 1.70 min. The synthesis is described in Scheme 3. Example 151: 1-[2-Chloro«6-(pyrid-2-ylamino)pyrid-4-yl-methyl]-5#5-dimethyl-3-(4-trifluoromethylsulfanylphenyl) imidazolidine-2# 4-dione MS (LC-MS): 521.09; retention time: 1.78 min. The synthesis is described in Scheme 3. Example 152: 5,5-Dimethyl-1-(5-phenyl[1,2,4]oxadiazol-3-ylmethyl)-3- (4-trifluoromethylsulfanylphenyl)-imidazolidine-2,4-dione MS (LC-MS): 462.10; retention time: 2.77 min. The synthesis is described in Scheme 4. Example 153: 1-(2-Imidazol-l-ylethyl)-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)imidazolidine-2,4-dione r MS (LC-MS): 398.10; retention time: 1.49 min. The synthesis is described in Scheme 4. Example 154: 1-[2-(4-Chlorophenyl)oxazol-5-ylmethyl]-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)imidazolidine-2, 4-dione MS (LC-MS): 495.06; retention time: 2.99 min. The synthesis is described in Scheme 4. Example 155: Preparation of l-isoquinolin-5-yl-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)imidazoli-dlne-2,4-dione 50 0 mg (2.4 mmol) of 2- (isoquinolin-5-ylamino)-2- methylpropionitrile, 1.6 mg (0.013 mmol) of benzoic acid and 526 mg (2.4 mmol) of 4- (trif luoromethylthio) phenyl isocyanate in 4 ml of chlorobenzene were re fluxed for 2 days. The resulting mixture was filtered and the filtrate was evaporated to dryness. The intermediate imine was separated out by preparative HPLC chromatography (RP 18, acetonitrile, water, 0.01% TFA) . 60 mg of the resulting product were stirred for 1 hour at 40 °C with IN hydrochloric acid. The solvent was evaporated off and the residue taken up in sodium hydrogen carbonate solution and extracted with ethyl acetate. The combined organic phases were dried and the residue remaining after evaporation was purified by flash chromatography (Si02, methylene chloride/ methanol = 98/2) leading to 3 8 mg of the desired product. M+H+ = 432. LC/MS retention time = 1.245. Example 156: 5,5-Dimethyl-l-(5-phenyloxazol-4-ylmethyl)-3-(4-trifluoromethylsulfanylphenyl)imidazolidine-2,4-dione MS (LC-MS): 461.10, retention time: 2.63 min. The synthesis is described in Scheme 4. Example 157: 5, 5-Dimethyl-1- (l-methylpiperid-3-ylmethyl) -3-(4-trifluoromethylsulfanylphenyl)imidazolidine-2,4-dione MS (LC-MS): 415.15/ retention time: 1.63. The synthesis is described in Scheme 4. Example 158: 5,5-Dimethyl-1-(l-methylpiperid-3-ylmethyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione MS (LC-MS): 499.18; Retention time: 1.39. The synthesis is described in Scheme 4. Example 159: 1-[2-(4-Chlorophenyl)thiazol-4-ylmethyl]-5, 5-dimethyl-3- (4-trifluoromethylsulfanylphenyl) imidazolidine-2, 4-dione MS (LC-MS): 511.04; retention time: 3.12. The synthesis is described in Scheme 4. Example 160: 5,5-Dimethyl-1-(l-methyl-lH-imidazol-2-yl-methyl) -3- (4-trifluoromethylsulfanylphenyl) imidazolidine-2,4-dione MS (LC-MS): 398.10; retention time: 1.53. The synthesis is described in Scheme 4. Example 161: 1-(7-Methoxy-2-oxo-2H-chromen-4-ylmethyl)-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)imid-azolidine-2,4-dione MS (LC-MS): 492.48; retention time: 1.84. The synthesis is described in Scheme 4. Example 162: 5,5-Dimethyl-l-(5-methylestoxazol-3-yl-methyl)-3-(4-trifluoromethylsulfanylphenyl)imidazolidine-2,4-dione MS (LC-MS): 500.09; retention time: 2.52. The synthesis is described in Scheme 4. Example 163: 1- [5- (4-Methoxyphenyl) [1,2,4]oxadiazol-3-ylmethyl] -5, 5-dimethyl-3- (4-trifluoromethylsulfanyl-phenyl)imidazolidine-2,4-dione MS (LC-MS): 492.11; retention time: 1.87. The synthesis is described in Scheme 4. Example 164: 1-[5-(4-Methoxyphenyl)[1,2,4]oxadiazol-3-ylmethyl] -5, 5-dimethyl-3- (4-trif luoromethoxyphenyl) -imidazolidlne-2,4-dione MS (LC-MS): 476.13; retention time: 2.03. The synthesis is described in Scheme 4. Example 165: Methyl 5-[5,5-dimethyl-2,4-dioxo-3-(4-tri-fluoromethylsulfanylphenyl)imidazolidin-1-ylmethyl]-furan-2-carboxylate MS (LC-MS): 442.42; retention time: 1.74. The synthesis is described in Scheme 4. Example 166: 1-(l-Benzyl-lH-imidazol-2-ylmethyl)-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)imidazolidine-2, 4-dione MS (LC-MS): 474.13; retention time: 2.02. The synthesis is described in Scheme 4. Example 167: 1- (4-Dimethylaminopyrimidin-2-ylmethyl) -5,5-dimethyl-3- (4-trifluoromethylsulfanylphenyl) -imidazolidine-2,4-dione , M r MS (LC-MS): 439.46; retention time: 1.91. The synthesis is described in Scheme 4. Example 168: 1- [1-(4-Methoxybenzyl)-lH-imidazol-2-yl-methyl]-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl) imidazolidine-2,4-dione MS (LC-MS): 504.14; retention time: 2.24. The synthesis is described in Scheme 4. Example 169: 5,5-Dimethyl-l-[2-(l-methylpyrrolidin-2-yl)ethyl]-3-(4-trifluoromethylsulfanylphenyl)imidazolidine-2, 4-dione MS (LC-MS): 415.15; retention time: 1.66 min. The synthesis is described in Scheme 4. Example 170: 5,5-Dimethyl-l-(2-morpholin-4-ylethyl)-3-(4-trifluoromethylsulfanylphenyl)imidazolidine-2,4-dione MS (LC-MS): 417.13; retention time: 1.62 min. The synthesis is described in Scheme 4. Example 171: 1-[5-(2-Methoxyphenyl) [1,2,4]oxadiazol-3-ylmethyl] -5,5-dimethyl-3- (4-trifluoromethylsulfanyl-phenyl) imidazolidine-2,4-dione MS (LC-MS): 492.11; retention time: 2.67 min. The synthesis is described in Scheme 4. Example 172: 5,5-Dimethyl-1-(5-methylestoxazol-3-yl-methyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione MS (LC-MS): 383.33; retention time: 1.95 min. The synthesis is described in Scheme 4. Example 173: 1-(5-tert-Butyl[1,2,4]oxadiazol-3-ylmethyl)-5,5-dimethyl-3-(4-trifluoromethylsulfanyl-phenyl)imidazolidine-2,4-dione MS (LC-MS): 442.16; retention time: 2.64 min. The synthesis is described in Scheme 4. Example 174: 4-[5,5-Dimethyl-2,4-dioxo-3-(4-trifluoro-methylsulfanylphenyl)imidazolidin-1-ylmethyl]pyridine-2-carboxylic acid 4-methylbenzylamide; compound with trifluoroacetic acid MS (LC-MS): 542.16; retention time: 2.80 min. The synthesis is described in Scheme 5. Example 175: 4- [5,5-Dimethyl-2,4-dioxo-3-(4-trifluoro-methylsulfanylphenyl)imidazolidin-1-ylmethyl]pyridine-2-carboxylic acid (2-p-tolylethyl)amide MS (LC-MS): 556.18; retention time: 2.31. The synthesis is described in Scheme 5. Example 176: 4- [5,5-Dimethyl-2,4-dioxo-3-(4-trifluoro-methylsulfanylphenyl)imidazolidin-1-ylmethyl]pyridine-2-carboxylic acid 3,4-dimethoxybenzylamide MS (LC-MS): 588.16; retention time: 1.58. The synthesis is described in Scheme 5. Example 177: 4- [5,5-Dimethyl-2,4-dioxo-3-(4-trifluoro-methylsulfanylphenyl)imidazolidin-1-ylmethyl]pyridine-2-carboxylic acid benzylamide MS (LC-MS): 528.14; retention time: 1.77. The synthesis is described in Scheme 5. Example 17 8: 5,5-Dimethyl-1-[2-(4-oxo-2-thioxo-l,4-di-hydro-2H-quinazolin-3-yl)pyrid-4-ylmethyl]-3- (4-tri-fluoromethylsulfanylphenyl)imidazolidine-2,4-dione MS (LC-MS): 571.10; retention time: 2.3. The synthesis is described in Scheme 6 The two reaction schemes below describe the synthesis of products of formula (I) according to the present invention, especially among the products of Examples 178 to 200 below. Bis(4-amino-2-chlorophenyl) disulfide 76.8 g (0.4 mol) of 1,2-dichloro-4-nitrobenzene, suspended in 120 ml of water, were heated to 90°C and treated with a solution of 62.4 g (0.8 mol) of sodium sulfide and 12.8 g (0.4 mol) of sulfur in 200 ml of water. After refluxing the mixture for 5 hours, 6 g of carbon dioxide was bubbled through the solution, followed by a regular stream of air. The pH was adjusted to 5.5, the mixture was cooled to room temperature and the resulting precipitate was collected by filtration. The crude material was recrystallized from isopropanol to give 45 g (71%) of the desired product. M+H+ = 318. LC/MS retention time = 1.526. Bis[(2-chloro-4-(4,4-dimethyl-2,5-dioxo-3-pyrid-4-yl-methylimidazolidin-1-yl)]phenyl disulfide A solution of 13.7 g (69.5 mmol) of diphosgene in 100 ml of toluene was cooled to -20°C and treated with a solution of 5.0 g (15.8 mmol) of bis (4-amino-2-chlorophenyl) disulfide. The resulting mixture was stirred for 30 minutes at room temperature, refluxed for 1 hour and then evaporated to dryness. 2.53 g (about 6.86 mmol) of this material were dissolved in THF and treated with 2.0 g (9.5 mmol) of methyl 2-methyl-2-[(pyrid-4-ylmethyl)amino]propionate. The mixture was stirred for 3 hours at room temperature, evaporated to dryness and the resulting solid was purified by flash chromatography (Si02, methylene chloride/methanol = 97/3) to give 1.8 g (37%) of the desired product. M+H+ = 722. LC/MS retention time = 1.176. Example 179: Preparation of 3- (4-tert-butylsulfanyl-3-chlorophenyl) -5, 5-dimethyl-1-pyrid-4-ylmethylimidazoli-dine-2,4-dione trifluoroacetate 200 mg (0.28 mol) of bis [ (2-chloro-4-(4,4-dimethyl-2, 5-dioxo-3-pyrid-4-ylmethylimidazolidin-l-yl)]phenyl disulfide were dissolved in 10 ml of methanol and treated with 22 mg (0.56 mmol) of sodium borohydride. After stirring for 3 0 minutes at room temperature, the mixture was evaporated to dryness. The residue was dissolved in 10 ml of sulfuric acid (75%) and added to 20 ml of sulfuric acid (75%) saturated with isobutylene. The mixture was stirred for 20 minutes at room temperature and then added cautiously to a cooled solution of sodium hydroxide in water. The alkaline aqueous phase was extracted three times with ethyl acetate, the combined organic phases were dried over sodium sulfate and the material remaining after evaporation was filtered through silica gel (methylene chloride/methanol = 95/5). The resulting crude product was purified by preparative HPLC chromatography (RP 18, acetonitrile, water, 0.01% TFA) leading to 120 mg (81%) of the desired product. M+H+ = 418. LC/MS retention time = 1.249. General procedure 1A: Preparation of 3-(3-chloro-4-alkylsulfanylphenyl)-5,5-dimethyl-l-pyrid-4-ylmethyl-imidazolidine-2,4-diones 445 mg (0.62 mol) of bis[(2-chloro-4-(4,4-dimethyl-2,5-dioxo-3-pyrid-4-ylmethylimidazolidin-l-yl)]phenyl disulfide were dissolved in 15 ml of methanol and treated with 4 9 mg (1.24 mmol) of sodium borohydride. After stirring for 30 minutes at room temperature, 1.24 mmol of the respective alkyl halide were added and the resulting mixture was refluxed for 1 hour. The solvent was removed by evaporation and the remaining crude materials were purified by preparative HPLC chromatography (RP 18, acetonitrile, water, 0.01% TFA). Example 180: Preparation of 3-(3-chloro-4-isopropyl-sulf anylphenyl) -5,5-dimethyl -1 -pyrid- 4 -ylmethylimi -dazolidine-2,4-dione Synthesized according to the general procedure 1A. M+H+ = 404. LC/MS retention time = 1.196. Example 181: Preparation of 3-(3 -chloro-4 -isobutyl-sulfanylphenyl) - 5, 5 -dimethyl-1-pyrid-4-ylmethylimi-dazolidine-2,4-dione trifluoroacetate Prepared according to the general procedure 1A. M+H+ = 418. LC/MS retention time = 1.272. Example 182: Preparation of 3- (3-chloro-4-methyl-sulfanylphenyl)-5, 5-dimethyl-1-pyrid-4-ylmethylimi -dazolidine-2,4-dione Prepared according to the general procedure 1A. M+H+ = 376. LC/MS retention time = 1.054. Example 183: Preparation of 3-[3-chloro-4-(3-methoxy-propylsulfanyl)phenyl]-5,5-dimethyl-1-pyrid-4-ylme thyl-imidazolidine-2,4-dione trifluoroacetate Prepared according to the general procedure 1A. M+H+ = 434. LC/MS retention time = 1.096. Example 184: Preparation of 3-[3-chloro-4-(2-morpholin-4-ylethylsulfanyl)phenyl]-5,5-dimethyl-l-pyrid-4-yl-methylimidazolidine-2,4-dione trifluoroacetate Prepared according to the general procedure 1A. M+H+ = 475. LC/MS retention time = 0.792 Example 185: Preparation of 3-{3-chloro-4-[2-(1-methyl-pyrrolidin-2-yl)ethylsulfanyl]phenyl}-5,5-dimethyl-1-pyrid-4-ylmethylimidazolidine-2,4-dione trifluoroacetate Prepared according to the general procedure 1A. M+H+ = 473. LC/MS retention time = 0.865. Example 186: Preparation of 3-{3-chloro-4-[3-(4-methyl-piperazin-l-yl)propylsulfanyl]phenyl}-5,5-dimethyl-1-pyrid-4-ylmethylimidazolidine-2,4-dione trifluoroacetate Prepared according to the general procedure 1A. M+H+ = 502. LC/MS retention time = 0.795. Example 187: Preparation of 3- [3-chloro-4-(3-hydroxy-propylsulfanyl)phenyl]-5,5-dimethyl-l-pyrid-4-ylmethyl-imidazolidine-2,4-dione trifluoroacetate Prepared according to the general procedure 1A. M+H+ = 420. LC/MS retention time = 0.968. Example 188: Preparation of 3-[3-chloro-4-(2-hydroxy-ethylsulfanyl)phenyl]-5, S-dimethyl-l-pyrid^-ylmethyl-imidazolidine^, 4-dione trifluoroacetate Prepared according to the general procedure 1A. M+H+ = 406. LC/MS retention time = 0.921. Example 189: Preparation of [2-chloro-4-(4,4-dimethyl-2,5-dioxo-3-pyrid-4-ylmethylimidazolidin-l-yl)phenyl-sulfanyl]acetonitrile trifluoroacetate Prepared according to the general procedure 1A. M+H+ = 401. LC/MS retention time = 0.999. 3-nitro-4-trifluoromethoxyaniline 20 g (112.9 mmol) of 4-trifluoromethoxyaniline were dissolved in 50 ml of concentrated sulfuric acid at a temperature of 0 to 5°C, and treated with 3 0 ml of a 4/1 mixture of sulfuric acid and nitric acid. The mixture was stirred for 5 hours at 0°C and then poured into an ice-water mixture and basified with 20 0 ml of concentrated aqueous ammonia solution. Extraction with EE, drying with sodium sulfate, evaporation to dryness and recrystallization from ethyl acetate/heptane gave 15.5 g (63%) of the desired product. M+H+ = 223. LC/MS retention time = 1.378. Example 190: Preparation of trifluoroacetic acid; 5,5-dimethyl-3-(3-nitro-4-trifluoromethoxyphenyl)-l-pyrid-4-ylmethylimidazolidine-2,4-dione 2.27 g (11.5 mmol) of diphosgene in 1,2-dichloro-ethane were added at -20°C to 1.0 g (4.5 mmol) of 3-nitro-4-trifluoromethoxyaniline, dissolved in 20 ml of 1,2-dichloroethane. The mixture was stirred for 1 hour while being allowed to return to room temperature, and was then heated at 50°C for 2 hours. After leaving to stand overnight, the solvent was evaporated off and the residue was taken up in dry THF and treated with 937 mg (4.5 mmol) of methyl 2-methyl-2-[(pyrid-4-ylmethyl)amino]propionate. The mixture was stirred for 2 hours at room temperature and for 1 hour at 40°C, and then evaporated to dryness, and the remaining residue was purified (RP 18, acetonitrile, water, 0.01% TFA) to give 1.15 g (61%) of the desired product. M+H+ = 425. LC/MS retention time = 1.324. Example 191: Preparation of 3- (3-amino-4-tri£luoro-methoxyphenyl) -5, 5-dimethyl- 1-pyrid-4-ylittethylimi-dazolidine-2,4-dione 9.63 g (22.7 mmol) of 5,5-dimethyl-3-(3-nitro-4-trifluoromethoxyphenyl)-l-pyrid-4-ylmethylimidazolidine-2,4-dione trifluoroacetate were dissolved in semi-concentrated hydrochloric acid, heated to reflux and treated with 30 g of zinc dust. After 1.5 hours, the mixture was cooled, filtered and extracted twice with tert-butyl methyl ether. The aqueous phase was basified with 6N sodium hydroxide and extracted- with tert-butyl methyl ether, and the combined organic phases were dried over sodium sulfate. Evaporation of the solvent gave 5.0 g (56%) of the desired product. M+H+ = 395. LC/MS retention time = 0.948. Example 192: Preparation of 5,5-dimethyl-1-pyrid-4-yl-methyl-3-[4-(2,2,2-trifluoroethoxy)phenyl]imidazolidine-2,4-dione 68 8 mg (3.6 mmol) of 2,2,2-trifluoroethoxyaniline in 30 ml of methylene chloride were added at 0°C to 356 mg (3.6 mmol) of triethylamine and a solution of 356 mg (1.2 mmol) of triphosgene in 3 0 ml of methylene chloride. The mixture was stirred overnight while being allowed to return to room temperature. Next, the solvent was evaporated off and the residue was taken up in 15 ml of THF and treated with 100 mg (0.48 mmol) of methyl 2-methyl-2 -[(pyrid-4-ylmethyl)amino] propionate and 48.5 mg (0.48 mmol) of triethylamine. The mixture was stirred for 4 hours at room temperature and for 1 hour at 50°C, and then evaporated to dryness, and the remaining residue was purified by preparative HPLC chromatography (RP 18, acetonitrile, water, 0.01% TFA) to give 67 g (36%) of the desired product. M+H+ = 394. LC/MS retention time = 1.032. Example 193: Preparation of 3-(8-chloro-3,4,4-tri-methylthiochroman-6-yl)-5,5-dimethyl-1-pyrid-4-yl-methylimidazolidine-2,4-dione 200 mg (0.28 mol) of bis[(2-chloro-4-(4,4-dimethyl-2,5-dioxo-3-pyrid-4-ylmethylimidazolidin-l-yl)]phenyl disulfide were dissolved in 10 ml of methanol and treated with 22 mg (0.56 mmol) of sodium borohydride. After stirring for 3 0 minutes at room temperature, the mixture was evaporated to dryness. The residue was dissolved in 10 ml of sulfuric acid (75%) and added to 20 ml of sulfuric acid (75%) saturated with isobutylene. The mixture was stirred for 3 0 minutes at 40°C, while a regular airstream of isobutylene was bubbled through the solution. After leaving to stand overnight, the mixture was added cautiously to a cooled solution of sodium hydroxide in water. The alkaline aqueous phase was extracted three times with ethyl acetate, the combined organic phases were dried with sodium sulfate and the material remaining after evaporation was filtered through silica gel (95/5 methylene chloride/methanol). The resulting crude product was purified by preparative HPLC chromatography (RP 18, acetonitrile, water, 0.01% TFA) to give 70 mg (56%) of the desired product. M+H+ = 444. LC/MS retention time = 1.240. Example 194: Preparation of 1-(2-chlorothiazol-5-yl-methyl)-5,5-dimethyl-3-(4-trifluoromethylsulfanyl-phenyl)imidazolidine-2,4-dione trifluoroacetate 200 mg (0.65 mmol) of 5,5-dimethyl-3-(4-trifluoromethylsulf anylphenyl)imidazolidine-2,4-dione, 115 mg (0.82 mmol) of potassium carbonate and 276 mg (1.64 mmol) of 2-chloro-5-chloromethylthiazole were dissolved in 2 ml of DMF and stirred at room temperature for 2 days. The mixture was poured into water and extracted three times with ethyl acetate, the combined organic phases were dried over sodium sulfate and the material remaining after evaporation was purified by preparative HPLC chromatography (RP 18, acetonitrile, water, 0.01% TFA) to give 143 mg (50%) of the desired product. M+H+ = 436. LC/MS retention time = 1.784. Example 195: Preparation of 3- [3-chloro-4-(propane-2-sulfonyl)phenyl]-5,5-dimethyl-1-pyrid-4-ylmethyl-imidazolidine-2,4-dione 40 mg (0.1 mmol) of 3-(3-chloro-4-isopropyl-sulfanylphenyl)-5,5-dimethyl-l-pyrid-4-ylmethylimida-zolidine-2,4-dione were dissolved in 2 ml of methylene chloride and treated with a solution of 37 mg (0.15 mmol) of m-chloroperbenzoic acid in 2 ml of methylene chloride. The reaction was monitored by TLC and stopped when the sulfoxide and the sulfone were formed in equal amounts. The mixture was evaporated to dryness and purified by flash chromatography (Si02, 98/2 methylene chloride/methanol) to give 4 mg of 3- [3-chloro-4-(propane-2-sulfonyl)phenyl]-5,5-dimethyl-1-pyrid-4-ylmethylimidazolidine-2,4-dione and 7 mg of 3- [3-chloro-4-(propane-2-sulfinyl)phenyl]-5,5-dimethyl-1-pyrid-4-ylmethylimidazolidine-2,4-dione. M+H+ = 436. LC/MS retention time = 0.970. Example 196: Preparation of 3- [3-chloro-4-(propane-2-sulf inyl) phenyl] -5, 5-dimethyl-1-pyrid-4-ylmethylimi-dazolidine-2,4-dione Prepared as described above. M+H+ = 420. LC/MS retention time = 0.932. 2-(Isoquinolin-5-ylamino)-2-methylpropionitrile: 5.0 g (34.7 mmol) of 5-aminoisoquinoline, 5.1 ml (69.4 mmol) of acetone and 945 mg (6.94 mmol) of zinc chloride were dissolved in 100 ml of acetonitrile and treated at 0°C with 6.9 g (69.4 mmol) of trimethylsilyl cyanide. The mixture was refluxed for 3 hours, the solvent was then evaporated off and the residue was taken up in 200 ml of sodium hydrogen carbonate and extracted 3 times with ethyl acetate. The combined organic phases were dried and the residue remaining after evaporation was purified by flash chromatography (Si02, 95/5 methylene chloride/methanol) to give 6.0 g (82%) of the desired product. M+H+ = 212. LC/MS retention time = 0.696. General procedure 2: Synthesis of alkylsulfanylanilines 1.1 g (8 mmol) of 4-aminothiophenol and 896 mg (8 mmol) of potassium tert-butoxide were dissolved in 10 ml of DMF and stirred for 45 minutes under an argon atmosphere. Next, 8.8 mmol of the corresponding alkyl bromide were added, the mixture was stirred for 3 hours at room temperature, poured into water and extracted with ethyl acetate. The combined organic phases were dried and evaporated. The residual product was essentially pure and could be used without further purification. 4-(3-Methoxypropylsulfanyl)phenylamine Prepared according to the general procedure 2. M+H+ = 197. LC/MS retention time = 0.777. 4-Isopropylsulfanylphenylamine Prepared according to the general procedure 2. M+H+ = 266. LC/MS retention time = 0.173. 4-[3-(4-Methylpiperazin-l-yl)propylsulfanyl]phenylamine Prepared according to the general procedure 2. M+H+ = 168. LC/MS retention time = 0.894. General procedure 3: Preparation of 3-(3-chloro-4-alkylsulfanylphenyl)-5,5-dimethyl-1-pyrid-4-ylmethyl-imidazolidine-2,4-diones 371 mg (2.3 mmol) of carbonyldiimidazole, 41 mg (0.5 mmol) of imidazole and 1.9 mmol of the respective alkylsulfanylaniline were dissolved at 0°C in 10 ml of THF and stirred for 1 hour. Next, 280 mg (1.35 mmol) of methyl 2-methyl-2- [ (pyrid-4-ylmethyl) amino] propionate dissolved in 5 ml of THF were added and the mixture was refluxed for 5 hours. The solvent was then evaporated off and the material remaining after evaporation was purified by preparative HPLC chromatography (RP 18, acetonitrile, water, 0.01% TFA). Example 197: Preparation of 5,5-dimethyl-3-(4-methyl-sulfanylphenyl)-l-pyrid-4-ylmethylimidazolidine-2,4-dione trifluoroacetate Prepared according to the general procedure 3. M+H+ = 342. LC/MS retention time = 0.942. Example 198: Preparation of 3-[4-(3-methoxypropyl-sulf anyl) phenyl] -5, 5-dimethyl-1-pyrid-4-ylme thylimi-dazolidine-2,4-dione trifluoroacetate Prepared according to the general procedure 3. M+H+ = 400. LC/MS retention time = 1.007. Example 199: Preparation of 3- (4-isopropylsulfanylphenyl) -5, 5-dimethyl-l-pyrid-4-ylmethylimidazolidine-2# 4-dione trifluoroacetate Prepared according to the general procedure 3. M+H+ = 370. LC/MS retention time = 1.096. Example 200: Preparation of 5,5-dimethyl-3-{4-[3-(4-methylpiperazin-l-yl)propylsulfanyl]phenyl}-l-pyrid-4-ylmethylimidazolidine-2,4-dione trifluoroacetate Prepared according to the general procedure 3. M+H+ = 468. LC/MS retention time = 0.689 Example 201; 5,5-Dimethyl-l-(6-methoxyquinolin-4-yl-methyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dlone 0.1 g of sodium hydride (60%) is added to a solution of 0 . 65 g of 5,5-dimethyl-3-(4-trifluoromethoxyphenyl)-imidazolidine-2,4-dione in 40 ml of anhydrous THF, under an inert atmosphere of argon at a temperature in the region of 20°C. Stirring is maintained at this temperature for 30 minutes. 0.47 g of 4-chloromethyl-6-methoxyquinoline dissolved in 10 ml of THF is added. The reaction mixture is refluxed for 16 hours. After cooling, 100 ml of water and 75 ml of ethyl acetate are added. After separation of the phases by settling, the organic phase is dried over sodium sulfate, filtered and then concentrated under reduced pressure. The brown oil obtained is purified by flash chromatography (Si02/ 50/50 EtOAc/cyclohexane by volume as eluent, Ar). The fractions containing the product are concentrated under reduced >ressure. 0 . 36 g of 5,5-dimethyl-1-(6-methoxyquinolin-4-^lmethyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-Lione is thus obtained, the characteristics of which are is follows: XH NMR spectrum (300 MHz, (CD3)2SO d6, 6 in ppm) : 1,45 [s: 6H); 3.96 (s: 3H); 5.10 (broad s: 2H); 7.46 (dd, J = ) and 3 Hz: 1H); 7.54 (d, J = 3 Hz: 1H); 7.56 (broad d, J = 9 Hz: 2H); 7.61 (d, J = 4.5 Hz: 1H); 7.68 (broad d, J = ) Hz: 2H) ; 8.00 (d, J = 9 Hz: 1H) ; 8.72 (d, J = 4.5 Hz: .H) . Mass EI m/z=459 M+. base peak m/z=213 C12H9N202+ m/z = 172 CnHi0NO+ 7he compound 5,5-dimethyl-3-(4-trifluoromethoxyphenyl)-.midazolidine-2,4-dione is prepared according to the >rocedure described in Example 63. 3reparation of 4 -chloromethyl-6-methoxyquinoline 1.16 ml of triethylamine and 0.64 ml of lethanesulfonyl chloride are successively added to a solution of 1. 2 g of 4-hydroxymethyl-6-methoxyquinoline .n 45 ml of dichloromethane, under an inert atmosphere of irgon at a temperature in the region of 20°C. Stirring is :ontinued at this temperature for 3 hours. The reaction ledium is concentrated under reduced pressure to give a jrown residue. The product is used without further mrification in the following step. XH NMR spectrum (300 MHz, (CD3)2SO d6, 6 in ppm): 3.97 [s: 3H) ; 5.30 (s: 2H) ; 7.48 (dd, J= 9 and 3 Hz: 1H) ; '.52 (d, J = 3 Hz: 1H) ; 7.62 (d, J = 4.5 Hz: 1H) ; 8.00 [d, J = 9 Hz: 1H); 8.75 (d, J = 4.5 Hz: 1H). Mass EI m/z=207 M+" m/z=172 (M - Cl)+ base peak m/z=157 (m/z=172 - CH3)+ m/z=129 (m/z=157 - CO) + Preparation of 4-hydroxymethyl-6-methoxyquinoline 17 ml of a 1M solution of LiAlH4 in THF is added dropwise to a solution of 4 g of 4-ethoxycarbonyl-6-methoxyquinoline in 100 ml of anhydrous THF, under an inert atmosphere of argon at a temperature in the region of 5°C. The reaction medium is maintained at a temperature in the region of 20 °C for 16 hours with stirring and 50 ml of water and 50 ml of ethyl acetate are added. After separation of the phases by settling, the organic phase is dried over sodium sulfate, filtered and then concentrated under reduced pressure. The foam obtained is purified by flash chromatography (Si02, EtOAc as eluent, Ar). The fractions containing the product are concentrated under reduced pressure. 0.86 g of 4-hydroxymethyl-6-methoxyquinoline is thus obtained, the characteristics of which are as follows: XH NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm): 3.93 (s: 3H) ; 5.02 (d, J = 5.5 Hz: 2H) ; 5.57 (t, J = 5.5 Hz: 1H) ; 7.30 (d, J = 3 Hz: 1H) ; 7.38 (dd, J = 9 and 3 Hz: 1H) ; 7.50 (d, J = 4.5 Hz: 1H) ; 7.92 (d, J = 9 Hz: 1H) ; 8.69 (d, J = 4.5 Hz: 1H). Mass EI, m/z=189 M+> base peak m/z=174 (M - CH3)+ m/z=160 (M - CHO)+ m/z = 146 (m/z = 174 - CO)+ m/z=117 (m/z=146 - CHO)+' Example 2 02: 5,5-Dimethyl-1-(6-hydroxyquinolin-4-yl-methyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione 6 ml of a 1M solution of boron tribromide in CH2C12 are added to a solution of 0.26 g of 5,5-dimethyl-1- (6-methoxyquinolin-4-ylmethyl)-3-(4-trifluoromethoxyphenyl) imidazolidine-2,4-dione in 40 ml of dichloro-methane, under an inert atmosphere of argon at a temperature in the region of 0°C. The reaction medium is maintained at a temperature in the region of 20°C for 16 hours with stirring. 5 ml of methanol are added dropwise. After stirring for 30 minutes at this temperature, 50 ml of water, 30 ml of CH2C12 and 10 ml of saturated NaHC03 solution are added. After separation of the phases by settling, the organic phase is dried over sodium sulfate, filtered and then concentrated under reduced pressure. The beige-colored foam obtained is purified by flash chromatography (Si02, EtOAc as eluent, Ar). The fractions containing the product are concentrated under reduced pressure. 0,17 g of 5,5-dimethyl-l-(6-hydroxyquinolin-4-ylmethyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione is thus obtained, the characteristics of which are as follows: XH NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm): 1.46 (s: 6H); 5.00 (broad S: 2H); 7.30 to 7.40 (mt: 2H); 7.51 (d, J = 4.5 Hz: 1H); 7.55 (broad d, J = 8.5 Hz: 2H); 7.69 (d, J = 8.5 Hz: 2H) ; 7.94 (d, J= 9 Hz: 1H) ; 8.64 (d, J = 4.5 Hz: 1H) ; 10.12 (unresolved complex: 1H) . Mass EI m/z=445 M+" m/z = 199 CiiH7N202+ m/z = 158 Ci0H8NO+ base peak Example 203: 5,5-Dimethyl-1-(7-methoxyquinolin-4-yl-methyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2#4-dione The product is prepared according by following the procedure described in Example 59, starting with 0.94 g of methyl 2-methyl-2-[(7-methoxyquinolin-4-ylmethyl)-amino]propanoate instead of methyl 2-methyl-2-[(quinolin-4-ylmethyl) amino] propanoate used in Example 59, and 1.7 g of 4-(trifluoromethoxyphenyl) isocyanate. After purification by flash column chromatography (Si02, 70/3 0 cyclohexane/EtOAc by volume and then 90/10 CH2Cl2/MeOH by volume as eluents, Ar) , 1.45 g of the expected product are obtained. XH NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm): 1.44 (s: 6H); 3.96 (s: 3H); 5.12 (broad S: 2H); 7.35 (dd, J = 9 and 3 Hz: 1H) ; 7.47 (d, J = 3 Hz: 1H) ; 7.49 (d, J = 4.5 Hz: 1H) ; 7.55 (broad d, J = 9 Hz: 2H) ; 7.68 (broad d, J = 9 Hz: 2H); 8.19 (d, J = 9 Hz: 1H); 8.80 (d, J = 4.5 Hz: 1H). Mass EI m/z=459 M+' base peak m/z=444 (M - CH3)+ m/z = 213 Ci2H9N202+ m/z = 172 CnHioNO+ Preparation of methyl 2-((7-methoxyquinolin-4-yl-methyl)amino)propanoate A mixture of 1.23 g of methyl a-aminoisobutyrate hydrochloride and 1.12 ml of triethylamine in 30 ml of dichloromethane is stirred at 0°C for 20 minutes. Next, 1 g of magnesium sulfate and 1.5 g of 7-methoxyquinoline-4-carbaldehyde are added. Stirring is continued for 15 hours at room temperature and the mixture is then concentrated under reduced pressure. The residue is taken up in 3 5 ml of methanol, the solut ion obtained is cooled to 0°C and 0.31 g of sodium borohydride is then added portionwise. The reaction medium is stirred at a temperature in the region of 2 0°C for 15 hours. The reaction medium is concentrated under reduced pressure. The residue obtained is taken up in 100 ml of EtOAc. The precipitate formed is filtered off and the filtrate is concentrated under reduced pressure and then purified by flash column chromatography (Si02/ EtOAc as eluent, Ar) to give 0.95 g of the expected product. XH NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm) : 1.35 (s: 6H) ; 2.63 (t, J = 7.5 Hz: 1H) ; 3.70 (s: 3H) ; 3.93 (s: 3H); 4.05 (d, J = 7.5 Hz: 2H); 7.28 (dd, J = 9 and 3 Hz: 1H) ; 7.41 (d, J = 3 Hz: 1H) ; 7.43 (d, J = 4.5 Hz: 1H); 8.12 (d, J = 9 Hz: 1H); 8.76 (d, J = 4.5 Hz: 1H) . Mass CI m/z=289 MH+ base peak m/z=229 (M - C2H402) + Preparation of 7-methoxyquinoline-4-carbaldehyde A mixture of 1.9 g of selenium oxide dissolved in 35 ml of dioxane is added dropwise to a solution of 2.7 g of 4-methyl-7-methoxyquinoline in 35 ml of dioxane preheated to 65°C. At the end of the addition, the brown suspension is heated at a temperature in the region of 80°C for 5 hours. The reaction medium is stirred for 16 hours at a temperature in the region of 20 °C. The greenish suspension is suction-filtered and then washed with EtOAc. The filtrate is concentrated under reduced pressure. The suspension obtained is crystallized from isopropyl ether to give 1.54 g of 7-methoxyquinoline-4-carbaldehyde. *H NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm): 3.99 (s: 3H) ; 7.48 (dd, J = 9 and 3 Hz: 1H) ; 7.57 (d, J = 3 Hz: 1H) ; 7.90 (d, J = 4.5 Hz: 1H) ; 8.89 (d, J = 9 Hz: 1H) ; 9.19 (d, J = 4.5 Hz: 1H) ; 10.52 (s: 1H) . Mass CI m/z = 188 MH+ base peak Preparation of 4-methyl-7-methoxyquinoline 4 g of triphenylphosphine, 5.3 g of lithium chloride, 14 ml of tetramethyltin and 2.1 g of bis(triphenylphosphine)palladium(II) chloride are added to a solution of 6 g of 4-bromo-7-methoxyquinoline in 100 ml of DMF, under an inert atmosphere of argon at a temperature in the region of 20°C. The reaction medium is heated at a temperature in the region of 12 0°C for 16 hours. After cooling, the insoluble material is filtered off. The filtrate is concentrated under reduced pressure. The residue obtained is taken up in 3 00 ml of EtOAc and 3 00 ml of water. After separation of the phases by settling, the organic phase is dried over magnesium sulfate, filtered and then concentrated under reduced pressure. The oil obtained is taken up in 300 ml of EtOAc and 300 ml of water and then acidified with hydrochloric acid to pH 1. The aqueous phase is basified with sodium hydroxide to pH 10 and then extracted with 3 00 ml of EtOAc. After separation of the phases by settling, the organic phase is dried over magnesium sulfate, filtered and then concentrated under reduced pressure to give 2.7 g of 4-methyl-7-methoxyquinoline, the characteristics of which are as follows: *H NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm): 2.65 (s: 3H) ; 3.94 (s: 3H) ; 7.23 (broad d, J = 4.5 Hz: 1H) ; 7.28 (dd, J = 9 and 3 Hz: 1H) ; 7.40 (d, J = 3 Hz: 1H); 8.01 (d, J = 9 Hz: 1H); 8.58 (d, J = 4.5 Hz: 1H). Mass EI m/z=173 M+' base peak m/z=158 (M - CH3)+ m/z=143 (M - CH20)+' m/z=130 (m/z=158 - CO)+ Preparation of 4-bromo-7-methoxyquinoline 22.74 g of 4-hydroxy-7-methoxyquinoline are added to 200 g of phosphorus oxybromide preheated to a temperature in the region of 110°C. The reaction medium is heated at this same temperature for 3 hours. The reaction medium is poured while hot into a mixture of 5 00 ml of EtOAc and 500 ml of ice-water. The medium is neutralized with potassium carbonate to pH 7. After separation of the phases by settling, the organic phase is dried over magnesium sulfate, evaporated under reduced pressure and then purified by column chromatography (Si02, 50/50 EtOAc/cyclohexane by volume as eluents, Ar) , to give 14.6 g of the expected product. XH NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm) : 3.97 (s: 3H); 7.43 (dd, J = 9 and 3 Hz: 1H); 7.49 (d, J = 3 Hz: 1H) ; 7.79 (d, J = 4.5 Hz: 1H) ; 8.06 (d, J = 9 Hz: 1H); 8.67 (d, J = 4.5 Hz: 1H). Mass EI m/z=237 M+' base peak 4-Hydroxy-7-methoxyquinoline is prepared according to the process described in: J. Am. Chem. Soc., 68, 1268, 1946. Example 204: 5,5-Dimethyl-l-(7-hydroxyquinolin-4-yl-methyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dlone A mixture of 0.89 g of 5,5-dimethyl-1-(7-methoxy-quinolin-4-ylmethyl)-3-(4-trifluoromethoxyphenyl)imi-dazolidine-2,4-dione and 5.5 g of pyridine hydrochloride is heated at a temperature in the region of 220°C for 4 hours. After cooling, 200 ml of water and 100 ml of CH2C12 are added. After separation of the phases by settling, the organic phase is dried over sodium sulfate, filtered and then concentrated under reduced pressure. The solid obtained is purified by flash chromatography (Si02, 4 0/60 EtOAc/CH2Cl2 by volume as eluent, Ar) . The fractions containing the product are concentrated under reduced pressure. 85 mg of 5,5-dimethyl-1-(7-hydroxyquinolin-4-ylmethyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione are thus obtained, the characteristics of which product are as follows: XH NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm) : 1.45 (s: 6H) ; 5.08 (broad s: 2H) ; 7.24 (dd, J = 9 and 3 Hz: 1H) ; 7.30 (d, J = 3 Hz: 1H) ; 7.38 (d, J = 4.5 Hz: 1H) ; 7.55 (broad d, J = 9 Hz: 2H) ; 7.68 (broad d, J = 9 Hz: 2H) ; 8.10 (d, J = 9 Hz: 1H) ; 8.71 (d, J = 4.5 Hz: 1H); from 9.90 to 10.50 (broad unresolved complex: 1H), Mass EI m/z=445 M+' base peak m/z=430 (M - CH3)+ m/z = 199 Cn^NaCV m/z = 158 C10H8NO+ Example 205; 5, 5-Dimethyl-l- (2-aminoquinolin-4-ylmethyl) -3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione 0.44 g of tosyl chloride is added to a solution of 0 . 8 g of 5, 5-dimethyl-l- (N-oxyquinolin-4-ylmethyl) -3- (4-trifluoromethoxyphenyl)imidazolidine-2,4-dione in 10 ml of chloroform, under an inert atmosphere of argon at a temperature in the region of 5°C. After stirring for 3 0 minutes at this same temperature, 1.5 ml of 32% aqueous ammonia are added. The temperature is allowed to rise to 20°C. The reaction medium is stirred at a temperature in the region of 20°C for 16 hours. 100 ml of water are added. After separation of the phases by settling, the organic phase is dried over sodium sulfate, filtered and then concentrated under reduced pressure. The solid obtained is purified by flash chromatography (Si02, EtOAc as eluent, Ar) . The fractions containing the product are concentrated under reduced pressure. 200 mg of 5,5-dimethyl-1-(2-aminoquinolin-4-ylmethyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione are thus obtained, the characteristics of which are as follows: XH NMR spectrum (300 MHz, (CD3)2SO d6, 6 in ppm): 1.49 (s: 6H) ; 4.96 (broad s: 2H); 6.36 (broad s: 2H)/ 6.81 (s: 1H) ; 7.23 (mt: 1H) ; 7.51 (mt: 2H) ; 7.58 (broad d, J = 9 Hz: 2H) ; 7.68 (broad d, J = 9 Hz: 2H) ; 7.91 (d, J = 8.5 Hz: 1H). Mass EI m/z=444M+' base peak m/z=429 (M - CH3)+ m/z = 198 CnH8N30+ m/z=158 C10H10N2+ Example 206: 5,5-Dimethyl-1-(N-oxyquinolin-4-ylmethyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione 0.78 g of m-chloroperbenzoic acid is added to a solution of 1. 95 g of 5,5-dimethyl-1-(quinolin-4-yl-methyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione in 200 ml of chloroform and 10 ml of methanol, under an inert atmosphere of argon at a temperature in the region of 20°C. The reaction medium is stirred at a temperature in the region of 2 0°C for 4 hours. A further 0.8 g of m-chloroperbenzoic acid is added. The reaction medium is concentrated under reduced pressure. The product is crystallized from isopropyl ether to give 1. 76 g of 5,5-dimethyl-l-(N-oxyquinolin-4-ylmethyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione, the characteristics of which are as follows: XH NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm): 1.45 (s: 6H) ; 5.09 (broad s: 2H) ; 7.55 (broad d, J = 8.5 Hz: 2H); 7.63 (d, J = 4.5 Hz: 1H); 7.68 (broad d, J = 8.5 Hz: 2H) ; 7.85 (broad t, J = 8.5 Hz: 1H) ; 7.91 (broad t, J = 8.5 Hz: 1H) ; 8.35 (broad d, J = 8.5 Hz: 1H) ; 8.56 (d, J = 4.5 Hz: 1H); 8.64 (broad d, J = 8.5 Hz: 1H). Mass ES m/z=446 MH+ base peak Example 207: 5,5-Dimethyl-1-(2»chloroquinolin-4-yl-methyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione 0.17 ml of phosphorus oxychloride is added to a solution of 4 ml of DMF and 2 ml of toluene, under an inert atmosphere of argon at a temperature in the region of 5°C. After stirring for 3 0 minutes at this same temperature, 0.4 g of 5,5-dimethyl-1-(N-oxyquinolin-4-yl-methyl)-3 -(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione in 10 ml of toluene is added. The reaction medium is stirred at a temperature in the region of 5°C for 2 and a half hours. The temperature is allowed to rise to 20°C. The reaction medium is concentrated under reduced pressure. The residue obtained is taken up in 50 ml of EtOAc and washed with saturated NaHC03 solution. After separation of the phases by settling, the organic phase is dried over sodium sulfate, filtered and then concentrated under reduced pressure. The product is crystallized from isopropyl ether to give 0.37 g of 5,5-dimethyl-1-(2-chloroquinolin-4-ylmethyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione, the characteristics of which product are as follows: XH NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm) : 1.50 (s: 6H) ; 5.17 (broad s: 2H) ; 7.56 (broad d, J = 8.5 Hz: 2H) ; 7.71 (broad d, J = 8.5 Hz: 2H) ; 7.76 (s: 1H) ; 7.76 (resolved t, J = 8 and 1.5 Hz: 1H) ; 7.89 (resolved t, J = 8 and 1.5 Hz: 1H); 8.03 (broad d, J = 8 Hz: 1H) ; 8.31 (broad d, J = 8 Hz: 1H). Mass EI m/z=463 M+' base peak m/z=448 (M - CH3)+ m/z=428 (M - Cl)+ m/z=358 (m/z=428 - C4H60)+ m/z = 217 CnH6N2OCl+ m/z=176 Ci0H7NCl+ Example 208: 5,5-Dimethyl-1-(2-chloropyrid-4-ylmethyl)-3-(4-trifluoromethoxyphenyl)lmidazolldine-2,4-dlone 0.02 8 g of sodium hydride is added to a solution of 0 .1 g of 5,5-dimethyl-3-(4-trifluoromethoxyphenyl)-imidazolidine-2,4-dione in 2 ml of anhydrous dimethylformamide, under an inert atmosphere of argon at a temperature in the region of 20°C, stirring is continued at this temperature for 30 minutes, 0.1 g of 2-chloro-4-(bromomethyl)pyridine in 2 ml of dimethyl-formamide is added, followed by addition of ice-water after reaction for 10 minutes. The reaction mixture is deposited on a cartridge 2 0 mm in diameter packed with 17 g of 50 /im octadecyl-grafted silica conditioned successively with acetonitrile and then with water. Elution was performed by gradient using a mixture (water/acetonitrile) of from 0 to 100% acetonitrile. The fractions containing the expected product are concentrated under reduced pressure. 0.13 0 g of crude product is thus obtained, and is purified by a double chromatography using a cartridge packed with 10 g of conditioned 20-40 /xm silica, and then eluted with a mixture (cyclohexane/ethyl acetate) (8/2), (v/v), at a flow rate of 5 ml/minute. The fractions between 30 and 75 ml are concentrated under reduced pressure. 0.1 g of 5,5-dimethyl-l-(2-chloropyrid-4-ylmethyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione is thus obtained in the form of a white powder, the characteristics of which are as follows: m.p. 134°C Mass EI m/z=413 M+' base peak + . m/z=398 (M - CH3)+ + m/z=203 C8H4NO2F3 m/z=167 C7H4N2OCI m/z=126 C6H5NC1+ XU NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm) : 1.44 (s: 6H) ; 4.67 (s: 2H) ; 7.50 (broad d, J = 5.5 Hz: 1H) ; 7.54 (broad d, J = 9 Hz: 2H) ; 7.61 (broad s: 1H) ; 7 .66 (broad d, J = 9 Hz: 2H) ; 8.40 (d, J = 5.5 Hz: 1H) . The compound 5,5-dimethyl-3-(4-trifluoromethoxyphenyl)-imidazolidine-2,4-dione is described in Example 63. Example 209s 5,5-Dimethyl-1-(2-ethoxypyrid-4-ylmethyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione 0.015 g of sodium hydride is added to a solution of 0 .175 g of 5,5-dimethyl-3-(4-trifluoromethoxyphenyl)-imidazolidine-2,4-dione in 2 ml of anhydrous dimethyl-formamide, under an inert atmosphere of argon at a temperature in the region of 2 0°C, stirring is continued at this temperature for 30 minutes, and a solution of 0.185 g of 2-ethoxy-4- (bromomethyl) pyridine in 2 ml of anhydrous dimethylformamide is added, followed by addition of ice-water after reaction for 10 minutes. The reaction mixture is deposited on a cartridge 3 7 mm in diameter packed with 65 g of 40-60 ^m octadecyl-grafted silica conditioned successively with a mixture (water/acetonitrile) (5/95), (v/v), and then with a mixture (water/acetonitrile) (95/5), (v/v). Elution was performed with a mixture (water/ acetonitrile), (95/5) , (v/v) for 20 minutes, followed by a linear gradient of from 5% to 95% acetonitrile over 60 minutes, at a flow rate of 10 ml/minute. The fractions between 70 0 and 760 ml are concentrated under reduced pressure. 0 .145 g of 5,5-dimethyl-l-(2-ethoxypyrid-4-ylmethyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4- dione is thus obtained, the characteristics of which are as follows: Mass EI m/z=423 M+' m/z=408 (M - CH3)+base peak m/z=395 (M - C2H4)+- m/z=203 C8H4N02F3+-XH NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm) : 1.32 (t, J = 7 Hz: 3H) ; 1.42 (s: 6H) ; 4.30 (q, J *= 7 Hz: 2H); 4.58 (broad s: 2H); 6.85 (broad s: 1H); 7.01 (broad d, J = 5.5 Hz: 1H); 7.52 (broad d, J = 8.5 Hz: 2H); 7.63 (broad d, J = 8.5 Hz: 2H) ; 8.10 (d, J = 5.5 Hz: 1H) . The compound 5,5-dimethyl-3-(4-trifluoromethoxyphenyl)-imidazolidine-2,4-dione is described in Example 63. Example 210; 5,5-Dimethyl-l-(2-ethylpyrid-4-ylmethyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione 0.009 g of sodium hydride is added to a solution of 0 . 064 g of 5,5-dimethyl-3-(4-trifluoromethoxyphenyl)~ imidazolidine-2,4-dione in 1 ml of anhydrous dimethyl- formamide, under an inert atmosphere of argon at a temperature in the region of 20°C, stirring is continued for 30 minutes at this temperature, and a solution of 0 . 062 g of 2-ethyl-4- (bromomethyl) pyridine in 0 . 5 ml of anhydrous dimethylformamide is added, followed by addition of ice-water after reaction for 10 minutes. The reaction mixture is deposited on a cartridge 27 mm in diameter packed with 25 g of 40-60 [iva octadecyl-graf ted silica conditioned successively with a mixture (water/acetonitrile) (5/95) (v/v) and then with a mixture (water/acetonitrile) (95/5) (v/v). Elution was performed with a mixture (water/ acetonitrile) (95/5) (v/v) for 2 0 minutes, followed by a linear gradient of from 5% to 95% acetonitrile over 60 minutes, at a flow rate of 10 ml/minute. The fractions between 75 0 and 7 90 ml are concentrated under reduced pressure. 0.06 g of 5,5-dimethyl-l-(2-ethylpyrid-4- ylmethyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione is thus obtained, the characteristics of which are as follows: Mass EI m/z=407 M+> base peak m/z=392 (M - CH3)+ m/z=203 C8H4N02F3+- m/z=120 C8Hi0N+ XH NMR spectrum (400 MHz, (CD3)2SO d6, 8 in ppm) : 1.27 (t, J = 7.5 Hz: 3H) ; 1.44 (s: 6H) ; 2 .75 (q, J = 7.5 Hz: 2H) ; 4.54 (s: 2H) ; 7.10 (broad d, J = 5.5 Hz: 1H); 7.15 (broad s: 1H); 7.39 (broad d, J = 8.5 Hz: 2H); 7.49 (d, J = 8.5 Hz: 2H); 8.26 (d, J = 5.5 Hz: 1H). The compound 5,5-dimethyl-3-(4-trifluoromethoxyphenyl) imidazolidine-2,4-dione is described in Example 63. Example 211: 5,5-Dimethyl-1-(2-chloropyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione 0.046 g of sodium hydride is added to a solution of 0 .175 g of 5,5-dimethyl-3-(4-trifluoromethylsulfanyl-phenyl)imidazolidine-2,4-dione in 3 ml of anhydrous dimethylformamide, under an inert atmosphere of argon at a temperature in the region of 20°C, stirring is continued at this temperature for 30 minutes, and a solution of 0.166 g of 2-chloro-4-(bromomethyl)pyridine in 2 ml of anhydrous dimethylformamide is added, followed by addition of ice-water after reaction for 10 minutes. The reaction mixture is deposited on a cartridge 37 mm in diameter packed with 65 g of 40-60 /zm octadecyl-grafted silica conditioned successively with a mixture (water/acetonitrile) (5/95) (v/v) , and then with a mixture (water/acetonitrile) (95/5) (v/v). Elution was performed with a mixture (water/ acetonitrile) (95/5) (v/v) for 20 minutes, followed by a linear gradient of from 5% to 95% acetonitrile over 60 minutes, at a flow rate of 10 ml/minute. The fractions between 740 and 7 80 ml are concentrated under reduced pressure. 0.03 g of 5,5-dimethyl-l-(2-chloropyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)-imidazolidine-2,4-dione is thus obtained in the form of a white powder, the characteristics of which are as follows: m.p. 111°C Mass CI m/z = 447 MNH4+ m/z=430 MH+ base peak XH NMR spectrum (300 MHz, (CD3)2SO d6, 8 in ppm): 1.44 (s: 6H) ; 4.67 (broad s: 2H) ; 7.49 (broad d, J = 5.5 Hz: 1H); 7.61 (broad s: 1H); 7.70 (broad d, J = 8.5 Hz: 2H); 7.88 (broad d, J = 8.5 Hz: 2H); 8.38 (d, J = 5.5 Hz: 1H). Preparation of 5, 5-dimethyl-3- (4-trifluoromethyl- sulfanylphenyl)imidazolidine-2,4-dione 5.12 ml of triethylamine and 2.8 g of methyl a-aminoisobutyrate hydrochloride are added to a solution of 4 g of 4-trifluoromethylsulfanylphenyl isocyanate in 40 ml of toluene, under an inert atmosphere of argon at a temperature in the region of 20°C. The mixture thus obtained is ref luxed for 24 hours and then cooled to a temperature in the region of 20°C. The reaction mixture is concentrated to dryness under reduced pressure and the residue obtained is taken up in ethyl ether and filtered. 5 . 3 g of 5,5-dimethyl-3-(4-trifluoromethylsulf anylphenyl) imidazolidine-2,4-dione are thus obtained, the characteristics of which are as follows: Mass CI m/z = 322 MNH4+ m/z=102 triethylamineH* base peak XU NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm): 1.44 (s: 6H); 7.62 (broad d, J= 8.5 Hz: 2H); 7.85 (broad d, J = 8.5 Hz: 2H) ; 8.72 (unresolved complex: 1H) . The insoluble material thus obtained is taken up in dichloromethane and then washed with water. 2.76 g of 5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)imida-zolidine-2,4-dione are thus obtained, and are used for the rest of the synthesis. Example 212; 5, 5-Dimethyl-l- (2-ethoxypyrid-4-ylmethyl) -3-(4-trifluoromethanesulfanylphenyl)imidazolldlne-2,4-dione 0.049 g of sodium hydride is added to a solution of 0 .185 g of 5,5-dimethyl-3-(4-trifluoromethylsulfanyl phenyl) imidazolidine-2,4-dione in 3.2 ml of anhydrous dimethylformamide, under an inert atmosphere of argon at a temperature in the region of 20°C, stirring is continued at this temperature for 3 0 minutes, and a solution of 0 .184 g of 2-ethoxy-4-(bromomethyl)pyridine in 2 ml of dimethylformamide is added, followed by addition of ice-water after reaction for 10 minutes. The reaction mixture is deposited on a cartridge 37 mm in diameter packed with 65 g of 40-60 /xm octadecyl-graf ted silica conditioned successively with a mixture (water/acetonitrile) (5/95) (v/v) and then with a mixture (water/acetonitrile) (95/5) (v/v). Elution was performed with a mixture (water/ acetonitrile) (95/5) (v/v) for 2 0 minutes, followed by a linear gradient of from 5% to 95% acetonitrile over 60 minutes, at a flow rate of 10 ml/minute. The fractions between 520 and 7 00 ml are concentrated under reduced pressure. The residue thus obtained is purified by flash chromatography using a cartridge packed with 2 g of conditioned 15-35 jxm silica, and then eluted with a mixture (eyelohexane/ethyl acetate) (9/1) (v/v). The fractions containing the expected product are concentrated under reduced pressure. 0.01 g of 5,5-di-methyl-1-(2-ethoxypyrid-4-ylmethyl)-3-(4-trifluoromethanesulf anylphenyl) imidazolidine-2,4-dione is thus obtained, the characteristics of which are as follows: Mass EI m/z = 439 M+- m/z=424 (M - CH3)+base peak m/z = 411 (M - C2H4)+-m/z = 219 C8H4NOSF3+-1H NMR spectrum (300 MHz, (CD3)2SO d6, 8 in ppm) : 1.32 (t, J = 7 Hz: 3H); 1.42 (s: 6H); 4.30 (q, J = 7 Hz: 2H); 4.58 (broad s: 2H); 6.86 (broad s: 1H); 7.01 (broad d, J = 5.5 Hz: 1H); 7.69 (broad d, J = 8.5 Hz: 2H); 7.88 (broad d, J = 8.5 Hz: 2H) ; 8.10 (broad d, J = 5,5 Hz: 1H) . The compound 5,5-dimethyl-3-(4-trifluoromethylsulfanyl-phenyl)imidazolidine-2,4-dione is described in Example 211. Example 213; 5,5-Dimethyl-1-(2-ethylpyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione 0.021 g of sodium hydride is added to a solution of 0 .13 5 g of 5,5-dimethyl-3-(4-trifluoromethylsulfanyl- phenyl)imidazolidine-2,4-dione in 2 ml of anhydrous dimethyIformamide, under an inert atmosphere of argon at a temperature in the region of 20 °C, stirring is continued at this temperature for 3 0 minutes and a solution of 0.126 g of 2-ethyl-4-(bromomethyl)pyridine in 1 ml of anhydrous dimethylformamide is added, followed by addition of ice-water after reaction for 10 minutes. The reaction mixture is deposited on a cartridge 37 mm in diameter packed with 65 g of 40-60 /xm octadecyl-grafted silica conditioned successively with a mixture (water/acetonitrile) (5/95) (v/v) and then with a mixture (water/acetonitrile) (95/5) (v/v). Elution was performed with a mixture (water/ acetonitrile) (95/5) (v/v) for 20 minutes, followed by a linear gradient of from 5% to 95% acetonitrile over 6 0 minutes, and elution with 100% acetonitrile for 10 minutes, at a flow rate of 10 ml/minute. The fractions between 800 and 880 ml are concentrated under reduced pressure. 0.12 0 g of 5,5-dimethyl-1-(2-ethylpyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)-imidazolidine-2,4-dione is thus obtained, the characteristics of which are as follows: Mass EI m/z=423 M+> base peak m/z = 408 (M - CH3) + m/z=219 C8H4NOSF3 + - m/z = 120 C8Hi0N+ lH NMR spectrum (4 0 0 MHz, (CD3)2SC d6, 8 in ppm) : 1.23 (t, J = 7.5 Hz: 3H) ; 1.42 (s: 6H) / 2.75 (q, J = 7.5 Hz: 2H) ; 4.62 (broad s: 2H) ; 7.25 (broad d, J = 5.5 Hz: 1H) ; 7.30 (broad S: 1H) ; 7.70 (d, J = 8.5 Hz: 2H) ; 7.88 (d, J = 8.5 Hz: 2H); 8.43 (d, J = 5.5 Hz: 1H). The compound 5,5-dimethyl-3-(4-trifluoromethylsulfanyl-phenyl)imidazolidine-2,4-dione is described in Example 211. Example 214; 5,5-Dimethyl-1-(2-bromopyrid-4-ylmethyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione 0.023 g of sodium hydride is added to a solution of 0 . 081 g of 5,5-dimethyl-3-(4-trifluoromethoxyphenyl)-imidazolidine-2,4-dione in 2 ml of anhydrous dimethyl-formamide, under an inert atmosphere of argon at a temperature in the region of 2 0°C, stirring is continued at this temperature for 35 minutes, and a solution of 0.071 g of 2-bromo-4- (bromomethyl)pyridine in 1 ml of anhydrous dimethylformamide is added, followed by addition of ice-water after reaction for 15 minutes. The reaction mixture is deposited on a cartridge 16 mm in diameter packed with 5 g of 40-60 /zm octadecyl-graf ted silica conditioned successively with a mixture (water/acetonitrile) (5/95) (v/v) and then with a mixture (water/acetonitrile) (95/5) (v/v). Elution was performed by a linear gradient of from 5% to 95% acetonitrile over 30 minutes, followed by a mixture (water/acetonitrile) (5/95) (v/v) for 10 minutes, at a flow rate of 10 ml/minute. The fractions between 90 and 100 ml are concentrated under reduced pressure. 0.015 g of 5,5-dimethyl-1-(2-bromopyrid-4-ylmethyl)-3-(4- trifluoromethoxyphenyl)imidazolidine-2,4-dione is thus obtained in the form of a white foam, the characteristics of which are as follows: Mass EI m/z=457 M+- base peak m/z=442 (M - CH3)+ m/z = 211 C7H4N2OBr+ m/z = 203 C8H4N02F3+- m/z=170 C6H5NBr+ XH NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm) : 1.44 (s: 6H) ; 4.67 (broad s: 2H) ; 7.52 (broad d, J = 5.5 Hz: 1H); 7.54 (broad d, J = 9 Hz: 2H); 7.66 (broad d, J = 9 Hz: 2H) ; 7.75 (broad s: 1H) ; 8.37 (d, J = 5.5 Hz: 1H) . The compound 5,5-dimethyl-3-(4-trifluoromethoxyphenyl) imidazolidine-2,4-dione is described in Example 63. Example 215; 5, 5-Dimethyl-l- (2-f luoropyrid-4-ylmethyl) -3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione 0.025 g of sodium hydride is added to a solution of 0 . 096 g of 5,5-dimethyl-3-(4-trifluoromethylsulfanyl-phenyl)imidazolidine-2,4-dione in 2 ml of anhydrous dimethylformamide, under an inert atmosphere of argon at a temperature in the region of 20°C, stirring is continued at this temperature for 25 minutes, and a solution of 0 . 060 g of 2-fluoro-4-(bromomethyl)pyridine in 1 ml of anhydrous dimethylformamide is added, followed by addition of ice-water after reaction for 15 minutes. The reaction mixture is deposited on a cartridge 16 mm in diameter packed with 5 g of 40-60 /im octadecyl-grafted silica conditioned successively with a mixture (water/acetonitrile) (5/95) (v/v) and then with a mixture (water/acetonitrile) (95/5) (v/v). Elution was performed by a linear gradient of from 5% to 95% acetonitrile over 30 minutes, followed by a mixture (water/acetonitrile) (5/95) (v/v) for 10 minutes, at a flow rate of 5 ml/minute. The fractions between 105 and 125 ml are concentrated under reduced pressure. 0.069 g of 5,5-dimethyl-1-(2-fluoropyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione is thus obtained in the form of a white solid, the characteristics of which are as follows: m.p.: 82°C Mass EI m/z=413 M+' base peak m/z=398 (M - CH3)+ m/z = 219 C8H4NOSF3+* m/z = 151 C7H4N2OF+ m/z = 110 C6H5NF+ *H NMR spectrum (300 MHz, (CD3)2SO d6, 6 in ppm) : 1.45 (s: 6H); 4.72 (broad s: 2H); 7.29 (broad s: 1H) ; 7.43 (broad d, J = 5.5 Hz: 1H) ; 7.71 (broad d, J = 8.5 Hz: 2H); 7.89 (broad d, J = 8.5 Hz: 2H) ; 8.23 (d, J = 5.5 Hz: 1H). The compound 5,5-dimethyl-3-(4- trifluoromethylsulfanylphenyl)imidazolidine-2,4-dione is described in Example 211. Example 216; 5,5-Dimethyl-1-(2-cyanopyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione 0.037 g of sodium hydride is added to a solution of 0 .13 9 g of 5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl) imidazolidine-2,4-dione in 4 ml of anhydrous dimethylformamide, under an inert atmosphere of argon at a temperature in the region of 2 0°C, stirring is continued at this temperature for 3 0 minutes, and a solution of 0.090 g of 2-cyano-4-(bromomethyl)pyridine in 1 ml of anhydrous dimethylformamide is added, followed by addition of ice-water after reaction for 15 minutes. The reaction mixture is deposited on a cartridge 20 mm in diameter packed with 10 g of 40-60 ^m octadecyl-grafted silica conditioned successively with a mixture (water/acetonitrile) (5/95) (v/v) and then with a mixture (water/acetonitrile) (95/5) (v/v). Elution was performed by a linear gradient of from 5% to 95% acetonitrile over 30 minutes, followed by a mixture (water/acetonitrile) (5/95) (v/v) for 10 minutes, at a flow rate of 5 ml/minute. The fractions between 210 and 230 ml are concentrated under reduced pressure. 0.1 g of 5,5-dimethyl-1-(2-cyanopyrid-4-ylmethyl)-3-(4- trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione is thus obtained in solid form, the characteristics of which are as follows: m.p.: 148°C Mass EI m/z=420 M+" base peak m/z = 405 (M - CH3) + m/z=219 C8H4NOSF3+' m/z = 158 C8H4N30+ m/z=117 C7H5N2+ *H NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm) : 1.44 (s: 6H) ; 4.74 (broad S: 2H) ; 7.72 (broad d, J = 9 Hz: 2H) ; 7.81 (dd, J = 5.5 and 2 Hz: 1H) ; 7.89 (broad d, J = 9 Hz; 2H); 8.15 (broad s: 1H); 8.72 (broad d, J = 5.5 Hz: 1H). The compound 5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl) imidazolidine-2,4-dione is described in Example 211. Example 217; 5, 5-Dimethyl-1- (2-hydroxycarbonylpyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2, 4-dione A solution of 0.09 g of 5,5-dimethyl-l-(2-cyanopyrid-4-ylmethyl)-3-(4- trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione in 5 ml of 5N hydrochloric acid is refluxed for about 16 hours. The reaction mixture is concentrated under reduced pressure and the crude product thus obtained is purified by flash chromatography using a cartridge 20 mm in diameter packed with 10 g of conditioned 20-40 /im silica, and then eluted with a mixture (dichloromethane/methanol) (9/1) (v/v) at a flow rate of 8 ml/minute. The fractions between 4 0 and 200 ml are concentrated under reduced pressure. 0.06 g of 5,5-dimethyl-l-(2-hydroxy-carbonylpyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl) imidazolidine-2,4-dione is thus obtained, the characteristics of which are as follows: Mass EI m/z=439 M+" m/z=395 (M - C0NH2)+base peak m/z = 219 C8H4NOSF3+" m/z = 185 C7H9N202S+ XH NMR spectrum (300 MHz, (CD3)2SO d6, 8 in ppm) : 1.45 (s: 6H) ; 4.76 (broad S: 2H) ; 7.70 (d, J = 8.5 Hz: 2H); 7.72 (mt: 1H); 7.89 (d, J = 8.5 Hz: 2H); 8.12 (broad s: 1H); 8.68 (d, J = 5.5 Hz: 1H). Example 218; 5,5-Dimethyl-l-[2-(methylamino)carbonyl-pyrid-4-ylmethyl] -3- (4-trifluoromethanesulfanylphenyl) -imidazolidine-2,4-dione 0.025 g of methylamine hydrochloride, 0.005 g of hydroxybenzotriazole hydrate, 0.105 ml of triethylamine and 72 mg of 1-(3-dimethylaminopropyl)-3-ethylcarbodi-imide hydrochloride are successively added to a solution of 0.055 g of 5,5-dimethyl-l-(2-hydroxycarbonylpyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl) imidazolidine-2,4-dione in 2 ml of dichloromethane, under an inert atmosphere of argon at a temperature in the region of 20°C, and stirring is continued at this temperature for about 16 hours. The reaction mixture is washed with water and the organic phase is dried over magnesium sulfate, filtered and then concentrated under reduced pressure. The crude product thus obtained is purified by flash chromatography using a cartridge 16 mm in diameter packed with 5 g of conditioned 2 0-40 /im silica, and then eluted with a mixture (dichloromethane/methanol) (95/05) (v/v) at a flow rate of 10 ml per minute. The fractions containing the expected product are concentrated under reduced pressure. 0.013 g of 5,5-dimethyl-1-[2-(methylamino)carbonylpyrid-4-ylmethyl] -3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione is thus obtained in the form of a white powder, the characteristics of which are as follows: Mass EI m/z=452 M+" m/z=395 (M - C2H3ON)+ base peak m/z=219 C8H4NOSF3+' m/z = 148 C8H8N20+ XH NMR spectrum (300 MHz, (CD3)2SO d6, 8 in ppm) : 1.44 (s: 6H); 2.85 (d, J = 5 Hz; 3H); 4.76 (broad s: 2H) ; 7.67 (dd, J = 5 and 2 Hz: 1H); 7.70 (broad d, J = 8.5 Hz: 2H); 7.89 (broad d, J = 8.5 Hz: 2H); 8.10 (broad s: 1H); 8.60 (d, J = 5 Hz: 1H)/ 8.75 (broad q, J = 5 Hz: 1H). Example 219 : 5, 5-Dimethyl -1 - (2-aminocarbonylpyrid-4 -yl-methyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2, 4-dione A solution of 0.04 g of 5,5-dimethyl-1-(2-cyanopyrid-4-ylmethyl)-3-(4- trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione in 1 ml of 98% sulfuric acid is maintained at 40°C for 3 0 minutes. The mixture is taken up in 15 ml of ice-water and then neutralized with normal sodium hydroxide solution. The solution thus obtained is extracted with 100 ml of ethyl acetate. The organic phase is dried over magnesium sulfate, filtered and then concentrated under reduced pressure, and the crude product thus obtained is purified by flash chromatography using a cartridge 16 mm in diameter packed with 5 g of conditioned 20-40 /xm silica, and then eluted with dichloromethane at a flow rate of 10 ml per minute. The fractions containing the expected product are concentrated under reduced pressure. 0 . 017 g of 5,5-dimethyl-l-(2-aminocarbonylpyrid-4-yl-methyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolid-ine-2,4-dione is thus obtained in the form of an amorphous white powder, the characteristics of which are as follows: Mass EI m/z=438 M+' base peak m/z=423 (M - CH3)+ m/z=393 (M - CH3N0) + m/z = 219 C8H4NOSF3+- m/z = 135 C7H7N20+ *H NMR spectrum (300 MHz, (CD3)2SO d6, S in ppm) : 1.44 (s: 6H) ; 4.76 (broad s: 2H) ; from 7.60 to 7.70 (mt: 2H) ; 7.71 (broad d, J = 8.5 Hz: 2H) ; 7.89 (broad d, J = 8.5 Hz: 2H) ; 8.11 (broad S: 2H) ; 8.60 (d, J= 5.5 Hz: 1H) . Example 220t 5,5-Dimethyl-l-(2-morpholinopyrid-4-yl-methyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione A sealed 2.5 ml tube containing 0.05 g of 5,5-dimethyl-1-(2-chloropyrid-4-ylmethyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione, 0 . 5 ml of dimethylformamide, 0.034 g of potassium carbonate and 0.021 ml of morpholine is placed in a Personal Chemistry Emrys Optimiser microwave oven. The mixture is irradiated with magnetic stirring at 210°C for about 50 minutes. The reaction mixture is deposited on a Bond Elut Varian reference 1225-6053 cartridge containing 2 g of SCX phase conditioned with dimethylformamide. Washing with methanol is performed, followed by elution with 2M ammoniacal methanol. The ammoniacal fractions are concentrated to dryness under reduced pressure. The residue thus obtained is purified by flash chromatography using a cartridge 16 mm in diameter packed with 2 g of conditioned 15-35 /xm silica, and then eluted with a mixture (cyclohexane/ethyl acetate) (8/2) (v/v) at a flow rate of 10 ml/minute. The fractions between 160 and 260 ml are concentrated to dryness under reduced pressure. 0.01 g of 5,5-dimethyl-l-(2-morpholinopyrid-4-ylmethyl)-3-(4-trifluoromethoxy-phenyl)imidazolidine-2,4-dione is thus obtained in the form of a powder, the characteristics of which are as follows: Mass EI m/z = 464 M+" m/z=433 (M - CH30)+ base peak m/z = 419 (M - C2H50) + m/z = 407 (M - C3H50) + m/z = 379 (M - C4H5NO) + m/z = 203 C8H4N02F3+* m/z=176 Ci0Hi2N2O+- XH NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm) : 1.42 (s: 6H) ; 3.44 (broad t, J - 5 Hz: 4H) ; 3.72 (broad t, J = 5 Hz: 4H); 4.53 (broad s: 2H) ; 6.75 (broad d, J = 5.5 Hz: 1H); 6.85 (broad s: 1H); 7.54 (broad d, J = 8.5 Hz: 2H) ; 7.64 (d, J = 8.5 Hz: 2H) ; 8.10 (d, J = 5.5 Hz: 1H). Example 221; 5,5-Dimethyl-l-(2-morpholinopyrid-4-yl-methyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2, 4-dione A sealed 2.5 ml tube containing 0.05 g of 5,5-dimethyl-1-(2-chloropyrid-4-ylmethyl)-3-(4- trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione and 0.5 ml of morpholine is placed in a Personal Chemistry Emrys Optimiser microwave oven. The mixture is irradiated with magnetic stirring at 160°C for about 70 minutes. The reaction mixture is purified by preparative LC/MS. The fractions containing the expected product are concentrated to dryness under reduced pressure. The residue thus obtained is taken up in methanol and then deposited on a Bond Elut Varian reference 1225-6053 cartridge containing 2 g of SCX phase conditioned with methanol. Washing with methanol is performed, followed by elution with 2M ammoniacal methanol. The ammoniacal fractions are concentrated to dryness under reduced pressure. 0 . 03 g of 5,5-dimethyl-l-(2-morpholinopyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2, 4-dione is thus obtained in the form of a powder, the characteristics of which are as follows: Mass EI m/z=480 M+' m/z=449 (M - CH30)+ base peak m/z = 435 (M - C2H50) + +. m/z=423 (M - C3H50) + .+. m/z = 219 C8H4NOSF3 m/z = 176 Ci0Hi2N2O' XH NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm) : 1.42 (s: 6H) ; 3.45 (broad t, J = 5 Hz: 4H); 3.71 (broad t, J = 5 Hz: 4H); 4.54 (broad S: 2H); 6.75 (broad d, J = 5.5 Hz: 1H); 6.84 (broad s: 1H); 7.68 (broad d, J = 8.5 Hz: 2H) ; 7.88 (d, J = 8.5 Hz: 2H) ; 8.09 (d, J = 5.5 Hz: 1H). Example 222: 5,5-Dimethyl-l-(2-dimethylaminopyrid-4-yl-methyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2, 4-dione A sealed 2.5 ml tube containing 0.05 g of 5,5-dimethyl-1-(2-chloropyrid-4-ylmethyl)-3-(4- trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione, 0.4 ml of isopropylamine and 0.1 ml of dimethylformamide is placed in a Personal Chemistry Emrys Optimiser microwave oven. The mixture is irradiated with magnetic stirring at 14 0°C for about 13 0 minutes. The reaction mixture is purified by preparative LC/MS. The fractions containing the expected product are concentrated to dryness under reduced pressure. The residue thus obtained is taken up in methanol and then deposited on a Bond Elut Varian reference 1225-6053 cartridge containing 2 g of SCX phase conditioned with methanol. Washing with methanol is performed, followed by elution with 2M ammoniacal methanol. The ammoniacal fractions are concentrated to dryness under reduced pressure. 0.013 g of 5,5-dimethyl-l-(2-dimethylaminopyrid-4-ylmethyl)-3- (4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione is thus obtained in the form of a powder, the characteristics of which are as follows: Mass CI m/z=439 MH+ base peak XH NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm) : 1.42 (s: 6H) / 3.03 (s: 6H) ; 4.53 (broad s: 2H) ; 6.62 (broad d, J = 5.5 Hz: 1H) ; 6.65 (broad s: 1H) ; 7.68 (broad d, J = 8.5 Hz: 2H); 7.87 (d, J = 8.5 Hz: 2H); 8.03 (d, J = 5.5 Hz: 1H). Example 223 : 5,5-Dimethyl-1 - (2 -methylaminopyrid-4 -yl -methyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2, 4-dione A sealed 2.5 ml tube containing 0.1 g of 5,5-dimethyl-1-(2-chloropyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione, 0.5 ml of N-methyl-2-pyrrolidone, 0.016 mg of methylamine hydrochloride and 0.064 ml of triethylamine is placed in a Personal Chemistry Emrys Optimiser microwave oven. The mixture is irradiated with magnetic stirring at 180°C for about 80 minutes. The reaction mixture is purified by preparative LC/MS. The fractions containing the expected product are concentrated to dryness under reduced pressure. The residue thus obtained is taken up in methanol and then deposited on a Bond Elut Varian reference 1225-6054 cartridge containing 3 g of SCX phase conditioned with methanol. Washing with methanol is performed, followed by elution with 2M ammoniacal methanol. The ammoniacal fractions are concentrated to dryness under reduced pressure. The residue thus obtained is purified by flash chromatography using a cartridge 16 mm in diameter packed with 2 g of conditioned 15-35 /zm silica, and then eluted with dichloromethane at a flow rate of 5 ml/minute. The fractions containing the expected product are concentrated to dryness under reduced pressure. 0.021 g of 5,5-dimethyl-1-(2-methylaminopyrid-4-ylmethyl)-3-(4- trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione is thus obtained in the form of an amorphous white powder, the characteristics of which are as follows: Mass EI m/z=424 M+' base peak m/z = 396 (M - CH2N) + m/z=219 C8H4NOSF3+- m/z = 120 C7H8N2+' 1H NMR spectrum (300 MHz, (CD3)2SO d6, 8 in ppm) : 1.42 (s: 6H); 2.77 (d, J = 5 Hz: 3H); 4.48 (broad S: 2H) ; 6.42 (mt: 1H) ; 6.46 (broad s: 1H) ; 6.52 (broad d, J = 5.5 Hz: 1H); 7.69 (broad d, J = 8.5 Hz: 2H); 7.89 (broad d, J = 8.5 Hz: 2H); 7.94 (d, J = 5.5 Hz: 1H). Example 224: 5,5-Dimethyl-1-(2-cyclohexylaminopyrid-4 -ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2, 4-dione A sealed 2.5 ml tube containing 0.1 g of 5,5-dimethyl-1-(2-chloropyrid-4-ylmethyl)-3-(4- trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione, 0.2 ml of N-methyl-2-pyrrolidone and 0.4 ml of cyclohexylamine is placed in a Personal Chemistry Emrys Optimiser microwave oven. The mixture is irradiated with magnetic stirring at 2 00°C for about 50 minutes. The reaction mixture is purified by preparative LC/MS. The fractions containing the expected product are concentrated to dryness under reduced pressure. The residue thus obtained is taken up in methanol and then deposited on a Bond Elut Varian reference 1225-6054 cartridge containing 3 g of SCX phase conditioned with methanol. Washing with methanol is performed, followed by elution with 2M ammoniacal methanol. The ammoniacal fractions are concentrated to dryness under reduced pressure. The residue thus obtained is purified by flash chromatography using a cartridge 16 mm in diameter packed with 2 g of conditioned 15-35 /xm silica, and then eluted with dichloromethane at a flow rate of 5 ml/minute. The fractions between 15 and 45 ml are concentrated under reduced pressure. 0 . 017 g of 5,5-dimethyl-l-(2-cyclohexylaminopyrid-4-ylmethyl)-3-(4- trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione is thus obtained in the form of an amorphous powder, the characteristics of which are as follows: Mass EI m/z=492 M+- m/z=449 (M - C3H7 m/z=435 (M - C3H7 m/z=410 (M - C6Hi m/z=219 C8H4NOSF3H m/z=175 CnH15N2+ m/z=98 C6H12N+ XH NMR spectrum (400 MHz, (CD3)2SO d6, 5 in ppm) : from 1.10 to 1.40 (mt: 5H) ; 1.43 (s: 6H) ; from 1.55 to 2.0 0 (mt: 5H); 3.67 (mt: 1H); 4.45 (s: 2H); 6.2 8 (d, J = 8 Hz: 1H); 6.44 (broad s: 1H); 6.46 (broad d, J = 5.5 Hz: 1H); 7.68 (broad d, J = 9 Hz: 2H) ; from 7.85 to 7.95 (mt: 3H) . Example 225: 5,5-Dimethyl-1-(2-isopropylaminopyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)imidazo-lidine-2,4-dione A sealed 2.5 ml tube containing 0.1 g of 5,5-dimethyl-1-(2-chloropyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione, 0.2 ml of N-methyl-2-pyrrolidone and 0.4 ml of isopropylamine is placed in a Personal Chemistry Emrys Optimiser microwave oven. The mixture is irradiated with magnetic stirring at 200°C for about 70 minutes. The reaction mixture is purified by preparative LC/MS. The fractions containing the expected product are concentrated to dryness under reduced pressure. The residue thus obtained is taken up in methanol and then deposited on a Bond Elut Varian reference 1225-6027 cartridge containing 5 g of SCX phase conditioned with methanol. Washing with methanol is performed, followed by elution with 2M ammoniacal methanol. The ammoniacal fractions are concentrated to dryness under reduced pressure. The residue thus obtained is purified by flash chromatography using a cartridge 16 mm in diameter packed with 2 g of conditioned 15-35 fim silica, and then eluted with dichloromethane at a flow rate of 5 ml/minute. The fractions between 10 and 35 ml are concentrated to dryness under reduced pressure. 0.008 g of 5,5-dimethyl-1-(2-isopropylaminopyrid-4-ylmethyl)-3-(4- trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione is thus obtained in the form of an amorphous powder, the characteristics of which are as follows: Mass EI m/z = 452 M+* m/z=437 (M - CH3)+base peak m/z = 410 (M - C3H6)+- m/z = 219 C8H4NOSF3+' m/z=134 C8H10N2+- m/z = 58 C3H8N+ lK NMR spectrum (3 00 MHz, (CD3)2SO d6, 5 in ppm) : 1.13 (d, J = 6.5 Hz: 6H) ; 1.42 (s: 6H) ; 3.98 (mt : 1H) ; 4.45 (broad s: 2H) ; 6.27 (broad d, J = 7.5 Hz: 1H); 6.42 (broad s: 1H) ; 6.46 (broad d, J = 5.5 Hz: 1H) ; 7.68 (broad d, J = 8 Hz: 2H); 7.88 (broad d, J = 8 Hz: 2H) ; 7.90 (d, J = 5.5 Hz: 1H). Example 226: 5,5-Dimethyl-l-(2-piperidinopyrid-4-yl-methyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolid-ine-2,4-dione A sealed 2.5 ml tube containing 0.1 g of 5,5-dimethyl-1-(2-chloropyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione, 0.2 ml of N-methyl-2-pyrrolidone and 0.4 ml of piperidine is placed in a Personal Chemistry Emrys Optimiser microwave oven. The mixture is irradiated with magnetic stirring at 200°C for about 30 minutes. The reaction mixture is purified by preparative LC/MS. The fractions containing the expected product are concentrated to dryness under reduced pressure. The residue thus obtained is taken up in methanol and then deposited on a Bond Elut Varian reference 1225-6027 cartridge containing 5 g of SCX phase conditioned with methanol. Washing with methanol is performed, followed by elution with 2M ammoniacal methanol. The ammoniacal fractions are concentrated to dryness under reduced pressure. The residue thus obtained is purified by flash chromatography using a cartridge 16 mm in diameter packed with 2 g of conditioned 15-35 fim silica, and then eluted with dichloromethane, at a flow rate of 5 ml/minute. The fractions between 10 and 30 ml are concentrated to dryness under reduced pressure. 0.07 g of 5,5-dimethyl-1-(2-piperidinopyrid-4-ylmethyl)-3-(4- trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione is thus obtained in the form of an amorphous powder, the characteristics of which are as follows: Mass EI m/z=478 M+" base peak m/z = 449 (M - C2H5) + m/z = 422 (M - C4H8)+' m/z=395 (M - C5H9N)+ m/z=219 C8H4NOSF3+- m/z = 161 C10H13N2+ m/z=84 C5Hi0N+ XH NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm) : 1.42 (s: 6H); from 1.45 to 1.65 (mt: 6H); 3.52 (broad t, J = 5 Hz: 4H) ; 4.52 (broad S: 2H) ; 6.64 (broad d, J = 5.5 Hz: 1H) ; 6.83 (broad s: 1H) ; 7.68 (d, J = 8.5 Hz: 2H); 7.88 (d, J = 8.5 Hz: 2H); 8.04 (d, J = 5.5 Hz: 1H). Example 227; 5,5-Dimethyl-l-[2-(4-methylpiperazino)pyrid-4-ylmethyl]-3-(4-trifluoromethanesulfanylphenyl)-imidazolidine-2,4-dione A sealed 2.5 ml tube containing 0.1 g of 5,5-dimethyl-1-(2-chloropyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione, 0.2 ml of N-methyl-2-pyrrolidone and 0.4 ml of N-methylpiperazine is placed in a Personal Chemistry Emrys Dptimiser microwave oven. The mixture is irradiated with magnetic stirring at 200°C for about 3 0 minutes. The reaction mixture is purified by preparative LC/MS. The fractions containing the expected product are concentrated to dryness under reduced pressure. The residue thus obtained is taken up in methanol and then deposited on a Bond Elut Varian reference 1225-6027 cartridge containing 5 g of SCX phase conditioned with methanol. Washing with methanol is performed, followed by slution with 2M ammoniacal methanol. The ammoniacal fractions are concentrated to dryness under reduced pressure. The residue thus obtained is purified by flash chromatography using a cartridge 16 mm in diameter packed with 2 g of conditioned 15-35 /zm silica, and then eluted with dichloromethane, at a flow rate of 5 ml/minute. The fractions between 105 and 135 ml are concentrated to dryness under reduced pressure. 0.028 g of 5,5-dimethyl-1-[2-(4-methylpiperazino)pyrid-4-ylmethyl]-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione is thus obtained in the form of an amorphous powder, the characteristics of which are as follows: Mass EI m/z=493 M+- m/z=423 (M - C4H8N)+- base peak m/z = 219 C8H4NOSF3+- m/z = 176 C10H14N3+ 1H NMR spectrum (300 MHz, (CD3)2SO d6, 8 in ppm) : 1.42 (s: 6H) ; 2.23 (s: 3H) ; 2.40 (broad t, J = 5 Hz: 4H); 3.50 (broad t, J = 5 Hz: 4H) ; 4.53 (broad s: 2H) ; 6.70 (broad d, J = 5.5 Hz: 1H); 6.85 (broad s: 1H); 7.69 (d, J = 8.5 Hz: 2H) ; 7.88 (d, J = 8.5 Hz: 2H) ; 8.07 (d, J = 5.5 Hz: 1H) . Example 228: 5,5-Dimethyl-1-(2-phenylaminopyrid-4-yl-methyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2, 4-dione A sealed 2.5 ml tube containing 0.1 g of 5,5-dimethyl-1-(2-chloropyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione, 0.2 ml of N-methyl-2-pyrrolidone and 0.4 ml of aniline is placed in a Personal Chemistry Emrys Optimiser microwave oven. The mixture is irradiated with magnetic stirring at 2 0 0 ° C for about 3 0 minutes. The react ion mixture is purified by preparative LC/MS. The fractions containing the expected product are concentrated to dryness under reduced pressure. The residue thus obtained is taken up in methanol and then deposited on a Bond Elut Varian reference 1225-6027 cartridge containing 5 g of SCX phase conditioned with methanol. Washing with methanol is performed, followed by elution with 2M ammoniacal methanol. The ammoniacal fractions are concentrated to dryness under reduced pressure. The residue thus obtained is purified by flash chromatography using a cartridge 16 mm in diameter packed with 2 g of conditioned 15-35 /xm silica, and then eluted with dichloromethane, at a flow rate of 5 ml/minute. The fractions between 40 and 85 ml are concentrated to dryness under reduced pressure. 0 . 082 g of 5,5-dimethyl-1-(2-phenylaminopyrid-4-ylmethyl)-3-(4-tri- fluoromethanesulfanylphenyl)imidazolidine-2,4-dione is ■thus obtained in the form of an amorphous powder, the characteristics of which are as follows: Mass EI m/z=486 M+" m/z=485 (M - H)+ base peak m/z=417 (M - CF3) + m/z = 182 Ci2H10N2+-XH NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm) : 1.46 (s: 6H) ; 4.55 (broad s: 2H) ; 6.80 (broad d, J = 5.5 Hz: 1H) ; 6.84 (broad s: 1H) ; 6.88 (broad t, J = 7.5 Hz: 1H) ; 7.25 (dd, J = 8 and 7.5 Hz: 2H) ; 7.67 (broad d, J = 8 Hz: 2H); 7.69 (d, J = 8.5 Hz: 2H); 7.88 (broad d, J = 8.5 Hz: 2H); 8.01 (d, J = 5.5 Hz: 1H); 9.01 (broad S: 1H) . Example 229; 5,5-Dimethyl-1-[2-(4-piperazino)pyrid-4-ylmethyl]-3-(4-trifluoromethanesulfanylphenyl)-imidazolidine-2,4-dione A sealed 2.5 ml tube containing 0.1 g of 5,5-dimethyl-1-(2-chloropyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione, 0.6 ml of N-methyl-2-pyrrolidone and 0.123 g of piperazine is placed in a Personal Chemistry Emrys Optimiser microwave oven. The mixture is irradiated with magnetic stirring at 200°C for about 30 minutes. The reaction mixture is purified by preparative LC/MS. The fractions containing the expected product are concentrated to dryness under reduced pressure. The residue thus obtained is taken up in methanol and then deposited on a Bond Elut Varian reference 1225-6027 cartridge containing 5 g of SCX phase conditioned with methanol. Washing with methanol is performed, followed by elution with 2M ammoniacal methanol. The ammoniacal fractions are concentrated to dryness under reduced pressure. The residue thus obtained is purified by flash chromatography using a cartridge 16 mm in diameter packed with 2 g of conditioned 15-35 /xm silica, and then eluted with dichloromethane, at a flow rate of 5 ml/minute. The fractions between 45 and 110 ml are concentrated to dryness under reduced pressure. 0.042 g of 5,5-dimethyl-1-[2-(4-piperazino)pyrid-4-ylmethyl] -3-(4- trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione is thus obtained in the form of an amorphous powder, the characteristics of which are as follows: Mass CI m/z=480 MH+ base peak *H NMR spectrum (300 MHz, (CD3)2SO d6, 8 in ppm) : 1.43 (s: 6H) ; 2.79 (broad t, J = 5 Hz: 4H) ; 3.41 (broad t, J = 5 Hz: 4H); 4.52 (broad s: 2H); 6.69 (broad d, J = 5.5 Hz: 1H) ; 6.82 (broad s: 1H) ; 7.69 (broad d, J = 8.5 Hz: 2H) ; 7.88 (d, J = 8.5 Hz: 2H) ; 8.06 (d, J = 5.5 Hz: 1H) . Example 230: 5,5-Dimethyl-l-(2-ethylaminopyrid-4-yl-methyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2, 4-dione A sealed 2.5 ml tube containing 0.1 g of 5,5-dimethyl-1-(2-chloropyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione, 0.5 ml of N-methyl-2-pyrrolidone, 0.019 g of ethylamine hydrochloride and 0.064 ml of triethylamine is placed in a Personal Chemistry Emrys Optimiser microwave oven. The mixture is irradiated with magnetic stirring at 200°C for about 120 minutes. The reaction mixture is purified by preparative LC/MS. The fractions containing the expected product are concentrated to dryness under reduced pressure. The residue thus obtained is taken up in methanol and then deposited on a Bond Elut Varian reference 1225-6027 cartridge containing 5 g of SCX phase conditioned with methanol. Washing with methanol is performed, followed by elution with 2M ammoniacal methanol. The ammoniacal fractions are concentrated to dryness under reduced pressure. The residue thus obtained is purified by flash chromatography using a cartridge 16 mm in diameter packed with 2 g of conditioned 15-35 /im silica, and then eluted with dichloromethane, at a flow rate of 5 ml/minute. The fractions between 280 and 300 ml are concentrated to dryness under reduced pressure. 0 . 033 g of 5, 5-dimethyl-l- (2-ethylaminopyrid-4-ylmethyl) -3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione is thus obtained in the form of an amorphous powder, the characteristics of which are as follows: m.p. = 136°C Mass EI m/z = 438 M+" m/z=423 (M - CH3)+base peak m/z = 395 (M - C2H5N) + m/z = 369 (M - CF3) + m/z=121 C7H9N2+' m/z = 44 C2H6N+ XH NMR spectrum (300 MHz, (CD3)2SO d6, 8 in ppm) : 1.14 (t, J = 7 Hz: 3H); 1.44 (s: 6H); 3.26 (mt: 2H); 4.47 (broad s: 2H) ; 6.40 (broad t, J = 5.5 Hz: 1H) ; 6.45 (broad s: 1H) ; 6.50 (broad d, J = 5.5 Hz: 1H) ; 7.69 (broad d, J = 8.5 Hz: 2H) ; 7.89 (broad d, J = 8.5 Hz: 2H); 7.92 (d, J = 5.5 Hz: 1H). Example 231: 5,5-Dimethyl-1-(2-benzylaminopyrid-4-yl-methyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2, 4-dione A sealed 2.5 ml tube containing 0.1 g of 5,5-dimethyl-1-(2-chloropyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione, 0.2 ml of N-methyl-2-pyrrolidone and 0.4 ml of benzylamine is placed in a Personal Chemistry Emrys Optimiser microwave oven. The mixture is irradiated with magnet ic st irring at 2 0 0 ° C for about 3 0 minutes. The reaction mixture is purified by preparative LC/MS. The fractions containing the expected product are concentrated to dryness under reduced pressure. The residue thus obtained is taken up in methanol and then deposited on a Bond Elut Varian reference 1225-6027 cartridge containing 5 g of SCX phase conditioned with methanol. Washing with methanol is performed, followed by elution with 2M ammoniacal methanol. The ammoniacal fractions are concentrated to dryness under reduced pressure. The residue thus obtained is purified by flash chromatography using a cartridge 16 mm in diameter packed with 2 g of conditioned 15-35 /xm silica, and then eluted with dichloromethane, at a flow rate of 5 ml/minute. The fractions between 10 and 50 ml are concentrated to dryness under reduced pressure. 0.035 g of 5,5-dimethyl-1-(2-benzylaminopyrid-4-ylmethyl)-3-(4- trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione is thus obtained in the form of an amorphous powder, the characteristics of which are as follows: m.p. 144°C Mass EI m/z=500 M+' base peak m/z = 431 (M - CF3) + m/z=196 Ci3Hi2N2+' m/z = 106 C7H8N+ m/z=91 C7H7+ 1H NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm) : 1.39 (s: 6H) ; 4.47 (broad s: 2H) ; 4.48 (d, J = 6 Hz: 2H) ; 6.51 (broad S: 1H) ; 6.54 (broad d, J = 5.5 Hz: 1H) ; 7.02 (broad t, J = 6 Hz: 1H); from 7.15 to 7.35 (mt: 5H); 7.68 (broad d, J = 8.5 Hz: 2H); 7.89 (d, J = 8.5 Hz: 2H); 7.92 (d, J = 5.5 Hz: 1H). Example 232; 5,5-Dimethyl-l-[2-(4-methoxybenzylamino)-pyrid-4-ylmethyl]-3-(4-trifluoromethanesulfanylphenyl)-imidazolidine-2,4-dione A sealed 2.5 ml tube containing 0.1 g of 5,5-dimethyl-1-(2-chloropyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione, 0.2 ml of N-methyl-2-pyrrolidone and 0.4 ml of para-methoxybenzylamine is placed in a Personal Chemistry Emrys Optimiser microwave oven. The mixture is irradiated with magnetic stirring at 200°C for about 30 minutes. The reaction mixture is purified by preparative LC/MS. The fractions containing the expected product are concentrated to dryness under reduced pressure. The residue thus obtained is taken up in methanol and then deposited on a Bond Elut Varian reference 1225-6027 cartridge containing 5 g of SCX phase conditioned with methanol. Washing with methanol is performed, followed by elution with 2M ammoniacal methanol. The ammoniacal fractions are concentrated to dryness under reduced pressure. The residue thus obtained is purified by flash chromatography using a cartridge 16 mm in diameter packed with 2 g of conditioned 15-35 /xm silica, and then eluted with dichloromethane, at a flow rate of 5 ml/minute. The fractions between 5 and 55 ml are concentrated to dryness under reduced pressure. 0.035 g of 5,5-dimethyl-1-[2-(4-methoxybenzylamino)pyrid-4-ylmethyl] -3-(4- trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione is thus obtained in the form of an amorphous powder, the characteristics of which are as follows: Mass EI m/z=530 M+- m/z = 461 (M - CF3) + m/z=136 C8Hi0NO+ m/z=121 C8H90+ base peak XH NMR spectrum (300 MHz, (CD3)2SO d6, 8 in ppm) : 1.39 (s: 6H) ; 3.72 (s: 3H) ; 4.39 (d, J = 5.5 Hz: 2H) ; 4.46 (broad s: 2H) ; 6.48 (broad s: 1H); 6.53 (broad d, J = 5.5 Hz: 1H) ; 6.87 (broad d, J = 8.5 Hz: 2H) ; 6.93 (t, J = 5.5 Hz: 1H) ; 7.25 (broad d, J = 8.5 Hz: 2H) ; 7.68 (broad d, J = 8.5 Hz: 2H) ; 7.89 (broad d, J = 8.5 Hz: 2H) ; 7.92 (d, J = 5.5 Hz: 1H) . Example 233; 5,5-Dimethyl-1-(2-aminopyrid-4-ylmethyl)-3-(4-tri fluoromethanesulfanylphenyl)imidazolIdine-2,4-dione. 0.5 ml of trif luoroacetic acid is added to a solution of 0.035 g of 5,5-dimethyl-l-[2-(4-methoxybenzylamino)pyrid-4-ylmethyl] -3-(4- trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione in 0.5 ml of dichloromethane at a temperature in the region of 2 0 ° C, and s t irr ing is cont inued at this same temperature for 5 hours. The reaction mixture is purified by preparative LC/MS. The fractions containing the expected product are concentrated to dryness under reduced pressure. The residue thus obtained is taken up in methanol and then placed on a Bond Elut Varian reference 1225-6027 cartridge containing 5 g of SCX phase conditioned with methanol. Washing with methanol is performed, followed by elution with 2M ammoniacal methanol. The ammoniacal fractions are concentrated to dryness under reduced pressure. 0.015 g of 5,5-dimethyl-1-(2-aminopyrid-4-ylmethyl) -3-(4- trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione is thus obtained in the form of a powder, the characteristics of which are as follows: m.p.: 161°C Mass EI m/z=410 M+* base peak m/z=395 (M - CH3)+ m/z = 219 C8H4NOSF3+' m/z = 148 C7H6N30+ m/z=107 C6H7N2+ lH NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm) : 1.43 (s: 6H) ; 4.46 (broad s: 2H) ; 5.86 (broad s: 2H) ; 6.46 (broad s: 1H); 6.53 (broad d, J = 5.5 Hz: 1H); 7.69 (broad d, J = 8.5 Hz: 2H); 7.84 (d, J = 5.5 Hz: 1H); 7.89 (broad d, J = 8.5 Hz: 2H). Example 234; 5# 5-Dimethyl-1-(2-acetamidopyrid-4-yl-methyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2, 4-dione A solution of 0.050 g of 5,5-dimethyl-1-(2-aminopyrid-4-ylmethyl)-3-(4- trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione in 5 ml of acetic anhydride is stirred under an inert atmosphere of argon for 24 hours at a temperature in the region of 8 0°C. The reaction mixture is purified by preparative LC/MS. The fractions containing the expected product are concentrated to dryness under reduced pressure. The residue thus obtained is taken up in methanol and then placed on a Bond Elut Varian reference 1225-6027 cartridge containing 5 g of SCX phase conditioned with methanol. Washing with methanol is performed, followed by elution with 2M ammoniacal methanol. The ammoniacal fractions are concentrated to dryness under reduced pressure. 0.006 g of 5,5-dimethyl-1-(2-acetamidopyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione is thus obtained in the form of a powder, the characteristics of which are as follows: Mass EI m/z = 452 M+- m/z=410 (M » C2H20)+-base peak m/z=395 (m/z=410 - CH3)+ m/z = 219 C8H4NOSF3+' m/z=150 C8Hi0N2O+- m/z=107 C6H7N2+ m/z=43 C2H30+ XR NMR spectrum (300 MHz, (CD3)2SO d6, 5 in ppm) : 1.44 (broad s: 6H) ; 2.11 (s: 3H) ; 4.65 (broad s: 2H) ; 7.15 (broad d, J = 5.5 Hz: 1H); 7.68 (broad d, J = 8.5 Hz: 2H) ; 7.89 (broad d, J = 8.5 Hz: 2H) ; 8.14 (broad s: 1H) ; 8.27 (d, J = 5.5 Hz: 1H) ; 10.49 (unresolved complex: 1H). Example 235: 5,5-Dimethyl-1-(2-tert-butoxycarbonyl-aminopyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanyl-phenyl)imidazolidine-2,4-dione 0 . 05 g of 5,5-dimethyl-l-(2-aminopyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione is added portionwise to a solution of 0.029 g of di-tert-butyl dicarbonate in 0.65 ml of tert-butyl alcohol, under an inert atmosphere of argon at a temperature in the region of 20 °C, and stirring is continued at this temperature for 24 hours. The reaction mixture is concentrated to dryness under reduced pressure. The residue thus obtained is purified by flash chromatography using a cartridge 16 mm in diameter packed with 5 g of conditioned 20-40 /an silica, and then eluted with a mixture (cyclohexane/ethyl acetate) (8/2) (v/v). The fractions between 260 and 400 ml are concentrated under reduced pressure. 0.035 g of 5,5-dimethyl-l-(2-tert-butoxycarbonylaminopyrid-4-ylmethyl)-3- (4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione is thus obtained, the characteristics of which are as follows: Mass CI m/z=511 MH+ base peak XH NMR spectrum (300 MHz, (CD3)2SO d6, 8 in ppm) : 1.43 (s: 6H) ; 1.4 9 (s: 9H) ; 4.6 3 (broad s: 2H) ; 7.0 8 (broad dd, J = 5.5 and 1.5 Hz: 1H) ; 7.68 (broad d, J = 9 Hz: 2H); 7.84 (broad s: 1H); 7.87 (broad d, J = 9 Hz: 2H); 8.19 (d, J = 5.5 Hz: 1H); 9.73 (broad s: 1H). Example 236: 5, 5-Dimethyl-1- (2-methylsulfonylaminopyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)-imidazolidine-2,4-dione 0.010 ml of methanesulfonyl chloride is added to a solution of 0.050 g of 5,5-dimethyl-l-(2-aminopyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2, 4-dione in 0.4 ml of pyridine, under an inert atmosphere of argon at a temperature in the region of 2 0°C, and stirring is continued at this temperature for 2 hours. The reaction mixture is poured into 50 ml of saturated sodium bicarbonate solution and then extracted with 2x50 ml of ethyl acetate. The organic phase is dried over magnesium sulfate, filtered and then concentrated to dryness under reduced pressure. 0 . 020 g of 5,5-dimethyl-1-(2-methylsulfonylaminopyrid-4-ylmethyl)-3-(4-trifluoromethanesulfanylphenyl)imidazolidine-2,4-dione is thus obtained in the form of a white powder, the characteristics of which are as follows: m.p.: 208°C Mass EI m/z=488 M+* base peak m/z=473 (M - CH3)+ m/z = 409 (M - S02CH3) + m/z = 219 C8H4NOSF3+- m/z = 185 C7H9N202S+

Documents:

1730-chenp-2005 abstract duplicate.pdf

1730-chenp-2005 claims duplicate.pdf

1730-chenp-2005 description (complete) duplicate-1.pdf

1730-chenp-2005 description (complete) duplicate-2.pdf

1730-chenp-2005 description (complete) duplicate-3.pdf

1730-chenp-2005 description (complete) duplicate-4.pdf

1730-chenp-2005 description (complete) duplicate-5.pdf

1730-chenp-2005 description (complete) duplicate-6.pdf

1730-chenp-2005 description (complete) duplicate-7.pdf

1730-chenp-2005 description (complete) duplicate-8.pdf

1730-chenp-2005 description (complete) duplicate.pdf

1730-chenp-2005-abstract-c.pdf

1730-chenp-2005-abstract.pdf

1730-chenp-2005-claims.pdf

1730-chenp-2005-cliams-c.pdf

1730-chenp-2005-correspondnece-others.pdf

1730-chenp-2005-correspondnece-po.pdf

1730-chenp-2005-description complete-c.pdf

1730-chenp-2005-description(complete).pdf

1730-chenp-2005-form 1.pdf

1730-chenp-2005-form 18.pdf

1730-chenp-2005-form 26.pdf

1730-chenp-2005-form 3.pdf

1730-chenp-2005-form 5.pdf

1730-chenp-2005-pct.pdf